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

	
Smokefree legislation is just one of a number of tobacco control 
policies introduced in the UK in the last decade in an attempt to curb the harm 
caused by smoking. Whilst such legislation is known to have reduced non1
smokers’ exposure to environmental tobacco smoke, less is known about whether 
the introduction of a smoking ban encourages existing smokers to attempt to quit 
and to seek support to do so from appropriate sources such as their general 
practitioner. High quality data are needed to evaluate the effectiveness of 
legislation in prompting smokers to change their smoking behaviour, and data 
collected routinely in primary care may provide such an opportunity. However, 
there is little contemporary evidence about the quality of the smoking data 
recorded in primary care, nor how best to analyse these data, which must be 
addressed before the resource can be used to evaluate the effectiveness of 
tobacco control policies. 
 

Initially, a systematic review was undertaken to assess the impact of 
national comprehensive smokefree legislation on population smoking prevalence, 
cigarette consumption and quitting behaviour. Then, the quality of smoking status 
and cessation intervention recording in The Health Improvement Network (THIN) 
database, a large database of UK primary care records, was investigated using 
indirect standardisation to compare rates of recording with external data sources. 
Having identified Autoregressive Integrated Moving Average  (ARIMA) interrupted 
time series analysis as an appropriate method to assess the impact of smokefree 
legislation on measures of smoking1related clinical activity recorded in THIN data, 
several sensitivity analyses were untaken to assess the impact of decisions that 
must be taken during the data analysis process. In the light of this knowledge, 
ARIMA models were used to investigate changes in the rate of recording of 
patients’ smoking status, delivery of cessation advice, referral of smokers to 
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specialist cessation services and prescribing of smoking cessation medications in 
the months leading up to, and after, the introduction of smokefree legislation. 
 
The findings of the systematic review provide some evidence that in 
populations where well1enforced, comprehensive smokefree policies have been 
implemented quitting activity increased in the run up to, and/or following, the 
introduction of the legislation. Assessment of the quality of the smoking 
information recorded in THIN showed that the data have improved in recent 
years, such that the recorded prevalence of smoking is now similar to that 
reported in national surveys. Some uncertainty does, however, remain about the 
quality of recording of the delivery of cessation advice or referral of smokers to 
cessation services. ARIMA modelling highlighted a 6.2% increase in Nicotine 
Replacement Therapy (NRT) prescribing in the six months before smokefree 
legislation was introduced in England, and a 13.2% increase in bupropion 
prescribing in the three months pre1ban. A 5.5% decline in NRT prescribing and a 
13.7% decline in bupropion prescribing were seen in the nine months post1
legislation, declines which were offset to an extent, but not completely, by 
prescribing of varenicline which was first available on prescription in December 
2006. Similar, though non1statistically significant, patterns were seen in Scotland, 
Wales and Northern Ireland, where the smaller number of practices in THIN in 
these countries reduced the power to detect small changes in prescribing. In 
England, the patterns of change in prescribing did not differ with patient sex, age 
group, medical history or social class.  
 
		The improved quality of the smoking data recorded in the THIN 
dataset suggests that primary care data may be a valuable resource with which to 
evaluate the effectiveness of tobacco control policies such as smokefree 
legislation. The significant increases in prescribing of NRT and bupropion in the 
run1up to the introduction of smokefree legislation in the UK suggest that smokers 
   3 
looking to quit may seek support to do so from primary care, though the decline 
in rates of prescribing post1legislation suggests that this positive change may not 
be sustained. This may represent a missed opportunity to maximise the impact of 
smoking bans by ensuring that smokers are aware of, and indeed access, 
cessation support available through primary care both before and after legislation 
is enacted, and should be noted by policy makers planning the introduction of 
smokefree legislation elsewhere. Ensuring that smokers are aware of, and indeed 
access, the effective support that is available through primary care to help them 
quit may be one way to maximise the positive impacts of smokefree legislation 
and reduce the health and economic burdens of continued tobacco use. 
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Smoking is arguably the most preventable threat to public health worldwide1, 
responsible for the deaths of some 100 million people globally in the twentieth 
century, and with the potential to kill one billion before the end of this century2. In 
2009 an estimated 81,400 adults aged over 35 in England died from smoking1
related illness; 23% of all deaths amongst men and 14% of deaths amongst 
women can be attributed to the effects of smoking3. These deaths included 37,500 
from cancer, 22,000 from respiratory disease and 20,600 from diseases of the 
circulatory system3. At least half of all smokers, and possibly as many as two1
thirds4, will die prematurely as a result of their smoking behaviour, on average 
eight years earlier than if they hadn’t smoked5. Smokers are also at risk of 
conditions which, although they might not kill them, result in significant loss of 
quality of life, such as asthma, osteoporosis, cataracts and hip fracture2.  
 
In 2003, at least 12,000 deaths in the United Kingdom (UK) were attributable to 
non1smokers’ exposure to environmental tobacco smoke6, and, in addition, young 
people exposed to role1models who smoke are more likely to become smokers 
themselves7. Expectant mothers exposed to tobacco smoke, through either active 
or passive smoking, place the health and survival of their unborn child at 
significant risk8. 
 
Smoking also places a considerable economic burden on both individuals and 
society. In March 2010 the cost of a typical packet of 20 cigarettes in the most 
popular price category stood at £6.29, rendering the yearly cost of smoking 20 
cigarettes daily just less than £23009. This cost hits the poor, who spend a larger 
   20 
proportion of their income on cigarettes than more affluent smokers, the 
hardest10. The financial cost of smoking for a country’s healthcare system is 
staggering; the direct cost of smoking to the National Health Service (NHS) was 
an estimated £5.2 billion in 20051611. 
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Cigarette consumption in the UK rose steadily after the opening of the nation’s 
first commercial cigarette production factory in the 1850s, following a pattern 
seen throughout the industrialised world whereby the behaviour was adopted by 
men first, with the ‘innovation’ then diffusing to boys, women, and, finally, girls12. 
Figure 1.1 shows the prevalence of cigarette smoking (and, for men, the 
prevalence of smoking all types of tobacco) in Britain since 1948. Figures from the 
General Lifestyle Survey (GLF), now the standard point of reference for smoking 
statistics∗, are broadly comparable to those from the Tobacco Advisory Council 
(TAC), the main source of statistics from 1948 to 1971.  
 
As Figure 1.1 illustrates, major reductions in adult smoking prevalence were 
achieved in Britain between 1972 and the early 1990s. However, throughout the 
mid1 to late11990s, and during the first part of the 21st century, there was 
relatively little further decline in the proportion of men and women smoking, 
though there was evidence of renewed decline in the second half of the 2000s. 
The most recent figures from the 2008 GLF suggest that 22% of men and 21% of 
women in Britain are regular cigarette smokers13. However, these crude figures 
disguise significant variations in smoking prevalence and quitting behaviour 
between sub1groups within the population.  
 
                                          
∗ Prior to 2008 the General Lifestyle Survey was known as the General Household 
Survey 
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GLF data weighted from 1998 onwards to account for non1response; weighted and non1weighted data shown for 1998 for comparison. 
 
Source: TAC14 and GLF13 
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Smoking is a behaviour that more often than not begins during the teenage 
years13; in the UK about 450 children start smoking every day15, with 5% of boys 
aged 11115, and 7% of girls, smoking at least one cigarette per week16. The 
prevalence of smoking has been highest amongst adults aged 20 to 24 since the 
late 1980s, and the lowest smoking rates are seen in the oldest age group. Whilst 
members of this oldest age group are more likely to have ever been smokers, 
they are also more likely to have given up smoking, or died as a result of their 
smoking behaviour13. 
 
A gradient in smoking prevalence across social classes seems to have been 
present in the 1930s, and has persisted to the present day17, driven by differential 
uptake of smoking in young people, and differential quit rates as a cohort ages18. 
Men and women living in households headed by someone in a manual occupation 
have always been more likely to be smokers compared to those where the head of 
household is in non1manual employment. In 1972, smoking prevalence amongst 
men and women in manual households in England was 58% and 49% 
respectively, falling to 28% and 26% respectively by 200813. For men living in 
non1manual households, smoking prevalence fell from 45% in 1972 to 16% in 
2008, with the prevalence for women declining from 40% to 16%. Variations in 
smoking prevalence by social class are a major driver of health inequalities; it is 
estimated that half the difference in survival to age 70 observed between those in 
social class I and those in social class V in the UK is due to a higher smoking 
prevalence in the more deprived group10.  
 
Finally, the prevalence of smoking varies with geographical location throughout 
the UK. Arguably, only a part of this variation is attributable to geographical 
variations in demographic and socioeconomic characteristics, with the role of 
area1level contextual factors over and above individual characteristics being 
vigorously debated19, 20. Whilst the prevalence of current smoking in both England 
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and Wales in 2008 was 21%, in Scotland 24% of adults were smokers13. Smoking 
prevalence estimates for Northern Ireland, obtained from the Continuous 
Household Survey (CHS), a survey comparable to the British GLF, suggest an 
adult smoking prevalence of 24%21. The proportion of adults who have never 
smoked regularly is the same in all jurisdictions of the UK, so, assuming the 
survey designs of the GLF and CHS produce nationally representative indicators of 
smoking behaviour, the variation in prevalence is likely to be due to different 
proportions of smokers having quit13. GLF data for England is also available at the 
level of the nine Government Office Regions, showing a clear north1south divide in 
the prevalence of current smoking. This pattern is mainly the result of variations 
in the number of heavy smokers (those smoking over 20 cigarettes a day) in each 
region13.  
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The most recent figures from the GLF suggest that two thirds of smokers over the 
age of 16 would like to quit altogether13, with health and financial motivations 
commonly being cited as reasons to do so22. Indeed, it is never too late for 
smokers to benefit from quitting; regardless of the age at which they give up, ex1
smokers can expect to live longer than those who continue to smoke5. Positive 
health changes begin to take effect just eight hours after smoking the last 
cigarette as the amount of nicotine and carbon monoxide in the blood falls, blood 
oxygen levels return to normal and blood circulation improves23. Health benefits 
continue to accrue with increasing duration of cessation, such that after ten years 
of abstinence an ex1smoker’s risk of developing lung cancer falls to about 30150% 
of the risk for a continuing smoker, and continues to fall with increasing 
abstinence24. A smoker’s excess risk of coronary heart disease is reduced by half 
after one year of cessation, and after 15 years their risk is similar to that of a 
never1smoker24.  
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Figure 1.2 summarises the major tobacco control strategies which have been 
implemented in the UK since 1999 in an attempt to reduce smoking uptake, 
increase the number of smokers who quit, reduce non1smokers’ exposure to 
environmental tobacco smoke and reduce the health and economic burdens of 
tobacco use. A more detailed history is available from Action on Smoking and 
Health (ASH)25. 
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Arguably the most groundbreaking and publicised of these changes is the 
introduction of smokefree legislation, introduced primarily as a means to reduce 
non1smokers’ exposure to environmental tobacco smoke but also in the hope that 
legislation would prompt changes in existing smokers’ smoking behaviour. Since 
the turn of the 21st century, more than 50 countries and states worldwide have 
implemented legislation at least partially banning smoking in enclosed or 
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substantially enclosed public places26. Pressure to introduce smokefree legislation 
in the UK first began to mount in the late 1990s, with the publication of evidence 
highlighting the harmful effects of passive smoking27. Figure 1.3 summarises the 
main events since 2003 which concluded with the introduction of smokefree 
legislation in each jurisdiction of the UK, and Table 1.1 details the legal 
requirements of this legislation and the penalties for breaking the law.  
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Country 
Date 
enacted 
Extent of the legislation Penalties for breaking the law 
England28 
1st July 
2007 
 
It is illegal to smoke in: 
1 virtually all 'enclosed' and 
'substantially enclosed' public 
places and workplaces 
1 public transport and work vehicles 
used by more than one person 
1 staff smoking rooms and indoor 
smoking areas are no longer 
allowed 
Exemptions include designated rooms 
in: 
1 mental health units (though illegal 
in England from 1st July 2008) 
1 residential care/nursing homes  
1 prisons  
1 adult hospices  
1 hotels 
 
 
Individual smokers: 
1 fixed penalty notice of £50 
(reduced to £30 if paid in 15 days) 
or a maximum fine of £200 if 
prosecuted and convicted by a 
court. 
Failure to display no1smoking signs:  
1 a fixed penalty notice of £200 
(reduced to £150 if paid in 15 
days) or a maximum fine of £1000 
if prosecuted and convicted by a 
court. 
Failing to prevent smoking in a 
smokefree place:  
1 a maximum fine of £2500 if 
prosecuted and convicted by a 
court.  
 
Northern 
Ireland29 
30th April 
2007 
Wales30 
2nd April 
2007 
Scotland31 
26th 
March 
2006 
 
It is illegal to smoke in: 
1 most indoor places other than 
private homes 
1 almost all workplaces, including 
lorries and vans. 
1 staff smoking rooms and indoor 
smoking areas are no longer 
allowed 
Exemptions include designated rooms 
in: 
1 adult care homes. 
1 adult hospices. 
1 psychiatric hospitals and psychiatric 
units. 
1 Hotels 
 
 
Individual smokers: 
1 fixed penalty notice of up to £50 or 
a maximum fine of £1000 if 
prosecuted and convicted by a 
court. 
Those in control of no1smoking 
premises: 
1 a fixed penalty notice of £200 for 
allowing people to smoke or failing 
to display warning notices. Refusal 
to pay or failure to pay could result 
in prosecution and a fine of up to 
£2,500. 
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The Chief Medical 
Officer challenges 
the UK 
government to 
ban smoking in 
public places. 
The presidents of 
13 Royal medical 
collages call for a 
complete ban on 
smoking in the 
workplace. 
The Wanless Report ‘Securing 
Good Health for the Whole 
Population’ recommends a 
ban on smoking in the 
workplace. 
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compelling 
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Scotland’s First 
Minister 
announces the 
country will 
implement a total 
ban on smoking in 
work and 
enclosed public 
places. 
United Kingdom 
 
England 
 
Scotland 
 
Wales 
 
Northern Ireland 
Key 
Events occurring in... 
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The Scottish Parliament passes the 
Smoking, Health and Social Care 
(Scotland) bill on 30th June which 
will ban all smoking in all work and 
enclosed public places. The bill 
receives Royal Assent on 5th 
August. 
Scotland goes 
smokefree on 26th 
March 2006. 
The Northern 
Ireland Minister 
announces 
smoking will be 
banned in all 
workplaces in the 
province by April 
2007.  
On 19th September, the 
First Minister announces 
smokefree regulations 
will come into effect the 
following April. 
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National smoking bans have proved an undoubted success in meeting their 
primary aim of reducing non1smokers' exposure to environmental tobacco 
smoke32, but the effect of legislation on current smokers’ smoking behaviour is 
less certain. It is hoped the introduction of smokefree legislation will encourage 
smokers to attempt to quit by increasing social pressures not to smoke, reducing 
opportunities and sensory cues to do so, and creating an enabling environment 
which helps smokers who wish to quit to succeed in doing so33. 
 
Before the recent trend towards state1wide and national smoking bans, many 
individual workplaces in the UK and elsewhere had already introduced worksite 
smokefree policies. Early studies which focused on the impact of these workplace 
smokefree policies on employees’ smoking behaviour identified reductions in 
cigarette consumption and suggested a small decline in smoking prevalence. For 
example, a systematic review of evidence from 26 studies carried out in the 
United States, Australia, Canada and Germany between 1984 and 1993 concluded 
that totally smokefree workplaces are associated with a fall of 3.8% in smoking 
prevalence (95% CI 2.814.7%) and continuing smokers consuming 3.1 fewer 
cigarettes per day (95% CI 2.413.8)34.  
 
A more recent systematic review of peer1reviewed literature published to June 
2005 also examined the impact of legislation on workers in companies or 
worksites introducing smokefree policies, either independently or alongside wider 
community restrictions35. This reported a median reduction in cigarette 
consumption of 2.2 cigarettes per day (interquartile range 11.7 to 13.3), a median 
increase of 4.1% in self1reported attempts to quit smoking (interquartile range 1
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0.7 to +6.8%) and a median reduction in the self1reported prevalence of tobacco 
use among employees of 3.4% (interquartile range 11.4 to 16.3%).  
 
Recently, attempts have been made to synthesise evidence assessing the impact 
of the state and national smokefree regulations introduced in the last decade. A 
Cochrane review published in April 2010 attempted to evaluate the impact of 
legislative smoking bans for reducing exposure to environmental smoke as well as 
on measures of smoking prevalence, tobacco consumption and smoking 
cessation36. This review concluded that the effect of smoking bans on smoking 
prevalence is unclear; ten studies reported changes in smoking prevalence as an 
outcome measure, with eight indicating a slight fall in prevalence and two 
reporting no change. Small reductions in prevalence were noted in most 
population1based studies, particularly amongst working men, but prevalence 
remained unchanged or inadequately assessed in workplace1based studies.  
Similarly, there was inconsistent evidence for declines in tobacco consumption and 
increases in smoking cessation activity associated with the introduction of 
smoking bans. However, there are several reasons why the conclusions from this 
review must be interpreted with caution.  
 
The extent of smokefree legislation varies considerably between locations, with 
exemptions applying in some places but not others. The Cochrane review mixes 
evidence from locations with comprehensive and partial legislation, and the 
criteria used to differentiate comprehensive legislation from partial legislation are 
unclear. Some locations, such as Norway, Sweden, Kentucky and California, where 
designated smoking rooms are allowed under the terms of the smokefree law, are 
listed as having comprehensive legislation, despite recognition that such 
exemptions greatly weaken or completely eliminate the effectiveness of smokefree 
legislation2. Arguably, it may be more appropriate to consider only the evidence 
from countries with comprehensive legislation, so as not to potentially dilute the 
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estimated effect of such laws. Similarly, no mention is made about the degree of 
enforcement of smokefree legislation in various locations. If legislation is poorly 
enforced it is perhaps not surprising that the effects of a ban on smoking 
behaviour appear limited.  
 
The Cochrane review does not always separate evidence from studies of smoking 
prevalence and cigarette consumption in particular subgroups of the population, 
such as hospitality workers, with evidence from the general population. Again, it 
would perhaps have been more appropriate to consider general population data 
only. When smokefree legislation was introduced, hospitality workers, for 
example, may suddenly have found themselves unable to smoke indoors whilst 
working, whereas workers in other occupations may have already been subject to 
workplace smoking restrictions for many years. Therefore, a greater change in 
smoking behaviour may be expected amongst hospitality workers, and mixing this 
evidence with that from the general population could overestimate the apparent 
impact of smokefree legislation in the population as a whole.  
 
The criteria used to assess the quality of the studies included in the Cochrane 
review are most appropriate for assessing randomised controlled trials, though no 
such studies are actually included in the review. An alternative quality1assessment 
scale may be more appropriate in this context to allow assessment of factors 
other than the risk of bias, such as the representativeness of the results and 
applicability of conclusions to the general population.  
 
Individual studies are only included in the Cochrane review if the outcome was 
measured six months or more after the introduction of smokefree legislation. 
However, this criterion may exclude evidence of temporary, short1term changes in 
smoking behaviour which occurred in the initial six months after the introduction 
of a ban. It is reasonable to suggest that smokers 
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ahead of the introduction of smokefree legislation, in preparation for the 
impending ban, but by potentially excluding relevant studies the Cochrane review 
may fail to capture some of this complexity surrounding the effects of smokefree 
legislation on smoking1related behaviour.  
 
Finally, the Cochrane review pays little attention to the difficulties of evaluating 
smoking bans when they are introduced as just one part of a programme of 
tobacco control measures in a given location, and does not discuss other control 
initiatives that may have been introduced at the same time as smokefree 
legislation in the locations studied. It is very difficult to attribute apparent changes 
in smoking behaviour to smokefree legislation if there are other tobacco control 
interventions taking place at the same time.  
 
The above discussion highlights just how difficult it is to synthesise the evidence 
regarding the effect of smokefree legislation on population smoking behaviour, 
and another, non1systematic, review of academic and grey literature was beset by 
similar problems37. To address these issues and to try to isolate the population1
level effects of comprehensive smokefree legislation a new systematic review was 
conducted as part of this thesis, including only peer1reviewed studies examining 
national or state1level population impacts of comprehensive smokefree laws. This 
review excludes evidence from countries where smokefree legislation makes 
provisions for designated smoking rooms, and excludes studies which evaluate the 
effect of legislation only in specific subgroups of people, such as hospitality 
workers. The studies included examined the impact of smokefree laws on smoking 
behaviour in jurisdictions which implemented legislation independently of other 
major tobacco control measures, allowing an assessment of the effects of 
smokefree legislation in isolation. Finally, the review evaluates changes in 
population smoking behaviour both before and after the introduction of smokefree 
legislation and places no restrictions on the length of the follow1up period 
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necessary for inclusion. The following section of this chapter presents the methods 
and results of this review. 
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The legal requirements of smokefree legislation vary considerably between 
locations worldwide, as does the degree of enforcement and compliance with any 
ban. Only countries and states which, by the 31 December 2008, had enacted 
comprehensive legislation (defined as covering at least all workplaces, including 
bars and restaurants, with no provision for designated smoking rooms) were 
included in the search (see Table 1.2 for included locations). No language 
restrictions were applied, and the search was not limited to particular study 
designs. Studies were only included if they reported effects of smokefree 
legislation in the general population. No criteria for the length of follow1up were 
set, given that it is unclear whether any response to the introduction of a smoking 
ban will be immediate or delayed, temporary or sustained. 
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PubMed, CINAHL, PsycINFO and the Conference Proceedings Citation Index1
Science (CPCI1S) were searched for studies, published between January 2002 and 
November 2009, presenting evidence on smoking prevalence, cigarette 
consumption, quitting behaviour, and beliefs about the impact of smokefree 
legislation. The search syntax included terms for 'smoking' and 'legislation', based 
on the Cochrane Tobacco Addiction Group's core search strategies (see Appendix 
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8.1 for the complete search syntax). In addition, experts in the field were 
contacted to identify any additional relevant studies not previously identified, and 
the bibliographies of retrieved references were also scanned for further relevant 
publications. All article titles identified in the literature search were screened by 
one author, and the abstracts of articles deemed potentially relevant to this 
review were assessed by two authors. In the event of disagreement, the opinion 
of a third author was sought.  
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6469A+3 04.12.08 Arizona 01.05.07 
-/.(8/B 02.07.06 Colorado 01.07.06 
.3( 22.12.07 Delaware 27.11.02 
84/673( 30.03.08 District of Columbia 02.01.07 
E/.8/B 02.01.07 Hawaii 16.11.06 
/CF/343(< 10.12.04 Illinois 01.01.08 
3(393 24.01.08 Iowa 01.07.08 
-/.;6+56 02.03.07 Maine 01.04.04 
/1-A4+567./43(< 29.03.04 Maryland 01.01.08 
.-,-3B 01.03.06 Massachusetts 05.07.04 
 
Minnesota 01.10.07 
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New Jersey 15.04.06 
England 01.07.07 New Mexico 15.06.07 
Northern Ireland 30.04.07 New York 24.07.03 
Scotland 26.03.06 Ohio 07.12.06 
Wales 02.04.07 Rhode Island 31.03.05 
 
Washington 08.12.05 
3(3<3
  
Alberta 01.01.08 -8;.34+3
 
British Columbia 31.03.08 Australian Capital Territory 01.12.06 
New Brunswick 01.10.04 New South Wales 02.07.07 
Nova Scotia 01.12.06 Queensland 01.07.06 
Nunavut Territory 01.02.04 South Australia 31.10.07 
Ontario 31.05.06 Tasmania 01.01.06 
Quebec 30.05.08 Victoria 01.07.07 
Yukon Territory 15.05.08 Western Australia 31.07.06 
 
 
The initial searches identified 3,204 studies, of which 37 abstracts appeared 
potentially relevant and were read in full. Of these, eight met the inclusion criteria 
and full papers were obtained. The abstracts of five further articles were judged 
unclear; these papers were read in full to assess their relevance to the aims of 
this review. Figure 1.4 details the process of article1identification after searching. 
Excluded studies did not report outcomes relevant to the aims of this review or 
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summarised the findings of studies that had already been identified for inclusion 
(n=15), reported findings in specific population sub1groups only, such as bar 
workers (n=3), or reported data from locations where smokefree legislation is not 
comprehensive in coverage (n=11).  
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The methodological designs used in the studies deemed eligible for inclusion in 
this review were varied, and no single quality assessment tool was appropriate for 
appraising all studies. The criteria defined by the Cochrane Effective Practice and 
Organisation of Care (EPOC) Group40 were used to assess the quality of studies 
employing time series analytic methods, giving a score out of six for each study. 
The Newcastle1Ottawa Scale41 was used to assess the methodological quality of 
prospective cohort, quasi1experimental and cross1sectional studies; scale items 
were not always relevant and thus quality score denominators vary with study 
design and are presented in Table 1.3. 
 
 
  
   
34 
&'&* +,	

 
Where appropriate, the results of studies include in this review have been 
combined using meta1analysis. However, many of the studies are heterogeneous 
in their research design and outcome measures and, thus, it was not possible to 
undertake meta1analysis to pool their results. In these instances, a narrative 
synthesis is presented. 
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Of the eight studies included in this review, three report findings from Scotland421
44, two from England45, 46, two (based on the same dataset, though with different 
study periods and using different analytical methods) from New Zealand47, 48, and 
one from the Republic of Ireland49. In all these locations, enforcement of the ban 
and compliance with the legislation has been excellent2. 
 
Two studies employed a quasi1experimental prospective cohort design, comparing 
behaviour trends from a location where smokefree legislation had been introduced 
with trends in a cohort from a different location without smokefree legislation. 
Five presented analyses of repeated cross1sectional data collected before and 
after the introduction of a smokefree policy and two modelled repeated cross1
sectional data from multiple time points pre1 and post1legislation using time series 
analysis methods. The quality scores of studies included in this review are mixed, 
though all studies with the exception of one44 met at least three quarters of the 
assessed criteria relevant to that study design. The variations in the quality score 
denominators between different study designs means it is not possible to 
synthesise the scores further.  
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Table 1.3 summarises the methods and results of the eight included studies, 
subdivided to show evidence relating to the impact of the introduction of 
smokefree legislation on smoking prevalence, cigarette consumption, smoking 
cessation behaviours and smokers’ beliefs about smokefree legislation.  
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a) Smoking prevalence 
 
Citation Location Quality 
Score 
Date 
legislation 
introduced 
Methods Main results 
Elton PJ, 
Campbell P. 
200845 
 
England 6/8 
(Newcastle 
Ottawa 
Scale) 
01.07.07 Repeated cross1sectional postal survey of 
2,054 people 3 months before the 
introduction of the smoking ban, and 1,938 
respondents 3 months post1ban.  
The age and sex1standardised prevalence of smoking was 22.4% in the pre1
legislation survey, and 22.6% in the post1legislation survey, a non1
significant change.  
Haw SJ, 
Gruer L. 
200742 
Scotland 6/8 
(Newcastle 
Ottawa 
Scale) 
26.03.06 Repeated cross1sectional face1to1face 
survey carried out 017 months pre1
legislation and 6112 months post1ban. 
Smoking prevalence was 35.6% (646/1815) pre1legislation and 35.1% 
(644/1834) post1legislation.  
 
 
b) Cigarette consumption 
 
Citation Location Study 
quality 
Date 
legislation 
introduced 
Methods Main results 
Elton PJ, 
Campbell P. 
200845 
 
England 6/8 
(Newcastle 
Ottawa 
Scale) 
01.07.07 Repeated cross1sectional postal survey of 
2,054 people 3 months before the 
introduction of the smoking ban, and 
1,938 respondents 6 months later. 
The proportion of smokers reporting smoking 20 or more cigarettes per day 
declined significantly from 27.6% of smokers pre1legislation to 21.8% post1
ban (p=0.044). 
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c) Smoking cessation behaviours  
 
Citation Location Study 
quality 
Date 
legislation 
introduced 
Methods Main results 
Hackshaw L, 
McEwen A, 
West R and 
Bauld L. 
201046 
England 7/8 
(Newcastle 
Ottawa 
Scale) 
01.07.07 Repeated cross1sectional surveys 
analysing data from 10,560 adults 
surveyed between January 2007 and 
December 2008 who reported having 
smoked in the past 12 months.  
8.6% smokers reported having made a quit attempt in July and August 2007, 
significantly more than the 5.7% who reported doing so in July and August 
2008 (Fisher's Exact = 0.022). Younger age groups were more likely to 
report making a quit attempt in response to legislation, though there were no 
significant differences with respect to gender, social grade or cigarette 
consumption.  
Hyland A, 
Hassan LM, 
Higbee C, 
Boudreau C, 
Fong GT, 
Borland R et 
al. 200944 
Scotland 6/9 
(Newcastle 
Ottawa 
Scale) 
26.03.06 Quasi1experimental prospective cohort 
study involving telephone surveys of a 
nationally1representative sample of adult 
smokers and non1smokers in Scotland 
(n=1122) and the UK (n=1474), surveyed 
in February and March 2006, before the 
introduction of the Scottish legislation, and 
one year later. 
No statistically significant differences in the number of respondents reporting 
having quit smoking or having made a cessation attempt by 2007 were 
observed comparing Scotland to rest of UK. The number of respondents 
reporting having used NRT in the six months prior to the baseline survey was 
higher in Scotland compared to the rest of the UK (OR 1.9; 95% CI 1.212.9), 
though there was a significantly greater decrease in NRT use in Scotland 
after the enactment of legislation than in the rest of the UK.  
Lewis SA, 
Haw SJ, 
McNeill A. 
200843 
Scotland 5/6 
(Cochrane 
EPOC 
scale) 
26.03.06 Interrupted time series analysis of data 
from January 2004 to December 2006 of 
over1the1counter (OTC) nicotine 
replacement therapy (NRT) sales data, 
comparing Scotland to rest of the UK. 
The usual New Year peak in NRT sales was accentuated in Scotland in 2006 
but not in the rest of the UK. The number of units of NRT sold from January 
to June 2006 in Scotland increased by 13,766 units per month compared to 
the same period in the previous two years, and the value of sales increased 
by £116,459 per month. No significant increase was seen in the rest of the 
UK. There was no significant increase in NRT sales in the second half of 2006 
in Scotland compared to previous years.  
Wilson N, 
Thomson G, 
Grigg M, 
Afzal R. 
200547 
New 
Zealand 
8/8 
(Newcastle 
Ottawa 
Scale) 
10.12.04 Repeated cross1sectional surveys 
comparing the number of smokers 
registering with the national Quitline 
between 1 December 2004 and 31 January 
2005 (the 'intervention period') with the 
same period 12 months earlier (the 'pre1
intervention' period).  
In the intervention period the caller registration rate was 395 per 100,000 
smokers aged 15+ per month, compared to 272 per 100,000 in the pre1
intervention period (RR 1.44, 95% CI 1.3911.51). The rate of distribution of 
vouchers for subsidised NRT also increased significantly between the two 
periods (RR 1.92, 95% CI 1.8212.03). The proportion of registrations in the 
35144 year age group increased in the intervention period (p = 0.01), but no 
other significant changes in the distribution of callers by sex or ethnic group. 
The weekly caller registration rate also increased in the week in which the 
smoking ban was introduced relative to the average for the three weeks 
beforehand (RR 1.69, 95% CI 1.5211.88). This increase persisted into the 
following week, even though it was the week preceding Christmas day (RR 
1.27, 95% CI 1.1411.42). 
Wilson N, 
Sertsou G, 
Edwards R, 
Thomson G, 
Grigg M, Li J. 
200748 
New 
Zealand 
6/6 
(Cochrane 
EPOC 
scale) 
10.12.04 Interrupted time series analysis of data 
from December 2002 to November 2005 of 
the number of smokers registering 
monthly with the national Quitline and the 
volume of NRT vouchers issued by the 
Quitline service.  
The usual southern1hemisphere summer dip in caller registration and issuing 
of NRT vouchers disappeared in December 2004 and January 2005, despite a 
concurrent reduction in advertising expenditure on cessation promotion. The 
number of monthly callers increased significantly in December 2004 
(p=0.025) compared to the rest of the study period. There was no significant 
increase in the number of NRT vouchers issued per month as a result of 
smokefree legislation.   
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d) Beliefs about smokefree legislation 
 
Citation Location Study 
quality 
Date 
legislation 
introduced 
Methods Main results 
Fong GT, 
Hyland A, 
Borland R, 
Hammond D, 
Hastings G, 
McNeill A et 
al. 200649 
Republic 
of 
Ireland 
7/9 
(Newcastle 
Ottawa 
Scale) 
29.04.04 Quasi1experimental prospective cohort 
study involving telephone surveys of a 
nationally1representative sample of 
smokers in Ireland (n=769) and the UK 
(n=416), surveyed before the introduction 
of smokefree legislation in Ireland 
(December 2003 1 January 2004) and 819 
months after its implementation 
(December 2004 1 January 2005). 
Post1legislation, 60% of continuing smokers said law had made them cut 
down on the amount they smoke (95% CI 55164%), 46% more likely to quit 
(95% CI 41150%) and 14% (95% CI 11117%) said the law had led them to 
use stop smoking medications like the nicotine patch or gum. Of those who 
had quit by the second wave, 80% of quitters said the law made them more 
likely to have quit smoking (95% CI 71188%), 88% (95% CI 81195%) said it 
helped them stay quit, and 34% (95% CI 24145%) said it made them more 
likely to use pharmacotherapy.  
Hackshaw L, 
McEwen A, 
West R and 
Bauld L. 
201046 
England 7/8 
(Newcastle 
Ottawa 
Scale) 
01.07.07 Repeated cross1sectional surveys 
analysing data from 10,560 adults 
surveyed between January 2007 and 
December 2008 who reported having 
smoked in the past 12 months.  
In July and August 2007, 19% of all smokers making a quit attempt reported 
doing so in response to the introduction of the smoking ban.  
 

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Two studies presented data illustrating the effect of the introduction of smokefree 
legislation on smoking prevalence. In Bury, England, the self1reported smoking 
status of adults questioned three months before the introduction of the smoking 
ban and again six months later showed no significant reduction in age and sex1
standardised smoking prevalence45. In Scotland, there was a marginal, but non1
statistically significant, decrease in smoking prevalence, from 35.6% 017 months 
before smokefree legislation was enacted to 35.1% 6112 months afterwards42.  
Figure 1.5 shows the results of a meta1analysis combining the results of these two 
studies using a fixed effects model. As can be seen, this meta1analysis suggests 
that smoking prevalence declined non1significantly by 0.1% between the pre1 and 
post1legislation surveys (95% CI 13.4 to 3.3%). 
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Just one study presented data quantifying the effect of smokefree legislation on 
self1reported cigarette consumption. In England, the proportion of ‘heavy’ 
smokers (who consumed 20 cigarettes a day or more) declined significantly from 
27.6% respondents three months pre1ban to 21.8% respondents three months 
post1legislation (p=0.044)45.  
Overall  (I-squared = 0.0%, p = 0.841)
Haw & Gruer (2007)
Elton & Campbell (2008)
-0.08 (-3.42, 3.26)
-0.50 (-5.79, 4.79)
0.20 (-4.11, 4.51)
  0-6 -4 -2 2 4 6
 
Absolute change in smoking prevalence (%)
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Two studies presented data on self1reported quit attempts comparing survey 
responses before and after the introduction of smokefree legislation. In England a 
significant increase in the number of smokers reporting making a quit attempt 
was seen in the two months after the introduction of smokefree legislation 
compared to the same period in the following year46. Conversely, in Scotland 
there was no significant increase in the number of smokers who reported having 
quit smoking or having made a cessation attempt in the year after the 
introduction of smokefree legislation44.    
 
Several studies reported increases in markers of cessation activity in the months 
before and after the introduction of a smokefree policy. In New Zealand there was 
an increase in the number of callers registering with the national Quitline in the 
month before and month after smokefree legislation was enacted compared to 
previous years, despite the legislation being introduced just before Christmas and 
during the southern1hemisphere summer, factors which in other years have 
reduced cessation activity47, 48. Four studies presented data illustrating the effect 
of the introduction of smokefree legislation on smokers' use of NRT. Two studies 
from Scotland found that the proportion of smokers reporting using NRT44, as well 
as the volume and value of NRT sales43, increased in the months before the 
introduction of legislation. In New Zealand an increased number of NRT vouchers 
were issued through the national telephone Quitline in the two month period 
spanning the introduction of smokefree legislation, despite a concurrent reduction 
in the amount of money spent advertising cessation programmes47. However, the 
same data, when analysed as a monthly time series rather than two cross1
sectional surveys, failed to find a significant increase in the number of NRT 
vouchers issued per month at the time smokefree legislation was introduced48.  
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In two surveys respondents were asked about the impact of smokefree legislation 
on their smoking behaviour. Respondents believed that the introduction of 
smokefree legislation made them more likely to quit49, prompted them to attempt 
to quit46, and helped them to remain abstinent49. In the Republic of Ireland, 60% 
of continuing smokers self1reported that the introduction of smokefree legislation 
made them cut down on the amount they smoke (95% CI 55164%)49. 
 
% +85-88+6(

In populations where well1enforced, comprehensive smokefree policies have been 
implemented, there is some evidence that quitting activity increased in the run up 
to, and/or following, the introduction of the legislation. In all jurisdictions, 
substantial proportions of smokers and successful quitters reported that 
smokefree legislation helped them make positive changes in their smoking 
behaviour, and there is consistent evidence that heavier smokers succeed in 
reducing their average daily cigarette consumption after the introduction of a 
smokefree policy. However, there is no evidence to date to suggest that these 
changes in smoking behaviour translate into population1level reductions in 
smoking prevalence. 
 
Despite the large number of nations and states worldwide which have 
implemented comprehensive smokefree legislation, the published literature 
included in this review represents the experiences of just four jurisdictions, 
perhaps reflecting the relatively recent introduction of smokefree legislation, 
delays in the publication of research findings or difficulties in designing and 
conducting studies to identify and attribute changes in smoking behaviour to 
national bans. Further evidence is needed to determine whether the experiences 
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of the places included here differ from those of other locations with 
comprehensive smoking bans in place. 
 
The evidence presented here is drawn from studies with diverse methods and 
outcome measures, making synthesis difficult. A limitation of many studies is their 
failure to take into account secular trends in smoking behaviour prior to the 
implementation of smokefree legislation. For example, as Figure 1.1 showed, 
smoking prevalence has shown a general downward trend in the UK since the 
1970s13 and it is crucial to isolate any additional effect of smokefree legislation 
over and above this longer1term trend. Though no additional weight is given here 
to studies with particular designs, many are limited by reliance on observational 
data, self1reported smoking behaviour and short follow1up periods. Though many 
of the repeated cross1sectional surveys scored highly against the criteria of the 
Newcastle Ottawa Scale for measuring study quality, they fail to account for 
trends in the outcome measure beyond a few months before the introduction of 
smokefree legislation. 
 
Attention must also be paid to the analytical techniques used in different studies; 
data from New Zealand’s telephone Quitline, when analysed as two cross1sectional 
surveys, showed a significant increase in the rate of distribution of NRT vouchers 
after the introduction of smokefree legislation47, though when this same dataset is 
analysed as a monthly time series no significant increase is reported48. The timing 
and duration of data collection in the pre1 and post1legislation survey waves may 
also be important given evidence of increased quitting activity in the months 
preceding the introduction of smokefree laws. Additionally, it has been suggested 
that the full effect of smokefree laws may not be seen immediately, particularly if 
they are introduced during the summer months when going outside to smoke is 
no deterrent45. It may also be the case that any positive effects of smokefree 
legislation on cigarette consumption and quitting behaviour are short lived, with 
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these returning to previous levels once the ‘novelty’ of the legislation has worn 
off. However, none of the included studies had data points beyond 18 months 
post1legislation and so examination of the long1term impact of legislation is not 
possible.  
 
The evidence synthesised in this review points to an increase in the number of 
smokers attempting to quit and seeking support to do so in the months 
immediately before and after the introduction of a comprehensive smokefree 
policy, a finding not reported by the recent Cochrane review given its requirement 
for included studies to have at least a six month follow1up period36. Three of the 
studies included in the review undertaken here are based on objective, routinely1
collected data43, 47, 48, strengthening the validity of the evidence they provide. 
Increased quitting activity in the run1up to a law being enacted may follow periods 
of public consultation, legal proceedings, and media publicity which render it likely 
that people are aware of impending regulations before their implementation date. 
One potential explanation for there being no change in either quit attempts or 
successful cessation rates in Scotland compared with the rest of the UK after the 
introduction of the Scottish smokefree policy could be because many Scottish 
smokers made their cessation attempts in the run1up to the legislation, rather 
than after its introduction44 and the pre1legislation survey in this study was carried 
out only one month prior to the smokefree policy being implemented. This 
explanation is supported by the increase in over1the1counter (OTC) NRT sales in 
Scotland in the months before smokefree legislation was enacted43. In addition, in 
the ‘control’ sample (the rest of the UK), the follow1up survey was carried out just 
prior to the introduction of smokefree policies in those countries, where enhanced 
quitting activity might already have been occurring. In England, for example, legal 
proceedings were completed in  February 2006 (17 months before the ban was 
enacted)  and 20% of general medical practitioners surveyed the following month 
    
44 
reported having seen an increase in patients asking about quitting following media 
publicity of the parliamentary vote50. 
 
The failure to detect a significant decline in smoking prevalence following the 
introduction of a smoking ban may reflect a lack of statistical power in these 
studies to detect small changes in prevalence, a problem which remained despite 
combining the results of two studies using meta1analysis. Just one study 
presented a power calculation, indicating it was powered to detect an absolute 
decline in smoking prevalence of 3.5%45. This effect size is similar to the decline 
in prevalence reported in the early reviews of the effects of workplace smoking 
bans34, 35. However, national and state1wide smoking bans might not realistically 
be expected to have such a large effect on prevalence, particularly in locations 
where there are already extensive workplace smoking restrictions. The evidence 
of increased quitting behaviour and reductions in cigarette consumption may 
instead suggest that, with the introduction of a smoking ban, although smokers 
may succeed in reducing their cigarette consumption many do not succeed in 
finally breaking their addiction.  
 
Although data for NRT sales in Scotland43 and the use of the telephone Quitline in 
New Zealand48 suggest that the effects of introducing smokefree legislation were 
short1lived, it remains possible that the quitting behaviour stimulated by the bans 
could translate into a decline in prevalence if a significant proportion of those who 
attempted to quit succeeded in remaining abstinent in the long1term. It is also 
possible that the introduction of smokefree legislation may not lead to an absolute 
increase in the number of smokers attempting to quit, but just change the way in 
which quit attempts are distributed over the course of a year, as observed in the 
English dataset46.   These competing hypotheses do suggest that it may be 
necessary for media campaigns and cessation support associated with smokefree 
policies to be offered in a more sustained way if more smokers are to succeed in 
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stopping. In Scotland, an intensive mass media cessation campaign did not 
continue beyond the introduction of the legislation43, and there was a restriction in 
the promotion of New Zealand's Quitline in the period following smokefree policy 
implementation48. Rather than seeing smokefree policies as the culmination of 
efforts, their impact on smoking behaviour might be maximised by more sustained 
activity, perhaps through the media and health services, around the importance of 
cessation and promotion of sources of support to help smokers quit. Galvanising 
support for the smokefree policy itself might also be important. In Scotland, 
support for smokefree legislation just prior to its implementation was associated 
with increased quit intentions one year later51. 
 
In all the locations studied, smokefree legislation was introduced largely 
independently of other major tobacco control measures. However, it is still difficult 
to attribute any changes in smoking behaviour to the introduction of legislation.   
Many of the studies reviewed here indicate increased quitting activity before the 
actual date legislation was implemented, and it is not known just how long before 
a law is enacted smokers may begin to take preparatory action. The preparatory 
period may overlap with the introduction of other tobacco control measures, such 
as the introduction of a new medication to aid smoking cessation, varenicline, in 
England six months before the smoking ban was introduced, and some of the 
changes in behaviour reported here may in fact be the result of these other 
measures.   
 
Finally, although some studies attempted to assess the differential impact of 
smokefree legislation by characteristics such as age, sex and social class, there 
were insufficient data to synthesise and draw meaningful conclusions. More 
research is needed to understand whether smokefree legislation prompts different 
changes in smoking behaviour across different sociodemographic groups.  
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In conclusion, the introduction of smokefree policies seems to have influenced 
quitting activity and reduced daily cigarette consumption amongst heavier 
smokers, though there is insufficient evidence to determine whether or not this 
translates into reduced population smoking prevalence. Smokers may need 
further support to ensure that the increased quitting activity and positive 
attitudinal changes which bans appear to cause are fully capitalised on and lead to 
sustained decreases in population smoking prevalence.  
 
There is a lack of research examining the pathways by which the introduction of 
smokefree legislation might exert an impact on smoking behaviour. Similarly, it is 
not known whether other tobacco control policies or interventions could, when 
introduced alongside smokefree legislation, ensure that as many smokers as 
possible succeed in quitting. If the introduction of smokefree legislation 
encourages smokers to attempt to quit, as suggested by the results of this 
systematic review, smokers may seek help to stop from appropriate sources. One 
potential source of cessation support is from primary health care professionals. In 
the UK, all people are entitled to register with a general practitioner (GP), and GPs 
and practice nurses have a range of interventions at their disposal to aid 
cessation. The introduction of smokefree legislation may prompt smokers to seek 
cessation support from primary care, or prompt health care professionals to offer 
support even if this is not directly solicited by their patients. No studies to date 
have investigated rates of cessation activity in primary care at the time smokefree 
legislation is introduced. If there is no change in the rate of delivery of cessation 
advice to smokers, prescription of various pharmacological cessation aids, or 
referral of smokers to other sources of cessation support, this may highlight 
missed opportunities to increase impact of smoking bans. When smokefree 
legislation is introduced, simultaneous improvements in the provision of cessation 
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support to smokers through primary care could be one way of maximising the 
number of smokers who attempt to quit and who remain permanently abstinent. 
 
The following section of this chapter will consider the role primary health care 
professionals can play in changing smokers’ behaviour, discussing the 
effectiveness of the cessation interventions at their disposal and the factors that 
influence whether they are indeed likely to intervene with a smoker.  
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GPs are well1placed to encourage and support smokers to quit smoking, having at 
their disposal a range of interventions proven to increase the likelihood of 
successful cessation (Table 1.4). On average, adults in England see a GP 3.2 
times per year52, and, given an average workload of 81 surgery consultations per 
week53 and a national smoking prevalence of 21%13, GPs may see 17 smokers 
during the course of each week. In addition, practice nurses may see 13 smokers 
weekly, assuming a workload of 60 patients53. Each consultation represents an 
opportunity for health care professionals to assess a patient’s smoking behaviour 
and, if appropriate, advise and support them to quit.  
 
The reductions in morbidity and mortality achieved through smoking cessation 
mean that even cessation interventions with a limited success rate can be justified 
as cost1effective54. Indeed, ensuring that all smokers who want to quit receive 
effective smoking cessation interventions can prevent more premature loss of life, 
at greater value for money, than almost any other simple intervention known to 
medicine55.  
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Brief advice as part of a 
minimala intervention56 
No advice / usual 
care 
1.66 1.42 to 1.94 53 to 119 assuming unassisted quit rate of 2% 
Intensive advice as part of 
an intensiveb 
intervention56 
No advice / usual 
care 
1.84 1.60 to 2.13 44183 assuming unassisted quit rate of 2% 
Intensive intervention56 
Minimal 
intervention 
All smokers: RR 1.27 1.20 to 1.56 511143 assuming quit rate of 3.5% with a minimal intervention 
Smokers without smoking1related 
disease: 1.20 
1.02 to 1.43 6611429 assuming quit rate of 3.5% with a minimal intervention 
Smokers with smoking1related 
disease: 1.56 
1.35 to 2.03 28182 assuming quit rate of 3.5% with a minimal intervention 
Nicotine replacement 
therapy57 
Placebo / no NRT 
All types: 1.58 1.50 to 1.66 76 to 100 assuming unassisted quit rate of 2% 
Gum: 1.43 1.33 to 1.53 941152 assuming unassisted quit rate of 2% 
Patch: 1.66 1.53 to 1.81 61194 assuming unassisted quit rate of 2% 
Inhaler: 1.90 1.36 to 2.67 301139 assuming unassisted quit rate of 2% 
Oral tablets / lozenges: 2.00 1.63 to 2.45 34179 assuming unassisted quit rate of 2% 
Nasal spray: 2.02 1.49 to 3.73 181102 assuming unassisted quit rate of 2% 
Bupropion58 (Zyban) 
Placebo / no 
pharmacotherapy 
1.94 1.72 to 2.19 42169 assuming unassisted quit rate of 2% 
Varenicline59 (Champix) Placebo 2.33 1.95 to 2.80 28153 assuming unassisted quit rate of 2% 
Varenicline59 (Champix) Bupropion58  1.52 1.22 to 1.88 281114 assuming quit rate of 4% with bupropion 
 
a A minimal intervention was defined as that provided during a single consultation lasting less than 20 minutes, with or without the provision of a leaflet, and with up to one 
follow1up visit. 
b An intensive intervention was defined as that involving a greater time commitment at the initial consultation, the use of additional materials other than a leaflet, or more than 
one follow1up visit. 
c Number needed to treat = 1 ÷ |risk difference| 
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GPs are more likely to deliver cessation interventions where a systematic 
approach is taken to identifying smokers and documenting this in their medical 
records60, and current UK guidelines laid down by the National Institute of Health 
and Clinical Excellence (NICE) recommend that general practices establish 
monitoring systems to ensure that all health care professionals have access to 
information on the current smoking status of their patients61. In addition, these 
guidelines, summarised in Table 1.5, outline the systematic approach that health 
care professionals should take to offering cessation advice and interventions to 
help smokers to quit. 
 
Despite these recommendations, previous work has suggested that GPs often do 
not take a systematic approach to identifying smokers and supporting all smokers 
to quit. A large body of literature from the UK and elsewhere has shown that GP 
and practice nurses’ management of smokers is influenced by several factors, 
which can be broadly grouped into patient characteristics, characteristics of the GP 
or nurse, cessation1specific knowledge and skills and structural factors62. These 
factors will now be discussed in turn. Given the likely variation between countries 
in tobacco control policies, health care systems and attitudes towards health 
promotion, this section will focus upon evidence from the UK.  
 
 
 
    
5
0
 
3A4/#,-+</4+(/876.93(3,+(,896:+(,+(1.+93.B53./
 	,-+<3(5/%D% 	./5699/(<3;+6(8>-1<3;/<?% 
Identification of 
smokers 
• Monitoring systems should be set up to ensure health care professionals (HCPs) 
have access to information on the current smoking status of their patients. This 
should include information on the most recent occasion on which advice to stop 
was given, the nature of advice offered and the response to that advice. 
• Patients should be asked about their smoking at least 
once a year and a note kept of when the question was 
last asked. 
Assessment of 
readiness to quit 
• People who smoke should be asked how interested they are in quitting.  
• Advice to stop smoking should be sensitive to individual preferences, needs and 
circumstances.  
• The smoking status of those who are not ready to stop should be recorded and 
reviewed once a year. Smokers not ready to quit should be advised to consider the 
possibility and advised to seek help in the future. 
 
Delivery of brief 
cessation advice 
• Everyone who smokes should be advised to quit, except in exceptional 
circumstances. 
• GPs and nurses in primary and community care should take the opportunity to 
advise all patients who smoke to quit when they attend a consultation. 
• GPs should advise current smokers to stop during 
routine consultations at least once a year, offer a 
prescription for NRT or bupropion, offer further support 
by way of referral to a specialist service, record the 
response to that advice, and arrange follow up where 
appropriate.  
• Advice should not be limited to patients with smoking 
related diseases but it may help to link advice to 
patients’ reasons for consulting. 
• Practice nurses should be prepared to encourage known 
smokers to stop and offer assistance where possible.  
• GPs and practice nurses should receive sufficient 
practical and theoretical training to enable them to 
deliver opportunistic advice to encourage and support a 
cessation attempt, and to offer accurate advice on NRT 
or bupropion. 
Prescription of 
pharmacotherapy 
• HCPs should offer NRT, varenicline or bupropion, as appropriate, to people who are 
planning to stop smoking. 
• HCPs should not favour one medication over another, but choose the one that 
seems most likely to succeed.  
• If a smoker’s attempt to quit is unsuccessful using NRT, varenicline or bupropion, 
HCPs should not offer a repeat prescription within 6 months unless special 
circumstances have hampered the person’s initial attempt to stop smoking. 
Referral to NHS Stop 
Smoking Services 
• HCPs should offer smokers a referral to the NHS Stop Smoking Service. 
• Nurses who are trained stop smoking counsellors may ‘refer’ to themselves. 
Special groups of 
smokers 
• HCPs should target all women who smoke and who are either pregnant or are 
planning a pregnancy, and their partners and family members who smoke. 
• HCPs should monitor pregnant women’s smoking status and offer smoking 
cessation advice, encouragement and support throughout the pregnancy and 
beyond. 
• Varenicline and bupropion should not be offered to young people under 18 nor to 
pregnant or breastfeeding women. 
• If a pregnant woman expresses a clear wish to receive NRT, HCPs should use 
professional judgement when deciding whether to offer a prescription. 
• Local policy makers and commissioners should target hard to reach and deprived 
communities including minority ethnic groups, paying particular attention to their 
needs. 
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Patient1level socio1demographic factors including sex, age, level of education and 
deprivation, as well as their medical history and motivation to quit may influence 
the way in which GPs and other health care professionals manage smokers, 
though in some instances the evidence is mixed.  
 
In one study from the late11990s, 24.2% of smokers attending a consultation with 
their GP recalled discussing smoking when asked in a post1consultation 
questionnaire, and there was no variation by sex or age65. This is at odds with the 
findings of a more recent study of English NHS patients, where men and those 
aged 16135 or 81+ who had visited their GP or practice nurse in the past year 
were less likely to recall having received cessation advice from a primary health 
care professional in the previous 12 months20. However, no account was taken of 
the fact that men and young people visit their GP less frequently over the course 
of the year13 and therefore have fewer opportunities to receive advice.  
 
There is some evidence to suggest that men may be less likely to receive other 
cessation interventions. Amongst patients contributing data to a large database of 
electronic primacy care records, male smokers were less likely than females to 
receive a prescription for NRT and/or bupropion in a two1year period, after 
adjustment for age, deprivation and co1morbidities (OR 0.68, 95% CI 0.621
0.75)66. Smokers aged 25174 were more likely to receive a prescription than those 
aged 18124 and 75+. However, it is not clear whether this study adjusted for the 
number of visits each patient made to their GP in this period.  
 
A smoker’s socioeconomic status may also influence their management by primary 
health care professionals. After adjustment for sex, age and perceived health, one 
study reports an education1related gradient in the probability of a smoker 
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recalling receiving cessation advice – the older the age at which the smoker left 
education the less likely they were to report having received advice20. Similarly, 
after adjustment for sex, age and co1morbidities, smokers living in the most 
deprived areas were more likely to receive a prescription for NRT and/or 
bupropion in a two1year period than smokers living in the least deprived areas 
(OR 1.50, 95% CI 1.2611.78) 66. 
 
Smokers perceiving they have a smoking1related health problem, or those 
reporting poor self1rated health, are considerably more likely to recall having 
being given advice to quit20, 65, 67, 68, and there is consistent evidence from several 
studies that GPs prefer to discuss smoking with patients in the context of 
smoking1related health concerns. In one survey, 65% of GPs reported that linking 
the delivery of cessation advice to the complaints their patients present with was 
one of their three most1preferred approaches to discussing smoking, and 97% 
agreed that cessation advice was more effective when delivered in this way69. 
Some GPs feel that a smoker with smoking1related health problems is more likely 
to see quitting smoking as part of the treatment for relieving their symptoms, and 
will be more receptive to cessation advice70. On the other hand, some GPs suggest 
that raising the issue of smoking with patients displaying no smoking1related 
symptoms may be perceived by the patient as antagonistic and any cessation 
advice delivered may be less effective71. Smokers with health problems likely 
related to their tobacco use may also be more likely to receive pharmacotherapy 
to help them quit. Amongst patients contributing data to a large database of 
electronic primacy care records, those with a recorded history of asthma, chronic 
obstructive pulmonary disease (COPD), ischemic heart disease, hypertension or 
stroke were more likely to have received a prescription for NRT and/or 
bupropion66. 
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GPs may also be more likely to deliver cessation interventions where they 
perceive the patient will be receptive to advice and support and motivated to 
attempt to quit72. In one study, smokers who recalled receiving advice in a GP 
consultation were more likely than those who didn’t to report having thought 
about stopping or trying to stop (74% vs 43%, p=0.002),  were more likely to be 
intending to stop (50% vs 22%, p=0.003), and more likely to have made at least 
one quit attempt in previous year (68% vs 42%, p=0.012)67, though these 
findings do not, of course, imply a causal relationship. In another study, intending 
to give up smoking in the next four weeks was the only variable independently 
associated with smokers’ recalling having discussed NRT with their GP (OR 2.58, 
95% CI 1.2015.57)73. 
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International literature suggests that four main health care professional1level 
factors may be important in influencing the management of smoking in primary 
care – demographic characteristics, the doctor or nurse’s own smoking behaviour, 
their attitudes towards delivering smoking cessation advice and interventions, and 
a concern not to jeopardise the doctor1patient relationship. 
 
Reassuringly, in the only UK1based study to consider the effect of primary health 
care professionals’ demographic characteristics on their engagement in smoking 
cessation activity there was no evidence of associations between the age or sex of 
either GPs or practice nurse and whether they routinely monitored patients’ 
smoking status, gave cessation advice, recommended or prescribed NRT, provided 
other cessation assistance or referred smokers to other professionals to help them 
to quit74. 
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To my knowledge there are no recent studies from the UK investigating the 
relationship between health care professionals’ own smoking status and their 
engagement in smoking cessation activity. However, evidence from Finland, 
where primary care is also available free at the point of delivery, and the 
prevalence of smoking amongst GPs is similar to that in the UK, can perhaps be 
used to infer some conclusions. In 2001, 5% of male Finnish GPs, and 3% of 
females smoked (compared to 4% of GPs in England and Wales74), and, on the 
whole, a GP’s smoking status did not affect the proportion of their smoking 
patients they reported having delivered cessation advice to75. However, female 
GPs who smoked were less likely than non1smokers to advise pregnant women or 
those using oral contraceptives to quit, and male GPs who smoked daily were less 
likely than non1smokers to report that they always advise patients with tobacco1
related disease to stop smoking (71% vs 96%)75. 
 
The majority of GPs and practice nurses consider intervening against smoking to 
be part of their professional role, though a small minority of GPs’ attitudes are 
unlikely to facilitate their engagement in smoking cessation activity and provision 
of effective cessation support71. In 1992, 11% of GPs and 7% of practice nurses 
surveyed did not agree at least somewhat that smoking prevention should be an 
important part of their profession’s work76, and in 1994 13.3% of GPs agreed with 
the statement that ‘giving anti1smoking advice during routine consultation should 
not be part of my job’69. On a more positive note, there is evidence to suggest this 
situation has improved; in 1999, 96% of surveyed GPs accepted that intervening 
against smoking was part of their role, perhaps reflecting societal changes in 
attitudes towards smoking74.  
 
There is consistent evidence from several studies that a desire not to jeopardise 
the doctor1patient relationship is an important factor influencing GPs’ 
management of smokers, and in one study 9.8% of surveyed GPs agreed that one 
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of their top three problems encountered when discussing smoking with patients 
was that unwanted advice upsets this relationship69. GPs are keen to preserve a 
good relationship with their patients, and consider that a discussion of smoking in 
the context of smoking1related symptoms is more likely to be well1received than 
an abstract conversation72. GPs are also more likely to discuss smoking with 
patients they know well and with whom they have built up a good relationship72. 
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Some GPs and practice nurses report lacking the skills and knowledge to allow 
them to effectively support smokers to quit. Indeed, 5.6% of GPs surveyed in 
1994 agreed that one of their top three problems encountered when discussing 
smoking with patients was their own lack of skill69. In Scotland, 15% of GPs and 
33% of practice nurses surveyed in 1992 reported that a lack of skill was ‘very 
much’ or ‘quite a lot’ a factor limiting their smoking cessation activity76. 
 
Health care professionals may also be unaware of treatment options available for 
smokers who wish to quit and the effectiveness of these interventions. A 2002 
survey of GPs in England and Wales found that a minority were not prescribing 
NRT or bupropion to patients who had requested treatment, feeling that these 
products should not be available on NHS prescription, expressing concerns about 
their cost1effectiveness and, in the case of bupropion, the safety of the drug77. 
The findings of some studies suggest a lack of awareness amongst GPs about the 
safety of NRT in pregnancy; whilst 62% of GPs surveyed in one study believed 
NRT to be effective in pregnancy, and 70% believed it to be safer than smoking, 
only 45% believed NRT to be safe in pregnancy per se78.  
 
A substantial proportion of GPs and practice nurses report views that betray a lack 
of confidence in their ability to help smokers to quit. In Scotland, 37% of GPs and 
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47% of practice nurses surveyed in 1992 reported that feeling ineffective was 
‘very much’ or ‘quite a lot’ a factor limiting their smoking cessation activity76. In 
another study, only 40% of GPs reported feeling effective or very effective at 
helping smokers to quit, though 64% thought they would potentially feel so if they 
were to receive adequate training and support79. The findings of other studies are 
more encouraging – in a 1994 study a higher proportion of GPs, 84.8%, agreed 
that they were effective in persuading some patients to stop smoking69. 
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Several structural factors beyond the control of individual patients and health care 
professionals have been identified as potentially important in determining the 
extent of GPs’ and practices nurses’ engagement in smoking cessation promotion 
– their training, the time they have available to intervene with smokers, financial 
considerations and remuneration for smoking cessation activity. 
 
A Cochrane review concluded that training health professionals to deliver smoking 
cessation interventions increases the number of patients identified as smokers and 
the number offered advice and support to quit (though there is no strong evidence 
that this results in more smokers quitting)80. Despite the proven effectiveness of 
training, a lack of training at both undergraduate and postgraduate level has been 
raised in several studies as a factor limiting health care professionals’ engagement 
in smoking cessation activities. Amongst 303 GPs surveyed in 1999, just 28% 
reported having received training on the delivery of smoking cessation advice. 
However, in this study there was no relationship between a GP’s training and 
whether they routinely monitored patients’ smoking status, delivered cessation 
advice, recommended or prescribed NRT, provided other cessation assistance or 
referred smokers to other professionals to help them quit74. Amongst 459 practice 
nurses surveyed at the same time, those who reported having received training 
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on the delivery of advice were more likely than those who had not to say that they 
provided assistance such as counselling and leaflets for smokers wanting to quit, 
ran a stop smoking group and received referrals from GPs in the practice. Trained 
nurses were also more likely to report advising patients to telephone the national 
Quitline and to report recommending NRT74. 
 
Although the majority of newly1qualified doctors in 2001 reported feeling well1
prepared to advise their patients on the health risks of smoking, only 11% rated 
their ability to deliver practical guidance on smoking cessation in accordance with 
national guidelines as excellent or good. Just 17% of doctors felt well prepared to 
deliver advice on NRT and only 5% felt able to deliver good advice on the use of 
bupropion for smoking cessation81. A more recent study does not suggest much 
improvement in these figures – of 656 London medical students surveyed in 2006, 
33.2% reported feeling competent to counsel smokers (95% CI 29.6136.8%), 
though perceived competence was higher (44%) amongst students in more 
advanced stages of their training compared to those in the pre1clinical years82. 
When asked to rate the effectiveness of various smoking cessation interventions 
on a 41point Likert scale, the same medical students rated ‘willpower alone’ and 
advice from a GP in a similar manner82, suggesting a lack of awareness of the 
effectiveness of different means of helping smokers to quit.  
 
Pregnancy arguably provides a unique opportunity to support smokers to quit, at 
a time when they are perhaps more receptive to health promotion advice. Indeed, 
91% of Scottish GPs surveyed in 1992 reported raising smoking cessation 
routinely with pregnant women though only 49% said they would raise the topic 
with general patients76. However, at the same time 26% of GPs strongly agreed or 
agreed that they had not had sufficient training to enable them to deliver 
cessation counselling in pregnancy, perhaps going some way to explaining why 
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38% of GPs agreed or strongly agreed that they found delivering smoking 
cessation counselling to pregnant women difficult83.  
 
GPs frequently cite a lack of time as a factor limiting their engagement in smoking 
cessation activities – 26.9% of GPs surveyed in 1994 agreed that one of their top 
three problems encountered when discussing smoking with patients was that a 
lack of time prevented detailed discussion69. In another study also carried out in 
the mid11990s, 61% of GPs and 51% of practice nurses in Scotland reported that 
a lack of time was ‘very much’ or ‘quite a lot’ a factor limiting their smoking 
cessation activity76. In a more recent study, patients in England were less likely to 
recall having received cessation advice from a primary health care professional if 
they perceived the length of their consultation to have been inadequate20. 
 
There is mixed evidence whether offering GPs financial incentives to intervene 
with smokers may lead to their increased engagement with smoking cessation. In 
1990 a contract for GPs was implemented in the UK which directly linked their 
income to undertaking activities related to the prevention of cardiovascular 
disease. A fee was paid to GPs for running designated health promotion clinics 
targeted at particular high1risk groups within their practice population. However, 
the quality of these clinics was uneven, and often those patients most at risk of 
cardiovascular disease were the most unlikely to attend84. As a result, this 
payment structure was replaced in July 1993 by a banded payment scheme which, 
amongst other activities, rewarded GPs for opportunistically collecting and 
recording information about their patients’ smoking status, offering appropriate 
cessation advice and interventions to smokers and working with other individuals 
and agencies able to help with smoking cessation84. 
 
A survey of practices undertaken first in 1991 and repeated in 1994 showed a 
small increase (from 68% to 76%) in the proportion of practices who reported 
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that they always investigated patients’ smoking behaviour as part of opportunistic 
risk assessment, and an increase, from 25% to 37%, was also seen in the 
proportion of practices reporting routinely referring smokers to a stop smoking 
group84. No change, however, was reported in the number of practices offering 
simple verbal advice or literature or leaflets containing information on quitting. 
Analysis of patient records held within a large database of primary care records 
showed a temporary increase in the rate of recording of patients’ smoking status 
and the delivery of advice between 1993 and 199585. 
 
A small scale study of the introduction of a health promotion payment in a 
deprived area of Leicester, England, reported no significant impact on clinical 
activity86. Practices were able to claim £15 for each patient they identified who 
had smoked in the past year but who was not currently smoking and hadn’t done 
so for at least three months; in total, it was estimated GPs could claim between 
£285 and £1125 annually. However, there was no significant difference in the 
proportion of smokers who recalled receiving smoking cessation advice before and 
after the introduction of the payment86 and GPs themselves did not report having 
substantially changed their clinical practice or practice organisation in order to 
claim the new payments87. A qualitative study of GPs’ attitudes towards the 
payments highlighted strong negative views, with GPs feeling that the scheme 
would be viewed negatively by their patients and that the opportunity to claim 
payment would not make them raise smoking with patients where to do so might 
be perceived as confrontational87. Those GPs who claimed the largest amount of 
money under the scheme seemed simply to change the way they recorded their 
patients’ smoking status, rather than raising the topic of smoking more frequently 
with patients87.  
 
A major change to the organisation of UK primary care came with the introduction 
of a new contract for GPs in April 2004 which, though voluntary, was adopted by 
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all but a handful of practices88. Figure 1.6 outlines the key dates in the 
development and implementation of this contract89.  
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One aim of the 2004 contract was to improve the management of patients with 
chronic diseases and, to this end, a number of pay1for1performance targets were 
introduced, known as the Quality and Outcomes Framework (QOF). Under the 
terms of the QOF, approximately 8% of the payments available to GPs (the 
equivalent of approximately £10,800 per year) are related to the management of 
smoking, with practices’ performance against several specific targets being 
assessed. The precise requirements of these targets have changed slightly over 
time with revisions of the QOF, and Table 1.6 details the changes to the smoking1
related targets.  
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Hypertension 
  
The notes of patients with any one or combination of these conditions should contain a record of smoking status in the previous 15 months, except those who 
have never smoked where the smoking status need only be recorded once since diagnosis.  
 
Coronary heart disease 
Diabetes mellitus 
COPD 
TIA or stroke 
Asthma 
Chronic kidney disease     
 
Schizophrenia, bipolar 
disorder or other psychoses 
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 Hypertension 
The notes of current smokers should contain a 
record that smoking cessation advice has been 
offered within the last 15 months.  
The notes of current smokers should contain a record that smoking cessation advice has been offered or 
the patient has been referred to a specialist service, where available, within the last 15 months. 
Coronary heart disease 
Diabetes mellitus 
COPD 
TIA or stroke 
Asthma 
Chronic kidney disease     
 
Schizophrenia, bipolar 
disorder or other psychoses 
    
 
Recording of smoking status in the 
general population 
The notes of patients aged 15175 should contain at 
least one record of smoking status.  
 
The smoking status of patients aged 15+ should be 
recorded in every 27 months, except those who 
have never smoked where smoking status need be 
recorded only once.  
The smoking status of patients aged 15+ should be 
recorded every 27 months, except those who have 
never smoked where smoking status is to be 
checked annually until age 25. Ex1smokers are to 
be asked about smoking status on an annual basis 
until they have been a non1smoker for 3 years.  
Information provision The practice supports smokers in stopping smoking by a strategy which includes providing literature and offering appropriate therapy. 
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A study using primary care data from over 300 practices throughout the UK found 
that the introduction of the QOF led to increased rates of smoking cessation 
activity in primary care85. Though rates of recording of smoking status in patients’ 
electronic medical records had been increasing gradually since the year 2000, the 
rate of improvement was more marked from 2003, with an 88% increase 
observed between the first quarter of 2003 and the same period in 2004, just 
before the introduction of the QOF. The higher rate of recording of smoking status 
was sustained to the end of 2005 (the end of the period analysed in this study). A 
similar pattern was observed in rates of recording of cessation advice delivered to 
current smokers.  
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The evidence presented above suggests that primary health care professionals 
may not be equally likely to intervene with all smokers; characteristics of the 
smokers themselves, as well as the health care professional, may result in some 
smokers being more likely to be advised and supported to quit than others. 
Additionally, GPs may be receptive to external influences which may serve to alter 
the number of smokers with whom they intervene to encourage them to quit. 
Thus, GPs and other members of the primary healthcare team may potentially be 
influenced by national tobacco control initiatives, which, although not offering 
financial incentives to deliver cessation advice and support, may heighten their 
awareness of the importance of cessation and lead them to intervene with more 
smokers, regardless of whether their intervention is solicited by the patient.  
 
The next part of this chapter will evaluate the methods that have been used 
previously to measure the impact of health promotion interventions on clinical 
practice in primary care. This evaluation will allow the identification of a suitable 
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method that can be used to evaluate the impact of the introduction of smokefree 
legislation on the management of smoking in primary care. 

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As stated previously, to my knowledge no previous studies have evaluated the 
impact of the introduction of smokefree legislation on clinical practice in primary 
care, and, therefore, no precedent has been set defining the most appropriate 
way to do so. In order to select a method to use to undertake such an evaluation, 
this section outlines study designs that have been used previously to evaluate the 
introduction of health promotion interventions in primary care, focussing on 
policies intended to increase smoking cessation activity. The evidence presented 
here does not claim to represent a systematic search of the literature, but simply 
aims to illustrate the potential advantages and disadvantages of different ways of 
monitoring cessation activity in primary care and measuring the effect of 
interventions. The types of study design used can be broadly grouped into 
randomised controlled trials (RCTs), repeated cross1sectional studies with a before 
and after design, and interrupted time series analyses, which will now be 
discussed in turn.     
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RCTs are generally accepted as the study design which can provide the best 
quality of evidence for the effectiveness of an intervention. RCTs have been used, 
for example, to evaluate the effectiveness of training primary health care 
professionals to provide smoking cessation interventions91, offering financial 
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rewards to GPs and reimbursing patients’ drug costs92, theory1based interventions 
to increase physicians’ recommendations of smoking cessation services93 and the 
use of a desktop resource to prompt GPs to offer cessation advice94. However, the 
use of an RCT to evaluate the effect of smokefree legislation on the management 
of smoking in primary care is not possible. Even if this study was being designed 
before the legislation was introduced it would not be practically feasible, or 
perhaps even ethical, to randomise half the population to be subject to the new 
law whilst the other half were not. Thus, an alternative study design will be 
needed to evaluate the effect of the nation1wide smokefree law. 
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Repeated cross1sectional studies have been used to measure and compare clinical 
activity before and after the introduction of an intervention. For example, medical 
records from 310 general practices in Scotland were analysed to assess the 
impact of the QOF on the management of patients with coronary heart disease 
(CHD). The proportion of patients with CHD registered with a practice on 31st 
March 2004 (defined as the pre1QOF period) who had their smoking status 
recorded within the previous 15 months was compared with an identical measure 
calculated exactly one year later (designated post1QOF)95. Similarly, comparison 
of data collected before (June – September 2003) and after (November 2005 – 
January 2006) the introduction of the QOF has been used to assess the impact of 
the financial incentive on the provision of support for smoking cessation and 
smoking prevalence among patients with diabetes96. Both of these studies 
acknowledge the difficulty in directly attributing any observed changes in the 
phenomenon measured to the QOF – changes might in fact be the result of other 
interventions, improvements in the quality of data recorded in primary care, or 
just a continuation of a long1term trend. Additionally, the timing of the pre1 and 
post1intervention surveys may influence the magnitude of any change detected. 
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As noted already, there was an 88% increase in rates of recording of smoking 
status between the first quarter of 2003 and the first quarter of 2004, even 
though the QOF was not implemented until 1st April 200485. As Figure 1.6 shows, 
GPs would have been aware of the impending introduction of the QOF and its 
requirements as early as March 2003 and it is not unreasonable to suggest they 
may have begun to alter their data recording habits accordingly. In assessing the 
recording of smoking status in patients with CHD, the timing of the pre1QOF 
survey one day before the policy came into force may have resulted in the 
underestimation of the effect of the QOF on recording habits95. Ideally, clinical 
activity in primary care needs to be monitored for several months, if not years, 
before the introduction of smokefree legislation to ensure any changes in activity 
potentially attributable to the policy are not just a continuation of secular trends. 
A study design capable of achieving this is that of interrupted time series analysis.  
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A time series is a set of observations or measurements collected on an individual 
or phenomenon at multiple, ordered, points in time. Such a series can be analysed 
statistically to look for changes in the outcome variable coinciding with an 
‘interruption’ to the series, such as the introduction of an intervention, above and 
beyond any long1term trends. Using data from 1990 to 2005, a time series 
approach has been used to assess the impact of the QOF on the quarterly 
incidence of recording of patients’ smoking status and, in smokers, the receipt of 
cessation advice and prescriptions for NRT and bupropion, though changes in the 
series were only described subjectively and no quantitative analysis was 
undertaken85.  
 
Time series analysis is being used increasingly frequently in the biomedical 
sciences and public health to evaluate the impact of interventions, though, to 
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date, has rarely been used in the evaluation of tobacco control interventions; 
Figure 1.7 illustrates the increase in the number of English1language articles 
indexed in PubMed since 1980 with the term ‘time series analysis’ in either the 
title or abstract.  
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The rapid increase in the number of research studies utilising a time series 
analysis may reflect the fact that this method is argued to be the strongest study 
design which can be used when an RCT is not an option to evaluate the effect of 
interventions implemented at a known point in time97. Interrupted time series 
analysis allows the researcher to assess and quantify whether and how much an 
intervention changed an outcome of interest, whether any changes took place 
before the implementation of the intervention, coinciding with the intervention or 
were delayed, and whether the change was short1lived or sustained97. Given these 
advantages, and the drawbacks associated with other study designs, time series 
analysis provides the ideal method to use to assess the impact of smokefree 
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legislation on the management of smoking in primary care. The next section 
considers potential sources of data which can be subjected to a time series 
analysis to assess the impact of smokefree legislation on the management of 
smoking in primary care.  
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Interrupted time series analysis can be undertaken using any data which has been 
collected repeatedly over time. There are potentially two options for gathering 
data on the extent of smoking1related clinical activity in primary care – collecting 
data specifically for the purposes of this study, or analysing secondary data which 
has already been collected. The merits and drawbacks of these two approaches 
will now be discussed.  
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Data quantifying smoking1related activity in primary care could potentially be 
gathered by direct observation of clinicians’ work, or through questionnaire 
surveys of health professionals and/or patients. However, earlier research 
suggests that such methods of data collection may be unlikely to produce a true 
representation of either the underlying rate at which GPs deliver smoking 
cessation interventions or any additional impact of the introduction of smokefree 
legislation. A ‘Hawthorne effect’98 can occur when GPs are aware their activity is 
being monitored. In one study, distributing questionnaires eliciting information 
about smoking to patients before and after they consulted with a GP significantly 
increased GPs’ recording of having discussed smoking (OR 1.78, 95% CI 1.361
2.34)99. Many clinicians and patients may also refuse consent to take part in a 
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research study, and those who do refuse may not do so at random. For example, 
in one study GPs who agreed to be videotaped during consultations were younger, 
more likely to be working in teaching or training practices, and more likely to be 
known to the researcher100. Younger patients and those presenting with a mental 
health problem were more likely to withhold consent for video recording101. 
Directly questioning patients may also fail to produce unbiased estimates of the 
extent of cessation activity undertaken in primary care. Previous research has 
suggested that patients systematically over1report having being asked about their 
smoking behaviour by a GP, and smokers over1report having being advised to 
quit102.  
 
As the proposal for the work presented in this thesis was conceived only after 
smokefree legislation was introduced in the UK it was impossible to collect data at 
multiple time points before the smoking ban was enacted to enable assessment of 
secular trends in smoking1related clinical activity in primary care. An objective 
measure of clinical activity is needed which can provide data for the period prior 
to the introduction of smokefree legislation as well as afterwards. Analysing 
secondary data which has already been collected may be a way to achieve this.  
 
 (34B8+8678/56(<3.B<3;3
 
A growing volume of information is now recorded electronically in primary care 
during the course of patient care. Improvements in the quality of this data have 
been driven by feedback to GPs, financial incentives and evidence1based 
guidelines, and advances in computing mean that this volume of data can now be 
more easily processed and analysed by researchers103. 
 
Many studies have been undertaken using electronic data collected from a small 
number of practices, often located close to the institution undertaking the 
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research. However, as discussed in Section 1.2, smoking prevalence is known to 
vary across the UK and therefore underlying rates of smoking1related clinical 
activity in primary care may vary geographically. Ideally, therefore, data for this 
study data are required from practices throughout the UK to enable a nationally1
representative assessment of the impact of smokefree legislation on the 
management of smoking in primary care.  
 
In addition, the underlying rate at which primary health care professionals 
intervene with smokers has been shown to vary according to patient 
characteristics, as discussed in Section 1.1.1, and it may be that smokers with 
particular sociodemographic characteristics are more likely to seek and receive 
cessation support from a GP as a result of the introduction of smokefree 
legislation. In investigating the impact of smokefree legislation on the 
management of smoking in primary care it will therefore be crucial to assess pre1
legislation trends in the delivery of cessation interventions in different subgroups 
before considering any impact of smokefree legislation above and beyond these 
existing trends. In order to provide adequate statistical power to assess the 
impact of smokefree legislation in population subgroups, data from as many 
practices and patients as possible are needed, though obviously the time and cost 
of data collection will increase with the number of practices that must be visited.   
 
Fortunately, the UK has several datasets containing the electronic medical records 
from a large number of practices nationwide. The most well1known of these 
datasets is arguably the General Practice Research Database (GPRD)104, though 
QRESEARCH105 and The Health Improvement Network (THIN)106 are increasingly 
being utilised by researchers. The large size of these datasets potentially provides 
the power to split the population into subgroups and to explore variations in the 
impact of smokefree legislation on the management of smoking in primary care 
across the UK.  
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The use of such datasets is not, however, problem1free. There may be 
inaccuracies in the data recorded, and the practices who have chosen to 
contribute their data to a large dataset may not be representative of primary care 
in general – the self1selecting sample of practices may have received training or 
feedback to improve the quality of their record1keeping, and may only be included 
in the dataset once they prove their records exceed certain quality criteria103.  
Finally, but importantly, questions of data security, confidentiality and ownership 
arise when using data collected in primary care103. 
 
Despite these limitations, using a large dataset of primary care records would 
appear to offer the best source of data to analyse the impact of smokefree 
legislation on the management of smoking in primary care, offering a large 
amount of data for the period both before and after the implementation of the 
smoking ban, without the costs involved in primary data collection. 
 
Data from The Health Improvement Network (THIN) are available for use at the 
University of Nottingham, and hence this dataset will now be described in more 
detail.  
 
$ 						
 
The Health Improvement Network (THIN) is a dataset of electronic primary care 
medical records which, by July 2009, contained records for over 6.8 million 
patients from 446 practices throughout the UK. Data collection began in 2003 
following collaboration between the Epidemiology and Pharmacology Information 
Core (EPIC)107, who originally supplied data from the GPRD to researchers, and In 
Practice Systems (InPS), the developers of the Vision electronic practice 
management software108.  Approximately half of the patients whose medical 
records are included in THIN to date are alive and contributing data prospectively 
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to the dataset; historical data are available for the remaining patients, who have 
either died or transferred out of the practice. All practices participating in THIN 
use the Vision software for their prospective data recording. However, on joining 
THIN a practice uploads all its historical data to the dataset, much of which was 
recorded using the Value Added Medical Products (VAMP) practice management 
system.  
 
THIN contains details not only of consultations with members of the primary 
healthcare team, but also test results, issued prescriptions and the outcomes of 
hospital admissions. Clinical information, including patient smoking status, is 
recorded in THIN using Read Codes, a hierarchical dictionary of medical 
nomenclature109. Appendix 8.2 provides technical details about the recording of 
smoking information in THIN and how Read Codes can be used to determine a 
patient’s smoking status at a given point in time. A new, updated, version of the 
THIN dataset is released three or four times each year, with a lag of three to eight 
months between data being entered into a practice computer and that information 
being made available to researchers. With each new release of the dataset the 
number of practices contributing data to THIN increases as a result of recruitment 
of new practices, though a small number of practices also leave the scheme. 
These changes, along with individual patients registering or deregistering with a 
contributing practice, means the size of the THIN dataset is continually changing. 
The work presented in this thesis uses THIN version 0907, which contains data 
from 446 practices up to the end of July 2009. Data were used from 1 January 
2000 onwards, enabling the effects of the tobacco control initiatives introduced 
over the last decade to be captured. Inspection of the THIN data suggested there 
were very few changes in the recording of the outcomes of interest analysed in 
this thesis prior to 2000, justifying the selection of this start date.  
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All children and adults living in the UK are eligible to be registered with a GP. Care 
is provided free at the point of delivery, and therefore ability to pay is unlikely to 
influence the likelihood of an individual accessing medical care. Provided that the 
general practices contributing to THIN are representative of all UK practices, 
patients whose medical records are included in THIN are potentially representative 
of all sections of society, making the dataset a useful epidemiological resource for 
drawing conclusions relevant to the whole population.  
 
Figure 1.8 illustrates the demographic (age and sex) structure of the patient 
population registered with a THIN practice on 1st July 1996, 2000, 2004 and 
2008. For comparison, the UK population structures at these dates, derived from 
Office for National Statistics (ONS) mid1year population estimates110, are also 
shown. In all years there is generally good agreement between the age and sex 
structure of the THIN and UK populations. THIN slightly under1represents older 
teenagers and young adults, though the extent of under1representation has 
diminished over time. In each year there are marginally fewer children under the 
age of five registered with THIN practices compared to national population 
estimates, though this is of limited importance when using THIN to assess the 
management of smoking, given that smoking rarely begins this young.  
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There is some evidence to suggest that THIN may not be truly representative of 
the whole UK population in terms of patients' socio1economic characteristics. 
Since 2000, the number of recorded deaths in THIN has been approximately 5% 
lower than the number that would be expected if UK national age and sex1specific 
death rates are applied to the THIN population111. Over1representation of more 
affluent, and therefore more healthy112, patients with consequently lower mortality 
in THIN could be one explanation for this observation.  
 
Figure 1.9 shows the proportion of patients (of all ages) registered with a THIN 
practice on 1st July 2008 who are from Scotland, Wales, Northern Ireland and 
each Strategic Health Authority in England, expressed as a percentage of the ONS 
mid12008 estimate of the population of each region. A figure of 100% indicates 
the same proportion of patients in THIN are from that region as in the national 
population estimate. The figures inside each bar indicate the number of people in 
the THIN dataset in each region. 
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As Figure 1.9 shows, there is some disagreement between THIN and ONS data; 
the THIN dataset over1represents patients from the relatively more affluent areas 
of the UK, such as the South East Cost and the South Central regions, whilst 
under1representing those from generally more deprived areas, such as the North 
West and North East of England. 
 
A measure of socio1economic status for each patient in THIN is available in the 
form of a national quintile of the Townsend Index of Deprivation113. This measure 
combines information about unemployment, car ownership, housing tenure and 
overcrowding, albeit calculated at an ecological, rather than individual, level. 
Appendix 8.3 provides further details about the calculation of this index. Figure 
1.10 shows the proportion of patients aged 16+ registered in THIN on 1st July 
2008 in each quintile of the Townsend Index of Deprivation. If the THIN data are 
nationally representative it would be expected that 20% of THIN patients would 
be in each quintile of deprivation. However, it appears that THIN over1represents 
patients from the least deprived quintiles of the Townsend Index. A Townsend 
classification is missing for 4.2% of patients aged 16+ in THIN, perhaps because 
their postcodes had not been accurately entered onto their practice’s computer 
system.  
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In conclusion, the THIN dataset offers the opportunity to track pre1legislation 
trends in smoking1related clinical activity in primary care over many years, 
thereby enabling the best possible assessment of any additional impact of the 
introduction of smokefree legislation. As shown above, the dataset is 
representative of the UK population in terms of the age and sex of patients, 
allowing conclusions about the impact of smokefree legislation to be extrapolated 
to the whole population. In addition, the large size of the dataset increases the 
power to investigate the management of smoking in different population 
subgroups. Some questions do, however, remain about the socio1economic and 
geographic representativeness of THIN, which must be borne in mind when 
analysing the data and drawing conclusions. Overall, providing the smoking1
related data recorded in THIN are of good quality, the THIN dataset offers an 
excellent source of data with which to evaluate the effect of smokefree legislation 
on the management of smoking in primary care.  
 
 E				 
 
The ultimate aim of the work presented in the remainder of this thesis is to assess 
the impact of smokefree legislation on the management of smoking in primary 
care, using The Health Improvement Network (THIN) database of electronic 
primary care medical records. In order to meet this aim, the following objectives 
will be addressed: 
 
1) To assess the quality of smoking1status recording in THIN to determine 
whether patients who are smokers can be identified as such from their 
medical records. 
2) To assess the quality of the recording of smoking cessation interventions in 
THIN to determine the utility of the dataset for evaluating the impact of the 
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introduction of smokefree legislation on health care professionals’ 
management of smoking. 
3) To assess which analytical approach is most appropriate when using THIN 
data to evaluate the impact of smokefree legislation on the management of 
smoking in primary care. 
4) To compare rates of recording of patients’ smoking status in THIN before and 
after the introduction of smokefree legislation. 
5) To compare rates of recording in THIN of the following cessation interventions 
delivered to smokers before and after the introduction of smokefree 
legislation:  
a) Delivery of brief cessation advice by a member of the primary care team 
b) Referral to NHS Stop Smoking Services 
c) Prescriptions for NRT, bupropion and varenicline 
6) To assess whether the introduction of smokefree legislation had a differential 
impact on the management of smokers with different demographic and socio1
economic characteristics.  
 
Ethical approval for the use of THIN for the work that follows was granted by the 
Leicestershire and Rutland Research Ethics Committee. 
 
 			
 
031;/. reviews previous research investigating the quality of recording of 
patients’ smoking status in electronic primary care records, and presents several 
empirical studies assessing the quality of such data in THIN. 
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031;/. summarises existing knowledge about the quality of recording of 
smoking cessation interventions in electronic primary care records, and presents 
several empirical studies assessing the quality of this data in THIN. 
 
031;/.  describes the technique of interrupted time series analysis and 
considers how robust this method is when used to quantify the impact of an 
intervention on a time series. 
 
031;/.# uses interrupted time series analysis to evaluate the impact of 
smokefree legislation on rates of recording of patient smoking status and the 
delivery of smoking cessation medications in the four countries of the UK. 
 
031;/.%uses interrupted time series analysis to assess whether the 
introduction of smokefree legislation in England had a differential impact on the 
management of smokers with different demographic and socio1economic 
characteristics. 
 
031;/. summarises the main findings of the work presented in this thesis, 
discusses their implications, and suggests avenues for further research. 
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At the end of the previous chapter The Health Improvement Network (THIN) 
database was introduced as a source of data which can potentially be used to 
monitor the impact of smokefree legislation on the management of smoking in 
primary care. If THIN is to be used for this purpose it is essential to understand 
the quality of the smoking information recorded in the database.  
 
If the introduction of smokefree legislation leads more smokers to seek cessation 
support from primary care, an increase in the rate at which patients’ smoking 
status is documented in THIN may be seen at this time. However, it is crucial to 
understand any longer1term trends in the rate of recording of smoking status to 
ensure that any observed change at the time smokefree was introduced is related 
to the legislation and not simply a continuation of a secular trend. In the context 
of this research it is also important to appreciate whether the information 
recorded in THIN can identify those patients who were active smokers at the time 
smokefree legislation was introduced and who were, therefore, the potential 
subjects of any increased delivery of cessation interventions as a result of the 
smoking ban. Therefore, this chapter evaluates the quality of the smoking status 
information recorded in THIN and, following this, Chapter 3 evaluates the quality 
of recording of smoking cessation interventions.  
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Previous research has highlighted several potential shortfalls in the quality of 
smoking status data recorded in primary care records. This body of evidence will 
now be discussed and any potential data quality issues which must be addressed 
in THIN will be identified.  
 
 						*!
	!	
 
In an ideal world, all smoking status information recorded in THIN should be 
complete, correct and current1 that is, all observations a GP makes about a 
patient should be recorded114, these notes should be an accurate reflection of real 
life114, and they should be up1to1date115. However, the data recorded in THIN 
reflect routine clinical practice on the part of health care professionals and the 
quality of smoking information recorded in electronic medical records may be 
influenced by several factors, which may vary both between practices and over 
time. To date, few studies have attempted to assess the quality of smoking status 
data recorded in THIN, though analysis of other databases of primary care medical 
records highlights a pressing need to do so, as will be discussed below. Those 
studies that have attempted to evaluate THIN data have restricted their analysis 
of the quality of recorded smoking status information to particular age groups of 
patients or those with specific medical conditions. Therefore, the validity of THIN 
data for young, healthy populations remains unknown.  
 
In a 2002 survey of 336 GPs in England, 98% reported routinely recording a 
patient's smoking status, either on the practice computer system or in the 
patient's paper notes116, when the patient first registers with the practice, a figure 
which has changed little since 199974. There is no reason to suggest this figure 
may have worsened since 2002, particularly given that current UK guidelines 
recommend that general practices establish monitoring systems to ensure that all 
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health care professionals have access to information on the current smoking 
status of their patients61, and because the Quality and Outcomes Framework 
(QOF) rewards GPs for regularly updating their records of patients' smoking 
status. It could, therefore, be expected that the majority of patients should have a 
record of their smoking status documented and available to clinicians or 
researchers, though in some cases this may not be available in a patient’s 
electronic notes and may not have been updated since it was recorded during the 
registration process.  
 
Studies of electronic primary care medical records suggest that it is impossible to 
determine the smoking status of all patients from their notes, with the magnitude 
of the shortfall varying according to the study inclusion criteria. In 2004, just less 
than 40% of the 1.6 million patients aged 15175 registered in THIN had one or 
more smoking status Read Codes recorded in their medical records 	, a 
relatively small proportion though an increase from approximately 13% of patients 
in 200085. The incidence of recording of smoking status rises when the 
denominator is restricted to those with particular morbidities 1 over 80% of 
patients with a diagnosis of chronic obstructive pulmonary disease (COPD), 
ischemic heart disease or diabetes had their smoking status recorded, 75% of 
those who had suffered a stroke or transient ischemic attack (TIA), 66% of those 
with hypertension, and 57% of asthmatics. Similar findings are reported in studies 
assessing the completeness of smoking status recording in other databases of 
primary care records, such as the General Practice Research Database (GPRD)117, 
as well as smaller studies in selected practices118. Ascertainment bias may well be 
in operation in these cohorts, whereby doctors record the smoking status of the 
‘worst first’ 1 those who are most unwell, or showing signs of smoking1related 
disease119, 120.   
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The completeness of smoking status recording may vary according to patient age 
and gender. In 2006, 9.9% of women and 31.1% of men aged 21130 from 21 
general practices in England had no smoking status recorded in their electronic 
notes118, despite official statistics suggesting this is the age group with the highest 
smoking prevalence13. For both men and women, the proportion of patients with 
no smoking record fell with increasing age up to the age of 80, before beginning 
to increase again.  
 
Between April 2004 and April 2006 GPs were rewarded financially for meeting 
targets defined in the QOF requiring that the notes of patients aged 15175 
contained at least one record of smoking status, and that patients with particular 
chronic conditions had their smoking status documented at least every 15 
months. A study using THIN data from 1990 to March 2005 highlighted an 88% 
increase in the proportion of patients whose notes contained a record of their 
smoking status between the first quarter of 2003 and first quarter of 2004, during 
which time GPs were aware of the impending contractual changes, with the higher 
rate of recording being sustained to the end of the study period85. No studies have 
assessed the recording of smoking status in THIN beyond 2005, though 
amendments to the QOF (see Table 1.6), requiring the more frequent recording of 
smoking status in the general ‘healthy’ population, are likely to have increased the 
incidence of smoking status documentation in recent years.  
 
Many practices which contribute data to THIN have contributed data to the GPRD 
at some point in the past, and thus conclusions reached about one database may 
be equally applicable to the other. In a study comparing the electronic medical 
records of 138 GPRD patients with inflammatory bowel disease with their GPs’ 
personal recollections of their patients’ smoking histories, taken to be the gold 
standard, the GPRD was found to have a sensitivity of 78% (95% CI 52194%) for 
identifying current smokers, and a positive predictive value of 70% (95% CI 461
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88%). The GPRD performed less well in identifying former smokers, having a 
sensitivity of 53% (95% CI 28177%) and a positive predictive value of 60% (95% 
CI 32184%)121. However, the use of GPs’ personal recollections of their patients’ 
smoking histories as the gold standard in this study is highly questionable. 
Additionally, this study was carried out using data from 198811997, long before 
recent incentives were introduced to encourage the frequent updating of records 
of patients’ smoking status, and so the findings may be different if the study was 
repeated now.  
 
The same authors also studied a cohort of 225,308 GPRD patients without 
inflammatory bowel disease, of whom 21.5% were recorded as current smokers 
on 31 December 1996. Using indirect standardisation to estimate the true 
prevalence of current smoking, based on age and sex1specific smoking rates from 
the 1996 General Lifestyle Survey (GLF), the recorded prevalence of current 
smokers was found to be 79% of the expected prevalence121. Recording of ex1
smokers in the GPRD is much less complete than would be expected – just 7.7% 
of patients were identified as ex1smokers, 29% of the expected proportion. Of 
course, the use of indirect standardisation will produce estimates of the expected 
number of current and ex1smokers only as good as the GLF rates used for 
standardisation. The GLF relies on survey respondents to self1report their smoking 
status, and the relatively small sample size of the survey (a little over 7,000 
adults in 1996) means the results may not be representative of smoking 
behaviour throughout the whole of Great Britain.  
 
A study carried out in 2005 suggests discrepancies still persist between patients’ 
true smoking status and that recorded in their medical records. Of 87,861 patients 
aged 18+ registered with practices in Nottingham, UK, 13.9% had no record of 
smoking status in their medical records, with wide variation in the completeness 
of recording between practices122. Of those patients with no recorded smoking 
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status, 30.9% of those who responded to a questionnaire identified themselves as 
current smokers. 27.3% of patients who were recorded in their notes as current 
smokers denied smoking in the last 12 months, varying from 6.3% to 58.1% 
between practices. Taking patients’ questionnaire responses as the ‘gold standard’ 
indicator of smoking behaviour there were no significant differences in 
misclassification between men and women, though the proportion misclassified as 
current smokers did increase with increasing age. Bias may well have been 
introduced into this study if the proportion of patients returning the questionnaire 
in which they were asked to identify their current smoking status varied according 
to their current smoking behaviour or success of past quit attempts. Also, some 
misclassification would not be surprising if a patient’s smoking status was last 
recorded in their primary care notes a long time before they completed the 
questionnaire.  
 
All work using databases of electronic medical records requires assumptions to be 
made about how GPs use Read Codes (or other similar medical nomenclature) to 
record patient smoking status and other clinical information. However, these 
assumptions are not easily tested and may not always be correct. For example, 
many GPs have been found to use Read Code 137 (Tobacco Consumption) to 
record a patient as a current smoker, despite the fact that, in the hierarchical 
Read Code system, this is actually a parent code which has several child codes 
underneath it which give more specific detail about smoking status118. Read Codes 
may also have numbers attached to them which quantify a patient’s smoking 
behaviour, and some GPs may use the ‘Tobacco Consumption’ Read Code 
accompanied by a zero to indicate that the patient is not currently smoking118. 
Many studies highlight the use of Read Codes labelling a patient as never having 
smoked though earlier records suggest they were, at one point in time, a current 
smoker; this was the case in 4.4% of the 34.8% of patients recorded as never1
smokers in one study118. Researchers defining a patients’ smoking status using 
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their last recorded Read Code may well misclassify some people on these grounds. 
It is also possible that smoking information is not entered onto a practice 
computer using Read Codes, but instead is entered as free text which at present is 
not available to researchers using THIN. 
 
 					
 
The review of the literature presented in the previous section has highlighted 
several potential problems that might be encountered in the quality of smoking 
status data recorded in THIN. The following issues will be investigated in this 
chapter to address these questions of data quality and help judge whether THIN 
can be used to evaluate the impact of smokefree legislation on the management 
of smoking in primary care. 
 
/5;+6(  investigates the completeness of smoking status data recorded in 
THIN, assessing how many patients have a record of their smoking status in their 
medical notes and whether this has changed over time.  
 
/5;+6(# compares the prevalence of smoking recorded in THIN patients with 
national survey data to gauge whether THIN data provide nationally1
representative measures of smoking prevalence and help conclude whether all 
patients who are current smokers at any given point in time can be identified as 
such from their medical records. 
 
In both of these sections, variations in the quality of recording by patient sex and 
age, as well as by practice, will be considered. In addition, /5;+6(% 
investigates whether the quality of smoking status recording varies according to a 
patient’s medical history. 
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Finally, /5;+6( discusses whether it is possible to identify, and exclude from 
further analyses, those THIN practices with particularly poor recording of 
smoking1related information. 
 
The results of three smaller studies are included as appendices to this thesis:  
 
11/(<+K&  presents the results of a study, published in 	

, which 
assesses whether all patients registering with a practice in THIN do indeed have 
their smoking status recorded at registration as GPs claim to do.  
 
11/(<+K&# considers whether an individual smoking1status Read Code 
documented in a patient’s notes is a correct reflection of their smoking behaviour 
at that point in time. 
 
11/(<+K&% examines how up1to1date records of patients’ smoking status in 
THIN are and whether this has improved over time.  
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The literature reviewed in Section 2.2 suggests that some patients in THIN may 
not have their smoking status recorded in their electronic medical records, despite 
GPs’ claims that they routinely record the smoking status of all new patients who 
register with their practice. This section assesses whether there is a shortfall in 
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the recording of patients’ smoking status in THIN, whether this varies by patient 
demographic characteristics, and how these figures have changed over time. 
 
  /;06<8
 
For each year from 2000 to 2009 all patients were identified from the THIN 
dataset who were aged 16+ and registered with a practice on an index date of 1st 
July of that year. All records of smoking status, identified by relevant Read Codes 
(see Appendix 8.2), entered into patients’ notes on or after their registration date 
were extracted, and the proportion of patients each year with no record of 
smoking status on or before the index date was calculated. In addition, the 
proportion of patients with no recorded smoking status was assessed separately 
for subgroups of the population defined by sex and age group, and individually for 
each practice contributing data to THIN. The age groups used here, and 
throughout this thesis, are those used in the General Lifestyle Survey (GLF), the 
main source of smoking statistics in the UK at present, and are designed to 
capture and show variations in smoking behaviour across the life course. 
 
  /8-4;8
 
The number of patients aged 16+ registered with a THIN practice on 1st July of 
each year increased from 2,194,498 patients in 2000 to 2,575,195 in 2009, of 
whom 49% each year were male, with a mean age of 47 years (interquartile 
range 32161). The average number of years of medical records available for 
inspection for each patient increased from 13.9 years in 2000, to 15.8 years in 
2009.  
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Figure 2.1 shows the proportion of patients each year for whom it was impossible 
to assign a smoking status, having inspected all records recorded since the patient 
registered with the practice.  
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In 2000, 36.6% patients had no smoking status recorded in their notes since 
registering with their practice, improving to 10.1% in 2009. In all years there was 
considerable variation in the completeness of recording by practice, although this 
variation has reduced over time. In 2009, 53.5% of patients in the worst1
performing practice had no record of smoking status in their notes, compared to 
just 1.4% in the best1performing practice (interquartile range 6.5111.9%). 
 
As shown in Figure 2.2, the percentage of patients with no smoking status 
recorded differs by patient age group and sex. The percentage of patients with no 
smoking status recorded falls with increasing age group, and the older the age 
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group, the small the smaller the difference between men and women in the 
proportion of patients with missing data.  
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Historically, many practices may have used paper records instead of, or alongside, 
computerised clinical information systems, and patients' smoking status may not 
have been comprehensively documented electronically. However, the vast 
majority of practices are now computerised, with electronic records forming the 
main means of documenting patient care and proving compliance with QOF 
targets. Since the introduction of the QOF it is likely that practices will try hard to 
ensure all patients’ smoking status is documented in their notes. However, this 
study shows that in 2009 10.1% patients aged 16+ had no mention of smoking in 
their electronic medical records (and, as shown in Appendix 8.4, a small study 
undertaken as part of the work for this thesis suggests that many practices do not 
record the smoking status of all new patients at registration, despite GPs’ claims 
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to the contrary). Though this figure represents an improvement over time, if some 
of these patients with missing data are smokers it will be impossible to identify all 
patients who were the potential subjects of increased delivery of smoking 
cessation interventions at the time smokefree legislation was introduced.  
 
The fastest rate of improvement in the proportion of patients with a record of 
smoking status in their notes was seen between 2003 and 2005, suggesting that 
practices may have begun to improve their data recording in anticipation of the 
introduction of the QOF. The proportion of patients with a record of their smoking 
status has, however, continued to improve to the end of the study period, and 
thus the analytical method used to assess the impact of smokefree legislation on 
rates of recording of smoking status must be able to take this underlying trend 
into account.  
 
There is considerable variation in the completeness of smoking status recording 
and patterns of change over time between different demographic groups. This 
variation must be kept in mind when analysing the impact of smokefree legislation 
on the recording of patient smoking status. Indeed, as well as investigating the 
impact of legislation in the population as a whole, it may be appropriate to assess 
the impact of the smoking ban on recording separately in different population 
subgroups to take into account the different underlying trends. 
 
Additionally, there is considerable variation in the completeness of smoking status 
recording between practices. As the practices contributing data to THIN are 
anonymous it is impossible to approach them for further information to help 
understand any reasons for the inter1practice variation. As the recording habits of 
the general practices contributing data to THIN may not be representative of all 
UK practices, caution must be taken in extrapolating conclusions about the impact 
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of smokefree legislation on the recording of patient smoking status to UK primary 
care in general.  
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The previous section has shown that there have been recent improvements in the 
proportion of THIN patients with a record of their smoking status in their medical 
notes. However, these records may not necessarily be correct and may not allow 
the identification of all patients who were current smokers at the time smokefree 
legislation was introduced and who, therefore, would be potential subjects for an 
increase in the delivery of cessation interventions. 
 
Ideally, the optimal way to assess whether all patients who are current smokers at 
any point in time are recorded as such in THIN would be to approach patients 
directly and compare their self1reported smoking status with that recorded in their 
medical notes. However, this is impossible as all records in THIN are anonymised 
to protect practice and patient anonymity and, even if this were not the case, the 
size of the THIN dataset would be prohibitive. Arguably the best alternative is to 
compare the prevalence of particular smoking behaviours in the THIN population 
with prevalence measures from other sources, standardising where possible to 
ensure the populations being compared are comparable in terms of their 
demographic characteristics.  
 
Currently, the main source of statistics for monitoring smoking prevalence in 
Great Britain is a national, annual survey, the General Lifestyle Survey (GLF)13, 
with a comparable survey (the Continuous Household Survey) being undertaken in 
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Northern Ireland123. The GLF samples approximately 17,000 adults aged 16+ each 
year throughout England, Scotland and Wales, and provides self1reported 
measures of the prevalence of current smoking. The work presented in this 
section compares the smoking prevalence recorded in patients in THIN with 
prevalence estimates from the GLF. 
 
# /;06<8
 
To enable comparison of smoking prevalence estimates from THIN with those of 
the British GLF, the 23 THIN practices in Northern Ireland were excluded from this 
study (there is a mistake in the recording of smoking status in the data files for 
the Northern Irish Continuous Household Survey, making it impossible to include 
these practices in this analysis). For each year from 2000 to 2009 all patients 
were identified from the THIN dataset who were over the age of 16 and registered 
with a practice on an index date of 1st July of that year. Patients who registered 
with a practice within the previous three months, who may not have had their 
smoking status recorded, were excluded from this analysis (the QOF requires that 
the smoking status of newly1registering patients is recorded within three months 
for this recording to be financially rewarded90).  
 
Each patient’s year of birth and sex was identified, as well as the Strategic Health 
Authority within which their GP surgery was located. All records of smoking status, 
identified by relevant Read Codes, entered into patients’ notes on or after their 
registration date were extracted. Patients were classified as current smokers at a 
given index date if the most recent smoking status Read Code in their medical 
records prior to this index date identified them as such. All patients with no 
smoking information recorded in their notes were assumed not to be current 
smokers at that point in time. Previous authors have shown that the majority of 
    
93 
patients with missing smoking records in both THIN and the GPRD are either ex or 
non1smokers121, 124, so it can be argued that this assumption is valid.  
 
A direct comparison of smoking prevalence in THIN and the GLF is not appropriate 
because THIN has a slightly different demographic structure to the national 
population; even if THIN contained valid smoking data for all patients within this 
database one would expect smoking rates based on THIN data to differ from GLF 
estimates of national smoking prevalence.  Therefore, the following 
standardisation procedure was used to calculate what the smoking prevalence 
amongst THIN patients might be if THIN did have the same demographic structure 
as the British population (called the ‘GLF1predicted’ prevalence) and compared 
this with the recorded prevalence in THIN.  For each year between 2000 and 
2007, region, age group and sex1specific rates of current smoking were identified 
from the relevant GLF survey, weighted for non1response to give nationally 
representative indicators of smoking behaviour (at the time of writing, GLF data 
were not available for 2008 and 2009). These rates were applied to strata of the 
THIN population (similarly defined by age group, sex and region) at each index 
date using indirect standardisation125 to produce annual ‘GLF1predicted’ 
prevalence estimates for current smoking; these predicted prevalence estimates 
were then compared with the recorded prevalence figures.  
 
To investigate variations in the recording of current smokers between practices 
the expected prevalence of current smokers in each practice was calculated in the 
manner described above, again using age group, sex and Government Office 
Region as variables in the standardisation procedure. These predicted prevalence 
estimates were then compared with the proportion of patients in each practice 
recorded in their notes as current smokers.  
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The number of patients registered with a British THIN practice on 1st July of each 
year who had been registered for at least three months increased from 2,086,891 
patients in 2000 to 2,447,903 in 2009.   
 
Figure 2.3 shows changes over time in the predicted prevalence of current 
smoking in the THIN population, derived from GLF data, compared to the 
prevalence determined from patients' notes. 
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The GLF1predicted prevalence of current smoking in the THIN population has 
declined over time, such that in 2007 22.6% men and 19.4% women were 
predicted to be current smokers. The recorded prevalence of current smokers in 
THIN has in recent years approached the predicted smoking prevalence. In 2000, 
19.9% of men and 19.4% women were identified as current smokers, 69.6% and 
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78.0% of the predicted prevalence respectively. The gap between the recorded 
and GLF1predicted prevalence of smoking has closed over time, such that by 2007 
22.6% of men and 19.4% of women were recorded as current smokers, figures 
which, to one decimal place, are the same as the predicted prevalence figures. 
These national figures disguise significant variations between practices. For men 
and women combined, in 2007 the worst performing practice recorded just 33.8% 
of the predicted number of current smokers, whilst on the other hand one practice 
identified 190.3% of the predicted number of smokers (interquartile range 84.11
116.3%).  
 
There are some variations in the completeness of recording of current smoking by 
age group and sex, as shown in Figure 2.4. The recorded prevalence of current 
smoking in both men and women over the age of 50 is very similar to the 
predicted prevalence throughout the entire study period, and the agreement is 
also close for patients aged 35149. In younger patients the agreement between 
the GLF1predicted and recorded prevalence is closer for women than men, though 
there have been improvements over time in both genders.   
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In 2007 there is excellent agreement between the national smoking prevalence 
estimate derived from the electronic medical records in THIN and the estimate 
produced by the current ‘gold standard’, the GLF, and the agreement is also close 
in 2006. Though this does not mean that all patients recorded in THIN as smokers 
truly are, simply that a similar number of patients are recorded as smokers as 
predicted by the GLF, this is the best available evidence to suggest that THIN 
patients who were current smokers at the time smokefree legislation was 
introduced in the UK can be identified from their medical records.  
 
The assumption that all patients with no smoking status recorded in their THIN 
records are not current smokers may lead to the underestimation of smoking 
prevalence, though, as noted already, other work suggests this assumption is 
valid124. As Appendix 8.5 discusses, a small minority of patients have 
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contradictory smoking status Read Codes recorded in their notes on the same 
day, classifying them, for example, as both a current and non1smoker. Such 
patients were classified as having an unknown smoking status at that point in 
time, essentially labelling them as non1smokers for the purposes of this analysis 
and potentially leading to slight underestimation of the smoking prevalence in 
THIN. Similarly, that a substantial minority of patients’ most recent smoking 
status was recorded several years before the index may also bias prevalence 
estimates. However, this is perhaps not a problem in older patients recorded 
many years previously as never smokers, as very few people begin smoking after 
the age of 25126, and smoking status records are more up1to1date now than in the 
past, as discussed in Appendix 8.6.  
 
It is recognised that reliance upon self1reported measures of smoking behaviour in 
surveys such as the GLF may underestimate smoking prevalence, particularly 
among younger age groups. Although 16 and 17 year olds complete the GLF 
questionnaire in private, this is unlikely to be totally successful in encouraging 
honest answers, and rates of under1reporting might not be constant over time126, 
especially given reductions in the social acceptability of smoking. However, if 
patients misrepresented their smoking behaviour to their doctor there could also 
be a degree of underreporting in primary care data. Observed individual1level 
agreement between patients’ smoking status records in their medical notes and 
those ascertained through questionnaires suggests there are minimal data entry 
errors in primary care records120. However, the lack of biochemical data to 
validate patients’ self1recorded smoking status in THIN (and similarly in the GLF) 
means one cannot be sure whether smoking status records in either data source 
are a true reflection of reality.  It is unlikely, however, that validated smoking 
outcomes would ever be used routinely in national population surveys due to the 
expense incurred.  
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A study similar to this, undertaken in 1996 using GPRD medical records data, 
found a 20 percent shortfall in the proportion of primary care patients registered 
as current smokers compared to national prevalence estimates121. The THIN 
dataset, which is similar in structure to the GPRD, also shows a shortfall in 
recording historically85, though the situation has improved over time, suggesting 
that primary care data can now be used more confidently to identify current 
smokers. This is arguably a result, at least in part, of the QOF requirement for GPs 
to regularly record the smoking status of all patients85.  
 
General practices which contribute to the THIN dataset undergo assessment to 
ensure they are using their computer systems correctly, and thus they may not be 
representative of all British practices. The substantial variation in the 
completeness of recording in individual practices warrants further investigation, 
and may, at least in part, be explained by differences in the social class structure 
of their patient populations. The lack of a comparable indicator of social class in 
the GLF∗ and THIN data means this couldn't be used as a variable in the 
standardisation procedure, though part of the effect of social class is likely to be 
accounted for by using Government Office Region as a standardisation variable.  
 
In conclusion, the convergence between the recorded smoking prevalence of 
patients in THIN and the GLF1predicted estimate suggests that patients who were 
smokers at the time smokefree legislation was introduced, and who were the 
potential subjects of increased delivery of cessation interventions, can be 
identified from their medical records. The variation in the completeness of 
recording by patient sex and age group suggests again it might be important to 
investigate the impact of smokefree legislation on intervention recording in 
current smokers separately by subgroup. In addition, the observed variation by 
                                          
∗ An Index of Multiple Deprivation quintile is available in the GLF though not in all 
years, so this could not be used in the standardisation procedure even if it was 
proved to be a similar measure of deprivation as the Townsend Index available in 
THIN. 
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practice means it may not be appropriate to extrapolate conclusions about the 
impact of smokefree legislation generated using THIN data to the whole of the UK.   
 
% 						
	
				
 
% (;.6<-5;+6(
 
Previous studies have highlighted the differential recording of smoking status in 
patients with particular health concerns compared to those who are otherwise 
healthy. This may reflect a preference for GPs to discuss and record smoking 
behaviour in the context of smoking1related illness. Alternatively, smokers with 
health problems may have higher consultation rates, offering more opportunities 
for the discussion of smoking and subsequent documentation of their smoking 
status in their notes. 
 
In this section, the recorded prevalence of current smoking in THIN in patients 
with one or more defined chronic conditions is compared with the smoking 
behaviour self1reported by patients with the same conditions in the GLF. 
 
% /;06<8
 
For each year from 2000 to 2009 all patients were identified from the THIN 
dataset who were aged 16+ and registered with a British practice on an index 
date of 1st July of that year. Each patient’s year of birth and gender was 
identified, as well as the Strategic Health Authority within which their GP surgery 
was located. All records of smoking status, identified by relevant Read Codes, 
entered into patients’ notes on or after their registration date were extracted and 
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patients were classified as current smokers at a given index date if their most 
recent smoking1related entry in their medical records prior to this date identified 
them as such. The diagnostic codes listed in Appendix 8.7 were used to identify 
whether patients had a history prior to each index date of one or more of six 
chronic conditions (coronary heart disease (CHD), chronic obstructive pulmonary 
disease (COPD), stroke or transient ischemic attack (TIA), hypertension, diabetes 
mellitus and asthma). In the case of asthma, patients were only counted as active 
cases if they also had a prescription for an asthma medication recorded in their 
notes in the previous year, in line with QOF reporting guidelines90. 
 
For each year from 2000 to 2007, GLF respondents were grouped according to 
whether or not they reported having one or more of these same six conditions. 
Medical history, region, age and sex1specific rates of current smoking were 
calculated for each year and weighted for non1response to give a nationally 
representative measure of smoking behaviour. These rates were applied to strata 
of the THIN population (similarly defined by medical history, age group, sex and 
region) at each index date using indirect standardisation125 to produce annual 
‘GLF1predicted’ prevalence estimates for current smoking; these predicted 
prevalence estimates were then compared with the recorded prevalence figures.  
 
To investigate variations in the recording of smoking status between practices, the 
expected prevalence of smoking in each practice was calculated in the manner 
described above, again using medical history, age, sex and Government Office 
Region as variables in the standardisation procedure. These predicted prevalence 
estimates were then compared with the proportion of patients in each practice 
recorded in their notes as smokers.  
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Table 2.1 shows the number of patients aged 16+ registered in THIN each year 
with Read Codes in their notes which indicate the prevalence of one or more of 
the six chronic conditions. For comparison, the unstandardised national prevalence 
estimates derived from the GLF are shown, with their 95% confidence intervals.  

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Year 
THIN 
patients aged 
16+ 
Patients with 
1+ chronic 
conditions 
THIN 
prevalence 
(%) 
GLF prevalence 
(95% CI) 
2000 2,086,891 351,805 16.9 13.1 (12.5113.7) 
2001 2,228,890 399,221 17.9 13.4 (12.9114.0) 
2002 2,305,027 436,447 18.9 14.8 (14.2115.4) 
2003 2,361,012 473,399 20.1 13.8 (13.2114.3) 
2004 2,383,267 501,005 21.0 13.8 (13.3114.4) 
2005 2,441,596 536,250 22.0 14.4 (13.9114.9) 
2006 2,472,815 558,173 22.6 15.3 (14.8115.9) 
2007 2,499,927 571,864 22.9 13.7 (13.1114.3) 
2008 2,511,909 578,345 23.0 1 
2009 2,447,903 568,191 23.2 1 
 
 
The proportion of THIN patients with a history of one or more chronic conditions 
recorded in their notes has increased over time, despite little change in the GLF 
self1reported prevalence. However, in each year the recorded prevalence in THIN 
is considerably higher than the upper confidence interval of the GLF estimate. 
Possible reasons for these differences, and the implications for this analysis, will 
be discussed shortly.  
 
Figure 2.5 shows changes over time in the GLF1predicted and recorded prevalence 
of current smoking in the THIN population for patients with and without one or 
more of the six defined chronic conditions.  
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The extent of agreement between the GLF1predicted and recorded smoking 
prevalence is greater for the majority of the study period for patients with at least 
one of the six chronic conditions compared to those who are otherwise healthy. 
From 2000 to 2007 there is, on average, only 0.1% difference between the 
predicted and recorded prevalence of current smoking in patients with a history of 
chronic disease. Only in 2006 does the predicted and recorded smoking 
prevalence in patients without these six chronic conditions converge to the same 
extent.  
 
There is still a large degree of variation between practices in the completeness of 
recording of current smoking amongst patients with a history of chronic illness. In 
2007 the worst performing practice recorded 39.9% of the expected number of 
current smokers, whilst on the other hand one practice identified 339.0% of the 
expected number of smokers (median 110.7%, interquartile range 52.51252.5%).
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Smoking is a recognised risk factor for cardiovascular disease, type II diabetes 
and COPD, and worsens the symptoms of asthma. It could, therefore, be 
considered surprising that the prevalence of current smoking is lower in patients 
with one or more of these conditions than in those without. However, as Figure 
2.6 shows, the GLF1predicted and recorded prevalence of ex1smoking is higher 
amongst patients with chronic conditions, suggesting that many of these patients 
with a history of chronic illness may have succeeded in giving up smoking. 
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Since 2000 there is good agreement between the recorded smoking prevalence in 
THIN patients with one or more chronic conditions and the predicted prevalence of 
smoking derived from the GLF. The extent of agreement in patients with no 
recorded history of chronic conditions is less good, though has improved over 
time. These findings suggest that, at the time smokefree legislation was 
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introduced in the UK, smokers with and without chronic conditions can both be 
identified with relative confidence from their THIN records. However, identification 
of current smokers without a history of chronic disease may be more difficult 
before 2006.   
 
This study is subject to the limitations outlined previously in Section 2.5.4, though 
in addition it is worth considering the reasons for, and implications of, the 
discrepancy between the proportion of THIN patients recorded as having a history 
of chronic disease and the proportion of GLF respondents who self1report having 
such conditions.  
 
The Read Codes used to identify patients in THIN with chronic conditions are those 
that GPs must use from 2004 onwards in order to qualify for payments under the 
QOF. Once a patient is entered onto a disease register using one of these codes, 
GPs must then meet a number of other targets related to their care to qualify for 
QOF payments. Patients recorded as having coronary heart disease, for example, 
must have their blood pressure and cholesterol level measured and recorded 
every 15 months. Since 2004 it is, therefore, unlikely that a patient will be 
entered onto a disease register if they do not have the condition, as this will 
create work for the practice and may ultimately lose the practice money if the 
patient is not managed in the way demanded by the terms of the QOF.  
 
The GLF relies on patients to self1report their chronic conditions, which may give 
less reliable prevalence estimates than GP records, at least since 2004. Patients 
may fail to report conditions, perhaps because they do not perceive their condition 
is of a severity worth mentioning, do not know the correct medical terminology or 
are even unaware they have the condition. This may result in lower self1reported 
estimates of the prevalence of chronic disease than are recorded in THIN data.    
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Table 2.2 shows the prevalence of each of the six chronic conditions amongst 
patients in THIN in 2007, alongside the unstandardised prevalence from the 2007 
GLF with its 95% confidence interval. As can be seen, only the prevalence of 
diabetes recorded in THIN falls within the 95% confidence interval of the self1
reported estimate of diabetes prevalence from the GLF, perhaps because a 
diagnosis of diabetes and the subsequent treatment regime are particularly 
memorable and diabetics play a large role in managing the condition themselves. 
The difference between the recorded and self1reported prevalence is particularly 
marked in the case of hypertension, with approximately three times the 
proportion of patients being recorded as having high blood pressure in THIN than 
self1report having the condition in the GLF. For asthma, CHD, COPD and stroke or 
TIA the medical records in THIN give slightly higher prevalence estimates than the 
GLF. 
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Year 
THIN prevalence 
(%) 
GLF prevalence 
(95% CI) 
Asthma 5.4 4.6 (4.214.5) 
CHD 4.1 1.6 (1.411.8) 
COPD 1.7 0.5 (0.410.7) 
Diabetes 3.9 3.7 (3.414.0) 
Hypertension 14.0 4.5 (4.214.9) 
Stroke/TIA 1.8 0.7 (0.610.9) 
 
 
 
This disagreement between patients’ self1reported medical history and that 
recorded in their medical records suggests that in comparing THIN and GLF data 
we are comparing measures of smoking prevalence in two very different groups of 
patients and, as a result, we can be less confident in concluding that the recording 
of smoking status is more complete in THIN patients with a recorded history of 
chronic conditions.  
 
In conclusion, it appears that the ability to identify current smokers from their 
THIN records is historically more complete for patients with a history of chronic 
disease, though at the time smokefree legislation was introduced both smokers 
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with and without chronic conditions can potentially be identified. This conclusion is 
weakened by uncertainties over the accuracy of patients’ self1reported medical 
history, and again there is considerable variation between practices which may 
reduce the external validity of any conclusions drawn using THIN data about the 
impact of smokefree legislation on the management of smoking in primary care in 
the UK.  
 
Before 2006, the patients identified from their THIN records as smokers may 
represent relatively more of the patient population with a history of chronic 
disease than patients without. Smokers with a history of chronic disease may 
perhaps be more likely to seek or receive a cessation intervention, which may 
inflate the intervention rate seen in the period before smokefree legislation was 
introduced compared to that from 2006 onwards. If this is the case, any increased 
rate of intervention at the time smokefree legislation was introduced may not 
stand out as over and above the preceding trend. It will, therefore, be crucial to 
undertake a sensitivity analysis to determine whether the observed effect of the 
introduction of smokefree legislation on rates of intervention differ in smokers 
with and without a history of chronic disease compared to all smokers.  
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The previous sections of this chapter have highlighted large variations between 
practices in the proportion of patients whose smoking status has been recorded in 
their THIN records and the discrepancy between the recorded and predicted 
practice1level smoking prevalence. In using THIN to assess the impact of 
smokefree legislation on the management of smoking in primary care it is 
desirable to be able to identify all smokers accurately. Therefore, it might be 
advantageous to identify practices who are particularly poor at recording smoking1
related information and exclude them from further analyses.  
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It is difficult, however, to know how to identify practices whose data is below 
standard. One approach may be to only allow practices to contribute data to the 
planned studies investigating the impact of smokefree legislation once they have 
recorded the smoking status of at least a certain proportion of patients. This 
would, however, require the arbitrary selection of a cut1off point, though the 
impact of the choice of cut1off could be investigated. Figure 2.7 shows, for 
example, changes over time in the recorded and predicted prevalence of current 
smoking in the THIN population when practices are only allowed to contribute data 
once at least 75% of their patients aged 16+ have their smoking status recorded 
in their notes.  
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Comparing Figure 2.3 and Figure 2.7 shows that excluding practices who have not 
recorded the smoking status of at least 75% of their patients increases the 
recorded prevalence of smoking in the early part of the study period. There 
remains, however, a shortfall in the proportion of patients recorded as current 
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smokers compared to the predicted smoking prevalence based on the results of 
the GLF. There also still remains substantial variation between practices in the 
extent of agreement between the predicted and recorded smoking prevalence. In 
2007 the worst performing practice recorded 44.5% of the expected number of 
current smokers (compared to 33.8% when there was no restriction on practices 
contributing to the analysis), but there was no change in the upper extreme 
(190.3%) and interquartile range (84.1% 1 116.3%). Restricting the number of 
practices which contribute data to analysis of the impact of smokefree legislation 
will as a result reduce the number of patients included in the study. Given the size 
of the THIN dataset, this may not be problematic when analysing the impact of 
smokefree legislation in the population as a whole, but may reduce the power to 
investigate the effect of the smoking ban in population subgroups. Increasing the 
cut1off point for smoking status recording above which practices are allowed to 
contribute data to any further analyses will only reduce the population size further 
and is, therefore, undesirable.  
 
It is not possible to compare recorded and predicted smoking prevalence figures 
for individual practices as a means of identifying the point in time from which they 
were accurately recording current smokers as such in their medical records. A 
practice with a consistently lower recorded smoking prevalence than predicted 
may simply be in a more affluent area and serve fewer smokers, and vice versa. 
As noted previously, the lack of a comparable indicator of social class in the GLF 
and THIN data means this couldn't be used as a variable in the standardisation 
procedure, and so it is impossible to judge whether a practice with a relatively low 
or high recorded smoking prevalence is in fact documenting patients’ smoking 
status accurately. 
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The data presented above suggests that the quality of smoking status information 
recorded in THIN has improved considerably since 2000, and provides evidence to 
support the use of THIN to evaluate the effect of tobacco control policies such as 
the introduction of smokefree legislation. 
 
Since 2000, an increasing proportion of adults in THIN have had their smoking 
status recorded soon after registering with a general practice (see Appendix 8.4), 
and the number of patients whose smoking status can be identified from their 
primary care medical records has improved. The rate of reduction in the number 
of people with no smoking status documented in their medical record was greatest 
between 2003 and 2005, the period spanning the implementation of the 2004 GP 
contract, though improvements continue to be made to the point at which the 
THIN database ends in mid12009. For the purposes of investigating the impact of 
smokefree legislation on rates of recording of smoking status it will be necessary 
to distinguish changes in clinical activity occurring at the time legislation was 
introduced from the longer1term trend of continued improvements in data 
recording. 
 
Since 2000 the proportion of patients in THIN recorded as current smokers has 
gradually approached the number that would be expected if country, age group 
and sex1specific smoking rates from the GLF are applied to the THIN population; 
since 2006 the recording of current smokers is particularly complete. The ability to 
identify current smokers may differ by patient characteristics such as sex, age 
group and medical history, and thus it may be necessary to investigate the impact 
of smokefree legislation on rates of intervention delivery individually by subgroup.  
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As has been seen, there are sometimes large differences between practices in the 
quality of their recording of their patients’ smoking status. However, it is not 
possible to identify which practices are failing to record current smokers as such in 
their medical records, and the reduction in sample size caused by restricting 
practices which are allowed to contribute data to assessing the impact of 
smokefree legislation is not desirable. Therefore, conclusions drawn using THIN 
about the impact of smokefree legislation on the management of smoking in 
primary care may not be generalisable to primary care throughout the UK. 
 
Having evaluated the quality of the smoking status information recorded in THIN 
the next chapter of this thesis assesses the quality of recording of smoking 
cessation interventions. 
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The previous chapter investigated the quality of the smoking status information 
recorded in THIN, concluding that the completeness of recording and ability to 
identify current smokers has improved in recent years, with improvements 
potentially being driven by the introduction of the Quality and Outcomes 
Framework (QOF) in 2004. Before using THIN data to investigate the impact of 
smokefree legislation on the management of smoking in primary care it is also 
crucial to understand trends in the recording of smoking cessation interventions 
delivered by primary health care professionals. As well as rewarding GPs 
financially for documenting their patients’ smoking status, the QOF also rewards 
GPs for recording that they have offered cessation advice to smokers with 
specified chronic conditions. Thus, improvements in these data may also be seen 
in the period before and after the introduction of the QOF, which may potentially 
confound assessment of the impact of the introduction of smokefree legislation. 
 
Since 2000, new smoking cessation interventions have become available to 
smokers via GPs, such as referral to specialist cessation services or a prescription 
for a cessation medication. Again, an assessment of the patterns of recording of 
these interventions is vital to be sure that any observed change in the rate of 
delivery of these interventions at the time smokefree was introduced is related to 
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the legislation and not simply a continuation of longer1term term trends towards 
increased delivery and/or recording of these interventions. 
 
This chapter assess the quality of recording of smoking cessation interventions in 
THIN, beginning with a review of the existing literature to identify the data quality 
problems which might be encountered in the THIN data. 
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If THIN is to be used to investigate the effect of smokefree legislation on GPs’ 
management of smoking it is crucial to appreciate first how frequently GPs 
intervene with smokers and how completely they document this.  
 
It is difficult to know exactly how frequently cessation support is offered to 
smokers, and therefore how frequently we would expect to see such an 
intervention documented in a patient’s notes. As noted in Section 1.9.1, previous 
research has suggested that patients systematically over1report having being 
asked about their smoking behaviour by a GP, and smokers over1report having 
being advised to quit102. Large discrepancies have been reported between the 
proportion of patients who self1report having received cessation advice, the 
observed frequency with which GPs deliver advice, and the proportion of patients 
with advice documented in their medical records. In one study, conducted before 
the widespread adoption of electronic medical records, cessation advice was 
recorded in the notes of 30.9% of patients who reported having received advice 
and in just 28.6% of cases where advice was heard to have been delivered on an 
audio1tape of the consultation; in consultations where advice was heard, 26.1% of 
patients failed to report this intervention127. 
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The introduction of the QOF provided a financial incentive for GPs to document in 
smokers’ medical records that they have been offered cessation advice90. 
Specifically, GPs are rewarded for documenting having offered advice to smokers 
with specified chronic health conditions at least every 15 months, as noted in 
Table 1.690. Unsurprisingly, the QOF increased the rate at which cessation advice 
was documented in electronic records within THIN – a tripling of rates of advice 
recorded in medical records occurred in the year following the introduction of the 
QOF85. However, in the same period there was no concomitant increase in 
prescribing of nicotine replacement therapy (NRT) or bupropion, for which there is 
no QOF incentive, suggesting that perhaps the QOF simply increased GPs’ 
propensity to document cessation advice that they would have offered regardless, 
rather than actually increasing the rate at which they intervened with smokers128. 
It should be noted that in this study analysis was based on rates of interventions 
recorded in the notes of patients who were also identified as current smokers at 
that point in time. However, Section 2.4 showed that historically many patients 
had no mention of smoking status in their notes, and Section 2.5 suggests that 
the ability to identify current smokers was poor before 2006. Analysing 
intervention rates only in patients recorded as current smokers may exclude 
patients who were not recorded as a current smoker at a particular point in time 
but who had a cessation intervention recorded in their notes. This may lead to 
misunderstanding the rate at which smoking cessation interventions are delivered, 
as well as any changes in the intervention rate associated with the introduction 
the QOF.  
 
There are few estimates of the proportion of smokers that are referred by a 
primary health care professional to specialist stop smoking services. In 2008, a 
sample of 26 GPs from north London reported that they had recommended or 
referred half of the smokers they had seen in their last ten clinical sessions to a 
community cessation advisor and 16% to a specialist cessation service129. 
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However, from these data it is difficult to identify how many referrals this equates 
to over the course of, for example, one year. 
 
In addition to offering cessation advice or a referral to a cessation service, GPs are 
also able to prescribe smokers NRT, bupropion or varenicline to help them quit. 
Prescriptions for smoking cessation medications are issued automatically through 
a practice’s computer system, and thus a record of all prescriptions issued 
appears in THIN. Rates of prescribing derived from the THIN dataset are 
comparable to rates of prescription dispensing in England130, suggesting that 
patients do indeed redeem their prescriptions, though of course some patients 
may not actually use the medication as directed. 
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The review of the literature presented in the previous section has highlighted 
several potential shortfalls in the quality of smoking cessation intervention data 
that might be encountered in THIN. The following issues will be investigated in the 
remainder of this chapter to address these questions of data quality and judge 
whether THIN can be used to evaluate the impact of smokefree legislation on the 
management of smoking in primary care. 
 
/5;+6(  assesses whether the proportion of patients with a record in their 
notes that they have been offered smoking cessation advice has changed over 
time, and considers whether these records are a true reflection of the amount of 
cessation advice delivered. 
 
/5;+6(# investigates whether the proportion of patients who are recorded as 
having been referred to a smoking cessation service has changed over time, and 
    
115 
again considers whether these records are a true reflection of the number of 
patients who are truly referred. 
 
/5;+6(% assesses whether all patients with a record of cessation advice, 
referral or prescription of a smoking cessation medication in their notes are also 
recorded as being a smoker at that point in time. 
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One way to investigate whether all patients in THIN who are offered cessation 
advice have this offer documented in their medical records is to approach patients 
directly and compare their recollections of advice with their medical notes. 
Alternatively, GPs could be observed directly or video1recorded as they consult 
with patients and then records inspected to see whether any cessation advice 
delivered is recorded. However, as noted previously, these study methods are 
impossible as all data in THIN are anonymised to protect practice and patient 
anonymity, and, as discussed in Section 1.9.1, GPs’ behaviour may change if they 
know they are being observed. Given these difficulties, this section investigates 
changes over time in advice recording, and assesses the completeness of 
recording of cessation advice, by comparing rates of advice recorded in THIN with 
those recalled in a survey of NHS patients in England in the years since the 
introduction of the QOF.    
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For each year from 2000 to 2009, all patients from the THIN dataset who were 
over the age of 16 and registered with an English practice on an index date of 1st 
July in that year were identified. Each patient’s year of birth, sex and the Strategic 
Health Authority (SHA) within which their GP surgery was located were identified. 
Patients’ medical records were searched for Read Codes documenting the delivery 
of smoking cessation advice to that patient (see Appendix 8.8), and, for each 
year, the proportion of patients with a recording of cessation advice in the 12 
months prior to the index date was calculated.  
 
The Primary Care Trust (PCT) Patient Surveys monitor patients’ experiences of 
NHS services131. In 2004, 2005 and 2008, a simple random sample of patients 
was selected from each PCT in England, and a postal questionnaire administered 
asking whether the respondent had ‘definitely’ or ‘to some extent’ received 
cessation advice from a health professional (GP or nurse) at their GP surgery 
within the last 12 months. Completed questionnaires were received from 122,113 
patients in 2004, 116,939 in 2005 and 69,470 in 2008 (response rates of 47.4%, 
45.4% and 38.3% respectively).  
 
Previous work using the Patient Survey has shown that the provision of smoking 
cessation advice by primary health care professionals varies with patient sex and 
age20. Consequently, as Patient Survey respondents and patients in the THIN 
dataset have different demographic characteristics, directly comparing ‘raw’ data 
on smoking cessation advice received by patients in each source is not 
appropriate. Therefore, the following standardisation procedure was used to 
enable comparison of data from THIN and the Patient Surveys. For 2004, 2005 
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and 2008, age group∗, sex and SHA1specific rates of patients reporting having 
received smoking cessation advice within the last 12 months at least ‘to some 
extent’ were calculated from Patient Survey responses. These rates were applied 
to strata of the THIN population (similarly defined by age group, sex and SHA) at 
the corresponding index date using indirect standardisation125, producing 
estimates for annual rates of recalled cessation advice that might be expected 
from THIN patients, based on Patient Survey responses (referred to as ‘predicted 
recall rates’). Predicted recall rates were then compared graphically with the 
actual cessation advice rates documented in THIN patients’ medical records.   
 
  /8-4;8

Figure 3.1 shows, for each year from 2000 to 2009, the proportion of patients 
within THIN who had smoking cessation advice documented in their medical 
records in the previous 12 months and, for Patient Survey years, predicted recall 
rates.  
 
The proportion of THIN patients with cessation advice documented in their medical 
records in the past year increased considerably over the study period, from 1.2% 
of patients in 2000 to 10.9% in 2009, with the majority of this increase occurring 
between 2003 and 2005. However, although similar in 2004, the proportion of 
THIN patients predicted to recall having received cessation advice was 
subsequently lower and increased less over the survey period (6.6% of patients in 
2004, 8.3% in 2008). In 2004 there was good agreement between recording of 
cessation advice in THIN and recall rates adjusted for demographic differences in 
available data sources, but in both 2005 and 2008, agreement between recorded 
                                          
∗ The age groups used in the Patient Survey are different to those used in the GLF, 
hence the age categorisation used in this section is different to that used in all 
other work presented in this thesis. 
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and recalled cessation advice was much less strong with recall rates being much 
lower.    
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As was seen in the recording of patients’ smoking status, there is considerable 
variation between practices in the extent of agreement between rates of recorded 
and recalled cessation advice. In 2008, the rate of recorded cessation advice in 
one practice was 40.0% of the predicted recall rate, and at the other end of the 
spectrum the rate of recorded cessation advice in another practice was 540.6% of 
the predicted recall rate (interquartile range 84.21152.8%). 
 
The patterns of recorded and recalled advice also differed by patient sex and age 
group, as shown in Figure 3.2. The proportion of THIN patients with a record of 
advice at the end of the study period, and the difference between men and 
women, varies by age group, though in each subgroup there is a large increase 
between 2003 and 2005 in the proportion of patients with recorded advice. In 
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some subgroups, notably men and women between the ages of 36 and 65, there 
is closer agreement between recorded and recalled cessation advice. 
 
 
+,-./0/1.616.;+6(6713;+/(;83,/<%=C+;0./56.</<5/883;+6(
3<2+5/3(<1./<+5;/<./5344.3;/8DAB8/K3(<3,/,.6-1


   +85-88+6(3(<56(54-8+6(8
 
To my knowledge this study is the first to compare, at a population–level, 
smoking cessation advice recorded in medical records with patients’ recall of such 
advice reported in large surveys; in 2004 there was close agreement between 
both data sources but this decreased substantially in 2005 and 2008. 
 
Some of the longitudinal changes in the proportion of patients recalling cessation 
advice, or having this documented in their medical records, may be due to 
changes in population smoking prevalence. Ideally, this study would have 
assessed recorded and recalled advice within smokers only, but, as Section 2.5 
showed, the ability to identify smokers in THIN confidently was poor in the early 
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years of this analysis and it was impossible to identify respondents who were 
smokers from each Patient Survey. To allow interpretable, annual comparisons the 
results presented are, therefore, based on annual denominators of all patients (for 
THIN) and respondents (Patient Survey). However, between 2004 and 2005, the 
period when the gap between patient1reported and documented advice appears in 
Figure 3.1, there was little change in smoking prevalence in England13, and thus 
changes in smoking prevalence are unlikely to explain the divergent data.  
 
This study is limited by a lack of data on patients’ recall of smoking cessation 
advice prior to 2004 (the first Patient Survey, in 2003, asked whether respondents 
had 	 to get help to quit smoking from local health care services rather than 
whether they had received cessation support at their GP surgery). One 
explanation for the findings reported here is that patients’ propensity to recall 
advice may have changed over time – in the latter years of this study patients 
may simply have found cessation advice from health care professionals less 
memorable. However, for diminished recollections of advice to explain findings, 
patient recall would have to have diminished quite substantially in a relatively 
short period, so it seems likely that other reasons account for the difference.  
 
The relatively low Patient Survey response rates raise the possibility of response 
bias, with smokers or patients recalling advice perhaps being more or less likely to 
complete the survey. However, the response rates in 2004 and 2005 are very 
similar and the characteristics of respondents completing the survey in these two 
years are unlikely to have changed substantially. Again, therefore, it seems 
rational that other reasons also account for the divergence in recorded and 
recalled advice rates.  
 
The findings presented here are contrary to those from other studies, discussed in 
Section 3.2, which showed more patients recalling receiving advice than had this 
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documented in their medical records102, 127. Historically, GPs may not have 
documented all cessation advice delivered to smokers, though when asked a 
majority claim to have done this116; with the introduction of the QOF, from 2004 
onwards GPs may simply be documenting more of the advice that they give128. 
The failure to observe large increases in patients’ recall of cessation advice, with 
no concurrent increase in rates of prescribing of stop smoking medications128, 
tends to support this, and this finding is similar to that of a study mentioned 
earlier, where GPs who claimed the largest amount of money under a new health 
promotion payment scheme seemed simply to change the way they recorded their 
patients’ smoking status, rather than raising the topic of smoking more frequently 
with patients87.  
 
The divergence between rates of recording of advice and patient recall seen in 
Figure 3.1 is less easy to explain, unless there was an increase in the amount of 
advice being delivered in such a way that patients did not perceive it as advice.  
GPs have different approaches to advice giving132, and thus advice documented in 
patient records could reflect simply the briefest mention of smoking and not be of 
sufficient duration or intensity to be recalled as ‘advice’ by smokers133. 
Alternatively, GPs could be recording offers of advice that were not actually made 
or which were refused; if the latter occurred, patients would not necessarily report 
receiving advice whereas the offer could legitimately be recorded in medical 
records.  
 
In conclusion, this study shows an increase in the proportion of patients who have 
smoking cessation advice recorded in their medical records, though the proportion 
has increased much more slowly since 2005 than the rate of increase seen in the 
two years prior to this. The method used to assess whether there was a change in 
the rate of advice recording at the time smokefree legislation was introduced must 
be able to account for these underlying, long1term trends. Although this study 
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finds substantial increases in the number of patients with a record of cessation 
advice having been delivered in their primary care medical records, and a smaller 
increase in the proportion self1reporting having received advice, the discrepancies 
between these data sources and the inherent difficulties involved in interpreting 
each mean we cannot be sure whether the proportion of smokers being advised to 
quit by primary care health professionals has improved in recent years as much as 
the improved documentation rates would have us believe. Similarly, any changes 
in the rate of recording of cessation advice seen at the time smokefree legislation 
was introduced may not necessarily reflect a change in the number of smokers 
being advised to quit. 
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As discussed in Section 3.2, little is known about how frequently primary health 
care professionals refer smokers in their care to specialist stop smoking services 
and how completely they record their referrals in patients’ medical records. There 
are no financial incentives for GPs to refer smokers to stop smoking services, but 
the QOF incentives to record patients’ smoking status and the delivery of 
cessation advice may have increased GPs’ engagement in other types of cessation 
activity such as directing smokers who want to quit to specialist services which 
can help them do so.  
 
A secular change in the recording of referral of smokers to stop smoking services 
may confound assessment of changes in the rate of referral at the time smokefree 
legislation was introduced. In addition, any discrepancy between recorded and 
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actual referrals at the time the smoking ban was enacted will make it difficult to 
be certain that any observed changes in recording truly reflect a change in the 
number of smokers being referred for cessation support.  
 
In order to investigate changes over time in the recording of referrals to smoking 
cessation services and assess the completeness of recording, this study compares 
rates of referral recorded in THIN with those recalled in the ONS Omnibus Survey, 
a nationally1representative survey of adults in Britain, which has sampled 
approximately 1,600 people in October and November each year since 2000. 
 
# /;06<8
 
For each year from 2000 to 2008, all patients from the THIN dataset who were 
aged 16+ and registered with a practice in England, Scotland or Wales on an 
index date of 1st November in that year were identified. These patients' electronic 
notes were searched for Read Codes documenting referral to a smoking cessation 
service (see Appendix 8.9) and for each year the proportion of patients with a 
recorded referral in the 12 months prior to the index date was calculated.  
 
The ONS Omnibus Survey provides a measure of the number of self1reported 
smokers who also self1report having been referred or self1referred to a stop 
smoking group, clinic or service within the past year. There is no way to separate 
Omnibus Survey respondents who were referred to a cessation service by a 
primary care health professional from those who self1referred, and so this 
measure may not be directly comparable with referrals recorded in primary care 
records. However, there are no other sources of referral data, and so Omnibus 
Survey data will be used in the absence of a better alternative.  
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Omnibus Survey respondents and patients in the THIN dataset have different 
demographic characteristics, so directly comparing ‘raw’ data on referrals to 
smoking cessation services received by patients in each source is not appropriate. 
Therefore, the following standardisation procedure was used to enable comparison 
of data from THIN and the Omnibus Surveys. Given the small monthly sample size 
of the Omnibus Survey, data from October and November each year was 
combined. For each year, age group, sex and SHA1specific rates of patients 
reporting having been referred or self1referred to a cessation service within the 
last 12 months were calculated from Omnibus Survey responses. These rates 
were applied to strata of the THIN population (similarly defined by age group, sex 
and SHA) at the corresponding index date using indirect standardisation, 
producing estimates for annual rates of recalled referral that might be expected 
from THIN patients, based on Omnibus Survey responses (referred to as 
‘predicted referral rates’). Predicted referral rates were then compared graphically 
with the actual referral rates documented in THIN patients’ medical records.   
 
The small number of people questioned by the Omnibus Survey makes it difficult 
to produce meaningful comparisons of recorded and recalled referral in subgroups 
of the population defined by sex and age group, so this analysis was not 
undertaken. However, as in previous analyses, the variation in recording between 
practices was assessed. 
 
# /8-4;8
 
Figure 3.3 shows the proportion of patients aged 16 and above registered in THIN 
each year with a record of having being referred to a stop smoking service in the 
previous 12 months, alongside predicted referral rates. 
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The proportion of patients with a referral to a smoking cessation service recorded 
in their THIN records has remained relatively low across the study period, peaking 
at 0.3% of patients in the year up to 1st November 2004. The largest increase in 
recorded referral was seen between 2003 and 2004, and since 2004 the 
proportion has declined marginally each year.  
 
The proportion of patients predicted to recall referral increased steadily between 
2000 and 2006, though appears to have since levelled out. In each year there is a 
large difference between the proportion of THIN patients with referral recorded in 
their notes, and the proportion of patients predicted to recall referral based on the 
results of the Omnibus Survey.  
 
There is again variation between practices in the extent of agreement between 
rates of recorded and recalled referral. In 2007, several practices had no patients 
recorded as having been referred to a smoking cessation service, and at the other 
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end of the spectrum the rate of recorded referral in another practice was 113.8% 
of the predicted referral rate (interquartile range 0.016.6%). 
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To my knowledge this is the first study to compare, at a population–level, 
referrals to smoking cessation services recorded in medical records with patients’ 
recall of referral reported in large surveys.  
 
Again, some of the longitudinal changes in the proportion of patients recalling 
referral to a cessation service, or having this documented in their medical records, 
may be due to changes in population smoking prevalence. Given the difficulty in 
identifying current smokers in THIN in the early years of the study period, as 
demonstrated in Section 2.5, this study compares rates of recording and recall in 
all patients.  
 
As noted earlier, the large difference between the expected and recorded 
prevalence figures may reflect the nature of the question asked in the Omnibus 
Survey. Respondents were asked whether they had been referred 	4			
to a stop smoking service, and there is no way to distinguish between these 
means of referral. The Read Codes used in THIN will only identify referrals by a 
member of the primary healthcare team and thus comparing THIN and Omnibus 
Survey data is not comparing like with like.  
 
The difference between self1reported and recorded referral rates may also reflect 
that fact that there are no financial incentives in the QOF for GPs to record that 
they have referred smokers to other sources of help, and so many patients may 
indeed be referred but this not be documented in their medical records. 
Additionally, if GPs are referring patients to cessation support available within 
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their own practice this may not be considered a referral to a specialist cessation 
service nor recorded as such.  
 
In conclusion, this study shows if anything a small decrease in the proportion of 
patients who have a referral to a smoking cessation service recorded in their 
medical records since 2004, and this change may confound assessment of 
changes in the rate of referral at the time smokefree legislation was introduced. 
The method used to assess whether there was a change in the rate of referral 
recording at the time smokefree legislation was introduced must be able to 
account for this underlying trend. In addition, the discrepancy between recorded 
and recalled referrals at the time the smoking ban was enacted will make it 
difficult to be certain that any observed changes in recording truly reflect a 
change in the number of smokers being referred for cessation support.  
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A previous paper investigating the impact of the QOF on rates of recording of 
cessation advice and prescribing of smoking cessation medications based its 
analysis on rates of interventions recorded in the notes of patients who were also 
identified as smokers at that point in time85. However, Section 2.4 showed that 
historically many patients had no mention of smoking status in their notes, and 
Section 2.5 suggests that the ability to identify current smokers was poor before 
2006. Analysing intervention rates only in patients recorded as current smokers 
may exclude patients who were not recorded as a current smoker at a particular 
point in time but had a cessation intervention recorded in their notes. This may 
lead to misunderstanding the rate at which smoking cessation interventions are 
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delivered, as well as any changes in the intervention rate associated with the 
introduction of smokefree legislation.  
 
This study compares the rate of recording of cessation advice, referral to stop 
smoking services, and prescribing of smoking cessation medications in patients in 
THIN according to whether or not they are identified as a current smoker at the 
point in time intervention was recorded.  
 
% /;06<8
 
For each month from January 2000 to July 2009, all patients from the THIN 
dataset who were aged 16+ and registered with a practice in the UK for at least 
one day in the month were identified. Patients were classified as either smokers or 
non1smokers each month, based on the most recent smoking status Read Code in 
their medical records prior to the first day of each month. The combined time 
smokers, non1smokers and all patients spent registered in THIN each month was 
calculated, measured in person1months.  
 
Read Codes were used to identify patients with at least one record of cessation 
advice or referral to a cessation service in their notes in each month. Similarly, 
Multilex drug codes were used to identify patients with one or more prescriptions 
for NRT, bupropion or varenicline recorded in their notes each month (see 
Appendix 8.10 for drug codes). 
 
Monthly rates of recording of cessation advice, referral to a cessation service and 
prescribing of all smoking cessation medications were calculated separately for 
smokers, non1smokers and all patients, expressed as the number of patients with 
a record in that month per 100,000 person1months of follow1up time. The rate of 
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recording of each intervention in smokers, non1smokers and all patients was 
compared graphically.  
 
% /8-4;8
 
Figure 3.4 shows monthly rates of recording of cessation advice in all patients 
aged 16+ in THIN, as well as in patients recorded as smokers and patients not 
recorded as smokers. 
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As Figure 3.4 shows, some patients who are not recorded as smokers still have a 
record of cessation advice in their medical records. However, the rate of recording 
of advice in non1smokers is very low; across the study period, each month an 
average of just 139 non1smokers have a record of advice per 100,000 person1
months, compared to 3,744 smokers. 
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Figure 3.5 shows monthly rates of recording of referrals to smoking cessation 
services in all patients, smokers and non1smokers. 
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As Figure 3.5 shows, again some patients who are not recorded as smokers still 
have a record of referral to a cessation service in their medical records, though 
the rate of recording is again low. Across the study period, each month an 
average of just 1 non1smoker has a record of referral per 100,000 person1months, 
compared to 98 smokers. 
 
Figure 3.6 shows monthly rates of prescribing of all smoking cessation 
medications in all patients, smokers and non1smokers. 
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As was seen in the recording of advice and referral, some patients who are not 
recorded as smokers still have a prescription for a smoking cessation medication 
recorded in their medical records. Across the study period, each month an 
average of 83 non1smokers have a prescription recorded in their notes per 
100,000 person1months, compared to 913 smokers. 
 
The pattern of prescribing appears to be similar in patients identified as smokers 
and non1smokers – in both groups prescribing shows an increasing trend in the 
first half of the study period before levelling off or perhaps decreasing slightly 
from 2005 onwards. Peaks in prescribing are seen at the same time in smokers 
and non1smokers.   
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The results presented in this section show that smoking cessation interventions 
are sometimes recorded in the medical records of patients in THIN who are not 
also documented as a smoker. Rates of recording of interventions in non1smokers 
are generally low, particularly in the case of recording of cessation advice and 
referral of smokers to smoking cessation services.  
 
Analysis of rates of interventions recorded in the notes of current smokers may 
fail to give a complete picture of the pattern of recording as well as any changes 
in underlying trends associated with the introduction of smokefree legislation. 
Therefore, it may be worthwhile assessing and comparing the impact of smokefree 
legislation on rates of interventions recorded in both smokers and all patients.  
 
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The three studies undertaken in this chapter have highlighted several features of 
the recording of smoking cessation interventions in THIN which must be taken into 
account when using the data to investigate the impact of smokefree legislation on 
the management of smoking in primary care.  
 
Figure 3.1 demonstrated substantial increases in the rate of recording of cessation 
advice, particularly between 2003 and 2005, and less dramatic secular trends are 
also seen in the recording of referral of smokers to cessation services (Figure 3.3) 
and prescribing of smoking cessation mediations (Figure 3.6). The method used to 
assess the impact of smokefree legislation on the rate at which primary health 
care professionals intervene with smokers must be able to take account of these 
underlying trends. In addition, Figure 3.4, Figure 3.5 and Figure 3.6 illustrate 
distinct monthly variation in the rate of recording of smoking cessation 
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interventions, and again the method used to assess the impact of smokefree 
legislation on the rate at which primary health care professionals intervene with 
smokers must be able to take account of this variation. 
 
It remains unclear whether the rates of recording of cessation advice and referral 
of smokers to specialist cessation services are a true reflection of the rate at 
which GPs intervene with smokers. The improvements in the recording of smoking 
status shown in the previous chapter, and the comparability between rates of 
prescribing of smoking cessation medications in THIN and dispensing rates130, 
suggest these measures may be the most robust outcome variables with which to 
assess the impact of the introduction of smokefree legislation on the management 
of smoking in primary care. Despite the limitations discussed already in the 
methods used to validate the advice and referral data in THIN, changes in these 
outcome variables at the time smokefree legislation was introduced will still be 
investigated. However, it should be noted that any changes in the recording of 
advice or referral may not reflect true changes in the rate at which GPs intervene 
with smokers.  
 
Variations in the proportion of patients with recorded cessation advice and referral 
to a specialist cessation service, as well as variations between the recorded and 
recalled intervention rates, are seen in different population subgroups. As was 
suggested at the end of the previous chapter, it may be worthwhile investigating 
the impact of smokefree legislation on rates of intervention delivery individually by 
subgroup to take these underlying differences into account.  The variation 
observed between practices means again that conclusions drawn using THIN 
about the impact of smokefree legislation on the management of smoking in 
primary care may not be generalisable to primary care throughout the UK. 
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Finally, analysis of rates of interventions recorded in the notes of smokers only 
may fail to give a complete picture of the pattern of recording as well as any 
changes in underlying trends associated with the introduction of smokefree 
legislation. As a result, the method used to assess the impact of smokefree 
legislation on the rate at which primary health care professionals intervene with 
smokers must be able to compare rates of the recording of interventions in all 
patients as well as just those recorded as smokers at a given point in time. 
 
 
Having investigated the quality of smoking status recording in THIN in Chapter 2, 
and several issues surrounding the recording of smoking cessation interventions in 
this chapter, the following section of this thesis outlines the methods that will be 
used to investigate the impact of smokefree legislation on the management of 
smoking in primary care.  
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The previous chapters investigating the quality of the smoking information 
recorded in THIN demonstrated temporal and seasonal trends in the rates of 
recording of smoking status and cessation interventions which must be taken into 
account when assessing the impact of smokefree legislation on the management 
of smoking in primary care. An analytical approach known as 		$
	 is most appropriate to assess whether there was a statistically 
significant change in an outcome variable over and above any long1term trends at 
the time a policy intervention, such as smokefree legislation, is introduced. 
Therefore, this chapter will detail the interrupted time series analysis methods 
which will be used in Chapters 5 and 6 to assess whether the data recorded in 
THIN suggest that the introduction of smokefree legislation in the UK had an 
effect on the management of smoking in primary care. 
 
There are several approaches to interrupted time series analysis, but, to my 
knowledge, there is no authoritative review of the methods available describing 
which approach should be used in a particular situation. Additionally, there is no 
published literature assessing whether the results of an interrupted time series 
analysis are sensitive to the method used and the choices which the data analyst 
must make during the analysis process.  
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This chapter first provides an overview of the different approaches to interrupted 
time series analysis, before concluding which is the most appropriate to use in this 
research using data from THIN to assess the impact of smokefree legislation on 
the management of smoking in primary care. Then, one example, that of 
prescribing of nicotine replacement therapy (NRT), will be used to explain the 
stages involved in carrying out an interrupted time series analysis to assess the 
impact of a policy change on an outcome variable. This will include the description 
of an automated procedure written for the Stata134, the data management and 
statistical software used for the analyses presented in this thesis, which aids the 
analysis process. Finally, the results of several sensitivity analyses are presented 
which assess the implications of choices made during the data analysis process.  
 
  			
 
As introduced in Section 1.8.3, time series are encountered across many subject 
areas and consist of data collected on an individual or phenomenon at multiple, 
ordered, points in time. These measurements are usually taken at equally1spaced 
intervals, ranging from fractions of a second in an ECG trace of cardiac electrical 
activity, to monthly, yearly, or perhaps even less1frequently collected data.  
 
Time series are often described as stochastic, non1deterministic, realisations of an 
underlying data1generating process, meaning that the values of a series at each 
point in time are determined by both predictable and random elements (in 
contrast, a deterministic process is driven by entirely predictable forces)135. The 
essence of time series analysis is to model the underlying stochastic process 
which best represents a particular time series.    
 
One illustrative example of a time series will be used throughout this chapter to 
explain the principles of time series analysis and the methods used in this thesis 
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to assess the impact of smokefree legislation on the management of smoking in 
primary care. The time series in Figure 4.1 shows monthly rates of prescribing of 
NRT in THIN practices in England amongst smokers aged 16+. The series starts in 
April 2001, the month when NRT was first made available on NHS prescription. 
Appendix 8.11 lists the commands which can be used to analyse a time series in 
Stata and reproduce the figures presented in this chapter.    
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Figure 4.1 illustrates a fundamental, defining feature of time series data – 
observations at neighbouring points in time are related to each other. The series 
does not fluctuate randomly from one month to the next, but the magnitude of 
the observation in one month is usually close to that in the previous month. In the 
parlance of time series analysis, the data are said to be autocorrelated, or to 
exhibit serial dependency. The average autocorrelation between pairs of data 
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points at successive lags (or intervals) across the whole of a time series can be 
represented graphically in the form of an autocorrelation function, or ACF, as 
shown in Figure 4.2. The average autocorrelation between each data point across 
the whole of the time series and the data point one month previously (i.e. at a lag 
of 1) is high, with a correlation coefficient of 0.695 (as with all correlation 
coefficients, the autocorrelation can range from 11, indicating perfect negative 
autocorrelation, to +1, indicating perfect positive autocorrelation).  
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The increase in the degree of autocorrelation at lags 12 and 24 compared to the 
lags either side point to the presence of seasonal autocorrelation in the series – in 
monthly data such as this, the value of the series at one point in time is correlated 
with that 12 and 24 months previously. Many time series from the social sciences 
contain an element of seasonality136, whereby the level of a series varies over the 
course of a year and the annual pattern of behaviour is repeated from one year to 
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the next. The implications of seasonality for time series analysis will be discussed 
shortly.  
 
The shaded area in Figure 4.2 indicates 95% confidence intervals for the 
autocorrelation between data points at each lag, with the variance of each 
autocorrelation calculated as the inverse of the total sample size (in this case, 100 
data points)135. Autocorrelations which extend outside of the shaded area of the 
ACF indicate correlation at that lag greater than would be expected by chance 
alone.  
 
It is the autocorrelation present in a time series which demands specific analytical 
techniques and renders more traditional approaches to analysis inappropriate. 
Time series data violate the assumption of independence central to linear 
regression, and autocorrelation makes it difficult to assess whether any observed 
change in the pattern of a time series is significant and attributable to an 
intervention, or whether it is simply within the bounds of the ‘normal behaviour’ of 
the series137. 
 
If autocorrelation between data points is ignored, the standard errors of 
parameter estimates calculated through linear regression will be biased – positive 
autocorrelation decreases the apparent variability in the data resulting in lower 
standard errors, and negative autocorrelation increases the apparent variability 
producing higher standard errors138. The standard errors of point estimates may 
be inflated or deflated by up to 50% and the t1statistic by as much as 400%136. 
Thus, when assessing the effect of an intervention on a time series there is a 
strong chance of making either a type one error, rejecting a null hypothesis which 
is in fact true, or a type two error, failing to reject a null hypothesis which is in 
fact false. Therefore, the aim of the analytical techniques which will be outlined in 
this chapter is to model, and thereby statistically control, the autocorrelation in a 
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time series to enable accurate assessment of the impact of an intervention on a 
series136. 
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As noted in Section 1.8.3, in recent years there has been an increase in the 
number of articles in the published literature which analyse time series data to 
assess the impact of an intervention on the phenomenon under investigation. 
Such analysis is described as ‘interrupted time series analysis’, with the point in 
time at which the intervention was introduced marking an interruption to the 
series. Broadly speaking, interrupted time series analyses employ one of two main 
approaches to analysing such data, using either a regression framework, or a 
class of mathematical models known as Autoregressive Integrated Moving 
Average (ARIMA) models.  
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Using the most simple regression approach, a time series is divided into at least 
two segments with a break point between segments at the moment in time the 
intervention whose impact the analyst wishes to assess was introduced. Linear 
regression is then used to model the data in each segment of the series, with the 
regression line in each segment being allowed to exhibit a different level and trend 
if appropriate. The parameters of the fitted segmented regression model are then 
assessed to determine whether the level and/or the slope of the series changed 
significantly after the introduction of the intervention97.  
 
Figure 4.3 illustrates the fitting of a segmented regression model to the exemplar 
dataset to assess whether there was a permanent change in the level or slope of 
the prescribing series after the introduction of smokefree legislation. In order to 
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capture some of the non1linear trend in the series before the introduction of 
smokefree legislation in July 2007, the pre1intervention series has been divided 
into two segments with the break point in April 2004, the month the Quality and 
Outcomes Framework (QOF) was introduced.  
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The segmented regression model shown in Figure 4.3 assumes the data satisfy 
the independence assumption central to linear regression, though, as shown in 
Figure 4.2, it is clear there is significant autocorrelation present in the data. 
Drawing the ACF of the residuals from the segmented regression model (the 
difference between the observed values of the series and the values predicted by 
the regression model) allows the time series analyst to assess whether any 
autocorrelation has been adequately incorporated into the segmented regression 
model, or whether further steps must be taken to deal with any remaining serial 
dependency. The ACF of the residuals from the segmented regression model, 
shown in Figure 4.4, reveals significant autocorrelation at lags 1, 5, 6, 7, 12 and 
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24, suggesting the model has not adequately dealt with the autocorrelation 
present in the series and that this segmented regression model is invalid. In 
addition, the segmented regression model fits a linear trend through the data in 
each segment which is arguably not appropriate in this case, further invalidating 
the technique. 
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A modified form of segmented regression, known as Prais1Winsten regression, 
allows the time series analyst to incorporate autocorrelation at lag 1 into a model 
(though again assumes a linear trend through each segment). However, within a 
simple regression framework it is not possible to incorporate autocorrelation at 
other lags into the model.  
 
As suggested previously, the significant autocorrelation at lags 12 and 24 in the 
model residuals is indicative of a seasonal pattern in the monthly time series data. 
Some authors have dealt with the presence of seasonality in a time series by 
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attempting to estimate the seasonal component of the series, remove its effects 
from the data and then model the de1seasonalised series139. A common method 
used to estimate the seasonal component of a time series is to compute the 121
month centred moving average of the series, calculate the ratio of the original 
series to the moving average series for each month, and then compute the 
average of these ratios for each month of the year across the series140. Figure 4.5 
shows the seasonal component for the exemplar series, calculated in this manner.  
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Figure 4.5 demonstrates peaks and troughs in rates of prescribing of NRT over the 
course of each year. The highest prescribing rates are seen in January, February 
and March each year, with troughs in prescribing occurring in August and 
December. Peaks in prescribing may perhaps be associated with more people 
visiting the doctor with respiratory conditions over the winter months and smokers 
being offered support to quit, or more smokers visiting their surgery for cessation 
support at New Year141 or, in March, on national No Smoking Day142. The troughs 
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in prescribing may perhaps be attributable to holiday periods with fewer people 
visiting their GP, with some compensatory increased prescribing being seen in the 
months following these holiday periods.  
 
Having estimated the seasonal component of a time series, its effects may be 
removed from the series by dividing the value of the series in each month by the 
appropriate seasonal index. However, the time series analyst should be extremely 
cautious in undertaking such an activity as, although in theory this should remove 
all of the seasonality present in a series, a seasonal pattern may still remain143. 
The decomposition approach assumes the seasonal effect is entirely deterministic 
(i.e. that it has no stochastic, random component) and is constant from one year 
to the next over the entire course of the series. However, this assumption may 
not be valid, particularly in long series where the seasonal component may 
change over time140. As Figure 4.6 shows, the pattern of prescribing in the 
exemplar series differs between years, and so assuming a constant seasonal 
effect over the entire course of the series is not appropriate.  
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Some authors have incorporated seasonal effects into segmented regression 
models using dummy variables to represent each season of the year. Again, 
however, this assumes a deterministic seasonal effect, constant over the entire 
span of the time series. In addition, modelling seasonality using dummy variables 
can result in over1parameterisation of a model, particularly in the case of monthly 
data where 11 degrees of freedom may be needed144. 
 
It is expected that all of the series to be analysed in this thesis will contain a 
substantial seasonal component and, therefore, in the absence of an adequate 
way to remove all the seasonality from a series or incorporate it into a regression 
framework using dummy variables, segmented regression of the form 
demonstrated above will not be pursued further as a means of data analysis as it 
is unlikely to be able to model such data with complex seasonal patterns and 
autocorrelation.   
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Within the last 20 years, generalised additive models (GAMs) have been 
developed as an extension to linear segmented regression, and allow the 
relationship between a time series and several explanatory variables to be 
modelled using non1parametric smooth terms (such as spline functions) or non1
linear terms such as polynomial or exponential functions145. Any seasonality in a 
time series can be incorporated into a GAM using a smooth function rather than 
dummy variables. A recent extension to the GAM, the generalised additive mixed 
model (GAMM)146, allows the incorporation of autocorrelated error terms into a 
model. Such an approach has been used recently to model the impact of the 
introduction of smokefree legislation on hospital admissions for myocardial 
infarction in England, accounting for temperature, flu rates and the week of the 
year147. Exploratory analysis suggests that GAMMs give similar results to the 
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Autoregressive Integrated Moving Average (ARIMA) model which will be discussed 
shortly, though are more complex and computationally intensive to fit. Therefore, 
these models will not be further explored; instead the ARIMA class of models will 
now be introduced, which also provide a means of modelling univariate time series 
and dealing with complex patterns of seasonality and autocorrelation.  
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ARIMA methods provide a powerful modelling tool capable of incorporating the 
complex patterns of seasonality and autocorrelation likely to be evident in THIN 
data. There is no ‘one’ ARIMA model, rather a class of models which afford great 
flexibility when modelling time series of many different phenomena. The individual 
elements of the ARIMA class of models date back over 80 years, but George Box 
and Gwilym Jenkins are credited with combining these in 1976 into a 
comprehensive single class of model148; for this reason, the ARIMA approach to 
time series analysis is often described as the Box1Jenkins approach.   
 
An ARIMA model is built empirically from time series data and attempts to model 
mathematically the stochastic data1generating process which gave rise to the 
series, rather than adopting the deterministic approach of segmented regression 
where the analyst attempts to fit a pre1specified model to the data149. The 
empirical model1building approach of ARIMA analysis means such time series 
models routinely have R2 values (a measure of the adequacy of model fit) over 
0.9, indicating excellent model fit150.    
 
ARIMA methods are capable of modelling complex seasonal patterns in a time 
series, particularly when such seasonality has a stochastic component. Indeed, 
ARIMA methods should not be used with series that have been adjusted to 
remove the seasonal component, as the non1seasonal and seasonal components 
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of the model are best estimated simultaneously143. The empirical ARIMA approach 
to modelling seasonality requires fewer terms to account for seasonality, with 
perhaps only one extra degree of freedom being required144, another benefit of 
the ARIMA approach over segmented regression for modelling time series with a 
seasonal component.  
 
Dummy variables can be included in an ARIMA model to assess whether the 
mathematical model which best describes the data is different in one part of a 
time series compared to another, such as, for example, after smokefree legislation 
was introduced compared to the pre1legislation period. In this instance, a 
statistically significant change in the structure of the ARIMA model between time 
periods would be taken as evidence that the introduction of smokefree legislation 
had a significant effect on the outcome variable being modelled.     
 
 
Given the advantages of ARIMA modelling outlined above, this approach is the one 
that will be used to model THIN data and assess whether the introduction of 
smokefree legislation had a significant impact on the management of smoking in 
primary care. The following sections of this chapter explain in detail the 
mathematical basis of the ARIMA model and the stages involved in using such a 
model to assess the impact of an intervention on a time series.  
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Figure 4.7 outlines the general stages involved in time series analysis using 
ARIMA models. As with any data analysis, a crucial first step is for the analyst to 
familiarize themselves with their data and undertake a process of data cleaning. 
The data are then split into pre1intervention and post1intervention series, and an 
iterative procedure used to identify an appropriate model from the ARIMA class 
    
148 
which adequately describes the data1generating process which gave rise to the 
pre1intervention series. This iterative process involves first tentatively identifying 
a potential model, estimating the model parameters, and then undertaking several 
diagnostic checks to ensure the selected model is indeed appropriate. If the 
tentative model fails one or more of the diagnostic checks, a second model from 
the ARIMA class is proposed, and the estimation and diagnosis procedure 
repeated.   
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The iterative process of model identification, estimation and diagnosis is repeated 
until an ARIMA model is found which adequately describes the pre1intervention 
series and meets all diagnostic criteria. This selected model is then applied to the 
entire span of the time series, including the post1intervention data, and the 
analyst looks for evidence that the model does not fit the post1intervention series. 
If it does not fit, this is taken as evidence that the data1generating process 
changed significantly as a result of the introduction of the intervention, and 
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therefore that the intervention had a significant effect on the phenomenon under 
investigation.  
 
The following sections of this chapter work though each of the stages of 
interrupted time series analysis using ARIMA models, using the exemplar series to 
assess whether the introduction of smokefree legislation had a significant impact 
on rates of prescribing of NRT amongst smokers in the THIN dataset.  

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The first, crucial, stage in undertaking any time series analysis is to draw and 
inspect a time plot of the whole length of the series, such as that shown in Figure 
4.1. This section discusses a number of issues that must be addressed before 
starting the process of ARIMA model identification.   
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ARIMA models demand an observation is recorded for each point in time across 
the entire span of the series, though observations can take a value of zero. Given 
the longitudinal nature of the THIN dataset, the exemplar series being analysed 
here does not contain any missing data, nor do any of the series analysed in this 
thesis. However, there are several approaches to dealing with missing data should 
such a situation arise, and the choice of method can have an impact on the 
outcome of an interrupted time series analysis. Generally, missing data points 
should not be replaced with values representing the global or local mean of the 
series, as this can produce inaccurate estimates of the autocorrelation present in 
the series138. Similarly, ignoring the time points with missing data and analysing 
the shorter series will also produce inaccurate estimates of the serial dependence 
present in a series138. A more desirable approach is to impute maximum likelihood 
    
150 
estimates for the missing data, which has been shown to produce accurate 
estimates of the autocorrelation present in a series even when 40% of data points 
are missing138. An accurate assessment of the autocorrelation present in a series 
is a necessary pre1requisite of assessing the impact of an intervention on the 
series, as discussed previously in Section 4.2.1.  
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Outliers in a series, perhaps caused by measurement error or the impact of an 
unknown event, can have the same implications for analysis as the presence of 
missing data, biasing estimates of the level and slope of a series as well as the 
ACF. There are no obvious outliers in the exemplar series, but outliers in a series 
can be treated in the same way as missing data and replaced using a suitable 
imputation method135.  
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Time series data can potentially be collected at one temporal frequency, such as 
daily, and then aggregated to give measures at another frequency, such as 
weekly, monthly, quarterly or yearly. It is important that the frequency of data 
collection and temporal aggregation of a time series is appropriate to allow the 
hypothesised effect of an intervention to be assessed135. For example, if an 
intervention is introduced which is expected to have an effect on a series for the 
duration of just a few months, data collected yearly may fail to detect the 
temporary effect of the intervention. This issue must be addressed when planning 
the collection of any time series data, where financial and resource limitations 
may play a part in determining how frequently data can be collected. An 
advantage of the THIN dataset is that it allows data to be aggregated over any 
time period from daily upwards. The literature reviewed earlier suggests that the 
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effects of smokefree legislation may be seen in the months leading up to, and 
immediately after, the introduction of the policy, but potentially are not sustained 
in the longer1term. As a result, data aggregated quarterly or yearly are unlikely to 
detect these complex patterns. There is a necessary trade1off between temporal 
frequency and the computational demands involved in analysing time series with 
more data points. Therefore, data aggregated monthly will form the primary 
series analysed in this thesis, though a sensitivity analysis will be undertaken in 
Section 4.12.2 to assess whether data aggregated weekly results in similar 
estimates of the effect of the introduction of smokefree legislation on the 
exemplar time series.   
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Consideration must also be given to the length of a time series, though there are 
no accepted rules defining just how many data points are needed for time series 
analysis, and power calculation is difficult. A commonly1cited rule1of1thumb is that 
at least 50 data points are needed if an ARIMA model is to be fitted to a series, 
though simulation exercises suggest that three to five times this number may in 
fact be needed to determine whether the correct model has been chosen to 
represent a series135.  
 
The time series analysed in this thesis span the period from January 2000 (April 
2001 in the case of the NRT prescribing illustrated here) to July 2009, yielding a 
total of at least 100 monthly observations. Importantly, the study period includes 
data for a two1year period after the introduction of smokefree legislation in 
England, and slightly longer in the rest of the UK where legislation was introduced 
earlier, allowing the detection of any temporary effects of smokefree legislation or 
assessment of whether any impacts have been sustained. In addition, if a series is 
expected to contain a seasonal component then both the pre1 and post1
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intervention data must span enough seasons to enable detection and modelling of 
the pattern135. More consideration will be paid to seasonality in time series later in 
this chapter. 
 ## ./;0/./3(B;0./3;8;6<3;3234+<+;B
 
When planning the collection of data for an interrupted time series analysis, or 
before analysing data which have already been collected, it is crucial to consider 
several aspects of data quality which may influence the internal and external 
validity of a study151.   
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Ideally, identical methods should be used to collect the time series data at each 
point in time 1 instrumentation changes may invalidate an interrupted time series 
analysis, particularly if the means of observing the outcome variable changes at 
the same time the intervention under assessment is introduced and causes a 
change in the series which is mistaken for the effect of the intervention151. In this 
thesis, the use of automated methods to extract rates of smoking cessation 
activity from the THIN dataset for each month means the method of calculation of 
the outcome variable from the raw THIN data is constant over time and thus there 
are no instrumentation changes to confound assessment of the impact of the 
introduction of smokefree legislation.  
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The observations at each point in time must be directly comparable and there 
should be no changes over time in the composition of the population being 
studied151. In this thesis, consistent data extraction methods have been used to 
ensure that the population each month in whom rates of recording of smoking 
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status and intervention delivery are calculated consists of all THIN patients (or 
smokers in the analysis of cessation interventions) alive, actively registered with a 
participating practice, and aged 16 or over. This definition necessarily allows 
patients to move into and out of the denominator population each month and, 
therefore, the structure of the population with respect to patient characteristics 
such as sex, socio1economic status and medical history may vary from one month 
to the next. Such variation may result in these factors acting as confounders in 
the interrupted time series analysis, making it impossible to assess whether any 
observed changes result from the introduction of an intervention. Restricting the 
denominator to the same group of patients who are aged 16+ and registered in 
THIN for the whole of the 101year period studied here will not solve the potential 
confounding problem – over the course of the decade the average age of the 
denominator will increase by 10 years. The rate at which doctors intervene with 
smokers is known to vary by age62, and so the potential for confounding remains. 
Additionally, the socio1economic and health status of this constant group of 
patients may still change over time. A sensitivity analysis is presented in Section 
4.12.3 which assesses the potential degree of confounding caused by changes in 
denominator population characteristics over time.  
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When assessing the impact of an intervention on a time series it is important that 
any observed changes in a series can be attributed to the effect of that 
intervention only and not to other interventions or events which have had an 
effect on the series at the same time151. However, as shown in Figure 1.2 several 
tobacco control policies have been implemented in the UK over the past decade 
and the effects of some of these may confound the assessment of the impact of 
smokefree legislation on measures of clinical activity in primary care. The 
potential implications of this will be discussed in Section 4.12.4. 
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In many series some of the variation over time may be the result of differences in 
the number of days in each time period – the monthly value of retail sales, for 
example, will be determined in part by the number of 	 in each month. 
Similarly, the monthly rates derived from the primary care data analysed in this 
thesis will be determined in part by the number of days each month that surgeries 
are open, which ranges from 18 to 23 days per month across the study period. 
Some of the relatively low rates of NRT prescribing in December compared to 
other months, as discussed previously, may be due, for example, to practices 
being open for fewer days in December. In order to remove this source of 
variation, crude monthly rates can be adjusted for the number of surgery days per 
month using the following formula140:  
 
Adjusted rate = Unadjusted rate x Number of surgery days in monthAverage number of surgery days across all months  
 
The number of days practices were open in each month between January 2000 
and July 2009 was determined, accounting for closure at weekends, Christmas 
and Easter, and other bank holidays. The number and timing of bank holidays 
differs between jurisdictions of the UK, and so the number of surgery days each 
month was calculated separately for England, Scotland, Wales and Northern 
Ireland.   
 
Figure 4.8 shows the effect of this adjustment on the monthly rate of NRT 
prescribing. As can be seen, the adjustment increases the rate slightly in some 
months, and reduces it in others. Removing the effect of monthly variation in 
surgery days will now make it easier to detect and interpret other seasonal 
patterns in the series, and thus from this point forth all analyses and presented 
results will be based on adjusted data.  
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As noted previously, the essence of interrupted time series analysis using ARIMA 
methods is to fit an appropriate model to describe the data1generating process 
responsible for the pre1intervention data series, and then assess whether this 
process is altered by the introduction of the intervention. For this reason, 
identification of an appropriate ARIMA model is conventionally carried out on pre1
intervention data only135.  
 
It is a requirement of interrupted time series analysis that the intervention is 
introduced at a single, known point in time, allowing the separation of the pre1 
and post1intervention data. Smokefree legislation was introduced in England on 1st 
July 2007, and Figure 4.9 identifies the rate of prescribing of NRT observed in 
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THIN practices in England, highlighting the point at which smokefree legislation 
was implemented.  
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As the systematic review presented in Section 1.6 concludes, smokers may have 
attempted to quit in the months leading up to the introduction of smokefree 
legislation. It can be hypothesised that evidence in support of increased quitting 
activity may similarly be seen in THIN prescribing data. In order to test this 
hypothesis, and also to illustrate various aspects of ARIMA modelling and the 
implications of decisions made during the modelling process, this chapter will 
illustrate the use of interrupted time series analysis to assess whether there was a 
significant increase in the rate of prescribing of NRT to smokers in the month 
before the introduction of smokefree legislation in England, June 2007, and, if so, 
to quantify the magnitude of this effect. Visual inspection of Figure 4.9 suggests 
there may have been an increase in the rate of prescribing of NRT in June 2007, 
though it is difficult to be sure whether this is outside of the normal seasonal 
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pattern of prescribing. The method presented in the following sections will confirm 
whether indeed there was a statistically significant increase in NRT prescribing in 
June 2007, over and above the longer1term trend and seasonal pattern in the 
data. 
 
Initially, therefore, the data will be separated into a pre1intervention series 
spanning the period from April 2001 to May 2007, and a post1intervention period 
spanning the period from June 2007 to July 2009. The modelling techniques 
outlined in the remainder of this chapter can be followed and adapted to assess 
changes in prescribing, or any other outcome variable, in any time period.    
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In order to fit an ARIMA model to a time series dataset, the series must first be 
rendered stationary – the mean and variance of the data must be constant over 
time135. A series can be non1stationary as a result of several factors which can be 
identified from a time plot of the data and which will now be discussed in turn.  
 
Outliers will change the mean level of the series in the region of the aberrant point 
and so the mean will not be constant over time. As noted previously, outliers 
should be treated as missing data and replaced with imputed values135. There are 
no obvious outliers in Figure 4.9.  
 
As Figure 4.9 shows, there are slight differences in the variance of the series over 
time, with the magnitude of variation in the rate of prescribing from one month to 
the next being smaller at the start and end of the series compared to the middle 
section. In order to render the variance constant over time the series must be 
transformed – a log transformation is most commonly used. Even if the variability 
of a series does not change over time a log transformation may still be preferred – 
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a significant change of a given magnitude in a logged series is approximately 
equivalent to a percentage change in the unlogged data, perhaps a more intuitive 
way to present the results of ARIMA modelling.  
 
Figure 4.10 shows the logged pre1intervention series; as can be seen, logging the 
data has rendered the variance at the start of the series similar to that in the 
middle part of the study period.  
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The logged series shown in Figure 4.10 is still not stationary – there is a clear 
upwards trend in the data between 2001 and 2005 and thus the mean of the 
series is not constant over time. In order to remove the trend from a time series 
the data must be differenced – the value of the series at each point in time must 
be replaced by the value of the difference between that point and the data point in 
the preceding month, as shown for an excerpt of data in Table 4.1. Such a 
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difference cannot be calculated for the first value of the series, which is replaced 
with a missing value indicator.  
 
3A4/ 44-8;.3;+6(67<+77/./(5+(,67;0/46,,/<1./
+(;/.2/(;+6(8/.+/8
Month Value of logged series Differenced series 
May 2001 6.14 1 
Jun 2001 6.22 0.08 
Jul 2001 6.19 10.03 
Aug 2001 6.14 10.05 
Sep 2001 6.25 0.11 
Oct 2001 6.24 10.01 
Nov 2001 6.44 0.20 
Dec 2001 6.28 10.16 
Jan 2002 6.71 0.43 
Feb 2002 6.84 0.13 
Mar 2002 6.80 10.04 
Apr 2002 6.76 10.04 
 
 
Having differenced the logged pre1intervention series, the ACF of this differenced 
series must then be re1drawn to ensure that all evidence of non1stationarity has 
been removed. Figure 4.11 shows a time plot of the logged, differenced pre1
intervention series. 
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Significant autocorrelation remains in the series at lags 12, 24 and 36. This 
pattern of gradually diminishing autocorrelation at multiples of the seasonal order 
of the series is indicative of seasonal non1stationarity in a series. The series must 
be seasonally differenced in order to render it seasonally stationary – in the case 
of monthly data the value of the series at each point in time must be replaced by 
the value of the difference between that point and the data point in the same 
month of the previous year. Such seasonal differencing necessarily replaces the 
series with missing values for the first 12 months, and these months cannot then 
be used to fit the ARIMA model and assess the impact of an intervention. This is 
one reason why it is important to have a long pre1intervention data series when 
using ARIMA modelling.   
 
Figure 4.12 shows the ACF of the logged, first differenced and seasonally 
differenced pre1intervention series. There is no evidence of any remaining 
stationarity, either non1seasonal or seasonal in nature.  
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As the time plot of the logged, first differenced and seasonally differenced pre1
intervention series in Figure 4.13 shows, the trend has now been removed from 
the series and its variance is relatively constant over time. Occasionally it may be 
necessary to difference a series twice (i.e. compute the difference of an already1
differenced series) in order to render the series stationary, though this is rarely 
necessary. The analyst can now be satisfied that the series has been rendered 
stationary and can proceed to the next stage of analysis, model identification. 
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Having rendered the pre1intervention series stationary, the next stage of an 
interrupted time series analysis is to identify what form the autocorrelation 
present in a series takes and to build a mathematical model to represent the data1
generating process responsible for the series. There are two types of 
autocorrelation that may be present in a series – autoregressive and moving 
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average. This section details these in turn, and explains how the autocorrelation 
function (ACF) introduced already, and partial autocorrelation function (PACF), to 
be described shortly, can be used to assess whether a series contains such 
autocorrelation. Then, this knowledge will be used to determine the type of 
autocorrelation present in the exemplar series being used in this chapter to 
illustrate the principles of time series analysis.   
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If autoregressive autocorrelation is present in a time series, the value of the series 
at a particular point in time is a function of the value of the series at an earlier 
point in time, plus an error component. In an autoregressive process of order one 
– AR(1) – the value of a series at one point in time (Yt) is the sum of a fraction 
(Ø1) of the value of the series at the immediately preceding point in time(Yt11) 
and an error component (et)
135: 
 
Y = ∅Y + e                                                  
 
Similarly, in an AR(2) process the value of a series at any point in time is the sum 
of fractions of the values of the series at the two immediately preceding time 
pointsas well as an error component: 
 
Y = ∅Y + ∅!Y! + e 
 
Autoregressive processes produce characteristic patterns in the ACF of a 
stationary series. However, before considering these, it is necessary to introduce a 
related concept, the partial autocorrelation function (PACF). The PACF illustrates 
the autocorrelation present in a series at different lags having removed, or 
‘partialled out’, the effect of autocorrelation at intermediate lags135. It is not 
always possible to distinguish between autoregressive processes of different 
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orders on the basis of the ACF alone, but the PACF provides additional information 
to allow the analyst to correctly identify the order of autoregressive 
autocorrelation present in a series. Figure 4.14 shows the characteristic patterns 
seen in the ACF and PACF of time series displaying autoregressive autocorrelation 
of different magnitudes.  
 
Order of 
autoregressive 
process 
Value of AR 
parameter 
ACF PACF 
AR(1) 
Ø1 > 0 
  
Ø1 < 0 
  
AR(2) 
Ø1 > 0 
Ø2 > 0 
  
Ø1 < 0 
Ø2 > 0 
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As Figure 4.14 shows, autoregressive processes typically produce ACFs with 
gradually1decaying autocorrelation at increasing lags, a pattern which is the same 
for AR(1) and AR(2) processes (and indeed all autoregressive processes 
regardless of order). Recourse to the PACF is needed to distinguish the order of an 
autoregressive process; the PACF will show significant autocorrelation at lags 
corresponding to the order of the process. For example, the ACF of an AR(1) 
process where the direction of autocorrelation is negative will show gradually1
decaying autocorrelation alternating in sign, and the PACF will show significant 
negative autocorrelation at lag 1 only.    
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If moving average autocorrelation is present in a time series, the value of the 
series at a particular point in time is a function of the error component (the 
difference between the observed value of the series and that estimated by the 
ARIMA model) from the series at an earlier point in time and an error component 
at the current time. In a moving average process of order one – MA(1) – the 
value of a series at one point in time (Yt) is a function of a fraction (θ1) of the 
error component of the series at the immediately preceding point in time (et11)
and an error component at the current point in time (et)
135: 
 
Y =  e − θe 
 
Similarly, in an MA(2) process the value of a series at any point in time is a 
function of a fraction of the error component of the series at the two immediately 
preceding time points and an error component at the current point in time: 
 
Y =  e − θe − θ!e! 
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Figure 4.15 shows the typical patterns seen in the ACF and PACF of stationary 
time series displaying moving average autocorrelation. As can be seen, the ACF is 
more helpful here in distinguishing between moving average processes of different 
orders. As Figure 4.15 shows, moving average processes typically produce PACFs 
with gradually1decaying autocorrelation at increasing lags, and ACFs with 
significant autocorrelation at lags corresponding to the order of the process. 
 
Order of moving 
average process 
Value of MA 
parameter 
ACF PACF 
MA(1) 
θ1 > 0 
  
θ1 < 0 
  
MA(2) 
θ1 > 0 
θ2 > 0 
  
θ1 < 0 
θ2 < 0 
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It is possible that the data1generating process responsible for a time series is best 
represented by a mixed process combining both autoregressive and moving 
average autocorrelation. For example, a process combining autoregressive 
autocorrelation of order two with moving average correlation of order two may be 
represented by the following equation135:   
 
$% = ∅$% + ∅!$%! + &% − '&% − '!&%! 
 
Figure 4.16 shows the typical patterns seen in the ACF and PACF of stationary 
time series displaying mixed autoregressive and moving average autocorrelation. 
As can be seen, both the ACF and PACF of a mixed process show gradually1
decaying autocorrelation at increasing lags. 
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Order of 
autoregressive 
and moving 
average process 
Value of AR 
(Ø) and  
MA (θ) 
parameter 
ACF PACF 
ARMA(1,1) 
Ø1 > 0 
θ1 > 0 
  
Ø1 > 0 
θ1 < 0 
  
Ø1 < 0 
θ1 > 0 
  
Ø1 < 0 
θ1 < 0 
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Time series can also display autoregressive and moving average autocorrelation at 
seasonal lags. Figure 4.17 and Figure 4.18 show the characteristic patterns seen 
in the ACF and PACF of stationary monthly time series displaying seasonal 
autoregressive or moving average autocorrelation.  
 
Order of 
autoregressive 
process 
Value of AR 
parameter 
ACF PACF 
AR(1)12 
Ø1 > 0 
  
Ø1 < 0 
  
AR(2)12 
Ø1 > 0 
Ø2 > 0 
  
Ø1 < 0 
Ø2 > 0 
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Order of moving 
average process 
Value of MA 
parameter 
ACF PACF 
MA(1)12 
θ1 > 0 
  
θ1 < 0 
  
MA(2) 12 
θ1 > 0 
θ2 > 0 
  
θ1 < 0 
θ2 < 0 
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As Figure 4.17 shows, seasonal autoregressive processes typically produce ACFs 
with gradually1decaying autocorrelation at multiples of the number of seasons in a 
year. For data aggregated monthly this equates to autocorrelation at lags 12, 24, 
36 and so on. In data aggregated quarterly, autocorrelation would be observed at 
lags 3, 6, 9, 12 and so on, and in data aggregated weekly at lags 52, 104, 156 
and so on. For a seasonal autoregressive process the PACF will show significant 
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autocorrelation at multiples of the number of seasons in a year, with the absolute 
number of significant lags corresponding to the order of the process. As was seen 
in non1seasonal processes, the pattern in the ACF and PACF is reversed if seasonal 
moving autocorrelation is present in a series.  
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Finally, it is possible that a time series may be best represented by a model which 
combines elements of both non1seasonal and seasonal autocorrelation. Interaction 
between the non1seasonal and seasonal components of a model can produce 
‘satellite effects’ in the ACF, making interpretation difficult152. Figure 4.19 shows 
two examples of how non1seasonal and seasonal moving average behaviour may 
interact to produce an ACF which displays satellite effects. As can be seen, the 
non1seasonal autocorrelation is reflected either side of the seasonal 
autocorrelation.  
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Having outlined the two types of autocorrelation that may be present in a time 
series, and shown how the ACF and PACF of the data can be used to identify their 
presence, it is now appropriate to examine the ACF and PACF of the stationary 
pre1intervention exemplar series, with the aim of tentatively suggesting the type 
of autocorrelation present in the data and building an ARIMA model to represent 
the data1generating process.  
 
Figure 4.20 shows the ACF and PACF of the logged, first differenced and 
seasonally differenced pre1intervention series. This figure shows clearly that, 
unfortunately, autocorrelation functions are rarely as easy to interpret as the 
typical ACFs and PACFs in Figure 4.14 to Figure 4.19 suggest. However, it is worth 
bearing in mind that time series rarely contain autoregressive or moving average 
autocorrelation of an order higher than two151; in a re1analysis of 70 time series 
studies published in the academic literature, 80% of series could be satisfactorily 
represented by an AR(1) process153. Higher1order models can often be 
represented by mathematically1equivalent lower1order processes135; for example, 
an MA(2) process can almost always be adequately modelled using an AR(1) 
model150. In addition, it is likely that only a very small minority of time series will 
be best represented by a mixed model – only a few series in a thousand according 
to one estimate136. Therefore, a mixed model should not be adopted until more 
simple models involving just autoregressive or moving average parameters have 
been ruled out.   
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The significant autocorrelation at lags 12 and 24 in the PACF in Figure 4.20 hints 
at the presence of seasonal autoregressive autocorrelation of order two in the 
stationary series. It is not immediately obvious how to interpret the other 
significant autocorrelations in the PACF – there is, for example, unlikely to be non1
seasonal autoregressive autocorrelation of order six in the series, despite the 
significant autocorrelation at lag six in the PACF. The suggestion of seasonal 
autoregressive autocorrelation of order two does, however, provide a starting 
point for model identification and estimation.  
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An ARIMA model is conventionally described using the general syntax: 
 
 
 
 
 
 
ARIMA +p, d, q/+P, D, Q/3 
 
 
 
 
 
where: 
p = order of non1seasonal autoregressive autocorrelation 
d = order of non1seasonal differencing needed to obtain non1seasonal stationarity 
q = order of non1seasonal moving average autocorrelation 
P = order of seasonal autoregressive autocorrelation 
D = order of seasonal differencing needed to obtain seasonal stationarity 
Q = order of seasonal moving average autocorrelation 
s = seasonal order of series (number of seasons in a year)  
 
In Section 4.6.2 it was shown that the exemplar time series must be both first 
differenced and seasonally differenced into order to render it stationary; 
therefore, in this example, both d and D are equal to one. Having tentatively 
identified the existence of seasonal autoregressive autocorrelation of order two in 
the stationary series, the ARIMA model which potentially represents the pre1
intervention section of the exemplar time series can be written as: 
  
ARIMA +0,1,0/+2,1,0/! 
 
This specification provides a starting point for model identification. As discussed 
previously, model identification is an iterative process, with models being 
suggested, estimated, evaluated and refined until the most appropriate model is 
Non1seasonal 
component 
Seasonal 
component 
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found. The following sections detail the stages involved in estimating and 
evaluating an ARIMA model. 
 
  		
 
Having identified a tentative ARIMA model to describe the pre1intervention series, 
the ‘arima’ command in Stata can be used to estimate the values of the 
autoregressive and moving average parameters in the model. 
 
Stata uses maximum likelihood estimation (MLE) to select values for the model 
parameters which maximise the likelihood of the observed result125, returning 
point estimates along with a 95% confidence interval and Wald p1value. Table 4.2 
shows parameter estimates returned when an ARIMA(0,1,0)(2,1,0)12 model is 
fitted to the logged pre1intervention series.  
 
 
3A4/ 3.39/;/./8;+93;/876.>$DD$?>DD$?96</4
Parameter Estimate 95% confidence interval Wald p1value 
AR(1)12 10.416 10.061 to 10.771 0.022 
AR(2)12 10.285 10.025 to 10.554 0.032 
 
 
 
These parameter estimates can be substituted into the general formula for an 
autoregressive ARMA process described previously to show the mathematical 
process which describes the logged, pre1intervention time series: 
 
Y = −0.416 Y! + −0.285 Y!< + e 
 
Once a model has been estimated, the next step is to carry out various diagnostic 
tests to assess the model’s adequacy and, if necessary, find a more appropriate 
model to describe the series.  
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 & 	
 
As with other statistical modelling techniques, the aim of ARIMA model 
identification is to select the most parsimonious model, containing as few 
parameters as possible, which adequately represents the data154. This section 
outlines several checks that should be undertaken to ensure a selected model is 
parsimonious and appropriate. Attention will be paid to the statistical significance 
of the autoregressive and moving average parameters, restrictions on the 
magnitude of these parameters and features of the model residuals.  
 
 & ./344;0/96</413.39/;/.88;3;+8;+5344B8+,(+7+53(;
 
Guided by the principle of parsimony, no autoregressive or moving average 
parameters should be included in the final ARIMA model if they are not statistically 
significant at the 5% significance level. As can be seen in Table 4.2, the two 
autoregressive parameters are both statistically significant, suggesting that the 
tentative model selected may be an appropriate one to describe the data. On this 
criterion of parameter significance alone the ARIMA(0,1,0)(2,1,0)12 model can be 
accepted. However, other diagnostic tests for model adequacy must also be 
carried out before finally accepting a particular model.  
 
 & 6;0/96</413.39/;/.84+/C+;0+(;0/A6-(<8678;3;+6(3.+;B3(<
+(2/.;+A+4+;B
 
In order for a model to be selected as an appropriate representation of a data1
generating process, the values of the autoregressive and moving average 
parameters must fall within certain bounds, known as the bounds of stationarity 
and invertibility. These bounds apply to both the n
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model parameters. These bounds of stationarity for AR(1) and AR(2) processes, 
and bounds of invertibility for MA(1) and MA(2) processes are shown in Table 4.3.  

3A4/ 6-(<8678;3;+6(3.+;B3(<+(2/.;+A+4+;B76.96</413.39/;/.8
 
Bounds of stationarity for 
autoregressive parameters 
Bounds of invertibility for moving 
average parameters 
Order 1 
 
11 < Ø1 < 1 
 
11 < θ1 < 1 
 
Order 2 
 
11 < Ø2 < 1 
Ø1 + Ø2 < 1 
Ø2 – Ø1 < 1 
 
11 < θ2 < 1 
θ1 + θ2 < 1 
θ2 – θ1 < 1 
Ø = autoregressive autocorrelation parameter; θ = moving average autocorrelation parameter 
 
The autoregressive parameters estimated in Table 4.2 fall within the bounds of 
stationarity, and therefore the ARIMA(0,1,0)(2,1,0)12 model passes this diagnostic 
test. Parameter estimates close to, or outside of, the bounds of stationarity and/or 
invertibility may suggest that the time series has not been rendered stationary 
before fitting the ARIMA model, and the model estimating procedure may fail to 
converge to estimates of the parameters. If this occurs it is advisable to re1check 
whether the series has indeed been rendered stationary through non1seasonal 
and/or seasonal differencing prior to model fitting. 
 
 & ./3(B67;0/96</413.39/;/.85644+(/3.
 
Again following the guiding principle of parsimony, parameter estimates in a 
selected model should not be collinear. Table 4.4 shows the extent of collinearity 
between the AR(1)12 and AR(2)12 parameters included in the estimated model. 
 
 
3A4/  644+(/3.+;BA/;C//(96</413.39/;/.8
 
AR(1)12 AR(2)12 
AR(1)12 1 - 
AR(2)12 -0.365 1 
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The time series literature does not contain any specific guidance on the extent of 
correlation between parameter estimates that the analyst should be concerned 
about. However, a correlation coefficient of more than 0.8 is sometimes taken to 
indicate very high collinearity155 and would suggest a need for one of the collinear 
parameters to be removed from the model. In this instance collinearity between 
model parameters does not appear to be a problem.  
 
 &  ./;0/96</4./8+<-348(6.9344B<+8;.+A-;/<
 
Figure 4.21 shows the frequency distribution of the residuals from the 
ARIMA(0,1,0)(2,1,0)12 model, standardised to have a mean of zero and a standard 
deviation of one. This standardisation makes it easier to detect outliers – any 
residuals with an absolute value greater than three are worthy of further 
investigation140. The histogram is overlaid with a normal distribution with the 
same mean and standard deviation as the residuals. 
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An adequately1fitting ARIMA model will have residuals which are normally1
distributed with no obvious outliers. It appears that the ARIMA(0,1,0)(2,1,0)12 
model produces residuals which meet this diagnostic criterion.  
 
 &# 8;0/23.+3(5/67;0/96</4./8+<-34856(8;3(;62/.;+9/
 
Figure 4.22 shows the standardised model residuals plotted over time. In an 
appropriate ARIMA model the variance of the residuals will be relatively constant 
over time, and this does appear to be the case for the ARIMA(0,1,0)(2,1,0)12 
model. 
 
 
+,-./ 53;;/.146;6796</4./8+<-34862/.;+9/
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 &% ./;0/./8+<-348.3(<693(<+(</1/(</(;
 
Finally, the model residuals must be random and independent, resembling, in 
parlance borrowed from the field of engineering, a white noise process. The 
easiest way to assess this requirement is to plot an ACF of the model residuals, as 
shown in Figure 4.23. 
 
 
+,-./ 67./8+<-3487.69;0/>$DD$?>DD$?96</4
 
If the ACF shows no significant autocorrelation between residuals at any lag then 
the residuals are confirmed as random and independent, a white noise process, as 
is the case in Figure 4.23. However, an ACF may contain one or two significant 
autocorrelations purely by chance, and autocorrelation at higher lags is difficult to 
interpret, particularly in short time series, given the few pairs of observations 
which can be formed at high lags144. Therefore, a portmanteau test, the Ljung1Box 
Q test, can be carried out to assess whether the whole ACF up to a certain lag (lag 
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20 is most frequently used) is indicative of a white noise process140. The Ljung1
Box Q statistic is calculated as follows:  
 
= = >+> + 2/ ?+> − @/ AB!
C
BD
 
 
where  n = number of observations in series 
 h = maximum lag to be tested (commonly 20) 
 AB  = autocorrelation at lag k 
 
If the residual ACF is a white noise process, the Ljung1Box Q statistic follows a 
chi1squared distribution with (h1m) degrees of freedom, where m is the number of 
parameters in the ARIMA model fitted to the series140. Therefore, the null 
hypothesis of a white noise process can be rejected if the value of Q is larger than 
the critical value of the chi1squared distribution at the 5% significance level.  
 
The Ljung1Box Q test on the model residuals up to lag 20 shown in Figure 4.23 
yields a Q statistic of 18.79, which when tested against a chi1squared distribution 
using 18 degrees of freedom yields a p1value of 0.600, confirming that the 
residual ACF is indeed a white noise process.  
 
The diagnostic tests presented here suggest that an ARIMA(0,1,0)(2,1,0)12 model 
is a good representation of the logged pre1intervention data series. However, this 
model contains two parameters, and, in the light of the ambiguous PACF in Figure 
4.20, it may be that the series can also be represented by a simpler model 
containing just one parameter. When a model tentatively chosen to represent a 
time series fails one or more diagnostic tests, or if the analyst suspects a more 
parsimonious model may be possible, the next step is to suggest an alternative 
ARIMA model and to repeat the model estimation procedure and diagnostic tests. 
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  	!			
 
As the work presented thus far alludes to, identifying an appropriate ARIMA model 
to represent a pre1intervention series is an extremely time1consuming task, and it 
may not be immediately clear which of the class of ARIMA models is the best 
starting point for model identification. The time1consuming nature of model 
identification will be further amplified when many series are to be analysed, as is 
the case in this thesis which aims to assess the impact of smokefree legislation in 
subgroups of the population defined by categories such as age, sex and social 
class. The model chosen to represent rates of prescribing of smoking cessation 
medications in all smokers in England may not be the same, for example, as the 
model that best describes the time series of rates of prescribing in women and 
men separately. An automated procedure to help identify the most appropriate 
ARIMA model to represent a series is highly desirable.   
 
  -;693;+(,;0/96</4+</(;+7+53;+6(1.65/<-./
 
In order to help identify the best ARIMA model to describe a time series I have 
written a procedure in Stata (the ‘arimaintervention’ command) that, when told 
whether a time series requires a log transformation and/or differencing to render 
it stationary, fits several different ARIMA models to the pre1intervention data, 
systematically working through combinations of non1seasonal and seasonal 
autoregressive and moving average parameters of order zero, one and two. As 
noted previously, it is very unlikely that a series will best be represented by a 
model containing either autoregressive or moving average autocorrelation above 
order two, justifying the upper limit of two placed on the parameters in the 
models tested. For each model that is fitted, the automated procedure assesses 
whether the model estimation procedure converged to produce parameter 
estimates, assesses whether all parameters are statistically significant and fall 
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within the bounds of stationarity and invertibility, and uses a Ljung1Box Q test to 
judge whether the residuals are a white noise process. In addition, the procedure 
highlights the absolute magnitude of the largest standardised residual to allow 
detection of possible outliers and computes two estimates of model fit, R2 and the 
AIC, which will be discussed shortly. Further details regarding the specification of 
this automated procedure are presented in Appendix 8.12. 
 
Table 4.5 illustrates the output from this automated procedure applied to the pre1
intervention portion of the exemplar series, indicating, of the 81 different ARIMA 
models estimated in total, which pass the diagnostic tests of model adequacy and 
can, therefore, be considered as potential representations of the pre1intervention 
series. 
  
As Table 4.5 shows, four models meet all parameter diagnostic criteria and 
produce residuals which resemble a white noise process, suggesting they may 
adequately represent the data generating process behind the pre1intervention 
time series 1 ARIMA(0,1,0)(0,1,0)12, ARIMA(0,1,0)(1,1,0)12, 
ARIMA(0,1,0)(2,1,0)12 and ARIMA(0,1,0)(0,1,1)12. The absolute magnitude of the 
largest standardised residual for each of these models does not suggest there are 
any major residual outliers which might have allowed the selection of one model 
over the others as the best representation of the pre1intervention series. As can 
be seen, the R2 values indicating model fit are high for all models – over 0.90. 
However, R2 values are rarely used by time series analysts as measures of model 
fit or to choose one model over another. The value of R2 necessarily improves as 
more parameters are added to the ARIMA model, though the principle of 
parsimony suggests a contradictory need to choose the model with the fewest 
possible terms to model a time series143. Similarly, one model cannot be chosen 
over another on the basis of its sum of squared errors or likelihood, as the values 
of these can also be improved by increasing the number of terms in the model140.  
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3A4/ #6913.+86(67;0/3</J-35B67<+77/./(;96</48
Model 
(pdqPDQ) 
Did the 
model 
estimating 
procedure 
converge? 
Are all 
parameters 
statistically 
significant? 
Are all AR 
parameters 
within the 
bounds of 
stationarity? 
Are all MA 
parameters 
within the 
bounds of 
invertibility? 
Are the 
residuals 
a white 
noise 
process? 
R2 
Model 
AIC 
Largest 
standardised 
residual  
Possible 
model? 
010010      2.33 1141.28 0.923  
110010  
 
   2.41 1139.34 0.923 
 
210010  
 
   2.45 1138.68 0.924 
 
011010  
 
   2.44 1139.37 0.923 
 
111010    
 
 2.38 1137.83 0.925 
 
211010  
 
   2.44 1136.86 0.924 
 
012010  
 
   2.46 1138.29 0.924 
 
112010  
 
   2.45 1136.31 0.924 
 
212010  
   
 2.95 1142.50 0.932 
 
010110      2.53 1144.53 0.928  
110110  
 
   2.58 1142.84 0.929 
 
210110  
 
   2.60 1141.72 0.930 
 
011110  
 
   2.64 1142.94 0.929 
 
111110  
 
   2.65 1141.23 0.929 
 
211110  
 
   2.60 1139.82 0.930 
 
012110  
 
   2.61 1141.57 0.929 
 
112110  
 
   2.61 1139.57 0.929 
 
212110   
  
 3.05 1146.10 0.937 
 
010210      2.59 1145.33 0.932  
110210  
 
   2.61 1143.61 0.932 
 
210210  
 
   2.64 1143.23 0.934 
 
011210  
 
   2.70 1143.75 0.932 
 
111210  
 
   2.71 1142.14 0.932 
 
211210  
 
   2.63 1141.26 0.934 
 
012210  
 
   2.65 1142.84 0.933 
 
112210  
 
   2.64 1140.89 0.933 
 
212210  
 
 
 
 2.76 1146.10 0.938 
 
010011      2.68 1146.90 0.931  
110011  
 
   2.70 1145.27 0.931 
 
210011  
 
   2.71 1144.54 0.933 
 
011011  
 
   2.71 1145.43 0.931 
 
111011  
 
   2.74 1143.76 0.932 
 
211011  
 
   2.72 1142.56 0.933 
 
012011  
 
   2.74 1144.26 0.933 
 
112011  
 
   2.73 1142.29 0.933 
 
212011   
  
 3.09 1148.14 0.940 
 
010111  
 
   2.65 1145.01 0.932 
 
110111  
 
   2.67 1143.32 0.932 
 
210111  
 
   2.68 1142.71 0.933 
 
011111  
 
   2.69 1143.47 0.932 
 
111111  
 
   2.72 1141.82 0.932 
 
211111  
 
   2.69 1140.74 0.933 
 
012111  
 
   2.71 1142.38 0.933 
 
112111  
 
   2.71 1140.41 0.933 
 
212111  
 
 
 
 2.67 1144.19 0.937 
 
010211  
 
   2.61 1143.66 0.932 
 
110211  
 
   2.64 1141.97 0.932 
 
210211  
 
   2.65 1141.61 0.934 
 
011211  
 
   2.72 1142.14 0.932 
 
111211  
 
   2.72 1140.51 0.933 
 
211211  
 
   2.65 1139.63 0.934 
 
012211  
 
   2.68 1141.21 0.934 
 
112211  
 
   2.67 1139.28 0.934 
 
212211  
 
 
 
 2.75 1144.31 0.938 
 
010012  
 
   2.63 1145.07 0.932 
 
110012  
 
   2.66 1143.35 0.932 
 
210012  
 
   2.65 1142.83 0.934 
 
011012  
 
   2.69 1143.49 0.932 
 
111012  
 
   2.70 1141.85 0.932 
 
211012  
 
   2.67 1140.86 0.934 
 
012012  
 
   2.69 1142.47 0.933 
 
112012  
 
   2.69 1140.50 0.933 
 
212012 
  
 
 
 3.02 1145.49 0.938 
 
010112  
 
   2.62 1143.16 0.932 
 
110112  
 
   2.65 1141.44 0.932 
 
210112  
 
   2.65 1140.97 0.934 
 
011112  
 
   2.69 1141.57 0.932 
 
111112  
   
 2.73 1140.98 0.932 
 
211112  
 
   2.66 1139.01 0.934 
 
012112  
 
   2.69 1140.59 0.933 
 
112112  
 
   2.68 1138.63 0.933 
 
212112 
  
 
 
 3.10 1145.00 0.939 
 
010212  
 
 
 
 2.59 1142.97 0.933 
 
110212  
 
 
 
 2.73 1141.60 0.933 
 
210212  
 
 
 
 2.76 1140.91 0.935 
 
011212  
 
 
 
 2.83 1141.86 0.933 
 
111212  
 
 
 
 2.81 1140.11 0.934 
 
211212  
 
 
 
 2.77 1138.94 0.935 
 
012212  
 
 
 
 2.71 1140.53 0.934 
 
112212  
 
 
 
 2.75 1138.77 0.935 
 
212212  
 
 
 
 2.77 1142.42 0.938 
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The solution traditionally employed by time series analysts is to compute a 
measure of model fit which penalises the likelihood for each additional parameter 
included in a model. --0(			 (AIC) is the most frequently 
used measure, and is calculated as follows140: 
 
AIC = 2k − 2 ln+L/ 
 
where  k = number of autoregressive and moving average parameters in model 
 L = likelihood of estimated model 
 
Models with a smaller AIC (taking negative signs into account) are preferred over 
models with a larger AIC. Of the four ARIMA models identified as potentially 
adequate, ARIMA(0,1,0)(0,1,1)12 has the lowest AIC (1146.90) and so this model 
will be selected as the most appropriate model to represent the pre1intervention 
data series. Generally the model with the lowest AIC will have residuals that 
resemble a white noise process. However, on occasion it might be necessary, and 
is acceptable, to select a model with a slightly higher AIC but no residual 
outliers140. Should the exploration of model adequacy fail to identify any ARIMA 
models which adequately represent a series it is recommended that the series is 
checked again for outliers and to ensure the correct differencing transformation 
has been applied to render the series stationary. Additionally, the p1values 
estimated for the autoregressive and moving average parameters should be 
checked – a model with a parameter which is only marginally non1significant can 
acceptably be used to model a series.  
 
The selected ARIMA(0,1,0)(0,1,1)12 model produces an estimate for the one 
seasonal moving average parameter as shown in Table 4.6. As can be seen, this 
model parameter is highly statistically significant and falls within the bounds of 
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invertibility. As there is only one parameter in this model it is not necessary to 
undertake a check for collinearity of parameters. 
 
3A4/ %3.39/;/./8;+93;/876.>$DD$?>$DD?96</4
Parameter Estimate 
95% confidence 
interval 
Wald p1value 
MA(1)12 10.513 10.851 to 10.177 0.003 
 
 
Having identified an ARIMA model to represent the pre1intervention time series, 
the impact of an intervention on this series can now be assessed.  
 
 $ 		
 
In Section 4.9 the ARIMA(0,1,0)(0,1,1)12 model was selected as the best model 
from the ARIMA class to represent the pre1intervention time series. This model 
can now be applied to the whole time series, including the post1intervention data, 
and an assessment made as to whether there was a statistically significant 
increase in the rate of prescribing of NRT in smokers in THIN in England in June 
2007. 
 
The introduction of an intervention is a deterministic event with no stochastic 
component, and so can be modelled in an interrupted time series analysis using a 
dummy variable135. If the pre1intervention ARIMA(p,d,q)(P,D,Q)s model is 
represented as Nt, the impact assessment model can be written as: 
 
$% = H+I%/ + J% 
 
In the above equation, f(It), is a function representing the intervention component 
of the model136. This dummy variable can take several forms depending upon the 
impact the intervention is expected to have on the series, and prior to undertaking 
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any interrupted time series analysis one should review any existing literature and 
theory to formulate a hypothesis describing the expected effect135. 
 
The most simple effect of the introduction of an intervention is to cause an 
immediate, permanent increase or decrease in the level of the time series (often 
referred to as a step change), as illustrated in Figure 4.24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To assess whether the introduction of an intervention caused a step change in a 
time series, a dummy variable must be generated which takes the value 0 for all 
points in time before the introduction of the intervention, and the value 1 for all 
points in time at and after the introduction of the intervention.  
 
Another simple effect of the introduction of an intervention may be to cause a 
sudden but temporary change in the level of the series at that point in time, 
referred to in the time series literature as a pulse and illustrated in Figure 4.25.  
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A pulse may modelled to last just one time period, such as a month, or more than 
one period, spanning several months, using a dummy variable which takes the 
value 0 for all points in time before and after the intervention period, and the 
value 1 during the intervention period.  
 
As discussed in Section 4.6.1, this chapter seeks to illustrate the use of 
interrupted time series analysis by assessing whether there was a significant 
change in the rate of prescribing of NRT amongst smokers in June 2007 and, if so, 
to quantify the magnitude of this change. This equates to testing for a pulse effect 
in June 2007.  
 
In the model identification procedure documented above, an ARIMA model was 
chosen which best represented the log1transformed pre1intervention series. In 
assessing the impact of smokefree legislation on the series, the impact 
assessment model must be applied to the whole span of the series, including the 
post1intervention data, again once this has been log1transformed.  
 
Table 4.7 shows the parameter estimate for a pulse effect in June 2007 obtained 
when an impact assessment model is estimated including a dummy variable coded 
as 1 in June 2007 and 0 in all other months. 
 
3A4/ 6</44+(,;0//77/5;67
Change in prescribing in 
June 2007 
95% confidence 
interval 
Wald p1value 
0.175 0.111 to 0.240 <0.001 
 
 
The interrupted time series analysis suggests that there was a statistically 
significant increase in the rate of prescribing of NRT of 0.175 units on the 
logarithmic scale in June 2007 (equivalent to an increase of 17.5% in the original 
series).  
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In this example, the ARIMA model detected a statistically significant change in the 
outcome variable during the intervention period. However, if an interrupted time 
series analysis indicates there was no statistically significant change in an 
outcome variable during an intervention period it may be because the ARIMA 
model had a low probability of rejecting the null hypothesis of no significant 
change even if this hypothesis was false. 
 
The following section presents a method to assess the power of an ARIMA model 
to detect a change of a given magnitude in a time series. 
 
  	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Prior to starting data collection, many study designers undertake a power 
calculation to quantify the sample size needed to detect a specified effect size with 
a given level of statistical power. A power of 80% is often considered 
appropriate156. Such a calculation requires an estimate to be made of the effect 
size likely to be observed and the level of variance likely to exist in the data, 
estimates which may be difficult to make, particularly if there is no existing 
literature in the subject area as is the case with the work presented in this thesis. 
An alternative to this prospective power analysis is to compute a retrospective 
indication of the power of a study to detect a significant effect, using the variance 
observed in the sample to calculate the minimum effect size that could be 
detected with a statistical power of 80%157. 
 
Very few interrupted time series analyses published to date discuss the power of 
the analytical methods used, and it is only within the last five years that methods 
have been developed for computing the power of interrupted time series analysis 
carried out using ARIMA models158. The equation below shows the formula which 
    
189 
can be used to calculate the power of an ARIMA model to detect an effect size of 
magnitude δ158: 
 
 
Π+δ/ =  ΦL−Z∝/! −  δ/seP +δ/Q +  1 −  ΦLZ∝/! −   δ/seP +δ/Q 
 
 
where Φ = the cumulative distribution of the standard normal distribution 
 Z∝/! = the upper 11α/2 quantile of the standard normal distribution 
 δ = effect size 
 seP +δ/ = standard error of effect size derived from ARIMA model 
 
This equation can be solved for incremental values of δ in order to draw a power 
curve depicting the power of the ARIMA model to detect effect sizes of different 
magnitudes given the degree of variance observed in the time series. From this 
power curve, the minimum effect size which can be detected with 80% power can 
be determined. 
 
The standard error for the estimate of a pulsatile increase in the rate of 
prescribing of NRT in June 2007 is 0.033. Substituting this value into the equation 
above, the power curve shown in Figure 4.26 can be drawn. This power curve 
suggests that the minimum effect size which the ARIMA model can detect with 
80% power, given the degree of variation in the data, is a pulse of 0.092 in the 
logged series (equivalent to a 9.2% change in the unlogged data). The effect size 
actually estimated by the ARIMA model was a pulse of 0.175 in the logged series, 
larger than this minimum detectible effect, and hence there was a probability 
greater than 80% that the ARIMA model would detect as statistically significant 
the 17.5% change in NRT prescribing.  
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This chapter to this point has outlined the principles of ARIMA modelling and the 
use of interrupted time series analysis to assess the impact of an intervention on 
a series. In the following section, various sensitivity analyses will be presented 
which evaluate the impacts of ARIMA model misspecification and potential 
confounding on the conclusions reached regarding the impact of an intervention 
on a time series.  
 
  	!!	
 
  0//77/5;86796</49+881/5+7+53;+6(
 
As shown previously, interrupted time series using ARIMA modelling requires the 
identification of an appropriate model from the ARIMA class which best represents 
the pre1intervention data series. This can be a very1consuming process and, 
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unless automated methods such as that developed here are used to narrow down 
the number of potential models, an element of judgement is required in 
interpreting the series ACF and PACF at each iteration of the model selection 
process. It is possible that this element of subjectivity may lead different analysts 
to select different ARIMA models to represent the same data series. The use of 
different models to represent the pre1intervention data generating process may 
ultimately lead to different conclusions regarding the impact of an intervention on 
the series.    
 
The ‘arimaintervention’ command described earlier will also, for each ARIMA 
model estimated, calculate the magnitude of change in the outcome variable in 
the intervention period, along with 95% confidence intervals and a Wald p1value 
for the parameter. The results can then be scanned visually to assess whether the 
choice of model influences the magnitude and statistical significance of the change 
in the outcome variable estimated in the intervention period. 
 
In order to assess the impact of model misspecification, Table 4.8 shows the 
parameter estimates and p1values generated from different ARIMA models for the 
change in the rate of prescribing of NRT to smokers in June 2007.  
 
Shaded boxes in Table 4.8 indicate models which fit all diagnostic criteria and, 
before selection of the model with the lowest AIC, could potentially be used to 
represent the pre1intervention series. As can be seen, even if the non1seasonal 
and seasonal differencing components are misspecified a number of ARIMA 
models still pass all diagnostic tests and could potentially be used to model the 
series.  
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Model 
(pqPQ) 
Both first order and 
seasonal differencing 
Neither first order nor 
seasonal differencing 
First order differencing 
only 
Seasonal differencing 
only 
 
Point estimate (p1value) Point estimate (p1value) Point estimate (p1value) Point estimate (p1value) 
0000 0.380 (<0.001) 0.338 (0.215) 0.214 0.255 0.343 (0.076) 
1000 0.351 (0.847) 0.141 (0.499) 0.195 (0.972) 0.171 (<0.001) 
2000 0.311 (0.080) 0.139 (0.495) 0.194 (0.969) 0.136 (<0.001) 
0100 0.342 (0.655) 0.112 (0.536) 0.192 (0.961) 0.099 (0.087) 
1100 0.334 (0.372) 0.139 (0.496) 0.008 (0.956) 0.126 (<0.001) 
2100 0.312 (0.087) 0.221 (0.283) 0.000 (0.999) 0.136 (<0.001) 
0200 0.323 (0.156) 0.110 (0.532) 0.194 (0.969) 0.087 (0.052) 
1200 0.299 (0.004) 0.148 (0.451) 0.253 (0.951) 0.128 (<0.001) 
2200 0.211 (0.005) 0.160 (0.297) 0.073 (0.677) 0.127 (<0.001) 
0010 0.291 (0.001) 0.404 (0.382) 0.273 (<0.001) 0.426 (0.290) 
1010 0.287 (0.001) 0.120 (<0.001) 0.266 (<0.001) 0.139 (<0.001) 
2010 0.276 (0.001) 0.095 (<0.001) 0.259 (<0.001) 0.126 (<0.001) 
0110 0.286 (0.001) 0.092 (0.015) 0.262 (<0.001) 0.103 (0.076) 
1110 0.281 (0.002) 0.091 (<0.001) 0.263 (0.001) 0.122 (<0.001) 
2110 0.278 (0.001) 0.091 (<0.001) 0.248 (0.001) 0.121 (<0.001) 
0210 0.275 (0.001) 0.067 (0.032) 0.259 (<0.001) 0.085 (0.057) 
1210 0.260 (<0.001) 0.091 (<0.001) 0.262 (<0.001) 0.121 (<0.001) 
2210 0.259 (<0.001) 0.090 (<0.001) 0.285 (0.004) 0.121 (<0.001) 
0020 0.236 (<0.001) 0.406 (0.423) 0.298 (<0.001) 0.425 (0.299) 
1020 0.232 (<0.001) 0.127 (<0.001) 0.295 (<0.001) 0.125 (<0.001) 
2020 0.209 (<0.001) 0.112 (<0.001) 0.307 (<0.001) 0.115 (<0.001) 
0120 0.229 (<0.001) 0.096 (0.005) 0.295 (<0.001) 0.113 (0.062) 
1120 0.231 (<0.001) 0.110 (<0.001) 0.306 (<0.001) 0.109 (<0.001) 
2120 0.213 (<0.001) 0.109 (<0.001) 0.287 (<0.001) 0.107 (<0.001) 
0220 0.207 (<0.001) 0.066 (0.030) 0.305 (<0.001) 0.082 (0.058) 
1220 0.211 (<0.001) 0.108 (<0.001) 0.311 (<0.001) 0.107 (<0.001) 
2220 0.251 (<0.001) 0.109 (<0.001) 0.293 (<0.001) 0.107 (<0.001) 
0001 0.175 (<0.001) 0.376 (0.104) 0.283 (0.170) 0.422 (0.321) 
1001 0.176 (<0.001) 0.150 (0.007) 0.283 (0.171) 0.070 (0.003) 
2001 0.171 (<0.001) 0.135 (0.011) 0.269 (0.127) 0.070 (0.004) 
0101 0.176 (<0.001) 0.157 (0.003) 0.283 (0.171) 0.103 (0.074) 
1101 0.170 (<0.001) 0.135 (0.010) 0.242 (0.030) 0.069 (0.005) 
2101 0.172 (<0.001) 0.159 (0.004) 0.232 (0.040) 0.068 (0.006) 
0201 0.167 (<0.001) 0.110 (0.022) 0.268 (0.127) 0.084 (0.058) 
1201 0.146 (<0.001) 0.135 (0.011) 0.231 (0.024) 0.068 (0.006) 
2201 0.148 (<0.001) 0.135 (0.010) 0.276 (0.030) 0.068 (0.006) 
0011 0.175 (<0.001) 0.407 (0.384) 0.288 (0.004) 0.426 (0.294) 
1011 0.174 (<0.001) 0.127 (<0.001) 0.287 (0.004) 0.076 (0.002) 
2011 0.164 (<0.001) 0.118 (<0.001) 0.290 (0.005) 0.068 (0.005) 
0111 0.173 (<0.001) 0.096 (0.005) 0.286 (0.004) 0.103 (0.071) 
1111 0.183 (<0.001) 0.116 (<0.001) 0.283 (0.017) 0.065 (0.008) 
2111 0.170 (<0.001) 0.134 (<0.001) 0.372 (<0.001) 0.067 (0.006) 
0211 0.161 (<0.001) 0.066 (0.031) 0.286 (0.004) 0.052 (0.150) 
1211 0.168 (<0.001) 0.111 (<0.001) 0.351 (0.016) 0.065 (0.008) 
2211 0.148 (<0.001) 0.112 (<0.001) 0.258 (<0.001) 0.065 (0.009) 
0021 0.169 (<0.001) 0.403 (0.491) 0.275 (0.018) 0.418 (0.333) 
1021 0.166 (<0.001) 0.122 (<0.001) 0.272 (0.019) 0.074 (0.003) 
2021 0.154 (<0.001) 0.106 (<0.001) 0.307 (<0.001) 0.065 (0.009) 
0121 0.165 (<0.001) 0.094 (0.008) 0.296 (<0.001) 0.096 (0.030) 
1121 0.159 (<0.001) 0.102 (<0.001) 0.291 (0.029) 0.061 (0.014) 
2121 0.164 (<0.001) 0.102 (<0.001) 0.275 (0.010) 0.088 (0.011) 
0221 0.152 (<0.001) 0.065 (0.040) 0.268 (0.016) 0.045 (0.161) 
1221 0.138 (<0.001) 0.099 (<0.001) 0.295 (0.029) 0.063 (0.011) 
2221 0.146 (<0.001) 0.100 (<0.001) 0.229 (0.005) 0.063 (0.015) 
0002 0.175 (<0.001) 0.343 (0.560) 0.268 (0.229) 0.414 (0.214) 
1002 0.173 (<0.001) 0.092 (0.018) 0.272 (0.225) 0.076 (0.002) 
2002 0.162 (<0.001) 0.073 (0.038) 0.278 (0.201) 0.067 (0.008) 
0102 0.172 (<0.001) 0.063 (0.173) 0.272 (0.226) 0.106 (0.005) 
1102 0.183 (<0.001) 0.074 (0.036) 0.237 (0.065) 0.063 (0.011) 
2102 0.169 (<0.001) 0.080 (0.026) 0.219 (0.052) 0.067 (0.007) 
0202 0.160 (<0.001) 0.061 (0.110) 0.278 (0.200) 0.045 (0.188) 
1202 0.167 (<0.001) 0.166 (<0.001) 0.266 (0.084) 0.065 (0.009) 
2202 0.137 (<0.001) 0.077 (0.034) 0.229 (0.054) 0.064 (0.027) 
0012 0.169 (<0.001) 0.368 (0.455) 0.273 (0.029) 0.402 (0.240) 
1012 0.171 (<0.001) 0.122 (<0.001) 0.269 (0.027) 0.075 (0.004) 
2012 0.159 (<0.001) 0.106 (<0.001) 0.268 (0.025) 0.067 (0.012) 
0112 0.170 (<0.001) 0.084 (0.024) 0.287 (0.006) 0.098 (0.034) 
1112 0.182 (<0.001) 0.101 (<0.001) 0.289 (0.062) 0.063 (0.016) 
2112 0.167 (<0.001) 0.100 (<0.001) 0.261 (0.014) 0.128 (<0.001) 
0212 0.157 (<0.001) 0.068 (0.024) 0.263 (0.017) 0.050 (0.153) 
1212 0.140 (<0.001) 0.097 (<0.001) 0.293 (0.067) 0.065 (0.013) 
2212 0.167 (<0.001) 0.100 (<0.001) 0.280 (0.003) 0.065 (0.019) 
0022 0.174 (<0.001) 0.376 (0.480) 0.277 (0.023) 0.333 (0.010) 
1022 0.152 (<0.001) 0.122 (<0.001) 0.273 (0.025) 0.061 (0.030) 
2022 0.153 (<0.001) 0.118 (0.004)) 0.274 (0.028) 0.067 (0.037) 
0122 0.171 (<0.001) 0.086 (0.028) 0.291 (0.020) 0.099 (0.033) 
1122 0.181 (<0.001) 0.101 (<0.001) 0.285 (0.015) 0.045 (0.113) 
2122 0.171 (<0.001) 0.113 (<0.001) 0.284 (0.010) 0.051 (0.087) 
0222 0.156 (<0.001) 0.070 (0.023) 0.282 (0.027) 0.020 (0.484) 
1222 0.162 (<0.001) 0.103 (<0.001) 0.278 (0.012) 0.049 (0.102) 
2222 0.155 (<0.001) 0.102 (<0.001) 0.451 (<0.001) 0.070 (0.005) 
*Shaded boxes indicate models meeting all diagnostic criteria for model fit 
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There are large variations in the magnitude of change in the rate of prescribing in 
June 2007 estimated by the various ARIMA models, though the majority of models 
produce statistically significant estimates for an increase in the rate of prescribing. 
Several models produce non1statistically significant estimates of the change in 
NRT prescribing in June 2007, including the ARIMA(1,0,0)(0,0,0)12 model which 
passes all diagnostic tests for model adequacy.  
 
The results presented in Table 4.8 suggest that care must be taken when selecting 
an ARIMA model to represent a time series as the use of different models may 
ultimately lead to different conclusions being drawn about the effect of an 
intervention on the phenomenon under investigation.  
 
An important early stage in the ARIMA modelling procedure is to correctly identify 
the order of non1seasonal and seasonal differencing required to render a series 
stationary. There is a growing body of literature devoted to developing statistical 
methods which can identify whether a time series needs to be non1seasonally or 
seasonally differenced to induce stationarity, using what are called unit root tests, 
rather than relying on visual inspection of the series ACF. However, the most 
frequently used of these tests, the Dickey1Fuller test for non1seasonal non1
stationarity, is acknowledged to have poor power properties159 and its use has 
been labelled ‘misguided’160. There are no tests available for use in Stata to assess 
whether a time series needs to be seasonally differenced to remove seasonal non1
stationarity. As a result, the work presented in this thesis relies on visual 
assessment of the ACF to determine whether the series needs to be non1
seasonally or seasonally differenced to induce stationarity.  
 
The potential effects of model misspecification lend further weight to using an 
automated procedure to identify the most appropriate model to represent the 
data1generating process behind a pre1intervention time series, selecting the 
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model which passes all diagnostic tests and has the lowest AIC. In this thesis, a 
large number of population subgroups will be analysed to assess whether the 
introduction of smokefree legislation had a differential impact in different groups 
of patients. Applying the same automated procedure to each analysis will remove 
the element of subjectivity involved in identifying an ARIMA model and ensure 
that all results are generated using the same methodological procedure and are, 
therefore, comparable. 
 
  06+5/67;/916.343,,./,3;+6(
 
As noted earlier, a choice must be made early in the study design process about 
the degree of temporal aggregation (e.g. data collected weekly, monthly or 
yearly) most appropriate to detect the impact of the introduction of an 
intervention, bearing in mind the increased computational demands that come 
with analysing longer time series. Thus far, all analyses have been based on data 
aggregated monthly, and this section assesses whether different conclusions 
about the impact of smokefree legislation may be generated using data 
aggregated weekly.  
 
Figure 4.27 compares the shapes of the time series produced when the rate of 
prescribing of NRT in smokers in THIN is aggregated weekly and monthly. Both 
series have been appropriately adjusted to account for variations in the number of 
days general practices were open in each time period. Even after this adjustment 
there is a particularly large amount of variation in the weekly time series – the 
last week of the year in many years has a particularly low rate of recording, as 
well as other weeks seemingly randomly distributed throughout the series.  
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The very low rate of prescribing in some weeks of the year makes it impossible to 
adequately fit an ARIMA model to the weekly series – the model with significant 
and acceptable parameters and with the lowest AIC produces severely non1
normally distributed residuals, an outlier of 6.55 in magnitude and an R2 value of 
only 0.517. The inability to fit an ARIMA model to the weekly series means it is 
impossible to assess the impact of the introduction of an intervention on the 
weekly rate of prescribing of NRT. The majority of the time series analysed in this 
thesis show similar patterns when aggregated weekly, and, given a lack of the 
computing power necessary to model multiple weekly series, all analyses 
presented in the following chapters will be based on monthly data.  
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As mentioned in Section 4.5.5.2, the observations at each point in time in a series 
must be directly comparable and there should be no changes over time in the 
0
500
1,000
1,500
2,000
R
at
e 
pe
r 
10
0,
00
0 
pe
rs
o
n
-
m
o
n
th
s
 
01
 
Ja
n
 
20
00
01
 
Ja
n
 
20
02
01
 
Ja
n
 
20
04
01
 
Ja
n
 
20
06
01
 
Ja
n
 
20
08
01
 
Ja
n
 
20
10
 
Weekly data Monthly data
    
196 
composition of the population being studied151. In particular, there should be no 
change in the composition of the study population at the same time as the 
introduction of an intervention, such as smokefree legislation. However, in 
practice this is very difficult to achieve. In the work presented in this thesis it is 
desirable to use as many THIN patients’ data as possible, though defining the 
denominator population each month as all patients aged 16+ necessarily allows 
the structure of the population by characteristics such as sex to change over time. 
Similarly, restricting the denominator each month to the same group of patients 
who are registered in THIN throughout the whole of the study period may 
introduce confounding by age group – the population will become on average ten 
years older over the decade. This section assesses the potential degree of 
confounding by time1varying characteristics of the denominator population.   
 
The results presented thus far are based on rates of NRT prescribing in a 
denominator population of all patients aged 16+ registered in THIN each month. 
Figure 4.28 shows how the structure of the monthly denominator population 
changes over time with respect to sex and age group.  
 
As Figure 4.28 shows, there are only small changes over time in the proportion of 
the denominator who are male, as well as the proportion in different age groups, 
and so these factors are unlikely to act as major confounders when assessing the 
impact of the introduction of smokefree legislation on a time series.  
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Figure 4.29 shows changes over time in the proportion of the denominator from 
different regions of the UK and in different quintiles of the Townsend Index of 
Deprivation. There are some changes over time in the regional distribution of 
THIN patients, most notably a decline in the proportion from the Eastern region, 
caused by practices entering and leaving THIN as well as individual patients 
joining and leaving THIN practices. There are only very small changes over time in 
the proportion of patients in each quintile of the Townsend Index of Deprivation. 
Again, the relative stability of these variables over time mean these factors are 
unlikely to act as major confounders when assessing the impact of the 
introduction of smokefree legislation on a time series. 
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As discussed in Chapter 2, the recording of patient smoking status has improved 
over time – fewer patients have no mention of smoking in their medical records, 
and the proportion of patients recorded as current smokers has approached 
national estimates of smoking prevalence. Changes in recorded smoking 
prevalence amongst THIN patients may act as a confounder in any interrupted 
time series analysis – for example, an increase in the rate of prescribing of NRT 
may simply be the result of an increase in smoking prevalence amongst the 
denominator population. In addition, Figure 3.6 showed that prescriptions for 
smoking cessation medications are also recorded in the notes of patients who are 
not recorded as current smokers.  To assess whether these data recording 
practices confound the assessment of the impact of smokefree legislation on 
prescribing, Table 4.9 presents the estimated change in prescribing in June 2007 
in all patients, in those recorded as current smokers, and in those not recorded as 
current smokers.  
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Study population ARIMA model 
Change in 
prescribing in June 
2007 
95% CI 
Wald  
p1value 
All patients  (0,1,0)(0,1,1)12 0.153 0.085 to 0.221 <0.001 
Current smokers (0,1,0)(0,1,1)12 0.175 0.111 to 0.240 <0.001 
Non1current smokers (0,1,0)(0,1,1)12 0.111 10.035 to 0.257 0.136 
 
 
As the estimates for the change in prescribing in June 2007 presented in Table 4.9 
show, the estimated magnitude of increase was similar in all patients compared to 
an analysis restricted to just those patients recorded as current smokers, 
suggesting changing data recording habits do not confound assessment of the 
impact of smokefree legislation. There was no significant increase in prescribing in 
patients not recorded in their notes as current smokers. The direction of effect 
estimated in non1current smokers suggests there may have been an increase in 
prescribing in this group, though it failed to reach statistical significance. 
Application of the power calculation described in Section 4.11 suggests that the 
ARIMA model was only powered to detect a 20.8% change in prescribing in June 
2007 in non1current smokers (an effect of 0.208 in the logged series). 
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As noted in Section 4.5.5.3, when assessing the impact of an intervention on a 
time series it is important that the intervention was introduced independently of 
other changes which may also have an impact on the series. However, the 
introduction of smokefree legislation in the UK is just one of a raft of tobacco 
control measures introduced over the last few years. In December 2006 a new 
smoking1cessation medication, varenicline (Champix), was licensed for use in the 
UK and made available on NHS prescription, and in July 2007 the National 
Institute for Health and Clinical Excellence (NICE) published guidelines 
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recommending the use of varenicline as a clinically effective and cost1effective 
pharmacotherapy to assist smokers who wish to quit161. There is conflicting 
evidence about the impact of the introduction and subsequent endorsement of 
varenicline, with studies suggesting both that varenicline prescribing cannibalised 
that of NRT162 and conversely that it had no effect on NRT prescribing rates163. It 
is also conceivable that the availability of a new smoking cessation intervention 
provided a stimulus for increased smoking cessation activity in primary care, 
prompting health care professionals to offer smokers a prescription for NRT. The 
magnitude of the increase in prescribing of NRT in June 2007 identified in this 
chapter may, therefore, be influenced by the impact of the introduction of 
varenicline.  
 
Perhaps the most significant event to have occurred in primary care during the 
last decade was the introduction of the QOF, and Chapters 2 and 3 discussed the 
impact this had on rates of recording of patient smoking status, cessation advice 
and referral of patients to specialist cessation services. Accounting for the effect of 
the QOF in an interrupted time series analysis to assess the impact of smokefree 
legislation is difficult as it is not clear what form of dummy variable could be 
included in an impact assessment model to represent the increased electronic 
recording of smoking1related information seen as a result of the policy. Perhaps 
the best way to remove the effect of the QOF from assessment of the impact of 
smokefree legislation is to model the time series of data from the post1QOF period 
only. However, the exclusion of several years’ data from the pre1intervention time 
series seriously affects the ability to identify and model the underlying data1
generating process, and in many cases it becomes impossible to fit an ARIMA 
model to the pre1intervention series and hence to assess the impact of the 
introduction of an intervention on that series. For this reason, the results 
presented in the following chapter are based on the analysis of the entire span of 
available data, though a sensitivity analysis is undertaken to assess the impact of 
    
201 
analysing a shorter time series to account for the potential confounding effect of 
the QOF when assessing the impact of smokefree legislation on rates of recording 
of patients’ smoking status and the offer of cessation advice and referral to a 
specialist cessation service.  
 
  
 
This chapter has outlined the main approaches to interrupted time series analysis, 
concluding that the framework of the ARIMA model offers the most appropriate 
means to model the complex time trends and seasonal patterns seen in smoking1
related data recorded in THIN. The mathematical basis of the ARIMA model has 
been described, and a step1by1step guide to identifying and fitting an ARIMA 
model to assess the impact of an intervention on a time series has been provided. 
 
As noted, this model identification process is a complex, time1consuming 
procedure, and the development of the ‘arimaintervention’ command allows 
several ARIMA models to be estimated and their adequacy to be assessed. In 
addition, the command allows the analyst to judge whether the selection of 
different ARIMA models to describe a time series ultimately leads to different 
conclusions regarding the impact of an intervention on the outcome under 
investigation.  
 
The sensitivity analyses presented in this chapter show how many of the choices 
which must be made during the ARIMA modelling process may have an impact on 
the conclusions reached about the effectiveness of an intervention. Caution is, 
therefore, warranted when interpreting the results of the growing number of time 
series analyses presented in the public health literature. It is recommended that, 
when writing up the results of a time series analysis for publication, the analyst 
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should consider undertaking and describing the results of similar sensitivity 
analyses to those presented here to be confident in their conclusions.  
 
The following chapter uses the techniques explained here to assess the impact of 
smokefree legislation on rates of recording of patients’ smoking status and the 
delivery of smoking cessation interventions in each jurisdiction of the UK, and 
Chapter 6 assesses whether any effect of smokefree legislation varied between 
subgroups of the population. 
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The literature reviewed in Section 1.6 suggests that the introduction of smokefree 
legislation may increase quitting activity and reduce daily cigarette consumption 
amongst heavier smokers, though perhaps not translate into reduced population 
smoking prevalence. There is a lack of research examining the pathways by which 
the introduction of smokefree legislation might exert an impact on smoking 
behaviour. Similarly, it is not known whether other tobacco control policies or 
interventions could, when introduced alongside smokefree legislation, ensure that 
as many smokers as possible succeed in quitting.    
 
As noted previously, health care professionals working in primary care have at 
their disposal a range of smoking cessation interventions proven to increase the 
likelihood of a smoker quitting. The introduction of smokefree legislation may 
prompt smokers to seek cessation support from primary care, or prompt health 
care professionals to offer support even if this is not directly solicited by their 
patients. No studies to date have investigated rates of clinical activity related to 
smoking cessation in primary care at the time smokefree legislation was 
introduced. If there was no change in rates of delivery of cessation advice to 
smokers, prescription of pharmacological cessation aids, or referral of smokers for 
cessation support, this could suggest opportunities were missed to increase the 
impact of smoking bans. When smokefree legislation is introduced, simultaneous 
improvements in the provision of cessation support to smokers through primary 
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care could be one way of maximising the number of smokers who attempt to quit 
and who remain permanently abstinent. 
 
This chapter uses the time series methods explained previously to investigate 
whether there were changes in rates of smoking1related clinical activity in THIN 
practices that may be associated with the introduction of smokefree legislation. 
The analysis is in part hypothesis1driven, assessing whether changes in cessation 
activity comparable with those reported by other authors are evident in THIN. In 
addition, given the short pre1 and post1legislation data collection periods used in 
several of the studies reviewed in Section 1.6, this chapter utilises the longitudinal 
nature of the THIN dataset to explore just how long before the introduction of 
smokefree legislation any changes in clinical activity may become evident, and 
how long after a law is enacted they may persist.   
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For each month from January 2000 to July 2009 all patients were identified from 
the THIN dataset who were aged 16 or over and registered with a practice for at 
least one day of the month. Section 2.4 showed that a majority of new patients 
registering with a GP will have their smoking status recorded soon after 
registration, and this may confound assessment of changes in the rate of 
recording at the time smokefree legislation was introduced. Therefore, patients 
who registered with a practice within the previous three months were excluded 
from this analysis. Given that some patients registered or deregistered with a 
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practice part1way through each month, the combined time all eligible patients 
spent registered in THIN each month was calculated, measured in person1months.  
 
All records of smoking status, identified by relevant Read Codes (see Appendix 
8.2), entered into patients’ notes on or after their registration date were extracted 
from THIN. The number of patients with at least one record of their smoking 
status documented in their medical notes each month was calculated.  
 
Monthly rates of ascertainment of patients’ smoking status were calculated 
separately for each jurisdiction of the UK, expressed as the number of patients 
with a record of smoking status in that month per 100,000 person1months.  
 
2)&) 	
	-	
 
Patients registered in THIN each month from January 2000 to July 2009 were 
identified as detailed above and current smokers identified as those patients 
whose most recent smoking status Read Code in their medical records prior to the 
first day of each month classified them as such. The combined time all current 
smokers spent registered in THIN each month was calculated, again measured in 
person1months.  
 
Relevant Read Codes were used to identify current smokers with at least one 
record of cessation advice or referral to a cessation service in their notes in each 
month (see Appendices 8.8 and 8.9 for Read Codes). Similarly, Multilex drug 
codes were used to identify current smokers with one or more prescriptions for 
NRT, bupropion or varenicline recorded in their notes each month (see Appendix 
8.10). 
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Monthly rates of recording of cessation advice, referral to a cessation service and 
prescribing of NRT, bupropion, varenicline, or any of these medications, were 
calculated separately for each jurisdiction of the UK, expressed as the number of 
smokers with a record of an intervention being given in that month per 100,000 
person1months of follow1up time.  
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The extracted time series were modelled to assess the impact of the introduction 
of smokefree legislation, following the ARIMA procedure outlined in Chapter 4. 
First, the time plot and autocorrelation function (ACF) of each series was 
examined to identify whether differencing was needed to render the series 
stationary. Then, the ‘arimaintervention’ command developed for the purposes of 
this thesis (see Section 4.9.1 and Appendix 8.12) was used to fit a number of 
different ARIMA models to each series. The output from this command was 
assessed to choose the particular model from the ARIMA class which most 
appropriately described the stationary pre1intervention time series.  
 
Dummy variables were included in the interrupted time series models to assess 
the impact of smokefree legislation on each series, and, as suggested previously, 
the output of the arimaintervention command was assessed to ensure that any 
conclusions drawn about the statistical significance of changes to the series were 
robust to the choice of ARIMA model. Several intervention effects were modelled 
for each outcome variable, based upon hypotheses generated from the existing 
literature about the potential changes in smoking–related clinical activity that may 
be seen in primary care and also to allow exploration of the timing and duration of 
any changes. These intervention effects are illustrated in Figure 5.1 with respect 
to the date legislation was introduced in England. Previous research has suggested 
that the introduction of smokefree legislation in England in July 2007 may have 
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brought forward to the start of the year quit attempts that would have been made 
later in 200746. Therefore, a pulse effect was modelled in the first quarter of the 
year in which smokefree legislation was introduced to assess whether the ban 
increased smoking1related clinical activity at New Year and national No Smoking 
Day. Secondly, pulse effects lasting one, two, three, six and nine months before 
and after the introduction of legislation were modelled to assess whether rates of 
clinical activity changed before the smoking ban, and if so how long before, as 
well as how long any changes lasted. Finally, a permanent step change was 
modelled to assess whether there were abrupt, sustained changes in the outcome 
measures after the introduction of smokefree legislation. 
 
       
Introduction of smokefree 
legislation in England 
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To enable the expression of results as more intuitive percentage changes in the 
original outcome variable, all time series were logged before ARIMA model 
identification and impact assessment, even if logging was not necessary to 
stabilise the variance of the data. The estimates of percentage change in the 
original series are presented alongside their 95% confidence intervals and Wald p1
values.  
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Section 3.6 showed that some patients have a record of cessation advice, referral 
to a cessation service, or a prescription for a stop smoking medication in their 
medical notes even if they are not recorded at that point in time as a current 
smoker. Though their numbers are small, and the ratio of recording in current to 
non1current smokers has remained fairly stable over time, the results of time 
series analysis of rates of recording of smoking cessation interventions in only 
patients identified as smokers may be biased. Thus, a sensitivity analysis was 
undertaken modelling the impact of smokefree legislation on rates of recording of 
advice, referral and prescribing in all patients. The results of this sensitivity 
analysis are presented in Appendix 8.13 though discussed in the current chapter. 
 
Initially, the time series were modelled using all available data, from January 2000 
(or, in the case of medication prescribing, the first month these were made 
available on NHS prescription) to July 2009. However, Section 4.12.4 considered 
whether the increased recording of patients’ smoking status, cessation advice and 
referral in the run1up to the introduction of the QOF may confound assessment of 
the impact of smokefree legislation on the rates of recording of clinical activity in 
primary care. Analysis of a shorter time series including data from April 2004 only 
was proposed as a means to remove any confounding effect of the QOF. 
Therefore, the time series of rates of recording of patients’ smoking status, 
cessation advice and referral were additionally modelled using only data recorded 
from April 2004 onwards. These results are presented in Appendix 8.14. 
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Figure 5.2 shows monthly rates of recording of smoking status in THIN in each of 
the four jurisdictions of the UK. Vertical lines indicate the data collected in the 
month immediately after the introduction of smokefree legislation (July 2007 in 
England, April 2006 in Scotland, April 2007 in Wales and May 2007 in Northern 
Ireland).  
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In all countries rates of recording are initially low, increasing only slightly between 
January 2000 and the end of 2002. The rate of recording begins to increase more 
rapidly at the start of 2003, and this faster improvement is sustained to the end of 
2003 when all series reach a plateau. There is variation in the rate of recording 
from one month to the next in each country, though it is hard to tell whether this 
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variation forms a regular seasonal pattern. The magnitude of the monthly 
variation is similar in England, Scotland and Wales, though the month1to1month 
variation in Northern Ireland is much larger. Given this monthly variation it is 
difficult to judge visually whether there are any changes in the rate of recording 
around the introduction of smokefree legislation outside of the normal behaviour 
of the series.  
 
Table 5.1 shows the results of the ARIMA modelling assessing the impact of the 
introduction of smokefree legislation on monthly rates of recording of smoking 
status, expressed as percentage changes in each of the time periods studied. 
Figures in bold print highlight statistically significant results, a convention which 
will be used in all tables of results presented from this point forward.  

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	(,43(< 56;43(<
Intervention effect  
Estimate 
(%) 
95% CI 
(%) 
P1value 
Estimate 
(%) 
95% CI 
(%) 
P1value 
Q1 of SFL year 4.3 112.4 to 21.0 0.611 0.9 116.5 to 18.3 0.920 
1 month before 10.5 136.3 to 35.3 0.978 7.2 131.3 to 45.7 0.714 
2 months before 1.8 115.2 to 18.8 0.836 1.0 118.8 to 20.7 0.925 
3 months before 
  
#;6
% M$$$ 0.9 116.5 to 18.3 0.920 
6 months before 12.5 17.4 to 2.3 0.305 1.9 16.9 to 10.6 0.677 
9 months before 0.0 14.9 to 4.9 0.990 1.3 16.3 to 8.9 0.741 
1 month after 10.8 134.5 to 33.0 0.965 
 & 
 #;6
# M$$$
2 months after 12.8 124.4 to 18.8 0.798 
% 
;6
# $$$
3 months after 11.7 121.0 to 17.6 0.863 19.7 122.9 to 3.5 0.148 
6 months after 12.1 17.7 to 3.4 0.448 16.9 119.4 to 5.6 0.281 
9 months after 10.6 15.4 to 4.3 0.824 10.9 17.6 to 5.9 0.799 
Step change 10.8 13.3 to 1.7 0.525 10.6 13.1 to 1.8 0.617 
 
 
34/8 6.;0/.(./43(<
Intervention effect  
Estimate 
(%) 
95% CI 
(%) 
P1value 
Estimate 
(%) 
95% CI 
(%) 
P1value 
Q1 of SFL year 14.4 116.3 to 7.5 0.469 2.8 17.8 to 13.4 0.603 
1 month before 0.1 120.0 to 20.3 0.989 
 
;6
%$  M$$$
2 months before 10.6 118.2 to 17.0 0.945 
  
%;6
# $$$
3 months before 14.4 116.3 to 7.5 0.469 18.1 116.9 to 0.6 0.069 
6 months before 1.1 16.0 to 8.1 0.769 13.0 110.4 to 4.4 0.425 
9 months before 0.0 15.9 to 5.9 0.997 10.7 18.8 to 7.4 0.865 
1 month after 
 
$;6
% $$ 15.3 172.7 to 62.1 0.877 
2 months after 15.1 112.8 to 2.7 0.198 15.1 148.6 to 38.5 0.819 
3 months after 14.8 111.9 to 2.4 0.193 14.5 133.0 to 23.9 0.754 
6 months after 14.4 110.7 to 1.8 0.165 11.5 120.3 to 17.2 0.873 
9 months after 12.4 17.4 to 2.7 0.358 11.8 113.7 to 10.2 0.769 
Step change 11.5 14.2 to 1.2 0.280 11.5 16.8 to 3.9 0.586 
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The results shown in Table 5.1 suggest there was no significant change in the rate 
of recording of smoking status in any country of the UK in the first quarter of the 
year in which smokefree legislation was introduced, nor was there an abrupt post1
legislation change in the rate sustained to July 2009, the end of the study period. 
All four countries do, however, show significant short1lived reductions in the rate 
of recording either before or after the introduction of smokefree legislation, with 
no significant changes being detected which lasted more than three months.  
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Figure 5.3 shows monthly rates of recording of cessation advice amongst current 
smokers in THIN in each of the four jurisdictions of the UK. The time series show a 
similar pattern to those depicting rates of recording of smoking status; rates of 
advice recording are initially low, followed by a period of relatively rapid increase 
in 2003 and a levelling off from the start of 2004. 
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Again there is variation in the rate of recording from one month to the next in 
each country, with the largest magnitude of variation seen in Northern Ireland and 
the smallest in England. There appear to be peaks in the recording of advice in 
England, Wales and Northern Ireland at the start of 2007, a few months before 
the introduction of smokefree legislation, though again it is difficult to judge 
visually whether these peaks are outside of the normal behaviour of the series. 
 
Table 5.2 shows the results of the ARIMA modelling assessing the impact of the 
introduction of smokefree legislation on monthly rates of recording of cessation 
advice amongst current smokers in THIN. 
 
 
3A4/#+9/8/.+/83(34B8+867503(,/8+(./56.<+(,675/883;+6(3<2+5/
</4+2/./<;6896:/.8
	(,43(< 56;43(<
Intervention effect  
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 0.2 18.8 to 9.3 0.960 15.2 137.8 to 27.3 0.752 
1 month before 6.6 159.7 to 72.9 0.846 19.0 181.5 to 63.4 0.807 
2 months before 4.8 141.6 to 51.1 0.840 17.3 148.5 to 33.9 0.727 
3 months before 17.0 117.3 to 3.4 0.188 15.2 137.8 to 27.3 0.752 
6 months before 13.1 18.9 to 2.8 0.301 10.1 112.1 to 11.9 0.987 
9 months before 11.5 18.1 to 5.1 0.660 10.1 17.9 to 7.6 0.979 
1 month after 16.9 1110.7 to 96.8 0.896 7.3 128.1 to 42.6 0.687 
2 months after 18.7 169.0 to 51.5 0.776 2.7 127.3 to 32.7 0.862 
3 months after 11.8 118.8 to 15.1 0.834 0.5 125.9 to 26.9 0.970 
6 months after 12.5 111.7 to 6.7 0.588 0.5 121.4 to 22.5 0.963 
9 months after 10.7 17.9 to 6.6 0.859 2.0 110.7 to 14.6 0.763 
Step change 11.4 14.4 to 1.5 0.338 0.4 18.8 to 9.6 0.933 
 
 
34/8 6.;0/.(./43(<
Intervention effect  
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 3.4 147.1 to 54.0 0.895 12.0 116.6 to 12.5 0.785 
1 month before 9.7 179.5 to 98.9 0.831 123 166.1 to 20.1 0.296 
2 months before 7.0 158.7 to 72.7 0.835 16.1 118.9 to 6.7 0.350 
3 months before 3.4 147.1 to 54.0 0.895 14.5 115.3 to 6.3 0.414 
6 months before 4.7 131.0 to 40.3 0.797 11.6 19.7 to 6.6 0.704 
9 months before 3.6 111.4 to 18.6 0.641 10.8 17.8 to 6.2 0.828 
1 month after 18.2 144.4 to 27.9 0.655 12.7 185.4 to 80.1 0.949 
2 months after 12.0 128.2 to 24.3 0.884 13.4 158.0 to 51.3 0.904 
3 months after 13.4 126.3 to 19.5 0.770 13.4 147.8 to 41.0 0.880 
6 months after 12.1 113.8 to 9.7 0.730 12.8 127.7 to 22.1 0.826 
9 months after 12.9 114.3 to 8.4 0.611 14.3 119.7 to 11.2 0.589 
Step change 11.4 18.4 to 5.6 0.687 11.7 18.4 to 5.0 0.617 
 
 
Table 5.2 shows no significant changes in the rate of recording of cessation advice 
in current smokers in any of the intervention periods in any jurisdiction of the UK.  
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Figure 5.4 shows monthly rates of recording of referral to stop smoking services 
amongst current smokers in THIN. Rates of recording of referrals are much lower 
than those of recording of cessation advice, though, as discussed in Chapter 3, it 
is impossible to be sure whether all referrals are recorded in patients’ notes. In 
England the rate of recording of referral of smokers to stop smoking services 
shows a similar pattern to that of recording of smoking status and cessation 
advice. In Scotland and Wales, rates of recording of referral are higher at the start 
of the series than in England, but in Northern Ireland almost no smokers have a 
referral to a stop smoking service recorded before 2006.  
 
 
+,-./# 3;/867./56.<+(,67./7/..34;68;61896:+(,8/.2+5/8396(,8;5-../(;
896:/.8+(
 
It should be noted that rates of recording of referral in Northern Ireland are 
approximately ten times higher than those in the other three countries and the 
series have been drawn on different scales so that the monthly variation in each 
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country can still be seen clearly. The absence of referrals in Northern Ireland in 
the period before the introduction of smokefree legislation means there are not 
enough monthly data points with which to fit an ARIMA model. Therefore, 
modelling the impact of smokefree legislation on this outcome variable will only be 
carried out for England, Scotland and Wales. Possible reasons for the pattern of 
recording of referral in Northern Ireland will be considered in the discussion.  
 
In England, Scotland and Wales there is substantial monthly variation in the rate 
of recording of referral, with no clear seasonal patterns. There are no obvious 
changes in the series which may be attributable to the effect of smokefree 
legislation, though again it is difficult to tell given the high degree of variability in 
the data. 
 
Table 5.3 shows the results of the ARIMA modelling assessing the impact of the 
introduction of smokefree legislation on monthly rates of referral to stop smoking 
services amongst current smokers in THIN. 
 
As with the recording of cessation advice, Table 5.3 shows no significant changes 
in the rate of recording of referral to stop smoking services amongst current 
smokers in any of the intervention periods.  
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Intervention effect  
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 1.4 1177.3 to 180.0 0.988 5.4 189.1 to 100.0 0.910 
1 month before 19.9 1215.5 to 255.4 0.868 114.7 1127.2 to 97.9 0.798 
2 months before 8.3 1105.2 to 121.7 0.887 3.2 1103.9 to 110.3 0.953 
3 months before 2.5 167.7 to 72.7 0.944 5.4 189.1 to 100.0 0.910 
6 months before 1.7 155.4 to 58.8 0.954 12.0 146.7 to 42.7 0.930 
9 months before 0.4 124.8 to 25.5 0.978 13.4 132.9 to 26.1 0.822 
1 month after 17.9 1178.8 to 163.0 0.928 155.6 1233.2 to 121.9 0.539 
2 months after 122.7 1107.7 to 62.4 0.602 131.5 1126.9 to 63.9 0.517 
3 months after 117.4 188.2 to 53.5 0.631 121.6 189.9 to 46.8 0.537 
6 months after 111.1 155.8 to 33.6 0.626 18.1 153.8 to 37.5 0.728 
9 months after 16.9 145.3 to 31.5 0.726 6.2 118.1 to 30.5 0.617 
Step change 13.4 122.4 to 15.6 0.729 0.6 118.3 to 19.6 0.947 
 
 
34/8
Intervention effect  
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 0.5 124.8 to 25.8 0.972 
1 month before 117.1 181.2 to 47.1 0.602 
2 months before 17.6 144.5 to 29.4 0.689 
3 months before 0.5 124.8 to 25.8 0.972 
6 months before 13.2 116.2 to 9.9 0.633 
9 months before 12.8 113.3 to 7.7 0.599 
1 month after 19.4 156.0 to 94.8 0.615 
2 months after 11.4 146.2 to 43.4 0.951 
3 months after 12.4 135.1 to 30.3 0.886 
6 months after 14.3 120.5 to 12.0 0.606 
9 months after 11.1 114.1 to 11.9 0.864 
Step change 0.7 17.7 to 9.0 0.876 
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Figure 5.5 shows monthly rates of prescribing of NRT to current smokers in THIN. 
All four countries show a similar pattern of a slightly increasing trend in 
prescribing in the first half of the time period followed by a decreasing trend in the 
second half of the series. All series display a similar, regular seasonal pattern, 
with peaks in prescribing in the first three months of the year and troughs in the 
summer months. The lowest rates of prescribing are seen in England, though here 
the magnitude of variation in the series from one month to the next is smaller 
than in the other three countries. The rate of prescribing in Scotland and Wales, 
and the magnitude of the monthly variation, is slightly higher than in England. 
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Northern Ireland appears to have the highest rates of prescribing, but this series 
is also the most variable.  
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Table 5.4 shows the results of the ARIMA modelling assessing the impact of the 
introduction of smokefree legislation on monthly rates of prescribing of NRT to 
current smokers in THIN. 
 
There was no significant change in the rate of prescribing of NRT in any country of 
the UK in the first quarter of the year in which smokefree legislation was 
introduced, nor was there an abrupt post1legislation change in the rate which was 
sustained to the end of the study period. 
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	(,43(< 56;43(<
Intervention effect  
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 12.7 110.1 to 4.7 0.474 11.8 19.8 to 6.1 0.654 
1 month before # ;6 $ M$$$ 9.6 15.6 to 24.8 0.215 
2 months before % &;6 M$$$ 10.8 13.5 to 25.0 0.139 
3 months before $  #$;6# M$$$ 11.8 19.8 to 6.1 0.654 
6 months before %  ;6$ $$ 6.3 12.9 to 15.4 0.178 
9 months before 4.0 11.3 to 9.3 0.135 2.4 15.6 to 10.4 0.558 
1 month after 11.1 132.2 to 30.0 0.945 11.3 149.6 to 47.0 0.957 
2 months after 
% 
$;6
  $$ $ 16.1 116.9 to 4.6 0.265 
3 months after 
$ 
;6
  $$$ 15.5 114.2 to 3.1 0.208 
6 months after 
% 
;6
 $$$  15.7 112.3 to 0.9 0.091 
9 months after 
## 
;6
& $$$ 13.0 18.2 to 2.3 0.268 
Step change 11.7 14.4 to 1.0 0.229 1.8 11.7 to 5.3 0.313 
 
 
34/8 6.;0/.(./43(<
Intervention effect  
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 14.2 117.4 to 9.0 0.536 0.0 114.1 to 14.0 0.996 
1 month before 4.5 125.3 to 34.4 0.767 21.4 11.7 to 44.4 0.070 
2 months before 1.7 118.6 to 21.9 0.873 8.2 13.2 to 19.6 0.161 
3 months before 14.2 117.4 to 9.0 0.536 4.0 17.1 to 15.2 0.478 
6 months before 11.3 113.0 to 10.4 0.824 12.9 19.1 to 3.3 0.356 
9 months before 13.0 112.1 to 6.1 0.521 10.3 16.3 to 5.6 0.912 
1 month after 13.0 19.9 to 35.9 0.267 21.3 13.3 to 46.0 0.090 
2 months after 3.1 15.3 to 11.4 0.471   %;6 $$$
3 months after 1.9 16.1 to 9.9 0.647 & %;6 % $$#
6 months after 13.5 110.3 to 3.2 0.307 
% 
$%;6
% $$
9 months after 12.8 19.2 to 3.7 0.403 13.7 18.3 to 0.9 0.113 
Step change 11.1 14.4 to 2.2 0.512 10.5 12.8 to 1.8 0.676 
 
 
In England, statistically significant increases in the rate of prescribing of NRT are 
seen up to six months before the introduction of smokefree legislation. Whilst 
there was no significant change in prescribing in the first month after the smoking 
ban was enacted, significant declines in prescribing were estimated for the two 
month to nine month periods post1legislation. However, the reduced rate of 
prescribing was not sustained to the end of the study period. 
 
In Northern Ireland a significant increase in the rate of NRT prescribing was seen 
in the two and three month periods post1legislation, converting to a decline in the 
six month post1ban period, though no significant changes in the rate of 
prescribing were detected in Scotland or Wales. However, in many of the 
intervention periods where non1significant changes in prescribing were detected, 
the direction of the point estimates support the apparent pattern of an increase in 
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prescribing followed by a decrease, with the turning point being at, or close to, 
the time when smokefree legislation was introduced.  
 
2*) 5$	$

Figure 5.6 shows monthly rates of prescribing of bupropion to current smokers in 
THIN. Bupropion was first made available on NHS prescription in June 2000 and 
the number of prescriptions issued to patients in THIN increased rapidly. However, 
on 18 February 2001 the Mail on Sunday reported the deaths of 18 smokers after 
they had taken the drug, as well as a number of potential side1effects, including 
chest pain, seizures and depression164. Almost immediately after this article was 
published rates of prescribing in THIN plummeted and have not recovered.  
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The peak in bupropion prescribing in each country at the start of the time period is 
arguably an outlier when compared to prescribing rates in the remainder of the 
series, and as such the ARIMA modelling procedure must take account of this 
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anomaly. The outliers could be modelled by including a dummy variable in the 
ARIMA model, taking the value one for anomalous time points, and zero for all 
other months. However, it is not immediately clear how many months should be 
classed as anomalous time points. An alternative approach is to drop the first two 
years of data, modelling data from January 2002 onwards. This still leaves five 
years of observations (four in Scotland) with which to estimate the parameters of 
the ARIMA model which best represents the pre1intervention data, enough to take 
into account any underlying trend and seasonal pattern.  
 
Figure 5.7 illustrates the bupropion prescribing series from January 2002 onwards, 
with an enlarged scale on the y1axis allowing the monthly variation in the data to 
be observed. In England there seems to be a regular seasonal pattern in rates of 
prescribing of bupropion, again with peaks at the start of each year and troughs in 
the summer months. The presence of any seasonal pattern in Scotland, Wales and 
Northern Ireland is less obvious. In all four countries there appear to be increased 
rates of prescribing of bupropion just before the introduction of smokefree 
legislation, though, given the variability in the data, it is hard to tell whether the 
apparent increased prescribing is outside of the normal behaviour of the series.  
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Table 5.5 shows the results of the ARIMA modelling assessing the impact of the 
introduction of smokefree legislation on monthly rates of prescribing of bupropion 
in current smokers in THIN, using data from January 2002 onwards. 

The patterns in prescribing of bupropion are very similar to those seen in NRT 
prescribing. In all countries there was no significant change in the rate of 
prescribing of bupropion in the first quarter of the year in which smokefree 
legislation was introduced, nor was there an abrupt post1legislation change in the 
rate which was sustained to the end of the study period. 
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Intervention effect  
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 1.7 112.9 to 16.2 0.822 11.7 117.4 to 40.9 0.431 
1 month before    $ ;6%$ M$$$ 16.5 152.2 to 85.1 0.639 
2 months before & ;6&% M$$$ 8.3 132.9 to 49.6 0.693 
3 months before   ;6 $$$  11.7 117.4 to 40.9 0.431 
6 months before 7.1 10.4 to 14.5 0.062 5.0 18.8 to 18.7 0.479 
9 months before 5.2 11.8 to 12.3 0.147 4.6 18.1 to 17.3 0.474 
1 month after 16.8 140.1 to 26.6 0.691 134.0 1253.5 to 185.6 0.762 
2 months after 
# 
 ;6
 # $$# 127.6 1186.6 to 131.4 0.734 
3 months after 
 
;6
 $ $$ 122.2 1107.3 to 62.8 0.609 
6 months after 
 
##;6
 $ $$$ 15.1 138.8 to 28.5 0.765 
9 months after 
 
 %;6
& $$$ 14.7 132.0 to 22.6 0.735 
Step change 13.5 18.8 to 1.9 0.206 14.5 113.6 to 4.5 0.327 
 
 
34/8 6.;0/.(./43(<
Intervention effect  
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year $  &;6$ $$ & $#;6#%& $$ %
1 month before 7.6 159.4 to 74.6 0.825 145.9 1142.1 to 50.3 0.350 
2 months before 17.7 112.2 to 47.7 0.246 125.7 1109.7 to 58.4 0.550 
3 months before $  &;6$ $$ 12.8 142.4 to 36.9 0.891 
6 months before  ;6 % $$ & &;6 & $$$
9 months before 6.2 10.8 to 13.1 0.083 10.9 12.8 to 24.5 0.120 
1 month after 15.6 161.7 to 50.5 0.845 137.7 1107.1 to 31.7 0.287 
2 months after 110.5 148.7 to 27.7 0.590 112.2 138.7 to 14.3 0.366 
3 months after 17.6 134.2 to 19.0 0.575 
& 
%;6
  $$$ 
6 months after 16.7 116.7 to 34 0.192 114.9 132.1 to 2.3 0.090 
9 months after 
&$ 
 ;6
% $$$ 113.0 127.7 to 1.6 0.082 
Step change 16.9 114.7 to 0.8 0.078 16.4 115.8 to 3.0 0.181 
 
 
In England, statistically significant increases in the rate of prescribing of bupropion 
are seen up to three months before the introduction of smokefree legislation. 
Again there was no significant change in prescribing of bupropion in the first 
month after the smoking ban was enacted, though significant declines in 
prescribing were estimated for the two month to nine month periods post1
legislation.  
 
Some significant changes in bupropion prescribing were detected in Wales and 
Northern Ireland, corresponding to the patterns seen in England of increased 
prescribing before the smoking ban was enacted and reduced prescribing 
afterwards. The direction of the non1significant point estimates in Scotland also 
supports this pattern.  

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Figure 5.8 shows monthly rates of prescribing of varenicline to current smokers in 
THIN. Varenicline was first made available on NHS prescription in December 2006, 
and in July 2007 the National Institute of Health and Clinical Excellence (NICE) 
issued guidelines recommending GPs prescribe the drug to smokers who wish to 
quit. As was seen when bupropion first became available, rates of prescribing of 
varenicline increased rapidly soon after its introduction, reaching a similar rate of 
prescribing as bupropion within just a few months. Prescribing of varenicline does 
not, however, show the slump seen in rates of prescribing of bupropion. 
Unfortunately, the timing of the introduction of varenicline means there are not 
enough data from the pre1smokefree period to model the impact of the 
introduction of smokefree legislation on rates of prescribing of this medication.    
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Figure 5.9 shows monthly rates of prescribing of all smoking cessation 
medications (NRT, bupropion and varenicline) to current smokers in THIN in each 
of the four jurisdictions of the UK. The majority of this prescribing is NRT and 
therefore the patterns of prescribing of all medication are very similar to those of 
NRT discussed earlier.   
 
All four countries show a similar pattern of a slightly increasing trend in 
prescribing in the first half of the time period followed by a decreasing trend in the 
second half of the series. All series display a similar, regular seasonal pattern, 
with peaks in prescribing in the first three months of the year and troughs in the 
summer months. The lowest rates of prescribing are seen in England, though here 
the magnitude of variation in the series from one month to the next is smaller 
than in the other three countries. The rate of prescribing in Scotland and Wales, 
and the magnitude of the monthly variation, is slightly higher than in England. 
Northern Ireland appears to have the highest rates of prescribing, but this series 
is also the most variable.   
 
In England and perhaps Northern Ireland there appear to be increases in the rate 
of prescribing of all smoking cessation medications in the months immediately 
before the introduction of smokefree legislation which are not seen in other years. 
Again, however, it is difficult to judge whether these changes are outside of the 
normal behaviour of the series.  
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Intervention effect  
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 2.0 118.6 to 22.7 0.847 6.0 13.7 to 15.8 0.224 
1 month before  ;6%& M$$$ 17.4 10.4 to 35.2 0.055 
2 months before   $ ;6 M$$$ 10.0 11.7 to 21.6 0.093 
3 months before  #;6 % M$$$ 6.0 13.7 to 15.8 0.224 
6 months before  ##;6% M$$$ 5.6 12.4 to 13.5 0.172 
9 months before %  $;6 $$ 2.2 14.8 to 9.3 0.536 
1 month after 7.7 113.0 to 28.4 0.468 10.3 141.2 to 40.5 0.987 
2 months after 15.3 117.2 to 6.7 0.387 19.7 120.2 to 0.7 0.068 
3 months after 
$$ 
$;6
 $$ % 15.3 113.5 to 2.9 0.206 
6 months after 17.4 116.3 to 1.5 0.101 14.3 111.7 to 3.0 0.251 
9 months after 
%  
;6
 $$ 11.7 17.9 to 4.4 0.584 
Step change 12.2 15.6 to 1.2 0.209 10.5 13.1 to 2.0 0.683 
 
 
34/8 6.;0/.(./43(<
Intervention effect  
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 12.5 110.2 to 5.2 0.521 11.3 11.0 to 23.6 0.072 
1 month before 8.2 112.6 to 29.0 0.438 16.9 12.2 to 36.1 0.083 
2 months before 2.6 111.1 to 16.2 0.714 6.8 13.3 to 17.0 0.186 
3 months before 12.5 110.2 to 5.2 0.521 1.8 15.8 to 9.5 0.636 
6 months before 3.8 112.2 to 19.8 0.645 7.7 10.6 to 16.1 0.068 
9 months before 2.2 17.7 to 12.1 0.660 5.9 11.2 to 13.0 0.106 
1 month after 15.4 122.1 to 52.8 0.421 16.3 15.5 to 38.2 0.143 
2 months after 3.1 17.3 to 13.5 0.554 # &;6 $$
3 months after 4.3 15.4 to 14.0 0.381 7.0 10.6 to 14.7 0.071 
6 months after 0.1 17.4 to 7.5 0.985 10.1 16.2 to 6.0 0.978 
9 months after 13.1 19.0 to 2.7 0.294 11.7 16.6 to 3.1 0.490 
Step change 11.6 14.7 to 1.6 0.336 10.7 13.4 to 2.0 0.603 
 
 
 
The pattern of prescribing of all smoking cessation medications in England shown 
in Table 5.6 is very similar to those of prescribing of NRT and bupropion discussed 
previously. There is no evidence of a change in all prescribing in England in the 
first quarter of 2007, though significant increases in the monthly rate at which 
smokers were prescribed at least one of the three smoking cessation medications 
are observed up to nine months before the smoking ban was enacted. This period 
of increased prescribing is of a longer duration than the periods of increased 
prescribing estimated for NRT and bupropion. In England, a significant decrease in 
the rate of prescribing of all smoking cessation medications was estimated for the 
three and nine month periods after smokefree legislation was introduced, though 
not for the other intervention periods. As was seen in prescribing of NRT and 
bupropion, the decline in the rate of prescribing of all medication was not 
sustained to the end of the study period.  
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In all but one instance no significant changes in the rate of prescribing of all 
smoking cessation medications were detected in Scotland, Wales and Northern 
Ireland. Again, however, the direction of many of the point estimates support the 
apparent pattern of an increase in prescribing in the months leading up to the 
introduction of smokefree legislation followed by a decline in prescribing after the 
ban was enacted.  
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Appendix 8.13 shows the changes in the rates of recording of cessation advice, 
referral to cessation services and prescribing of cessation medications estimated 
to have occurred in all patients and not just those identified as smokers. The 
significance, magnitude and direction of the changes in all outcome variables are 
very similar when analysis is based upon intervention rates in all patients and not 
just those identified as smokers. 
 
Appendix 8.14 shows the changes in the rates of recording of patients’ smoking 
status, the delivery of cessation advice and referral of smokers to specialist 
cessation services estimated when analyses are based on data from April 2004 
onwards. Using the shorter series significant increases in the rate of recording of 
smoking status are detected in some intervention periods, as well as significant 
declines in others; there is no consistent pattern to the results comparing one 
country to another. A small number of significant changes in the recording of 
advice and referral are detected, contrary to the results presented earlier in this 
chapter, though again these do not form a consistent pattern over time nor when 
comparing one country with another. 
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The results presented in this chapter highlight increases in the rate of prescribing 
of NRT and bupropion in England in the six and three months respectively leading 
up to the introduction of smokefree legislation, and decreases in prescribing up to 
nine months afterwards. Rates of prescribing of all medications were increased up 
to nine months before the smoking ban was enacted. Similar patterns were seen 
in Scotland, Wales and Northern Ireland, though generally were not statistically 
significant.  
 
Some significant decreases in the rate of recording of patient smoking status were 
seen in all UK countries shortly before and/or after the introduction of smokefree 
legislation. No significant changes were observed in any country in either the rate 
of recording of cessation advice or referral of smokers to specialist cessation 
services.   
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All of the time series analysed in this chapter show monthly variation in the data, 
sometimes forming a regular seasonal pattern repeated from one year to the 
next. Additionally, many of the series demonstrate a distinct upwards or 
downwards trend prior to the introduction of smokefree legislation. The ARIMA 
modelling method used here is able to filter out any trends and seasonal variation 
to assess whether there were any changes in the outcome variables above and 
beyond the normal behaviour of the series that may be associated with the 
introduction of smokefree legislation. The same algorithm was used to calculate 
the rate of recording of smoking status and delivery of interventions for each 
month of the study period in each country of the UK. In addition, the same 
analytical method was applied to all time series, and the use of the automated 
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ARIMA model identification procedure described earlier in this thesis has removed 
the potential for subjectivity from the data analysis process.  
 
The results of the sensitivity analysis investigating changes in the rate of 
intervention recording in all patients, and not just those identified as current 
smokers, are encouraging. The similar changes in cessation advice, referral to 
cessation services and prescribing of cessation medications estimated to have 
occurred in all patients and current smokers suggest that improved recording of 
current smokers does not confound assessment of the impact of smokefree 
legislation on the series. The results of the sensitivity analysis using a shorter time 
series to assess the impact of smokefree legislation on the recording of patients’ 
smoking status and the delivery of advice and referral suggest that, on the whole, 
increased recording of these outcomes in the run1up to the introduction of the 
QOF does not confound assessment of the impact of smokefree legislation on 
these series. However, examination of the output of the automated ARIMA model 
fitting procedure for these shorter time series does highlight some difficulties in 
fitting models using a smaller number of data points. Whilst an appropriate ARIMA 
model could be identified for each of the shorter time series, often the conclusions 
drawn about the direction and statistical significance of changes in the outcome 
variables during the intervention periods were less robust to the choice of model 
compared to analysis of a longer time series.   
 
It should be remembered that one in twenty ARIMA models can be expected to 
produce a statistically significant estimate of a change in the outcome variable at 
the 5% significance level, and thus the results of multiple hypothesis testing 
should be interpreted with caution – some of the statistically significant results 
presented here may in fact be non1significant, and vice1versa. However, there is 
no recognised way to correct the p1values generated from interrupted time series 
analysis to account for such multiple hypothesis testing, and the need to do so 
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anyway has been vigorously debated in other types of study165. Instead, the 
strength of the ARIMA study design and plausibility of the results can be taken to 
support the significance of the findings reported here, as recommended when no 
correction for multiple significance testing is made165.  
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As discussed in Chapter 1, there are slight variations in the demographic and 
socio1economic structure of the THIN dataset compared to national population 
estimates, and so the results presented here may not be truly representative of all 
patients throughout the UK. Similarly, it was impossible to identify individual 
practices with poor smoking data recording, and so the monthly rates analysed in 
this chapter may be skewed by the inclusion of these practices in the analyses 
undertaken. Questions regarding the external validity of the results presented 
here can be addressed in part by analysing the impact of smokefree legislation on 
the management of smoking in individual subgroups of the population defined by 
demographic and socio1economic characteristics, analyses which will be 
undertaken in the next chapter.  
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A major limitation of interrupted time series analysis is the inability to draw causal 
links between any statistically significant changes in a series and the introduction 
of an intervention such as smokefree legislation. Any changes in a series may be 
the result of other known or unknown events which occurred at the same time. 
The significant reductions in the rate of recording of patient smoking status 
observed shortly before and/or after the introduction of smokefree legislation in all 
four UK countries may not be an effect of smokefree legislation; there is no 
plausible mechanism to suggest why the introduction of legislation would lead to 
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decreased recording, particularly as prior to smokefree legislation being 
introduced increased prescribing of smoking cessation medications was observed, 
suggesting greater rather than less smoking1related clinical activity in primary 
care at this time. Perhaps reductions in the rate of recording of patient smoking 
status at certain times are related to the annual QOF cycle, where practices must 
prove their compliance with QOF targets once a year, though further work is 
needed to confirm or refute this hypothesis. 
 
The increases in NRT and bupropion prescribing estimated to have occurred in 
England in the run up to the introduction of smokefree legislation do not appear to 
have been sustained post1legislation. This may be evidence that legislation 
brought forward to the start of the year quit attempts that would have been made 
in the second half of 2007, as has been suggested elsewhere46. However, the 
picture is complicated by the introduction of varenicline in December 2006. As 
seen in Figure 5.8, rates of prescribing of varenicline increased rapidly, and it is 
possible that prescribing of this new medication may have replaced some of the 
prescribing of NRT and bupropion, rather than increasing the overall level of 
prescribing, perhaps explaining some of the decline in NRT and bupropion 
prescribing observed post1legislation. Indeed, comparison of the magnitudes of 
declines in prescribing estimated by the ARIMA modelling show that the decline in 
all prescribing was generally less in all time periods than the declines seen in NRT 
and bupropion prescribing, suggesting that the declines in NRT and bupropion 
prescribing were partly, but not totally, offset by an increase in the prescribing of 
varenicline. Bupropion prescribing suffered the largest decrease, suggesting that 
GPs were more likely to prescribe varenicline as an alternative to bupropion, 
rather than instead of NRT. Interestingly, declines in prescribing of NRT, 
bupropion and all medications were not sustained to the end of the study period – 
inspection of the time plots suggests that rates of prescribing seem to increase 
again the first few months of 2009. It is not clear what may be responsible for 
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these apparent increases, though it may be that the introduction of smokefree 
legislation shifted quit attempts forward, resulting in reduced prescribing from July 
2007 to December 2008, which then picked up again in 2009. More data are 
needed to assess whether this apparent increase in prescribing at the start of 
2009 is sustained. 
 
In most countries, smokefree legislation has been introduced as just one of a raft 
of tobacco control measures, and thus it is always likely to be difficult to assess 
the true impact of legislation alone. In the UK, tax on over1the1counter NRT was 
reduced to 5% in July 2007, and it may be that smokers who previously would 
have gone to their GP to get NRT instead bought it over the counter, contributing 
to the decline in prescribing detected in THIN data. However, the post1legislation 
decline seen in the rates of prescribing of bupropion cannot be attributed to this 
tax change, and so perhaps other factors also explain the decline in NRT 
prescribing. 
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Prescribing of any medication does not necessarily mean patients will redeem 
their prescription and use the medication as directed, though the good agreement 
between THIN prescribing rates and rates of dispensed prescriptions suggests this 
first concern is not a major problem162. NRT is also available from sources other 
than a primary health care professional, such as through NHS Stop Smoking 
Services, and these prescriptions will not appear in THIN. In addition, some 
smokers may use NRT to support temporary abstinence from smoking166. 
Therefore, the changes in NRT prescribing reported here may not entirely reflect 
the impact of smokefree legislation on the total use of NRT or actual quitting 
activity. In Scotland, significant increases in over1the1counter sales of NRT were 
seen between January and June 2006, the six month period spanning the 
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introduction of smokefree legislation43. Any increased quitting activity which may 
have resulted from these purchases may have, at least in part, offset any 
reduction in the number of smokers attempting to quit attributable to the decline 
in prescribing in primary care.  
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In general, this study found few statistically significant changes in smoking1
related clinical activity in Scotland, Wales or Northern Ireland, though the 
direction of the point estimates of changes in prescribing are in line with the 
patterns seen in England. A power analysis suggests the failure to detect 
significant changes in Scotland, Wales and Northern Ireland may not be because 
the response to smokefree legislation was different in these jurisdictions to that 
England, but because the ARIMA models are not adequately powered to detect 
changes in prescribing of a similar magnitude to those significant changes 
detected in England. Table 5.7 shows the minimum effect size which the ARIMA 
models are powered to detect in each country for a change in each outcome 
variable six months before the introduction of smokefree legislation. In addition, 
the effect sizes estimated to have occurred in each series are shown.  
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	(,43(< 56;43(<
Outcome 
variable 
Estimate (95% CI) 
Minimum effect 
detectable with 80% 
power 
Estimate (95% CI) 
Minimum effect 
detectable with 80% 
power 
Smoking status 12.5 (17.4 to 2.3) 7.0 1.9 (16.9 to 10.6) 12.6 
Advice 13.1 (18.9 to 2.8) 8.4 10.1 (112.1 to 11.9) 17.0 
Referral 1.7 (155.4 to 58.8) 81.2 12.0 (146.7 to 42.7) 63.6 
NRT %> ;6$? $ 6.3 (12.9 to 15.4) 13.1 
Bupropion 7.1 (10.4 to 14.5) 10.6 5.0 (18.8 to 18.7) 19.5 
All prescribing >##;6%? & 5.6 (12.4 to 13.5) 11.4 
 
 
34/8 6.;0/.(./43(<
Outcome 
variable 
Estimate (95% CI) 
Minimum effect 
detectable with 80% 
power 
Estimate (95% CI) 
Minimum effect 
detectable with 80% 
power 
Smoking status 1.1 (16.0 to 8.1) 10.0 13.0 (110.4 to 4.4) 10.6 
Advice 4.7 (131.0 to 40.3) 50.8 11.6 (19.7 to 6.6) 11.4 
Referral 13.2 (116.2 to 9.9) 18.7 
  
NRT 11.3 (113.0 to 10.4) 16.7 12.9 (19.1 to 3.3) 8.9 
Bupropion >;6 %? # &>&;6 &? & 
All prescribing 3.8 (112.2 to 19.8) 22.9 7.7 (10.6 to 16.1) 11.7 
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As Table 5.7 shows, the ARIMA models for the prescribing series in Scotland, 
Wales and Northern Ireland are, on the whole, only powered to detect statistically 
significant changes of a magnitude much larger than the point estimates of 
change in these locations, and effects larger than the significant changes detected 
in England. Prescribing data in Scotland, Wales and Northern Ireland ought to be 
complete, given that prescriptions are issued electronically and a record 
automatically appears in THIN, and the regular seasonal pattern seen in these 
time series, similar to that seen in England, suggests recording is indeed 
complete. However, there are considerably fewer THIN practices in Scotland (43 
practices), Wales (30) and Northern Ireland (23) compared to England (350). The 
greater magnitude of monthly variation seen in the time series for Scotland, Wales 
and Northern Ireland, and hence the lower power to detect small changes in the 
series, may reflect the smaller number of practices in these locations.  
 
Figure 5.10 shows the 95% confidence intervals around the rates of prescribing of 
all smoking cessation medications in each country. As can be seen, the 95% 
confidence intervals are much wider around the time series from Scotland, Wales 
and Northern Ireland compared to England, and similar patterns are also seen in 
the prescribing of NRT and bupropion. The greater monthly variation in prescribing 
in Scotland, Wales and Northern Ireland, which increases the magnitude of effect 
size which can be detected as outside of the normal behaviour of the series, might 
not be a true reflection of prescribing in the country as a whole, but simply a 
reflection of the smaller number of practices in these countries. It has not been 
possible in this work to account for the wide variations between practices 
demonstrated previously in the apparent completeness of recording of smoking 
status and cessation interventions. Unfortunately, analysis of data from these 
countries with fewer practices contributing to THIN has greater potential to be 
skewed by aberrant data recording in one or two practices which may increase the 
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variability of the series and reduce the power to detect small changes in 
outcomes.  
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Figure 5.4 showed that the rate of recording of referral of smokers to stop 
smoking services is approximately ten times higher in Northern Ireland than 
elsewhere in the UK. However, the 95% confidence intervals around these 
estimates suggest that this might just be a reflection of the smaller number of 
practices in Northern Ireland, and rates of referral may indeed be comparable to 
the rest of the UK. The differences between England, Wales, Scotland and 
Northern Ireland in the width of the 95% confidence intervals around rates of 
recording of smoking status and cessation advice are less marked, explaining the 
similar variation and power to detect changes in these series (figures not shown 
here). 
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The significant increases in the rate of prescribing of NRT and bupropion in the 
run1up to the introduction of smokefree legislation suggests that smokers looking 
to quit may indeed seek support to do so from primary care, or that GPs may see 
the introduction of legislation as a chance to pro1actively encourage smokers to 
quit. However, the decline in rates of all prescribing post1legislation suggests that 
this positive change may not be sustained. It could be argued that this highlights 
a missed opportunity to maximise the impact of smoking bans by ensuring that 
smokers are aware of, and indeed access, cessation support in primary care both 
before and after legislation is enacted, and should be noted by policy makers 
planning the introduction of smokefree legislation elsewhere. 
 
The failure to detect significant changes in the recording of cessation advice and 
referral of smokers to stop smoking services again may reflect missed 
opportunities to maximise the impact of smokefree legislation, though incomplete 
recording of these interventions may also explain these results.   
 
This chapter has assessed the impact of smokefree legislation on the management 
of smoking in primary care in all adults in each part of the UK. The size of the 
THIN dataset offers the opportunity to investigate the impact of legislation in 
subgroups of patients and the results of these subgroup analyses are presented in 
the following chapter.     
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As outlined in the introduction to this thesis, variations in smoking prevalence by 
socioeconomic group are the major driver of health inequalities between rich and 
poor in the UK10. Reducing these inequalities is a priority for health policy and a 
specific target set by the Department of Health aims to halve the current 
prevalence of smoking in routine and manual groups by 2020167.  
 
To date little is known about which policies are most effective in reducing the 
inequalities in health caused by smoking, and it may be that policies which appear 
to improve the health of a population overall in fact widen inequalities in health if 
their benefits are concentrated in the most advantaged socio1economic groups168. 
The majority of studies which have attempted to evaluate the effects of 
population1level tobacco control policies on social inequalities in smoking have 
focused on the role of price, with the balance of evidence suggesting that 
increasing the cost of tobacco is most effective in reducing consumption and 
prevalence in adults with lower incomes and in manual occupations169. A 
systematic review of the effect of public and workplace tobacco control 
interventions on social inequalities in smoking found insufficient evidence of 
differential impacts of smokefree regulations by income, education level and 
ethnicity, inconsistent evidence of differential effects by age, and no evidence that 
restrictions have a differential impact in men and women169. 
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Few studies which have evaluated national, comprehensive smokefree legislation 
have also set out to do so in population subgroups. The recent Cochrane review of 
the impact of legislative smoking bans describes just two studies where results 
are presented separately for men and women36, and another study, published 
after the Cochrane review, reported that younger age groups were more likely to 
report having made a quit attempt in response to smokefree legislation, though 
there were no significant differences according to gender or social class46. In New 
Zealand, there were no changes in the proportion of smokers by sex or ethnic 
group registering with the national Quitline at the time smokefree legislation was 
introduced, though the proportion of registrations by smokers aged 35144 did 
increase47. The large size of the THIN dataset potentially provides the statistical 
power to assess the impact of smokefree legislation on the management of 
smoking in primary care in different population subgroups.  
 
This chapter uses THIN data to assess whether the changes in smoking1related 
clinical activity in primary care reported in all patients in the previous chapter 
differ by patient sex, age group, medical history and social class. As discussed 
previously, the small number of THIN practices in Scotland, Wales and Northern 
Ireland makes it difficult to detect small changes in clinical activity in these 
locations, and the power is likely to be compromised further by dividing the total 
population into smaller subgroups. In addition, changes in recording of smoking 
status seem unlikely to be related to the introduction of smokefree legislation, and 
the less robust quality of advice and referral data make it difficult to detect 
changes in these outcome variables. Therefore, this chapter will only assess the 
differential impact of smokefree legislation on prescribing of stop smoking 
medications in England. 
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As in the analysis of data for England as a whole, for each month from January 
2000 to July 2009 all patients were identified from the THIN dataset who were 
aged 16+ and registered with a practice for at least one day of the month. 
Current smokers were identified and, in addition, details of each patient’s age, 
sex, medical history and social class (measured by quintile of the Townsend Index 
of Deprivation) were extracted from their medical records.  
 
Monthly rates of prescribing of NRT, bupropion and all smoking cessation 
medications were calculated for each of the population subgroups shown in Table 
6.1, expressed as the number of smokers with a record each month per 100,000 
person1months of follow1up time. 
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All patients 1 437,933 
Gender 
Men 232,413 
Women 205,520 
Age group 
16119 20,101 
20124 42,225 
25134 90,805 
35149 143,898 
50159 68,595 
60+ 72,309 
Number of chronic conditions* 
0  362,268 
1+  75,665 
Townsend Index of Deprivation 
Least deprived 77,307 
Quintile 2 77,345 
Quintile 3 91,989 
Quintile 4 96,884 
Most deprived 76,743 
Missing 17,665 
*from asthma, chronic obstructive pulmonary disease, coronary heart disease, diabetes mellitus, 
hypertension and stroke or transient ischemic attack.  
 
 
Preliminary analysis showed that analysing rates of prescribing in individual 
groups of patients with each of the six chronic conditions resulted in inadequate 
power to detect small changes in prescribing in any group. These variables will 
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not, therefore, be used in this subgroup analysis and instead the composite 
variable indicating patients with one or more of these conditions will be used.  
 
Given the similarity demonstrated in the previous chapter between rates of 
prescribing in smokers and all in patients, this chapter only considers changes in 
rates of prescribing in smokers. 
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ARIMA modelling was used to assess the impact of the introduction of smokefree 
legislation on prescribing in each subgroup, using the procedure outlined in 
Chapter 4 and applied in Chapter 5. The same intervention effects were modelled 
in each subgroup as in all patients in England, and again results are presented as 
percentage changes in the outcome variable in the intervention period. 
 
There is no documented statistical method which can compare the results of 
several interrupted time series analyses to assess whether smokefree legislation 
had a differential effect in different population subgroups. Therefore, the 
magnitude of the effect sizes and 95% confidence intervals calculated in different 
subgroups will be compared visually and non1overlapping confidence intervals 
taken as evidence of a difference in effect between subgroups. 
 
Changes in NRT prescribing were estimated using data from April 2001, the first 
month the medication became available on NHS prescription. Changes in 
prescribing of bupropion and all smoking cessation medications were estimated 
using data from January 2002, removing the outlying peak in bupropion 
prescribing when this medication first became available on NHS prescription.  
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As noted previously, a record of all issued prescriptions appears automatically in 
THIN, and so there is no potential confounding effect of increased computer use 
associated with the QOF when investigating the impact of smokefree legislation, 
and therefore no need to model a shorter data series.   
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The analysis of data from all patients in England, presented in Section 5.3.4.1, 
showed there was no change in NRT prescribing in the first quarter of 2007, 
though significant increases in the rate of NRT prescribing were observed up to six 
months before the introduction of smokefree legislation. Significant declines in 
prescribing were estimated two to nine months post1legislation, though this 
decline was not sustained to the end of the study period.  
 
Figure 6.1 shows rates of prescribing of NRT by patient sex and whether they 
have a history of one or more chronic conditions.  
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The rate of prescribing of NRT in women is higher, though more variable, than 
that in men, and is also higher but more variable in patients with a history of one 
or more chronic conditions compared to those without. In all subgroups there 
appears to be a decline in prescribing after the introduction of smokefree 
legislation, though, given the monthly variation in the series, it is hard to tell 
whether there are any significant increases in prescribing before the introduction 
of the smoking ban.  
 
Figure 6.2 shows rates of prescribing of NRT by patient age group. The rate of 
NRT prescribing in all six age groups shows a regular seasonal pattern across the 
study period. The overall rate of prescribing is lowest in the two youngest age 
groups, though these groups also show the smallest variation in prescribing from 
one month to the next. In some age groups there appears to be an increase in 
prescribing immediately before the introduction of smokefree legislation, though it 
is hard to tell whether any increase is outside of the normal behaviour of the 
series. In all but the youngest and oldest age groups there appears to be a decline 
in NRT prescribing in the post1legislation period, though again the monthly  
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variation in the series makes it difficult to tell whether any decline would be 
judged statistically significant. 
 
Figure 6.3 shows rates of prescribing of NRT by quintile of the Townsend Index of 
Deprivation. All series show seasonal variation in the rate of NRT prescribing, 
though this seasonal pattern is less regular in patients whose Townsend 
classification is missing in their THIN records. The rate of prescribing is very 
similar in all Townsend quintiles, and in all groups of patients except those with 
missing data there appears to be a decline in NRT prescribing after the 
introduction of smokefree legislation.   
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Table 6.2 shows the estimates from interrupted time series analysis of changes in 
NRT prescribing before the introduction of smokefree legislation for each 
population subgroup, along with their 95% confidence intervals. Figures in bold 
print highlight statistically significant changes. Table 6.3 presents the estimates 
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for changes in NRT prescribing in the intervention periods after the introduction of 
smokefree legislation. 
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Increases in NRT prescribing were seen three months before the introduction of 
smokefree legislation in all population subgroups (except those with a missing 
Townsend score), and in most subgroups six months pre1ban. The point estimates 
presented in Table 6.2 suggest that the increase in prescribing may have been 
marginally greater in men compared to women, though the 95% confidence 
intervals around these estimates overlap, suggesting that the introduction of 
smokefree legislation did not have a differential effect according to patient sex. 
The magnitude of the increase in prescribing was similar in all age groups in the 
three month pre1legislation period and in those groups where significant changes 
were detected six months pre1ban, and again the confidence intervals overlap. 
Increases in NRT prescribing are seen both in patients with one or more chronic 
conditions and those who are otherwise healthy. The point estimates suggest that 
the increase in prescribing may have been marginally greater amongst those 
without a history of chronic disease than those with, though again the confidence 
intervals overlap. Finally, the overlapping confidence intervals for the estimates of 
the change in NRT prescribing according to Townsend score suggest that the 
introduction of smokefree legislation did not have a differential effect according to 
patient socio1economic status.  
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A decline in NRT prescribing was observed for both men and women for the nine 
month period after smokefree legislation was introduced. The decrease in 
prescribing may have been greater in women than men, though the 95% 
confidence intervals around these estimates overlap. No significant change in the 
rate of NRT prescribing was seen at any point after the introduction of smokefree 
legislation in patients aged 16119 and 60 and above, though the estimates of 
change in the other age groups are of a similar magnitude. A decline in 
prescribing was seen both in patients with one or more chronic conditions and 
those who are otherwise healthy. The decrease may have been greater in patients 
without chronic conditions, though the overlapping confidence intervals again 
suggest that the introduction of smokefree legislation did not have a differential 
effect according to patient medical history. A similar magnitude of decline in NRT 
prescribing was observed in all quintiles of the Townsend Index in the six month 
post1legislation period, and in all but the least deprived quintile up to nine months 
post1ban.  
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The analysis of bupropion prescribing data from all patients in England, presented 
in Section 5.3.4.2, showed a similar pattern of changes to those seen in NRT 
prescribing. Significant increases in the rate of prescribing were observed up to 
three months before the introduction of smokefree legislation, and declines in the 
prescribing of bupropion were estimated for the two to nine month periods post1
legislation, though were not sustained to the end of the study period. The 
magnitude of the decline in bupropion prescribing in all patients was much larger 
than that seen in NRT prescribing, though the confidence intervals around the 
estimates of change in bupropion prescribing were wider. 
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Figure 6.4 shows rates of prescribing of bupropion by patient sex and whether 
they have a history of one or more chronic conditions.  
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There is monthly variation in the rate of bupropion prescribing in each subgroup, 
though there is a less obvious seasonal pattern than was seen in the prescribing 
of NRT. The rate of prescribing of bupropion is similar in men and women, with 
both series showing an apparent increase in prescribing immediately before the 
introduction of smokefree legislation and a decline in the post1legislation period. 
However, it is difficult to judge visually whether this decline is simply a 
continuation of a longer1term decline in the rate of prescribing of bupropion. The 
rate of prescribing of bupropion is higher in patients with a history of one or more 
chronic conditions compared to those who are otherwise healthy, though both 
groups again appear to show an increase in prescribing immediately before the 
introduction of smokefree legislation and a decline in the post1legislation period.  
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Figure 6.5 shows rates of prescribing of bupropion by patient age group.  
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The rate of bupropion prescribing is highly variable from month to month in each 
age group. The overall rate of prescribing is very low in patients aged 16119, 201
24 and 60+ compared to the other age groups, making it difficult to see whether 
there were any changes in the rate of prescribing at the time smokefree 
legislation was introduced. In patients aged between 25 and 59 there appears to 
be an increase in prescribing just before smokefree legislation was introduced, 
and a decline in the post1legislation period, though again this decline may simply 
be a continuation of a longer1term trend. 
 
Figure 6.6 shows rates of prescribing of bupropion by quintile of the Townsend 
Index of Deprivation.  
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The rate of bupropion prescribing is very similar for each quintile of the Townsend 
Index of Deprivation, showing a large amount of monthly variation but no obvious 
seasonal pattern, and an apparent long1term decline in prescribing making it 
difficult to distinguish any additional decline after the introduction of smokefree 
legislation. 
 
Table 6.4 shows the estimates of changes in bupropion prescribing before the 
introduction of smokefree legislation for each population subgroup, and Table 6.5 
presents the estimates for changes in prescribing in the intervention periods after 
the introduction of smokefree legislation.
SFL0
50
100
150
200
R
at
e 
pe
r 
10
0,
00
0
pe
rs
on
-
m
on
th
s
Ja
n
 
20
00
Ja
n
 
20
01
Ja
n
 
20
02
Ja
n
 
20
03
Ja
n
 
20
04
Ja
n
 
20
05
Ja
n
 
20
06
Ja
n
 
20
07
Ja
n
 
20
08
Ja
n
 
20
09
Ja
n
 
20
10
 
Month
Least deprived
 
SFL0
50
100
150
200
R
at
e 
pe
r 
10
0,
00
0
pe
rs
on
-
m
on
th
s
Ja
n
 
20
00
Ja
n
 
20
01
Ja
n
 
20
02
Ja
n
 
20
03
Ja
n
 
20
04
Ja
n
 
20
05
Ja
n
 
20
06
Ja
n
 
20
07
Ja
n
 
20
08
Ja
n
 
20
09
Ja
n
 
20
10
 
Month
Quintile 2
 
SFL0
50
100
150
200
R
at
e 
pe
r 
10
0,
00
0
pe
rs
on
-
m
on
th
s
Ja
n
 
20
00
Ja
n
 
20
01
Ja
n
 
20
02
Ja
n
 
20
03
Ja
n
 
20
04
Ja
n
 
20
05
Ja
n
 
20
06
Ja
n
 
20
07
Ja
n
 
20
08
Ja
n
 
20
09
Ja
n
 
20
10
 
Month
Quintile 3
 
SFL0
50
100
150
200
R
at
e 
pe
r 
10
0,
00
0
pe
rs
on
-
m
on
th
s
Ja
n
 
20
00
Ja
n
 
20
01
Ja
n
 
20
02
Ja
n
 
20
03
Ja
n
 
20
04
Ja
n
 
20
05
Ja
n
 
20
06
Ja
n
 
20
07
Ja
n
 
20
08
Ja
n
 
20
09
Ja
n
 
20
10
 
Month
Quintile 4
 
SFL0
50
100
150
200
R
at
e 
pe
r 
10
0,
00
0
pe
rs
on
-
m
on
th
s
Ja
n
 
20
00
Ja
n
 
20
01
Ja
n
 
20
02
Ja
n
 
20
03
Ja
n
 
20
04
Ja
n
 
20
05
Ja
n
 
20
06
Ja
n
 
20
07
Ja
n
 
20
08
Ja
n
 
20
09
Ja
n
 
20
10
 
Month
Most deprived
 
SFL0
50
100
150
200
R
at
e 
pe
r 
10
0,
00
0
pe
rs
on
-
m
on
th
s
Ja
n
 
20
00
Ja
n
 
20
01
Ja
n
 
20
02
Ja
n
 
20
03
Ja
n
 
20
04
Ja
n
 
20
05
Ja
n
 
20
06
Ja
n
 
20
07
Ja
n
 
20
08
Ja
n
 
20
09
Ja
n
 
20
10
 
Month
Missing
 
    
2
4
9
 
3A4/% 03(,/8+(A-1.61+6(1./85.+A+(,+(	(,43(<A/76./;0/+(;.6<-5;+6(67896:/7.//4/,+843;+6(
 -A,.6-1 $$* 96(;0A/76./ 96(;08A/76./ 96(;08A/76./ %96(;08A/76./ 96(;08A/76./
4413;+/(;8 	(,43(< 1.7 (112.9 to 16.2)   >$ ;6%$? &>;6&%? > ;6? 7.1 (10.4 to 14.5) 5.2 (11.8 to 12.3) 
/(</.
/( 6.5 (16.4 to 19.3) 37.1 (11.5 to 75.8) >%%;6? %&>%;6#? $$>;6? $&>##;6%?
69/( 4.3 (16.0 to 14.6) >#$;6  &? &>;6%? 5.6 (12.1 to 13.4) 4.6 (11.3 to 10.5) 1.4 (14.3 to 7.1) 
,/,.6-1
%
 12.0 (112.4 to 36.3) 39.2 (1201.9 to 280.2) 16.0 (133.2 to 65.3) 5.9 (121.6 to 33.4) 5.2 (18.3 to 18.6) 1.9 (148.8 to 52.6) 
$
  15.9 (116.6 to 48.3) 11.0 (140.5 to 62.4) 3.9 (123.8 to 31.6) 3.8 (117.4 to 25.0) 6.1 (17.9 to 20.1) 7.1 (19.6 to 23.9) 
#
  1.3 (116.9 to 19.6) $>;6%$? 16.6 (11.2 to 34.4) 11.7 (11.1 to 24.4) 5.8 (13.3 to 14.8) 3.4 (16.7 to 13.5) 
#
  7.2 (15.1 to 19.6) 47.0 (114.3 to 108.3)  >&;6 $%? &%>#;6? >;6$? $%> #;6%?
#$
# 11.5 (12.7 to 25.7) 20.7 (128.2 to 69.5) 9.6 (19.6 to 28.8) 5.5 (110.0 to 20.9) 6.8 (12.6 to 16.1) >$ ;6 ?
%$= 9.1 (127.3 to 45.5) 22.6 (147.4 to 92.6) 10.7 (120.7 to 42.2) 11.2 (113.9 to 36.3) 8.2 (110.3 to 26.6) 8.8 (17.9 to 25.4) 
-9A/.6750.6(+5
56(<+;+6(8
$ 1.4 (118.5 to 21.3) %&> ;6#? $%>;6? 5.4 (12.0 to 12.9) &>$;6%? 5.4 (11.3 to 12.2) 
= 7.9 (17.8 to 23.7) 29.8 (131.0 to 90.6) 9.5 (16.6 to 25.6) 6.1 (16.8 to 19.0) 5.9 (13.5 to 15.4) 5.3 (13.2 to 13.8) 
6C(8/(<(</K
67/1.+23;+6(
/38;</1.+2/< 10.9 (12.5 to 24.4) 27.3 (142.2 to 96.8) 13.2 (114.4 to 40.8) 10.5 (19.1 to 30.0) 10.3 (10.3 to 20.9) >&;6%%?
*-+(;+4/ 9.7 (16.8 to 26.3) 40.2 (143.9 to 124.2) 15.8 (13.2 to 34.7) 13.2 (11.3 to 27.8) 9.1 (10.8 to 19.0) $>&;6&%?
*-+(;+4/ 15.2 (125.2 to 14.7) #>;6$ ?  >%;6%? 6.7 (12.9 to 16.3) 1.4 (17.0 to 9.8) 11.0 (17.0 to 5.0) 
*-+(;+4/  10.9 (116.0 to 14.3) 21.4 (14.8 to 47.6) 15.4 (14.8 to 35.7) 7.1 (17.4 to 21.6) 4.0 (16.6 to 14.6) 0.2 (17.3 to 7.7) 
68;</1.+2/< 11.4 (18.8 to 31.6) 11.1 (131.7 to 29.5) 0.5 (119.6 to 20.7) 2.6 (116.1 to 21.2) 6.0 (16.1 to 18.2) 6.5 (12.1 to 15.1) 
+88+(, 5.8 (19.1 to 20.7) 23.4 (115.3 to 62.1) 13.4 (18.9 to 35.8) 9.3 (16.9 to 25.5) 4.7 (14.2 to 13.7) 2.8 (13.7 to 9.3) 
 
3A4/%#03(,/8+(A-1.61+6(1./85.+A+(,+(	(,43(<37;/.;0/+(;.6<-5;+6(67896:/7.//4/,+843;+6(
 -A,.6-1 96(;037;/. 96(;0837;/. 96(;0837;/. %96(;0837;/. 96(;0837;/. ;/1503(,/
4413;+/(;8 	(,43(< 16.8 (140.1 to 26.6) 
#>
 ;6
 #? 
>
;6
 $? 
>
##;6
 $? 
>
 %;6
&? 13.5 (18.8 to 1.9) 
/(</.
/( 16.7 (148.4 to 35.1) 
$>
  ;6
%? 
#&>
$;6
&? 
%>
#;6
%%? 
%>
##;6
&? 
&>
 ;6
?
69/( 17.8 (137.8 to 22.2) 
 >
 &;6
 #? 
#>
% ;6
$%? 
$>
 ;6
%%? 
>
 ;6
? 12.3 (15.9 to 1.3) 
,/,.6-1
%
 83.9 (1408.1 to 575.8) 21.2 (160.9 to 103.3) 12.1 (145.0 to 69.1) 5.8 (136.6 to 48.1) 4.3 (131.5 to 40.0) 12.2 (19.5 to 5.1) 
$
  122.6 (163.6 to 18.4) 124.6 (155.9 to 6.6) 120.9 (146.2 to 4.4) 
 >
;6
 #? 
$ >
#;6
#%? 
 >
;6
##?
#
  16.2 (145.4 to 33.1) 118.3 (138.3 to 1.6) 
&>
#;6
#? 
&>
 ;6
% ? 
&>
$;6
  ? 12.6 (16.2 to 1.0) 
#
  12.1 (141.7 to 37.5) 
>
 ;6
 #? 
#>
#;6
 #? 
&>
#%;6
? 
%>
%&;6
&#? 
>
%;6
#%?
#$
# 13.6 (136.2 to 29.0) 
 >
$;6
 $? 
$>
&;6
 ? 
 #>
;6
#? 
 >
#;6
? 
#>
$&;6
$?
%$= 121.2 (166.5 to 24.1) 123.8 (157.1 to 9.5) 121.0 (146.4 to 4.4) 
$>
;6
&? 
&%>
$;6
%%? 
##>
$;6
$$?
-9A/.6750.6(+5
56(<+;+6(8
$ 111.9 (111.9 to 111.9) 125.1 (157.8 to 7.7) 122.3 (152.8 to 8.2) 
$#>
&;6
? 
 #>
&;6
#? 14.1 (19.9 to 1.6) 
= 118.8 (152.2 to 14.5) 123.0 (149.8 to 3.7) 119.2 (143.3 to 4.8) 114.6 (131.4 to 2.2) 
 >
;6
% ? 
 #>
$&;6
&?
6C(8/(<(</K
67/1.+23;+6(
/38;</1.+2/< 17.5 (162.3 to 47.4) 114.9 (154.2 to 24.3) 114.6 (139.5 to 10.3) 
>
;6
#$? 
$>
  ;6
%? 
>
$;6
?
*-+(;+4/ 15.8 (143.9 to 32.4) 
 >
$;6
 # ? 
#%>
%;6
  ? 
>
#;6
? 
  >
$;6
? 
&>
 ;6
?
*-+(;+4/ 6.2 (122.6 to 35.1) 13.8 (115.1 to 7.5) 15.7 (115.8 to 4.4) 15.4 (113.7 to 3.0) 
$>
;6
&? 11.2 (13.9 to 1.4) 
*-+(;+4/  13.2 (157.4 to 83.7) 15.3 (124.1 to 13.5) 18.8 (123.8 to 6.2) 
$>
;6
? 
&>
;6
? 
>
$$;6
#?
68;</1.+2/< 
$%>
% ;6
# &? 
>
 ;6
#&? 
%$>
#;6
%? 
$>
;6
#$? 
>
$;6
#? 
%>
;6
$?
+88+(, 116.3 (158.3 to 25.6) 119.9 (152.6 to 12.8) 114.5 (139.1 to 10.1) 18.1 (118.8 to 2.7) 
%>
%;6
#? 
 >
;6
 %?
 
    
250 
')& $	
			
-	
 
A significant increase in the rate of prescribing of bupropion was seen up to nine 
months before the introduction of smokefree legislation in men, but only two 
months before in women. Increases in prescribing before the introduction of 
legislation were detected only in patients between the ages of 25 and 59. An 
increased rate of prescribing was seen up to six months pre1legislation in patients 
with no history of chronic disease, though no significant changes were estimated 
in any pre1ban intervention period for patients with one or more chronic 
conditions. A significant increase in the rate of bupropion prescribing was detected 
in the third Townsend quintile up to two months before the introduction of 
smokefree legislation, and in the two least deprived quintiles in the nine month 
pre1legislation intervention period, though no change was seen in the population 
as a whole in this time period.   
 
')) $	
			
-	
 
A decline in bupropion prescribing after the introduction of smokefree legislation 
occurred in both men and women. Contrary to the pattern seen in analysis of 
rates of NRT prescribing, the decrease in bupropion prescribing may have been 
greater in men than women, though the confidence intervals around these 
estimates again overlap. Between two and three months post1legislation declines 
in bupropion prescribing were detected only in patients aged 35 to 59. However, 
the decline extended to patients aged 20124 and 60+ six to nine months post1
ban, and were also sustained to the end of the study period in these groups. A 
decline in prescribing was seen in patients with no history of chronic disease 
between six and nine months after the introduction of smokefree legislation, and 
in patients with one or more chronic conditions from nine months post1ban to the 
end of the study period. The magnitude of decline may have been smaller in 
patients with a history of chronic disease, though the confidence intervals do 
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overlap. A decline in the rate of bupropion prescribing was seen in the most 
deprived Townsend quintile immediately after the introduction of legislation, 
though declines of a similar magnitude were also seen across all Townsend 
quintiles in the nine month period post1ban. Permanent declines in bupropion 
prescribing, sustained to the end of the study period, are seen in all but the third 
quintile.    
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In all patients in England, increases in the rate of prescribing of all smoking 
cessation medications were seen extending up to nine months before the 
introduction of smokefree legislation, compared to the six and three month pre1
legislation increases seen in NRT and bupropion prescribing respectively. 
Significant declines in the rate of prescribing of all smoking1cessation medications 
were seen for the three and nine month periods after the introduction of 
smokefree legislation, though this decline was not sustained to the end of the 
study period.  
 
Figure 6.7 shows rates of prescribing of all smoking cessation medications by 
patient sex and whether they have a history of one or more chronic conditions. 
The patterns seen in the prescribing of all smoking cessation medications are 
similar to those observed in rates of NRT prescribing. The rate of prescribing of all 
smoking cessation medications in women is higher, though more variable, than 
that in men, and is also higher but more variable in patients with a history of one 
or more chronic conditions compared to those without. In all subgroups there is 
no obvious decline in prescribing after the introduction of smokefree legislation, 
though the monthly variation in the series does seem to reduce.  
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The rate of prescribing of all smoking cessation medications in all six age groups 
shows a regular seasonal pattern across the study period. The overall rate of 
prescribing is lowest in the two youngest age groups, though these groups also 
show the smallest variation in prescribing from one month to the next. In all age 
groups there appears to be an increase in prescribing in the month immediately 
before the introduction of smokefree legislation, though it is hard to tell whether 
any increase is outside of the normal behaviour of the series. The rate of 
prescribing does not appear to change substantially in any age group after the 
introduction of smokefree legislation. 
 
Figure 6.9 shows rates of prescribing of all smoking cessation medications by 
quintile of the Townsend Index of Deprivation.  
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All series show monthly variation in the rate of prescribing of all smoking 
cessation medications, though, as was seen in NRT prescribing, this seasonal 
pattern is less regular in patients whose Townsend classification is missing in their 
THIN records. The rate of prescribing is very similar in all Townsend quintiles, and 
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in all groups of patients there are no immediately obvious declines in prescribing 
after the introduction of smokefree legislation.  
 
Table 6.6 shows the estimates of changes in all prescribing before the introduction 
of smokefree legislation for each population subgroup, and Table 6.7 presents the 
estimates for changes in all prescribing in the intervention periods after the 
introduction of smokefree legislation.
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The majority of all smoking1cessation medication prescribing is for NRT, and so 
the patterns of change in all prescribing before the introduction of smokefree 
legislation presented in Table 6.7 are very similar to those seen in NRT 
prescribing. Increases in all prescribing are seen in all subgroups up to three 
months before legislation was enacted, with the exception of the youngest age 
group, and in many subgroups for the six and nine month pre1ban periods.  
Overlapping confidence intervals suggest the magnitude of the increase in 
prescribing was similar in men and women and across age groups. Increases in all 
prescribing were also seen in both patients with and without a history of chronic 
disease. The increase in prescribing may have been larger in patients with one or 
more chronic conditions; again, however, the confidence intervals around these 
point estimates overlap. Increases in prescribing were seen in all quintiles of the 
Townsend Index of Deprivation. The overlapping confidence intervals suggest that 
smokefree legislation had no differential impact on prescribing according to 
patient socio1economic group.  
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Significant declines in all prescribing are detected in very few population 
subgroups after the introduction of smokefree legislation. In the three month 
period post1legislation a decline in all prescribing was estimated to have occurred 
in the population as a whole, though the estimates of decline just fail to reach 
statistical significance when men and women are analysed separately. A 
significant decline in all prescribing is seen in women for the nine month period 
after the introduction of smokefree legislation, though the estimate of decline in 
men is only marginally non1significant. A decline in all prescribing is seen in 
patients aged 35149 in the nine month post1legislation period, but not in the other 
age groups. A significant decline in all prescribing is seen only in patients without 
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a history of chronic disease. Reductions in the rate of all prescribing are detected 
only in Townsend quintiles two and three, though in many other groups the 
estimates of change only marginally fail to reach statistical significance.  
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The results presented in this chapter suggest that there were similar changes in 
the prescribing of smoking cessation medications in different subgroups of the 
population before and after the introduction of smokefree legislation in England, 
and that the introduction of legislation did not have a differential effect on 
prescribing to patients with different characteristics.  
 
Increases in the prescribing of NRT and all smoking cessation medications before 
the smoking ban was enacted were seen in both men and women, in all age 
groups (except 16119 year olds in the case of all prescribing), in patients both 
with and without a history of chronic disease, and in all quintiles of the Townsend 
Index of Deprivation. Increases in the rate of prescribing of bupropion were also 
seen in both sexes, though significant changes were not detected in patients with 
a history of chronic disease, nor in the youngest and oldest age groups or most 
deprived Townsend quintiles.  
 
After the introduction of smokefree legislation declines in the rate of prescribing of 
NRT and bupropion were seen in both men and women. A decline in NRT 
prescribing was detected in all but the youngest and oldest age groups, and 
declines in bupropion prescribing were seen in patients over the age of 20, though 
there was no significant change amongst those aged 16119. Declines in the rate of 
prescribing of NRT and bupropion appear first in patients with no history of chronic 
disease and in patients in the most deprived Townsend quintiles, before extending 
to include those with one or more chronic conditions and less deprived groups.  
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To my knowledge, this study is the first to use data from primary care to assess 
the impact of smokefree legislation on the management of smoking in different 
population subgroups. The large size of the THIN dataset allows the population to 
be broken down into smaller groups whilst, on the whole, preserving statistical 
power to detect small changes in prescribing. 
 
As in the previous analysis of data from all patients in each of the four 
jurisdictions of the UK, the results of these subgroup analyses are strengthened 
by the use of ARIMA modelling which is able to filter out any secular trends and 
seasonal variation in prescribing to assess whether there were any changes in the 
outcome variables above and beyond the normal behaviour of the series that may 
be associated with the introduction of smokefree legislation.  
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The current study is, however, hampered by the two same problems identified in 
the previous chapter, namely the difficulty in attributing any changes in 
prescribing to smokefree legislation and a lack of power to detect small changes in 
the outcome variables in some subgroups. It is likely that these issues explain 
many of the patterns observed in the results, as will now be discussed.  
 
Declines in bupropion prescribing in many subgroups were sustained to the end of 
the study period. However, there were no permanent changes in the prescribing 
of NRT or all smoking cessation medications despite having adequate power to 
detect relatively small changes in these series. As noted previously, a new aid to 
smoking cessation, varenicline, became available on NHS prescription in 
December 2006 and in July 2007 NICE issued guidelines recommending GPs 
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prescribe it to smokers who wish to quit. It is possible that prescribing of 
varenicline compensated for the permanent decline in bupropion prescribing in 
these subgroups, with the result that there was no overall permanent change in 
the rate of prescribing of all smoking cessation medications. Thus, it is difficult to 
attribute any changes detected in an outcome variable to an intervention such as 
the introduction of smokefree legislation when, at the same time, other changes 
are taking place which may have an impact on the series.  
 
A lack of statistical power may explain the failure to detect an increase in all 
prescribing pre1legislation in smokers aged 16119, as well as explain the no 
change observed in bupropion prescribing in teenagers either before or after the 
smoking ban was enacted. As Figure 6.8 illustrates, the rate of all prescribing was 
lower in the two youngest age groups than in other ages, which will reduce the 
power of an ARIMA model to detect small changes in prescribing in younger 
patients. There is a less obvious seasonal pattern in bupropion prescribing than is 
seen in NRT and all prescribing, and this, combined with the overall low 
prescribing of bupropion in patients aged 16119, makes it difficult to detect small 
changes in bupropion prescribing in this subgroup.   
 
Table 6.8 shows the minimum effect size which the ARIMA models were powered 
to detect in NRT, bupropion and all prescribing in each subgroup six months 
before the introduction of smokefree legislation. In addition, the effect sizes 
estimated to have occurred in each series are shown. 
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Series 
Estimate 
observed in 
series (95% CI) 
Minimum 
effect 
detectable 
with 80% 
power 
Estimate 
observed in 
series (95% CI) 
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effect 
detectable 
with 80% 
power 
Estimate 
observed in 
series (95% CI) 
Minimum 
effect 
detectable 
with 80% 
power 
All patients 
%
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$
7.1  
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10.6 

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3.6  
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5.3 
16119 
5.9  
(15.0 to 16.9) 
15.6 
5.2  
(18.3 to 18.6) 
19.3 
7.0  
(12.8 to 16.8) 
14.0 
20124 
4.1  
(12.9 to 11.1) 
10.0 
6.1  
(17.9 to 20.1) 
20.1 
6.2  
(11.1 to 13.4) 
10.3 
25134 
%
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12.8 
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5.6 
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(12.6 to 16.1) 
13.4 
2.7  
(12.0 to 7.4) 
6.7 
60+ 
5.8  
(10.3 to 11.9) 
8.6 
8.2  
(110.3 to 26.6) 
26.2 
%
>#;6#?
&%
0 chronic 
conditions 
%%
> ;6&?
#
&
>$;6%?
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3.6  
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13.4 
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Least deprived 
&
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&%
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(10.3 to 20.9) 
15.1 

> ;6& ?
$$
Quintile 2 
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14.2 
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Most deprived 
2.5  
(12.4 to 7.4) 
7.0 
6.0  
(16.1 to 18.2) 
17.3 
 #
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Missing 
1.4  
(18.2 to 11.1) 
7.0 
4.7  
(14.2 to 13.7) 
12.8 
5.4  
(12.4 to 13.3) 
11.2 
Figures highlighted in bold are statistically significant at the 5% significance level 
 
 
As Table 6.8 shows, ARIMA modelling was only powered to detect a 15.6% change 
in NRT prescribing in smokers aged 16119 six months before smokefree legislation 
was introduced, a larger minimum detectable effect than was seen in any other 
subgroup for NRT prescribing. In every subgroup ARIMA modelling had less power 
to detect changes in bupropion prescribing compared to NRT, a reflection of the 
less obvious seasonal pattern and lower overall rate of prescribing of bupropion. 
Modelling was particularly underpowered to detect small changes in bupropion 
prescribing in the oldest and two youngest age groups.  
 
A similar lack of power may explain the failure to detect significant changes in 
prescribing in patients with a history of one or more chronic conditions when a 
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significant change has been detected in healthy patients. As Figure 2.3 showed, 
smoking prevalence is lower in patients in THIN with chronic conditions than in 
otherwise healthy patients, resulting in a smaller denominator of smokers with 
chronic conditions in whom to assess prescribing. This is likely to result in more 
variable monthly rates of prescribing and hence lower power to detect small 
changes that may be associated with the introduction of smokefree legislation. 
Similarly, smoking prevalence in THIN is lower in patients in the least deprived 
Townsend quintile, resulting in fewer smokers and less power to detect changes in 
prescribing in this group.  
 
Using primary care data to investigate differential impacts of smokefree legislation 
is complicated by the knowledge that underlying rates of smoking1related clinical 
activity vary according to patient characteristics, as outlined in Section 1.1.1, and 
patients with different characteristics also visit their GPs with different 
frequencies13. For each group of patients there is likely to be a ‘natural’ maximum 
rate of prescribing each month, driven by the frequency with which patients visit 
their GP and the likelihood of GPs intervening to offer smoking cessation support. 
In some cases, no increase in cessation activity before or after the introduction of 
smokefree legislation may be seen because GPs are already intervening at this 
maximum rate. For example, the introduction of smokefree legislation may be 
expected to have a different effect on patients according to their medical history. 
Underlying prescribing rates are higher in those with chronic conditions85, many of 
which are smoking1related, and therefore a smaller or no increase in prescribing 
when smokefree legislation is introduced might be expected in this subgroup.  
Assessing changes in prescribing in all smokers registered in THIN each month, 
regardless of whether they have actually visited their GP surgery, allows changes 
in the number of patients who visit their GP, perhaps prompted by smokefree 
legislation to seek cessation support, to be captured, as well as changes in the 
rate at which GPs offer interventions to smokers. Modelling monthly rates of 
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prescribing in patients who have visited their GP in the month in question would 
allow assessment of the potential impact of smokefree legislation purely on GPs 
clinical practice. However, it is very difficult to identify individual patient visits to a 
practice in THIN (though steps have been taken in the most recent update of the 
database to address this), and this would further reduce the number of smokers 
included in the denominator each month and hence further compromise the power 
to detect small changes in the outcome variables.   
 
This study has only assessed changes in prescribing in population subgroups 
defined by a single characteristic, though it is arguably important to assess 
whether there are any interactions between different patient characteristics to 
assess whether there was a differential impact of smokefree legislation in more1
specific groups of patients. For example, the underlying rate at which GPs 
intervene with smokers may be lower in young men, who visit a GP less 
frequently, compared to young women, and thus the impact of smokefree 
legislation may differ between these groups. Unfortunately, however, the lack of 
power demonstrated in the youngest age group and patients with one or more 
chronic conditions is likely to be compounded by further subdividing these patients 
according to other characteristics. In addition, as discussed in the previous 
chapter, one in twenty ARIMA models can be expected to produce a statistically 
significant estimate of a change in the outcome variable at the 5% significance 
level, and thus the results of multiple hypothesis testing should be interpreted 
with caution. However, as noted previously, the strength of the ARIMA study 
design and plausibility of the results can be taken to support the significance of 
the findings reported here165.  
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This study suggests that the changes in prescribing of smoking cessation 
medications in primary care reported in all patients in the previous chapter do not 
differ by patient sex, age group, medical history and social class, though a lack of 
power to detect small changes in prescribing hampers analysis in some 
subgroups. Reassuringly, these results do not imply that smokefree policies will 
widen inequalities in health as the benefit of increased prescribing before the 
introduction of smokefree legislation does not appear to be concentrated in the 
most advantaged socioeconomic groups. However, as smokefree legislation 
appears to have had a similar effect across all subgroups investigated this 
suggests that it may not be effective in reducing the inequalities in health caused 
by smoking.  
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Smokefree policies have been introduced in many locations worldwide and have 
been successful in reducing non1smokers’ exposure to environmental tobacco 
smoke. In addition, the limited body of existing research reviewed systematically 
in Chapter 1 suggests that in populations where well1enforced, comprehensive 
smokefree policies have been implemented, quitting activity in smokers increased 
in the run up to, and/or following, the introduction of the legislation, suggesting 
that smoking bans may also have a positive effect on smokers.  
 
The Health Improvement Network (THIN) database was introduced as a source of 
data which could potentially be used to monitor the impact of smokefree 
legislation on the management of smoking in primary care to assess whether this 
was a pathway through which legislation helped smokers to make positive 
changes in their smoking behaviour. Overall, the work presented in this thesis 
suggests that THIN is a valid tool to evaluate the effectiveness of tobacco control 
policies, such as smokefree legislation, providing data that cannot easily be 
collected from such a large number of patients using survey methods.  
 
Historically, many patients did not have their smoking status recorded in their 
primary care medical records, and the ability to identify current smokers from 
their notes was poor. Chapter 2 showed improvements in recent years in these 
measures; the proportion of patients whose smoking status is recorded in their 
medical records has increased to almost 90% in 2009, and the prevalence of 
current smoking amongst THIN patients has converged towards the prevalence 
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estimated from the General Lifestyle Survey, the current ‘gold standard’ source of 
smoking prevalence statistics. There does, however, remain some variation in the 
quality of smoking status recording in THIN between some population subgroups 
and individual practices.  
 
THIN data are also useful to investigate changes in the prescribing of smoking 
cessation medications as a record of all issued prescriptions appears automatically 
in the dataset. However, the dataset may be less useful to investigate changes in 
the recording of advice and referral as recorded rates may not be a true reflection 
of the number of smokers offered these cessation interventions. The findings 
presented in Section 3.4 suggest that the introduction of the QOF in 2004 may 
have prompted increased recording of cessation advice though perhaps not an 
increase in the amount of advice actually offered to smokers. There are no 
incentives for GPs to record having referred smokers to specialist cessation 
services, and the low rates of referral recording seen in primary care records may 
not be a true reflection of the actual number of smokers referred to specialist 
services for help to quit. With the proviso that recorded cessation advice and 
referral may not indicate the actual delivery of a cessation intervention, and that a 
prescription for a smoking cessation medication does necessarily mean the 
medication was used for quitting, the THIN dataset offers the chance to quantify 
long1term trends in the management of smoking in primary care and assess 
whether there were any changes in clinical activity above and beyond these trends 
at the time smokefree legislation was introduced.  
 
Chapter 4 outlined the use of ARIMA modelling to assess the impact of smokefree 
legislation on monthly recorded rates of smoking1related clinical activity in the 
THIN dataset, and the results of a number of novel sensitivity analyses were 
presented discussing the implications of decisions made during the data analysis 
process. An automated procedure was developed for the Stata data management 
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and statistical analysis package which allows several ARIMA models to be 
estimated and their adequacy to be assessed. In addition, the command allows 
the analyst to judge whether the selection of different ARIMA models to describe a 
time series ultimately leads to different conclusions regarding the impact of an 
intervention on the outcome under investigation. This procedure was then applied 
to investigate changes in the rates of recording of patients’ smoking status and 
the delivery of cessation interventions in the months leading up to, and after, the 
introduction of smokefree legislation in the UK. 
 
Increases in NRT prescribing occurred in the six months before smokefree 
legislation was introduced in England, and increases in bupropion prescribing 
three months pre1ban, followed by declines in the rate of prescribing of both 
medications up to nine months after the legislation was enacted. These declines 
were offset to an extent, but not completely, by prescribing of varenicline which 
was first available on prescription in December 2006. Similar, though non1
statistically significant, patterns were seen in Scotland, Wales and Northern 
Ireland, where the smaller number of practices in THIN in these countries reduced 
the power to detect small changes in prescribing. In England, the patterns of 
change in prescribing do not differ by patient sex, age group, medical history or 
social class.  
 
Some decreases in the rate of recording of patients’ smoking status were seen in 
all UK countries shortly before and/or after the introduction of smokefree 
legislation, though these may not be related to the introduction of smokefree 
legislation. No statistically significant changes were observed in any part of the UK 
in either the rate of recording of cessation advice or referral of smokers to stop 
smoking services.   
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The implications of the findings presented in this thesis, and the avenues for 
further research which arise from this work, can be broadly divided into three 
areas – those relating to the use of THIN, and primary care data more generally, 
for epidemiological and public health research, those concerning the methods that 
can be used to evaluate public health policies and those pertaining to the impacts 
of smokefree legislation. These will now be discussed in turn.  
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The demonstrated improvements in the quality of the smoking status data 
recorded in THIN, and comparability between the national smoking prevalence 
estimates from this dataset and those from the current ‘gold standard’, the 
General Lifestyle Survey, suggest that THIN could potentially be used to monitor 
national smoking trends. Further research demonstrating the continued 
concordance of THIN1recorded, GLF1predicted and actual GLF smoking prevalence 
estimates in future years would confirm the utility of THIN as a potential 
complement to national surveys. As THIN is so large, is released three or four 
times annually and has a lag of only three to eight months between clinical data 
becoming available, it has advantages over national survey data for monitoring 
national smoking prevalence. The standard error of the national smoking 
prevalence estimate derived from THIN is considerably smaller than that derived 
from the GLF and thus THIN can potentially provide more precise smoking 
prevalence estimates both nationally and at the level of Government Office 
Regions.  
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A major government1commissioned report in England, the Wanless report, has 
called for the organisations responsible for delivering community health services 
to make better use of data from primary care to help understand the prevalence 
of disease risk factors within their local populations54. Though THIN data are not 
identifiable at a geographical level finer than that of Government Office Regions, if 
the inter1practice variation in the quality of smoking data recording in THIN is 
representative of all UK practices, primary care data may not be suitable for local1
level smoking prevalence estimation. Some practices may need support to 
optimise their recording of patients’ smoking status before medical records data 
could be used for local estimates of smoking prevalence. However, once the 
quality of smoking status recording is deemed acceptable, primary care data may 
offer a less1costly means of monitoring smoking prevalence, both nationally and 
locally, than commissioned surveys. 
 
A recurring issue in the studies undertaken to assess the quality of the smoking 
status and intervention recording in THIN is the variation in data quality between 
practices contributing to the dataset, despite a certain amount of auditing being 
undertaken before a practice joins the dataset to assess the quality of their data 
recording170. In THIN it is impossible to know whether extremely low or high 
estimates of smoking prevalence and recorded cessation interventions in some 
practices are simply a reflection of the characteristics of the patients they serve. A 
practice serving a very affluent area may be expected, for example, to have fewer 
smokers in their care and therefore to deliver fewer cessation interventions. 
Further work in THIN is recommended to explore the variations in smoking 
information recording by practice. One approach that could be used to assess 
whether an apparently low smoking prevalence is in fact correct may be to 
undertake a case1control study using THIN data to  investigate whether the 
strength of association reported in other studies between smoking behaviour and 
an outcome such as lung cancer is replicated using the data recorded in that 
    
269 
practice. Alternatively, if the resources are available, a survey could be attempted 
to compare patients’ self1reported smoking behaviour and recall of cessation 
interventions with those recorded in their medical records, though such methods 
are subject to the limitations outlined in Section 1.9.1. 
 
The large size of the THIN dataset may provide an opportunity to quantify 
accurately smoking behaviour in particular groups of patients for whom data are 
currently lacking. The prevalence of smoking by women during pregnancy is 
currently measured only every five years using a national survey of approximately 
20,000 mothers171. In 2005, 33% of mothers reported smoking at some point 
before or during their pregnancy, and 17% reported smoking throughout 
pregnancy. Given the highly detrimental effects of smoking during pregnancy172, a 
more accurate, up1to1date knowledge of the extent of this behaviour is surely an 
important first step in planning and delivering heath services and health 
promotion interventions to reduce the number of women who smoke whilst 
pregnant. Further work to assess whether the quality of smoking status 
information recorded during pregnancy has improved in line with the 
improvements demonstrated in the population as a whole would be useful to 
assess whether THIN could be used for this purpose.    
 
This study assessed the impact of smokefree legislation in a limited number of 
population subgroups, though, given the number of patients in the THIN dataset 
and the amount of information potentially recorded about each person, THIN 
offers the opportunity to investigate the effect of a range of health promotion 
policies in a variety of different types of patient. Smoking prevalence is known to 
vary by ethnic group, and proportionally fewer smokers from minority groups 
attempt to quit smoking than smokers in the general population173. At present, 
few patients have their ethnicity recorded in THIN, though this may improve in the 
future as it is now a QOF requirement for practices to record the ethnic 
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background of all new patients registering with the practice. It is conceivable that 
practices may also record the ethnicity of their existing patients, and, as this is 
not a characteristic which changes over time, records can be back1dated to allow 
the classification of patients by ethnic group at the time smokefree legislation was 
introduced. It would be worthwhile monitoring the completeness of ethnicity 
recording in future updates of the THIN dataset to assess whether the 
completeness of recording improves to an extent that will allow exploration of the 
impact of smokefree legislation by ethnic group.  
 
As mentioned previously, other datasets of primary care records are available in 
the UK, such as the General Practice Research Database104 (GPRD) and 
QRESEARCH105. These datasets are similar to THIN (indeed, some practices 
historically contributed data to both the GPRD and THIN) and so it could be 
expected that the improvements in data quality presented in this thesis are also 
seen in the other datasets. The methods used here to investigate the quality of 
THIN data could equally be applied to GPRD and QRESEARCH data to enable 
researchers to understand and account for changes in smoking status and 
intervention data quality when undertaking studies investigating the impact of 
policies on these measures, or when using smoking information as an explanatory 
variable in other studies. Datasets of primary care records from other countries 
are also available to researchers106, and similar methods to those employed here 
could be used to assess the completeness of smoking status recording and the 
utility of the data for monitoring national smoking prevalence in these countries 
and investigating the impact of health policies on the management of smoking in 
primary care. 
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The recording of patients’ smoking status and smoking cessation interventions in 
THIN show long1term trends and seasonal variation which must be taken into 
account when assessing whether there were any changes in recording at the time 
smokefree legislation was introduced. The majority of the studies reviewed in 
Section 1.6 simply compared data from one or two surveys carried out before and 
after smokefree legislation was enacted, thus failing to capture and remove the 
confounding effects of underlying patterns of behaviour when investigating the 
impact of the smoking ban. The technique of interrupted time series analysis used 
in this thesis has proved a useful method to assess changes in measures of 
smoking1related clinical activity in primary care at the time smokefree legislation 
was introduced, taking into account long term trends and seasonal variation in the 
outcome variables and thus strengthening the conclusions drawn about the impact 
of legislation. ARIMA modelling could potentially be employed in evaluations of 
other health promotion policies using THIN data, or indeed using longitudinal data 
from other sources.   
 
The automated method developed in this thesis to aid ARIMA model selection 
removes the degree of judgement involved in selecting a model to represent a 
time series; its use is recommended for other studies undertaking interrupted 
time series analysis, particularly where multiple data series are being examined. 
This thesis presented a number of sensitivity analyses assessing the impacts of 
decisions which must be made during the process of using ARIMA modelling to 
carry out interrupted time series analysis. It is recommended that all analysts 
undertaking interrupted time series analysis carry out a range of sensitivity 
analyses to improve the confidence they hold in their results and conclusions, and 
report the findings of these analyses when writing up results for publication.  
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The longitudinal nature of the THIN dataset means this study benefited from up to 
115 monthly data points for each time series examined. However, data from other 
sources which could potentially be used to carry out interrupted time series 
analysis may not have the luxury of such a large number of data points. Further 
work is warranted to investigate how many data points are needed to successfully 
fit an ARIMA model to a time series and to assess the impact of an intervention on 
the outcome variable, and whether the length of the series which is analysed 
ultimately influences a study’s results and conclusions.  
 
A lack of power to detect small changes in a time series was encountered in the 
analyses presented in this thesis, particularly in assessing the impact of 
smokefree legislation in Scotland, Wales and Northern Ireland, and in subgroups 
of the population in England. Section 5.4 illustrated the wider confidence intervals 
around monthly measures of smoking1related clinical activity in Scotland, Wales 
and Northern Ireland, where there are relatively few THIN practices. However, 
despite the small number of practices, the number of smokers registered in THIN 
for whom data are available would be the envy of many experimental studies – in 
Scotland 48,880 smokers are registered in THIN on 1st July 2007, with 37,998 
smokers in Wales and 23,917 in Northern Ireland (compared to 440,802 in 
England). This raises the question as to whether these patients’ data could be 
used in alternative ways to assess the impacts of smokefree legislation on the 
management of smoking in primary care.  
 
Interrupted time series analysis may not be the best way to study the impact of 
smokefree legislation in smaller groups of patients, in whom monthly rates of 
clinical activity will be more variable over time resulting in lower power to detect 
small changes in an outcome variable. Further research would be valuable to 
assess whether a group of individuals in THIN can be followed over time in a 
quasi1experimental design. For example, trajectories of smoking behaviour before 
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and after the introduction of smokefree legislation could be tracked to assess 
whether smokers who attempt to quit are offered an intervention to help them do 
so, and whether those who do succeed in quitting remain abstinent. However, the 
ability to undertake such an analysis requires patients to have their smoking 
status recorded frequently in their medical records, which in turn is dependent 
upon how frequently patients visit their GP or practice nurse. In patients with a 
history of chronic disease, their smoking status should be recorded every 15 
months, potentially providing enough data to assess their smoking behaviour 
regularly and more power to investigate the impact of smokefree legislation on 
smoking behaviour than an interrupted time series analysis of aggregated rates of 
measures of clinical activity. A first stage in further work would be to assess just 
how frequently records of smoking status are updated and whether this varies by 
patient characteristic or practice.  
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The findings presented in Chapters 5 and 6 allow conclusions to be drawn about 
the impact of smokefree legislation on smokers’ behaviour, and recommendations 
to be made suggesting how any positive benefits of a new smoking ban might be 
maximised.  
 
The significant increases in the rate of prescribing of NRT and bupropion seen in 
all population subgroups in England in the run1up to the introduction of smokefree 
legislation suggests that smokers looking to quit may indeed seek support to do 
so from primary care. This new finding suggests that further qualitative research 
may be of value to explore smokers’ and health care professionals’ behaviours and 
attitudes related to smokefree legislation, investigating whether smokers actively 
sought cessation support from their general practice or whether GPs saw the 
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introduction of the smoking ban as an opportunity to encourage smokers pro1
actively to quit.  
 
The declines in NRT and bupropion prescribing seen after the introduction of 
smokefree legislation, which were not totally offset by prescribing of varenicline, 
suggest that the positive changes in prescribing seen pre1legislation were not 
sustained. Interestingly, similar patterns are seen in throughput figures from the 
NHS smoking cessation services in England174, Scotland175 and Wales176, where 
more smokers set quit dates or were treated in the months immediately before 
the introduction of smokefree legislation compared to other years, but there was 
no increase in the months after the smoking bans were enacted. Additionally, 
over1the1counter sales of NRT were increased in the six month period spanning 
the introduction of smokefree legislation in Scotland, but not in the longer term43, 
and self1reported NRT use was higher in Scotland than in the rest of the UK six 
months before the introduction of the Scottish legislation, and declined more post1
ban44.  
 
In England, the Department of Health gave local councils £29.5 million to help 
raise awareness about the impending smokefree legislation, and in some areas, 
such as the London Borough of Greenwich, campaigns were launched to 
encourage people to quit before the legislation was enacted177. However, it is 
known that many quit attempts do not succeed, and many long1term smokers 
have tried to quit several times1781180. As quitting is difficult and smokers may 
benefit from sustained cessation support over a long period of time, an 
opportunity may have been missed to maximise the impact of smokefree 
legislation. If campaigns such as that in place in Greenwich had been extended 
after smokefree legislation was introduced this may have ensured that smokers 
were reminded of the support available through primary care to help them quit at 
this time and measures of quitting activity might not have declined.  
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Reassuringly, the results presented in this thesis show that the benefits of 
increased prescribing of smoking cessation medications in the run1up to the 
introduction of smokefree legislation are not concentrated in particular population 
subgroups and are therefore not likely to widen inequalities in health. However, 
the similar change in prescribing observed across subgroups suggests that 
smokefree legislation may not be effective in reducing such inequalities either. 
Further work would be of benefit to understand whether any other public health 
interventions, such as media campaigns promoting the cessation support available 
in primary care or novel ways of making cessation support available in 
disadvantaged communities, have the potential when delivered alongside the 
introduction of smokefree legislation to increase quitting activity and reduce the 
devastating effects of tobacco use in the least advantaged sections of society.   
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-A9/<
(smok* OR tobacco) AND ((ban OR bans OR banned) OR (prohibit*) OR (restrict*) 
OR (policy OR policies) OR (legislat*) OR (regulat*) OR (law OR laws)) AND 
(Humans[Mesh]) Limits: Humans, Publication Date from 2002/01/01 to 
2009/11/30 
 

((smok* OR tobacco)) and (((ban OR bans OR banned) OR (prohibit*) OR 
(restrict*) OR (policy OR policies) OR (legislat*) OR (regulat*) OR (law OR laws)))  
Limiters 1 ; Published Date from: 20020101120091131  
 
8B5
((smok* OR tobacco) AND (ban OR bans OR banned) OR (prohibit*) OR (restrict*) 
OR (policy OR policies) OR (legislat*) OR (regulat*) OR (law OR laws)):Any Field 
and [2002 TO 2009]:PublicationYear 
 
6(7/./(5/.65//<+(,8+;3;+6((</K
5+/(5/
Topic=((smok* OR tobacco) AND ((ban OR bans OR banned) OR (prohibit*) OR 
(restrict*) OR (policy OR policies) OR (legislat*) OR (regulat*) OR (law OR laws)))  
Timespan=200212009. Databases=CPCI1S. 
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THIN data are provided to researchers in six files, linked by a unique patient 
identifier. The contents of these six files are outlined in Table 8.1.  
 
3A4/&;.-5;-./67;0/<3;38/;
3;37+4/(39/ 6(;/(;8
Patient Patient demographic and registration details 
Medical  Records of symptoms, diagnoses and interventions 
Therapy Formulation, strength, dose and quantity of prescribed medications 
Dosage Prescription dosage instructions recorded as free text 
Additional Health 
Data (AHD) 
Multiple types of data, including lifestyle indicators, test results and physical 
measurements 
Postcode Variable 
Indicators (PVI) 
Postcode1linked area based socioeconomic, ethnicity and environmental indices 
 
 
During clinical practice, primary health care professionals document smoking1
related information using Read Codes, and this information appears in the THIN 
dataset in either the Medical file or AHD file. Of 17,949,672 individual uses of a 
smoking1relevant Read Codes in the THIN dataset to the end of July 2009, 15.4% 
were recorded in the Medical file where researchers using THIN are able to view 
the specific Read Code entered and the date on which it was recorded. The 
majority of smoking1related Read Codes appear in the AHD file. Researchers can 
view the date each Read Code is recorded and, in addition, further information 
about the patient's smoking behaviour which may have been documented by the 
health care professional, such as whether the patient is a current, ex or never 
smoker, and, where relevant, the number of cigarettes smoked per day. 
 
Previous studies using primary care medical records typically define a patient's 
smoking status at any given point in time as the last recorded smoking status 
documented in their medical records. This is equally possible using THIN 1 a 
patient's medical history is searched for all occurrences of relevant Read Codes 
appearing in their electronic records prior to the reference date of interest, and 
the last recorded Read Code before the reference date is retained. There are 113 
different Read Codes used in the THIN dataset to record smoking behaviour, 
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including codes which describe smoking status, quantify tobacco consumption and 
detail the delivery of cessation interventions. In order to make the use of these 
codes more manageable, and to allow classification of patient smoking status at a 
given point in time, the 113 Read Codes were grouped as shown in Table 8.2 to 
give a categorical indicator of smoking status. Some Read Codes, such as '137..00 
Tobacco consumption', are ambiguous and in isolation cannot be used to classify a 
patient as, for example, a current rather than an ex1smoker. However, where 
such ambiguous Read Codes are recorded in the AHD file, the additional 
information which clinicians have the option to enter can be inspected for further 
information which can be used to more confidently assign a patient a known 
smoking status. Where no additional information is available to qualify an 
ambiguous Read Code, the Read Code is classified as indicating an unknown 
smoking status. 
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137P.00 Cigarette smoker Current 1,994,070 (13.86) 
6791.00 Health ed. 1 smoking Current 1,184,524 (8.23) 
8CAL.00 Smoking cessation advice Current 1,703,452 (11.84) 
1374.00 Moderate smoker 1 10119 cigs/d Current 144,897 (1.01) 
137R.00 Current smoker Current 215,581 (1.50) 
1373.00 Light smoker 1 119 cigs/day Current 102,677 (0.71) 
137P.11 Smoker Current 35,200 (0.24) 
1375.00 Heavy smoker 1 20139 cigs/day Current 76,238 (0.53) 
137G.00 Trying to give up smoking Current 66,572 (0.46) 
1372.11 Occasional smoker Current 36,754 (0.26) 
1372.00 Trivial smoker 1 < 1 cig/day Current 19,167 (0.13) 
137M.00 Rolls own cigarettes Current 22,087 (0.15) 
137J.00 Cigar smoker Current 11,779 (0.08) 
137H.00 Pipe smoker Current 12,794 (0.09) 
137..11 Smoker 1 amount smoked Current 17,478 (0.12) 
1376.00 Very heavy smoker 1 40+cigs/d Current 6,661 (0.05) 
8H7i.00 Referral to smoking cessation advisor Current 36,056 (0.25) 
8HTK.00 Referral to stop smoking clinic Current 27,862 (0.19) 
8B2B.00 Nicotine replacement therapy Current 26,161 (0.18) 
13p0.00 Negotiated date for cessation of smoking Current 19,737 (0.14) 
137C.00 Keeps trying to stop smoking Current 4,332 (0.03) 
137Q.11 Smoking restarted Current 2,613 (0.02) 
137d.00 Not interested in stopping smoking Current 116 (0.00) 
ZG23300 Advice on smoking Current 4,188 (0.03) 
137Q.00 Smoking started Current 1,839 (0.01) 
137b.00 Ready to stop smoking Current 10,867 (0.08) 
13p5.00 Smoking cessation programme start date Current 5,272 (0.04) 
137V.00 Smoking reduced Current 1,712 (0.01) 
137c.00 Thinking about stopping smoking Current 3,482 (0.02) 
E251.00 Tobacco dependence Current 2,362 (0.02) 
67H1.00 Lifestyle advice regarding smoking Current 1,972 (0.01) 
8B3f.00 Nicotine replacement therapy provided free Current 1,584 (0.01) 
8CAg.00 Smoking cessation advice provided by community pharmacist Current 102 (0.00) 
8BP3.00 Nicotine replacement therapy provided by community pharmacist Current 58 (0.00) 
745H200 Nicotine replacement therapy using nicotine inhalator Current 260 (0.00) 
745H100 Nicotine replacement therapy using nicotine gum Current 160 (0.00) 
8I39.00 Nicotine replacement therapy refused Current 45 (0.00) 
745H300 Nicotine replacement therapy using nicotine lozenges Current 63 (0.00) 
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745Hy00 Other specified smoking cessation therapy Current 52 (0.00) 
ZRBm200 Fagerstrom test for nicotine dependence Current 1,125 (0.01) 
137h.00 Minutes from waking to first tobacco consumption Current 1,188 (0.01) 
745H000 Nicotine replacement therapy using nicotine patches Current 1,223 (0.01) 
67A3.00 Pregnancy smoking advice Current 479 (0.00) 
9OO7.00 Stop smoking monitor verb.inv. Current 298 (0.00) 
137e.00 Smoking restarted Current 1,993 (0.01) 
8B3Y.00 Over the counter nicotine replacement therapy Current 385 (0.00) 
9OO8.00 Stop smoking monitor phone inv Current 227 (0.00) 
E251z00 Tobacco dependence NOS Current 236 (0.00) 
ZRBm211 FTND 1 Fagerstrom test for nicotine dependence Current 16 (0.00) 
ZV6D800 [V]Tobacco abuse counselling Current 10 (0.00) 
E251100 Tobacco dependence, continuous Current 9 (0.00) 
745H400 Smoking cessation drug therapy Current 133 (0.00) 
ZRh4.00 Reasons for smoking scale Current 3 (0.00) 
8I2I.00 Nicotine replacement therapy contraindicated Current 2 (0.00) 
ZRaM.11 MFS 1 Motives for smoking scale Current 1 (0.00) 
ZRaM.00 Motives for smoking scale Current 1 (0.00) 
)ZRao.00 Occasions for smoking scale Current 1 (0.00) 
137f.00 Reason for restarting smoking Current 49,774 (0.35) 
ZRh4.11 RFS 1 Reasons for smoking scale Current 1 (0.00) 
137S.00 Ex smoker Ex 2,326,595 (16.17) 
137F.00 Ex1smoker 1 amount unknown Ex 3 (0.00) 
137K.00 Stopped smoking Ex 38,630 (0.27) 
1379.00 Ex1moderate smoker (10119/day) Ex 73,832 (0.51) 
1378.00 Ex1light smoker (119/day) Ex 51,546 (0.36) 
137A.00 Ex1heavy smoker (20139/day) Ex 46,451 (0.32) 
1377.00 Ex1trivial smoker (<1/day) Ex 12,418 (0.09) 
137B.00 Ex1very heavy smoker (40+/day) Ex 2,748 (0.02) 
137T.00 Date ceased smoking Ex 14,839 (0.10) 
137N.00 Ex pipe smoker Ex 3,322 (0.02) 
137O.00 Ex cigar smoker Ex 2,042 (0.01) 
E251300 Tobacco dependence in remission Ex 1 (0.00) 
9hG1.00 Excepted from smoking quality indicators: Informed dissent Exception 5,827 (0.04) 
9hG0.00 Excepted from smoking quality indicators: Patient unsuitable Exception 3,103 (0.02) 
9hG..00 Exception reporting: smoking quality indicators Exception 85 (0.00) 
1371.00 Never smoked tobacco Never 4,493,667 (31.23) 
137L.00 Current non1smoker Ambiguousa 131,442 (0.91) 
1371.11 Non1smoker Ambiguousa 241,538 (1.68) 
9N2k.00 Seen by smoking cessation advisor Unknown 66,850 (0.46) 
13p..00 Smoking cessation milestones Unknown 47,405 (0.33) 
9OO..12 Stop smoking monitoring admin. Unknown 22,078 (0.15) 
137E.00 Tobacco consumption unknown Unknown 287 (0.00) 
9OO4.00 Stop smoking monitor 1st lettr Unknown 10,931 (0.08) 
13p1.00 Smoking status at 4 weeks Unknown 11,097 (0.08) 
9OOA.00 Stop smoking monitor.chck done Unknown 9,507 (0.07) 
9N4M.00 DNA 1 Did not attend smoking cessation clinic Unknown 10,610 (0.07) 
9OO..00 Anti1smoking monitoring admin. Unknown 7,444 (0.05) 
745H.00 Smoking cessation therapy Unknown 10,765 (0.07) 
9OOZ.00 Stop smoking monitor admin.NOS Unknown 6,765 (0.05) 
9OO2.00 Refuses stop smoking monitor Unknown 3,136 (0.02) 
4I90.00 Expired carbon monoxide concentration Unknown 3,080 (0.02) 
13p4.00 Smoking free weeks Unknown 2,124 (0.01) 
137g.00 Cigarette pack1years Unknown 1,662 (0.01) 
13p2.00 Smoking status between 4 and 52 weeks Unknown 1,727 (0.01) 
13p6.00 Carbon monoxide reading at 4 weeks Unknown 1,683 (0.01) 
E023.00 Nicotine withdrawal Unknown 596 (0.00) 
9OO..11 Stop smoking clinic admin. Unknown 2,113 (0.01) 
9OO3.00 Stop smoking monitor default Unknown 698 (0.00) 
137D.00 Admitted tobacco cons untrue ? Unknown 4,655 (0.03) 
13p3.00 Smoking status at 52 weeks Unknown 362 (0.00) 
9OO5.00 Stop smoking monitor 2nd lettr Unknown 334 (0.00) 
745Hz00 Smoking cessation therapy NOS Unknown 232 (0.00) 
9OO6.00 Stop smoking monitor 3rd lettr Unknown 64 (0.00) 
9OO9.00 Stop smoking monitoring delete Unknown 3 (0.00) 
ZV11600 [V]Personal history of tobacco abuse Unknown 1 (0.00) 
9OO1.00 Attends stop smoking monitor. Unknown 25,156 (0.17) 
137..00 Tobacco consumption Ambiguousb 821,305 (5.71) 
137Z.00 Tobacco consumption NOS Ambiguousb 2,076 (0.01) 
137a.00 Pipe tobacco consumption Ambiguousb 3,416 (0.02) 
137Y.00 Cigar consumption Ambiguousb 2,620 (0.02) 
137X.00 Cigarette consumption Ambiguousb 2,119 (0.01) 
6893.00 Tobacco usage screen Ambiguousb 473 (0.00) 
68T..00 Tobacco usage screen Ambiguousb 403 (0.00) 
ZV4K000 [V]Tobacco use Ambiguousb 27 (0.00) 
aNon1smoker unless further information available in AHD file to classify as ex or never smoker 
bUnknown smoking status unless further information available in AHD file to classify as current, ex or 
never smoker 
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The categorised version of the last recorded Read Code in a patient's notes prior 
to a given index date is taken as the patient's smoking status at that date. If the 
patient has no smoking Read Codes recorded in their notes their smoking status is 
defined as unknown. If more than one Read Code is recorded on the same day, 
and these contradict each other (e.g. one code indicating a never smoker and one 
code indicating a current smoker), the patient's smoking status is defined as 
unknown at that point in time.  
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The Townsend Index produces an ecological1level measure of material deprivation 
based on the combination of four equally1weighted census variables113: 
 
1 The percentage of all economically active residents aged 16164 (excluding 
students) who are unemployed. 
1 The percentage of all private households who do not possess a car or van. 
1 The percentage of all private households which are not owner1occupied. 
1 The percentage of all private households which are overcrowded (>1 person 
per room). 
 
Variables 1 and 4 are transformed using a log transformation to normalise their 
skewed distributions, and then z1scores are calculated for each variable:  
 
z − score = variable − mean+variable/standard deviation+variable/ 
 
The final Townsend Index is the sum of the four z1scores which, in the case of 
THIN, are categorised into quintiles to preserve patient anonymity. 
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Without being able to directly question each individual patient in THIN about their 
smoking status at any given point in time it is difficult to assess whether each 
record of smoking status documented in THIN is correct. However, it is possible to 
gain an estimate of the proportion of patients with data entry errors in their 
electronic medical records.  
 
/;06<8
 
Patients were identified from the THIN dataset who were over the age of 16 and 
registered with a practice on an index date of 1st July 2008. All records of 
smoking status, identified by relevant Read Codes, entered into a patient's notes 
on or after their registration date were extracted, and the last recorded Read Code 
prior to the index date were used to assign each patient a smoking status. To gain 
an appreciation of the correctness of smoking recording, the number of patients 
with two or more contradictory Read Codes documented as the last mention of 
smoking before the index date was calculated. In addition, the proportion of 
patients identified as never smokers on the basis of their last recorded Read Code, 
but who have a Read Code indicating current or ex smoking documented earlier in 
their medical histories, was also determined.  
 
/8-4;8
 
Table 8.3 illustrates discrepancies observed in the recording of patients’ smoking 
status, showing pairs of Read Codes recorded on the same day as the last record 
before the index date. The shaded cells highlight combinations of Read Codes 
which are contradictory; a patient cannot, for example, be both a current smoker 
and an ex1smoker at the same time.  
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Read Code 2 
Non Current Ex Total 
R
e
a
d
 C
o
d
e
 1
 Never 503 57,182 3,535 61,220 
Non 0 4 69 73 
Current 0 0 45,311 45,311 
Ex 0 0 0 0 
Total 503 57,186 48,915 106,604 
 
As can be seen, the recording of contradictory information is not an uncommon 
occurrence. In this case, of 2,511,909 patients registered in THIN on 1st July 
2008, 106,032 (4.2%) had two contradictory smoking1status Read Codes in their 
notes as the last smoking1related entry before the index date. A small number of 
patients had more than two contradictory smoking status Read1codes recorded at 
the same time; in the worst case scenario one patient was recorded 
simultaneously as a never, non, current and ex1smoker. 
 
The table below shows the proportion of patients identified as a never smoker on 
the basis of their last recorded Read Code who have a current or ex smoking Read 
Code recorded earlier in their medical history.  
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Number of never 
smokers 
Number with a previous 
current or ex1smoker code 
% illogical 
Men 508,857 58,282 11.5 
Women 689,578 86,200 12.5 
Total 1,198,435 144,482 12.1 
 
 
In 2008, 12.1% of never smokers have a Read Code recorded earlier in their 
medical records which contradicts this smoking status. Female never smokers are 
more likely than men to have evidence to the contrary recorded in their medical 
history, and there is also a gradient across age groups with older patients being 
more likely to have contradictory Read Codes (figures not shown). These figures 
indicate the persistence of the tendency noted in earlier studies for GPs to record 
patients as never smokers when they would perhaps better be described as ex1
smokers118.  
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It is difficult to know exactly how these apparent data entry errors have made it 
into patients’ electronic notes and ultimately into the THIN dataset. It is possible 
that the simple passage of time and consequent increasing number of 
consultations with a GP provide more opportunities for data entry errors to creep 
into a patient’s notes. In addition, the process of entering information on a 
patient’s smoking status onto the practice computer during the course of a 
consultation may introduce errors into the medical record; if GPs have to use a 
mouse to manually select the Read Code they wish to use from a list it might be 
easy for them to accidentally select a different code without realising.   
 
Patients with contradictory smoking status Read Codes in their medical notes 
must be coded as having an unknown smoking status at a particular point in time 
if these are the records closest to the index date. Such patients might not be 
current smokers and therefore may not be subject to increased delivery of 
smoking cessation interventions at the time smokefree legislation was introduced.  
 
It may be that the use of a patient’s last recorded Read Code is a relatively 
accurate way to identify current smokers, but perhaps cannot be relied upon to 
distinguish between ex and never smokers. In the context of the work presented 
in this thesis, investigating the management of smoking in primary care at the 
time smokefree legislation was introduced, the ability to identify current smokers 
is of primary importance as these are the patients who would be the subjects of 
increased delivery of smoking cessation interventions at the time smokefree 
legislation was introduced. The ability to identify ex and never smokers is of less 
importance, though this issue must be addressed by other researchers who need 
to be able to confidently identify these smoking behaviours. 
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Smoking is a behaviour which can change over time, and thus taking a patient's 
last recorded smoking status as indicative of their current smoking behaviour may 
not provide an accurate up1to1date indicator, particularly if the last recorded 
smoking status was documented long before the reference date of interest. This 
study investigates how long before a given index date THIN patients’ last recorded 
smoking status was documented in their medical records, assessing whether there 
has been an improvement in the currency of smoking status records over time, 
and discusses the implications for identifying THIN patients who were current 
smokers at the time smokefree legislation was introduced.  
 
/;06<8
 
For 2000, 2004 and 2008 all patients were identified from the THIN dataset who 
were over the age of 16 and registered with a practice on an index date of 1st July 
of that year. For all patients with a smoking Read Code in their medical history 
prior to each index date, the date of their last recorded smoking status was noted. 
Cumulative frequency graphs were drawn to show how long before each index 
date patients’ last recorded smoking status was documented.  
 
/8-4;8
 
Figure 8.1 illustrates, for those patients registered in THIN on 1st July 2000, 2004 
and 2008, how long before these dates their last recorded smoking entry in their 
medical records was documented. 
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There has been an improvement over time in the proportion of patients registered 
in THIN at a particular point in time who have comparatively recent recordings of 
their smoking status. Of those patients in THIN on 1st July 2000, just 8.4% had a 
smoking status recorded in their medical records in the last six months, 15.1% 
within the last year, and 27.0% within the last two years. By 2008, 17.1% of 
patients registered on 1st July had their smoking status recorded within the 
previous six months, 28.9% within the last year and 46.3% within the last two 
years. In all years, however, a sizeable minority of patients had their smoking 
status recorded many years before the index date of interest, with, at worst, 
smoking status being last recorded as early as 1942. 
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Although there have been improvements over time in the currency of smoking 
status records in THIN there remains a substantial minority of patients whose 
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smoking status has not been updated in the recent past. Very few people begin 
smoking after the age of 25126, and so it may not be a problem if the last recorded 
smoking status in people over this age indicates they were a never smoker at that 
point in time, regardless of how long ago this status was documented. However, 
some patients recorded many years ago as current smokers may since have quit, 
though with no further information available it is impossible to identify these 
patients. There is perhaps an argument for re1classifying patients last recorded as 
a current smoker many years ago as having an unknown smoking status. 
However, it is not obvious how long a current smoking code should be considered 
valid, and therefore this thesis takes the approach of leaving these patients 
classified as current smokers. Further work is warranted in this area, perhaps 
employing a modelling approach to predict smoking trajectories and allow more 
accurate estimation of population1level smoking prevalence at any point in time, if 
not allowing the identification of individual continuing smokers and quitters.  
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
H33..00 Asthma H331100 Intrinsic asthma with status asthmaticus 
H33..11 Bronchial asthma H331111 Intrinsic asthma with asthma attack 
H330.00 Extrinsic (atopic) asthma H331z00 Intrinsic asthma NOS 
H330.11 Allergic asthma H332.00 Mixed asthma 
H330.12 Childhood asthma H334.00 Brittle asthma 
H330.13 Hay fever with asthma H33z.00 Asthma unspecified 
H330.14 Pollen asthma H33z.11 Hyperreactive airways disease 
H330000 Extrinsic asthma without status asthmaticus H33z000 Status asthmaticus NOS 
H330011 Hay fever with asthma H33z011 Severe asthma attack 
H330100 Extrinsic asthma with status asthmaticus H33z200 Late1onset asthma 
H330111 Extrinsic asthma with asthma attack H33zz00 Asthma NOS 
H330z00 Extrinsic asthma NOS H33zz11 Exercise induced asthma 
H331.00 Intrinsic asthma H33zz12 Allergic asthma NEC 
H331.11 Late onset asthma H33zz13 Allergic bronchitis NEC 
H331000 Intrinsic asthma without status asthmaticus   

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H3...00 Chronic obstructive pulmonary disease H320200 Giant bullous emphysema 
H3...11 Chronic obstructive airways disease H320300 Bullous emphysema with collapse 
H31..00 Chronic bronchitis H320311 Tension pneumatocoele 
H310.00 Simple chronic bronchitis H320z00 Chronic bullous emphysema NOS 
H310000 Chronic catarrhal bronchitis H321.00 Panlobular emphysema 
H310z00 Simple chronic bronchitis NOS H322.00 Centrilobular emphysema 
H311.00 Mucopurulent chronic bronchitis H32y.00 Other emphysema 
H311000 Purulent chronic bronchitis H32y000 Acute vesicular emphysema 
H311100 Fetid chronic bronchitis H32y100 Atrophic (senile) emphysema 
H311z00 Mucopurulent chronic bronchitis NOS H32y111 Acute interstitial emphysema 
H312.00 Obstructive chronic bronchitis H32y200 MacLeod's unilateral emphysema 
H312000 Chronic asthmatic bronchitis H32yz00 Other emphysema NOS 
H312011 Chronic wheezy bronchitis H32yz11 Sawyer 1 Jones syndrome 
H312100 Emphysematous bronchitis H32z.00 Emphysema NOS 
H312300 Bronchiolitis obliterans H36..00 Mild chronic obstructive pulmonary disease 
H312z00 Obstructive chronic bronchitis NOS H37..00 Moderate chronic obstructive pulmonary disease 
H313.00 Mixed simple and mucopurulent chronic bronchitis H38..00 Severe chronic obstructive pulmonary disease 
H31y.00 Other chronic bronchitis H39..00 Very severe chronic obstructive pulmonary disease 
H31y100 Chronic tracheobronchitis H3y..00 Other specified chronic obstructive airways disease 
H31yz00 Other chronic bronchitis NOS H3y..11 Other specified chronic obstructive pulmonary disease 
H31z.00 Chronic bronchitis NOS H3y0.00 Chronic obstruct pulmonary dis with acute lower resp infectn 
H32..00 Emphysema H3y1.00 Chron obstruct pulmonary dis wth acute exacerbation, unspec 
H320.00 Chronic bullous emphysema H3z..00 Chronic obstructive airways disease NOS 
H320000 Segmental bullous emphysema H3z..11 Chronic obstructive pulmonary disease NOS 
H320100 Zonal bullous emphysema   
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G3...00 Ischaemic heart disease G32..11 Healed myocardial infarction 
G3...11 Arteriosclerotic heart disease G32..12 Personal history of myocardial infarction 
G3...12 Atherosclerotic heart disease G33..00 Angina pectoris 
G3...13 IHD 1 Ischaemic heart disease G330.00 Angina decubitus 
G30..00 Acute myocardial infarction G330000 Nocturnal angina 
G30..11 Attack 1 heart G330z00 Angina decubitus NOS 
G30..12 Coronary thrombosis G33z.00 Angina pectoris NOS 
G30..13 Cardiac rupture following myocardial infarction (MI) G33z000 Status anginosus 
G30..14 Heart attack G33z100 Stenocardia 
G30..15 MI 1 acute myocardial infarction G33z200 Syncope anginosa 
G30..16 Thrombosis 1 coronary G33z300 Angina on effort 
G30..17 Silent myocardial infarction G33z400 Ischaemic chest pain 
G300.00 Acute anterolateral infarction G33z500 Post infarct angina 
G301.00 Other specified anterior myocardial infarction G33z600 New onset angina 
G301000 Acute anteroapical infarction G33z700 Stable angina 
G301100 Acute anteroseptal infarction G33zz00 Angina pectoris NOS 
G301z00 Anterior myocardial infarction NOS G34..00 Other chronic ischaemic heart disease 
G302.00 Acute inferolateral infarction G340.00 Coronary atherosclerosis 
G303.00 Acute inferoposterior infarction G340.11 Triple vessel disease of the heart 
G304.00 Posterior myocardial infarction NOS G340.12 Coronary artery disease 
G305.00 Lateral myocardial infarction NOS G340000 Single coronary vessel disease 
G306.00 True posterior myocardial infarction G340100 Double coronary vessel disease 
G307.00 Acute subendocardial infarction G342.00 Atherosclerotic cardiovascular disease 
G307000 Acute non1Q wave infarction G343.00 Ischaemic cardiomyopathy 
G307100 Acute non1ST segment elevation myocardial infarction G344.00 Silent myocardial ischaemia 
G308.00 Inferior myocardial infarction NOS G34y.00 Other specified chronic ischaemic heart disease 
G309.00 Acute Q1wave infarct G34y000 Chronic coronary insufficiency 
G30A.00 Mural thrombosis G34y100 Chronic myocardial ischaemia 
G30B.00 Acute posterolateral myocardial infarction G34yz00 Other specified chronic ischaemic heart disease NOS 
G30X.00 Acute transmural myocardial infarction of unspecif site G34z.00 Other chronic ischaemic heart disease NOS 
G30X000 Acute ST segment elevation myocardial infarction G34z000 Asymptomatic coronary heart disease 
G30y.00 Other acute myocardial infarction G35..00 Subsequent myocardial infarction 
G30y000 Acute atrial infarction G350.00 Subsequent myocardial infarction of anterior wall 
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G30y100 Acute papillary muscle infarction G351.00 Subsequent myocardial infarction of inferior wall 
G30y200 Acute septal infarction G353.00 Subsequent myocardial infarction of other sites 
G30yz00 Other acute myocardial infarction NOS G35X.00 Subsequent myocardial infarction of unspecified site 
G30z.00 Acute myocardial infarction NOS G36..00 Certain current complication follow acute myocardial infarct 
G31..00 Other acute and subacute ischaemic heart disease G360.00 Haemopericardium/current comp folow acut myocard infarct 
G310.00 Postmyocardial infarction syndrome G361.00 Atrial septal defect/curr comp folow acut myocardal infarct 
G310.11 Dressler's syndrome G362.00 Ventric septal defect/curr comp fol acut myocardal infarctn 
G311.00 Preinfarction syndrome G363.00 Ruptur cardiac wall w'out haemopericard/cur comp fol ac MI 
G311.11 Crescendo angina G364.00 Ruptur chordae tendinae/curr comp fol acute myocard infarct 
G311.12 Impending infarction G365.00 Rupture papillary muscle/curr comp fol acute myocard infarct 
G311.13 Unstable angina G366.00 Thrombosis atrium,auric append&vent/curr comp foll acute MI 
G311.14 Angina at rest G38..00 Postoperative myocardial infarction 
G311000 Myocardial infarction aborted G380.00 Postoperative transmural myocardial infarction anterior wall 
G311011 MI 1 myocardial infarction aborted G381.00 Postoperative transmural myocardial infarction inferior wall 
G311100 Unstable angina G382.00 Postoperative transmural myocardial infarction other sites 
G311200 Angina at rest G383.00 Postoperative transmural myocardial infarction unspec site 
G311300 Refractory angina G384.00 Postoperative subendocardial myocardial infarction 
G311400 Worsening angina G38z.00 Postoperative myocardial infarction, unspecified 
G311500 Acute coronary syndrome G3y..00 Other specified ischaemic heart disease 
G311z00 Preinfarction syndrome NOS G3z..00 Ischaemic heart disease NOS 
G312.00 Coronary thrombosis not resulting in myocardial infarction Gyu3.00 [X]Ischaemic heart diseases 
G31y.00 Other acute and subacute ischaemic heart disease Gyu3000 [X]Other forms of angina pectoris 
G31y000 Acute coronary insufficiency Gyu3100 [X]Other current complicatns following acute myocard infarct 
G31y100 Microinfarction of heart Gyu3200 [X]Other forms of acute ischaemic heart disease 
G31y200 Subendocardial ischaemia Gyu3300 [X]Other forms of chronic ischaemic heart disease 
G31y300 Transient myocardial ischaemia Gyu3400 [X]Acute transmural myocardial infarction of unspecif site 
G31yz00 Other acute and subacute ischaemic heart disease NOS Gyu3500 [X]Subsequent myocardial infarction of other sites 
G32..00 Old myocardial infarction Gyu3600 [X]Subsequent myocardial infarction of unspecified site 

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C10E.00 Type 1 diabetes mellitus C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria 
C10E.11 Type I diabetes mellitus C10EL11 Type I diabetes mellitus with persistent microalbuminuria 
C10E.12 Insulin dependent diabetes mellitus C10EM00 Type 1 diabetes mellitus with ketoacidosis 
C10E000 Type 1 diabetes mellitus with renal complications C10EM11 Type I diabetes mellitus with ketoacidosis 
C10E011 Type I diabetes mellitus with renal complications C10EN00 Type 1 diabetes mellitus with ketoacidotic coma 
C10E012 Insulin1dependent diabetes mellitus with renal complications C10EN11 Type I diabetes mellitus with ketoacidotic coma 
C10E100 Type 1 diabetes mellitus with ophthalmic complications C10EP00 Type 1 diabetes mellitus with exudative maculopathy 
C10E111 Type I diabetes mellitus with ophthalmic complications C10EP11 Type I diabetes mellitus with exudative maculopathy 
C10E112 Insulin1dependent diabetes mellitus with ophthalmic comps C10EQ00 Type 1 diabetes mellitus with gastroparesis 
C10E200 Type 1 diabetes mellitus with neurological complications C10ER00 Latent autoimmune diabetes mellitus in adult 
C10E211 Type I diabetes mellitus with neurological complications C10F.00 Type 2 diabetes mellitus 
C10E212 Insulin1dependent diabetes mellitus with neurological comps C10F.11 Type II diabetes mellitus 
C10E300 Type 1 diabetes mellitus with multiple complications C10F000 Type 2 diabetes mellitus with renal complications 
C10E311 Type I diabetes mellitus with multiple complications C10F011 Type II diabetes mellitus with renal complications 
C10E312 Insulin dependent diabetes mellitus with multiple complicat C10F100 Type 2 diabetes mellitus with ophthalmic complications 
C10E400 Unstable type 1 diabetes mellitus C10F111 Type II diabetes mellitus with ophthalmic complications 
C10E411 Unstable type I diabetes mellitus C10F200 Type 2 diabetes mellitus with neurological complications 
C10E412 Unstable insulin dependent diabetes mellitus C10F211 Type II diabetes mellitus with neurological complications 
C10E500 Type 1 diabetes mellitus with ulcer C10F300 Type 2 diabetes mellitus with multiple complications 
C10E511 Type I diabetes mellitus with ulcer C10F311 Type II diabetes mellitus with multiple complications 
C10E512 Insulin dependent diabetes mellitus with ulcer C10F400 Type 2 diabetes mellitus with ulcer 
C10E600 Type 1 diabetes mellitus with gangrene C10F411 Type II diabetes mellitus with ulcer 
C10E611 Type I diabetes mellitus with gangrene C10F500 Type 2 diabetes mellitus with gangrene 
C10E612 Insulin dependent diabetes mellitus with gangrene C10F511 Type II diabetes mellitus with gangrene 
C10E700 Type 1 diabetes mellitus with retinopathy C10F600 Type 2 diabetes mellitus with retinopathy 
C10E711 Type I diabetes mellitus with retinopathy C10F611 Type II diabetes mellitus with retinopathy 
C10E712 Insulin dependent diabetes mellitus with retinopathy C10F700 Type 2 diabetes mellitus 1 poor control 
C10E800 Type 1 diabetes mellitus 1 poor control C10F711 Type II diabetes mellitus 1 poor control 
C10E811 Type I diabetes mellitus 1 poor control C10F900 Type 2 diabetes mellitus without complication 
C10E812 Insulin dependent diabetes mellitus 1 poor control C10F911 Type II diabetes mellitus without complication 
C10E900 Type 1 diabetes mellitus maturity onset C10FA00 Type 2 diabetes mellitus with mononeuropathy 
C10E911 Type I diabetes mellitus maturity onset C10FA11 Type II diabetes mellitus with mononeuropathy 
C10E912 Insulin dependent diabetes maturity onset C10FB00 Type 2 diabetes mellitus with polyneuropathy 
C10EA00 Type 1 diabetes mellitus without complication C10FB11 Type II diabetes mellitus with polyneuropathy 
C10EA11 Type I diabetes mellitus without complication C10FC00 Type 2 diabetes mellitus with nephropathy 
C10EA12 Insulin1dependent diabetes without complication C10FC11 Type II diabetes mellitus with nephropathy 
C10EB00 Type 1 diabetes mellitus with mononeuropathy C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
C10EB11 Type I diabetes mellitus with mononeuropathy C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
C10EB12 Insulin dependent diabetes mellitus with mononeuropathy C10FE00 Type 2 diabetes mellitus with diabetic cataract 
C10EC00 Type 1 diabetes mellitus with polyneuropathy C10FE11 Type II diabetes mellitus with diabetic cataract 
C10EC11 Type I diabetes mellitus with polyneuropathy C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
C10EC12 Insulin dependent diabetes mellitus with polyneuropathy C10FF11 Type II diabetes mellitus with peripheral angiopathy 
C10ED00 Type 1 diabetes mellitus with nephropathy C10FG00 Type 2 diabetes mellitus with arthropathy 
C10ED11 Type I diabetes mellitus with nephropathy C10FG11 Type II diabetes mellitus with arthropathy 
C10ED12 Insulin dependent diabetes mellitus with nephropathy C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma C10FH11 Type II diabetes mellitus with neuropathic arthropathy 
C10EE11 Type I diabetes mellitus with hypoglycaemic coma C10FJ00 Insulin treated Type 2 diabetes mellitus 
C10EE12 Insulin dependent diabetes mellitus with hypoglycaemic coma C10FJ11 Insulin treated Type II diabetes mellitus 
C10EF00 Type 1 diabetes mellitus with diabetic cataract C10FK00 Hyperosmolar non1ketotic state in type 2 diabetes mellitus 
C10EF11 Type I diabetes mellitus with diabetic cataract C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
C10EF12 Insulin dependent diabetes mellitus with diabetic cataract C10FL11 Type II diabetes mellitus with persistent proteinuria 
C10EG00 Type 1 diabetes mellitus with peripheral angiopathy C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
C10EG11 Type I diabetes mellitus with peripheral angiopathy C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
C10EG12 Insulin dependent diab mell with peripheral angiopathy C10FN00 Type 2 diabetes mellitus with ketoacidosis 
C10EH00 Type 1 diabetes mellitus with arthropathy C10FN11 Type II diabetes mellitus with ketoacidosis 
C10EH11 Type I diabetes mellitus with arthropathy C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
C10EH12 Insulin dependent diabetes mellitus with arthropathy C10FP11 Type II diabetes mellitus with ketoacidotic coma 
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy C10FQ00 Type 2 diabetes mellitus with exudative maculopathy 
C10EJ11 Type I diabetes mellitus with neuropathic arthropathy C10FQ11 Type II diabetes mellitus with exudative maculopathy 
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C10EJ12 Insulin dependent diab mell with neuropathic arthropathy C10FR00 Type 2 diabetes mellitus with gastroparesis 
C10EK00 Type 1 diabetes mellitus with persistent proteinuria C10FS00 Maternally inherited diabetes mellitus 
C10EK11 Type I diabetes mellitus with persistent proteinuria   

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G2...00 Hypertensive disease G240000 Secondary malignant renovascular hypertension 
G2...11 BP 1 hypertensive disease G240z00 Secondary malignant hypertension NOS 
G20..00 Essential hypertension G241.00 Secondary benign hypertension 
G20..11 High blood pressure G241000 Secondary benign renovascular hypertension 
G200.00 Malignant essential hypertension G241z00 Secondary benign hypertension NOS 
G201.00 Benign essential hypertension G244.00 Hypertension secondary to endocrine disorders 
G202.00 Systolic hypertension G24z.00 Secondary hypertension NOS 
G203.00 Diastolic hypertension G24z000 Secondary renovascular hypertension NOS 
G20z.00 Essential hypertension NOS G24zz00 Secondary hypertension NOS 
G20z.11 Hypertension NOS G2y..00 Other specified hypertensive disease 
G24..00 Secondary hypertension G2z..00 Hypertensive disease NOS 
G240.00 Secondary malignant hypertension   

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G61..00 Intracerebral haemorrhage G66..12 Stroke unspecified 
G61..11 CVA 1 cerebrovascular accid due to intracerebral haemorrhage G66..13 CVA 1 Cerebrovascular accident unspecified 
G61..12 Stroke due to intracerebral haemorrhage G660.00 Middle cerebral artery syndrome 
G610.00 Cortical haemorrhage G661.00 Anterior cerebral artery syndrome 
G611.00 Internal capsule haemorrhage G662.00 Posterior cerebral artery syndrome 
G612.00 Basal nucleus haemorrhage G663.00 Brain stem stroke syndrome 
G613.00 Cerebellar haemorrhage G664.00 Cerebellar stroke syndrome 
G614.00 Pontine haemorrhage G665.00 Pure motor lacunar syndrome 
G615.00 Bulbar haemorrhage G666.00 Pure sensory lacunar syndrome 
G616.00 External capsule haemorrhage G667.00 Left sided CVA 
G618.00 Intracerebral haemorrhage, multiple localized G668.00 Right sided CVA 
G61X.00 Intracerebral haemorrhage in hemisphere, unspecified G669.00 Cerebral palsy, not congenital or infantile, acute 
G61X000 Left sided intracerebral haemorrhage, unspecified G676000 Cereb infarct due cerebral venous thrombosis, nonpyogenic 
G61X100 Right sided intracerebral haemorrhage, unspecified G6W..00 Cereb infarct due unsp occlus/stenos precerebr arteries 
G61z.00 Intracerebral haemorrhage NOS G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
G63y000 Cerebral infarct due to thrombosis of precerebral arteries Gyu6200 [X]Other intracerebral haemorrhage 
G63y100 Cerebral infarction due to embolism of precerebral arteries Gyu6300 [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
G64..00 Cerebral arterial occlusion Gyu6400 [X]Other cerebral infarction 
G64..11 CVA 1 cerebral artery occlusion Gyu6500 [X]Occlusion and stenosis of other precerebral arteries 
G64..12 Infarction 1 cerebral Gyu6600 [X]Occlusion and stenosis of other cerebral arteries 
G64..13 Stroke due to cerebral arterial occlusion Gyu6F00 [X]Intracerebral haemorrhage in hemisphere, unspecified 
G64..00 Cerebral arterial occlusion Gyu6G00 [X]Cereb infarct due unsp occlus/stenos precerebr arteries 
G64..11 CVA 1 cerebral artery occlusion G65..00 Transient cerebral ischaemia 
G64..12 Infarction 1 cerebral G65..11 Drop attack 
G64..13 Stroke due to cerebral arterial occlusion G65..12 Transient ischaemic attack 
G640.00 Cerebral thrombosis G65..13 Vertebro1basilar insufficiency 
G640000 Cerebral infarction due to thrombosis of cerebral arteries G650.00 Basilar artery syndrome 
G641.00 Cerebral embolism G650.11 Insufficiency 1 basilar artery 
G641.11 Cerebral embolus G651.00 Vertebral artery syndrome 
G641000 Cerebral infarction due to embolism of cerebral arteries G651000 Vertebro1basilar artery syndrome 
G64z.00 Cerebral infarction NOS G652.00 Subclavian steal syndrome 
G64z.11 Brainstem infarction NOS G653.00 Carotid artery syndrome hemispheric 
G64z.12 Cerebellar infarction G654.00 Multiple and bilateral precerebral artery syndromes 
G64z000 Brainstem infarction G656.00 Vertebrobasilar insufficiency 
G64z100 Wallenberg syndrome G65y.00 Other transient cerebral ischaemia 
G64z111 Lateral medullary syndrome G65z.00 Transient cerebral ischaemia NOS 
G64z200 Left sided cerebral infarction G65z000 Impending cerebral ischaemia 
G64z300 Right sided cerebral infarction G65z100 Intermittent cerebral ischaemia 
G64z400 Infarction of basal ganglia G65zz00 Transient cerebral ischaemia NOS 
G66..00 Stroke and cerebrovascular accident unspecified F423600 Amaurosis fugax 
G66..11 CVA unspecified   
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c1...% Selective beta1adrenoceptor stimulants  3.1.1.1 
Bambuterol hydrochloride  
Fenoterol hydrobromide  
Formoterol fumerate  
Salbutamol 
Salmeterol 
Terbutaline sulphate  
c2...% Other beta1adrenoceptor stimulants 3.1.1.2 
Ephedrine hydrochloride  
Orciprenaline sulphate  
c3...% Anticholinergic bronchodilators  3.1.2.0 
Ipratropium bromide  
Tiotropium  
c4...% Xanthine bronchodilators   3.1.3.0 
Aminophylline  
Theophylline 
c5...% Compound bronchodilators 3.1.4.0 
Combivent® 
Duovent® 
c6...% Corticosteroids 
3.2.0.0 
Belcometasone bipropionate  
Budesonide  
Budesonide with formoterol fumerate  
Ciclesonide  
Fluticasone propionate  
Mometasone furoate 
6.3.2.0 
Betamethasone  
Cortisone acetate  
Deflazacort  
Dexamethasone  
Hydrocortisone  
Methlyprednisolone  
Prednisolone  
Triamcinolone  
c7...% Asthma prophylaxis  
3.3.1.0 Nedocromil sodium  
3.4.2.0 
Sodium cromoglicate  
Omalizumab  
cA...% Leukotriene receptor antagonists  3.3.2.0 
Montelukast 
Zafirlukast  

 

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6791.00 Health ed. 1 smoking 
67A3.00 Pregnancy smoking advice 
67H1.00 Lifestyle advice regarding smoking 
8CAL.00 Smoking cessation advice 
ZG23300 Advice on smoking 
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8H7i.00 Referral to smoking cessation advisor 
8HTK.00 Referral to stop smoking clinic 
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Multilex drug code Type Formulation Dose 
89112998 NICOTINE Chewing gum 2mg 
91248998 NICOTINE Chewing gum 2mg 
92840998 NICOTINE Chewing gum 2mg 
92841998 NICOTINE Chewing gum 2mg 
95727998 NICOTINE Chewing gum 2mg 
98904998 NICOTINE Chewing gum 2mg 
89110998 NICOTINE Chewing gum 4mg 
91248997 NICOTINE Chewing gum 4mg 
95727996 NICOTINE Chewing gum 4mg 
95727997 NICOTINE Chewing gum 4mg 
98904996 NICOTINE Chewing gum 4mg 
98904997 NICOTINE Chewing gum 4mg 
88288998 NICOTINE Inhalator 10mg 
88291998 NICOTINE Inhalator 10mg 
89863998 NICOTINE Lozenge 0.35mg 
92840997 NICOTINE Lozenge 0.35mg 
84442998 NICOTINE Lozenge 1.5mg 
84443998 NICOTINE Lozenge 1.5mg 
91248996 NICOTINE Lozenge 1mg 
98430998 NICOTINE Lozenge 1mg 
87920998 NICOTINE Lozenge 2mg 
87922998 NICOTINE Lozenge 2mg 
91162998 NICOTINE Lozenge 2mg 
91384998 NICOTINE Lozenge 2mg 
92889990 NICOTINE Lozenge 2mg 
87919998 NICOTINE Lozenge 4mg 
91848998 NICOTINE Lozenge 4mg 
92888990 NICOTINE Lozenge 4mg 
98082998 NICOTINE Lozenge 4mg 
92840996 NICOTINE Tabs 2mg 
92841997 NICOTINE Microtab 2mg 
92657998 NICOTINE Nasal spray 10mg/ml 
92836998 NICOTINE Nasal spray 10mg/ml 
93447992 NICOTINE Patch 0 
96844992 NICOTINE Patch 0 
96845992 NICOTINE Patch 0 
97737998 NICOTINE Patch 10 square cm 
96869992 NICOTINE Patch 10mg 
97739997 NICOTINE Patch 10mg 
97763997 NICOTINE Patch 10mg 
92892997 NICOTINE Patch 11mg/24 hr 
98581997 NICOTINE Patch 11mg/24 hr 
88005997 NICOTINE Patch 14mg 
97673997 NICOTINE Patch 14mg 
97740997 NICOTINE Patch 14mg 
84468998 NICOTINE Patch 14mg/24 hours 
96930992 NICOTINE Patch 15mg 
97739996 NICOTINE Patch 15mg 
97763996 NICOTINE Patch 15mg 
97737997 NICOTINE Patch 20 square cm 
88005996 NICOTINE Patch 21mg 
97673996 NICOTINE Patch 21mg 
97740996 NICOTINE Patch 21mg 
84466998 NICOTINE Patch 21mg/24 hours 
92892998 NICOTINE Patch 22mg/24 hr 
98581998 NICOTINE Patch 22mg/24 hr 
97737996 NICOTINE Patch 30 square cm 
96924992 NICOTINE Patch 30mg 
96868992 NICOTINE Patch 5mg 
97739998 NICOTINE Patch 5mg 
97763998 NICOTINE Patch 5mg 
88005998 NICOTINE Patch 7mg 
97673998 NICOTINE Patch 7mg 
97740998 NICOTINE Patch 7mg 
84469998 NICOTINE Patch 7mg/24 hours 
92309998 BUPROPION Modified release tablet 150mg 
92311998 BUPROPION Modified release tablet 150mg 
85397998 VARENICLINE Tabs 1mg 
85398998 VARENICLINE Tabs 500 micrograms 
85399998 VARENICLINE Tabs 500micrograms + 1mg 
85400998 VARENICLINE Tabs 1mg 
85401998 VARENICLINE Tabs 500 micrograms 
85403998 VARENICLINE Tabs 500micrograms + 1mg 
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To declare data to be time series data: 
	

To draw a simple time plot of a series:
	

To draw an autocorrelation function (ACF) up to lag 40: 

	89*/:
9	94&;&:: 

To draw a partial autocorrelation function (PACF) up to lag 40:
$
	89*/:
9	94&;&::

To generate a new variable containing the first difference of a series: 
	<+&	 

To generate a new variable containing the first seasonal difference of a series: 
	<&)	

To generate a new variable containing the first differenced and seasonally 
differenced series: 
	<+&&)	 
 
To fit an ARIMA model to a pre1intervention series: 
		=	>8	9$88?:	98+8@8:
 
Having fitted an ARIMA model, assess whether the parameters are collinear: 

8
		
 
To draw a histogram of the standardised residuals from an ARIMA model: 
$	
	8	
	<9	:
	
 
To draw a scatter graph of the standardised residuals over time: 
9
			:
 
To compute the Ljung1Box Q statistic on ARIMA model residuals up to lag 20: 
?	89)/:
NB. The p1value given by Stata does not use the correct number of degrees of 
freedom and should not be used. An external χ2 calculator should be used to test 
the Q statistic against a χ2 distribution with the number of degrees of freedom 
equal to 20 minus the number of parameters in the ARIMA model. 
 
To generate a dummy variable indicating the presence of an intervention in a 
given month e.g. July 2007: 
gen intervention = 0 
recode intervention 0=1 if month==tm(200717) 
 
To estimate the impact of an intervention on a series: 
	+&&)		8	9$8/8?:	98/8@8:
NB: If the series requires differencing (either first or seasonal) the prefix D1.S12, 
D1., or S12., must be placed before series variable on the left hand side of the 
command and d and D replaced by 0 on the right hand side. This is to ensure that 
the intervention variable is not itself differenced in the model estimation 
procedure. 
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The ‘arimaintervention’ command, accessed via a Stata ado. file, fits several 
different ARIMA models to a pre1intervention time series, systematically working 
through combinations of non1seasonal and seasonal autoregressive and moving 
average parameters of order zero, one and two. For each model, the output of the 
command indicates whether it is an adequate representation of the data, 
combining assessment of the statistical significance of the parameter estimates, 
whether the parameters fall within the bounds of stationarity and invertibility, and 
whether the residuals are a white noise process. In addition, the procedure 
highlights the absolute magnitude of the largest standardised residual to allow 
detection of possible outliers and computes two estimates of model fit, R2 and the 
AIC, which can be used to choose between several adequate models. The 
procedure also, for each model, estimates the magnitude of change in the 
outcome variable in the intervention period, along with 95% confidence intervals 
and a Wald p1value for the parameter. The results can then be scanned visually to 
assess whether the choice of model influences the magnitude and statistical 
significance of the change in the outcome variable estimated in the intervention 
period. 
 
The command is specified as follows:  
 
 
arimaintervention 	, time(	) logged(1) dif(1) seasdif(1) 
intstart(tm(200716)) intperiod(		) using("&") 
output(")")  
 
 
where:  
 
 
series = the name of the time series variable to be modelled 
 
timevar = the variable indicating the point in time each observation was measured 
 
logged = a binary variable to indicate whether the series should (1) or should not 
(0) be logged prior to model estimation 
 
dif = a binary variable to indicate whether the series should (1) or should not (0) 
be first differenced to induce stationarity prior to model estimation 
 
dif = a binary variable to indicate whether the series should (1) or should not (0) 
be seasonally differenced to induce stationarity prior to model estimation 
 
intstart = the first month of the intervention period 
 
interventionvar = a dummy variable coded 1 for all time points in the intervention 
period and 0 for all other time points 
 
dataset1 = the name of the dataset in which the time series data are stored 
 
dataset2 = the name of the dataset which will be created to store the results of 
the procedure 
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/56.<+(,675/883;+6(3<2+5/
 
	(,43(< 56;43(<
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 3.1 17.1 to 13.3 0.553 14.6 133.4 to 24.2 0.754 
1 month before 6.0 178.6 to 90.6 0.890 110.5 189.5 to 68.4 0.794 
2 months before 4.7 147.8 to 57.3 0.859 17.4 146.3 to 31.6 0.711 
3 months before 16.9 116.6 to 2.9 0.169 14.6 133.4 to 24.2 0.754 
6 months before 11.8 19.0 to 5.3 0.613 1.0 111.3 to 13.3 0.873 
9 months before 11.4 18.1 to 5.2 0.672 12.5 112.6 to 7.6 0.624 
1 month after 16.1 188.5 to 76.3 0.885 9.0 123.4 to 41.4 0.587 
2 months after 18.1 155.3 to 39.1 0.736 3.3 124.8 to 31.4 0.819 
3 months after 11.9 118.9 to 15.1 0.828 0.4 124.5 to 25.4 0.972 
6 months after 12.8 114.5 to 8.9 0.641 10.2 121.3 to 20.9 0.986 
9 months after 10.9 19.2 to 7.4 0.832 1.3 111.9 to 14.5 0.844 
Permanent change 11.4 14.3 to 1.6 0.371 0.0 19.5 to 9.6 0.994 
 
34/8 6.;0/.(./43(<
 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 5.0 152.0 to 61.9 0.864 13.6 127.1 to 20.0 0.765 
1 month before 7.6 173.7 to 88.8 0.855 123.6 171.0 to 23.8 0.330 
2 months before 8.4 175.5 to 92.3 0.844 18.9 125.4 to 7.6 0.292 
3 months before 5.0 152.0 to 61.9 0.864 16.7 120.7 to 7.4 0.353 
6 months before 4.0 124.6 to 32.6 0.784 12.9 112.6 to 6.7 0.550 
9 months before 2.3 113.5 to 18.2 0.773 12.2 110.7 to 6.3 0.612 
1 month after 13.5 140.0 to 32.9 0.849 10.1 1130.4 to 130.2 0.998 
2 months after 10.1 129.8 to 29.7 0.997 12.1 159.6 to 55.5 0.944 
3 months after 12.7 127.4 to 22.0 0.831 13.3 149.7 to 43.1 0.889 
6 months after 12.0 115.8 to 11.9 0.780 13.2 134.9 to 28.4 0.841 
9 months after 12.2 113.5 to 9.1 0.705 14.5 122.9 to 13.9 0.633 
Permanent change 11.6 18.4 to 5.2 0.645 12.1 19.9 to 5.7 0.603 
 
/56.<+(,67./7/..34;68;61896:+(,8/.2+5/8
 
	(,43(< 56;43(<
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 1.9 1169.6 to 173.5 0.982 10.4 177.1 to 97.9 0.816 
1 month before 18.0 1219.9 to 256.0 0.882 19.0 1118.2 to 100.2 0.872 
2 months before 7.3 1111.4 to 126.0 0.904 6.8 198.9 to 112.5 0.900 
3 months before 1.6 169.8 to 73.0 0.966 10.4 177.1 to 97.9 0.816 
6 months before 1.5 155.8 to 58.8 0.959 13.1 142.9 to 36.7 0.878 
9 months before 2.0 121.6 to 25.5 0.869 12.8 134.8 to 29.3 0.866 
1 month after 2.9 1193.5 to 199.3 0.977 152.3 1183.0 to 78.5 0.433 
2 months after 121.6 195.7 to 52.5 0.568 131.8 1114.9 to 51.3 0.453 
3 months after 116.5 179.7 to 46.6 0.608 122.8 185.4 to 39.9 0.476 
6 months after 110.2 144.3 to 23.9 0.557 19.9 150.4 to 30.7 0.634 
9 months after 16.4 134.8 to 22.1 0.660 5.7 12.1 to 13.5 0.151 
Permanent change 12.5 123.3 to 18.3 0.812 0.5 116.7 to 17.7 0.957 
 
34/8
 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 4.5 124.8 to 33.9 0.762 
1 month before 112.7 192.1 to 66.8 0.755 
2 months before 13.5 148.6 to 41.7 0.880 
3 months before 4.5 124.8 to 33.9 0.762 
6 months before 11.5 115.8 to 12.9 0.841 
9 months before 11.6 113.3 to 10.0 0.783 
1 month after 18.1 164.7 to 100.9 0.668 
2 months after 11.6 148.5 to 45.3 0.947 
3 months after 11.5 136.6 to 33.7 0.935 
6 months after 13.8 121.2 to 13.6 0.668 
9 months after 10.6 114.1 to 12.9 0.935 
Permanent change 0.7 19.1 to 10.4 0.896 
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Time series analysis of rates of recording of advice and referral produce very 
similar results in all patients compared to just those identified as current smokers. 
In both cases, no significant changes in the rate of recording of either advice or 
referral are seen in any intervention period in any jurisdiction of the UK. 
 
 

./85.+A+(,67
 
	(,43(< 56;43(<
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 10.3 16.7 to 6.0 0.919 13.0 111.0 to 5.0 0.466 
1 month before # &#;6 M$$$ 16.5 115.2 to 48.2 0.308 
2 months before  %;6 M$$$ 7.8 17.0 to 22.6 0.304 
3 months before $  $;6 $ M$$$ 13.0 111.0 to 5.0 0.466 
6 months before ## ;6& $$ 4.5 14.3 to 13.3 0.313 
9 months before 4.2 10.1 to 8.5 0.054 1.2 16.3 to 8.7 0.751 
1 month after 3.5 115.1 to 22.1 0.712 3.3 130.9 to 37.5 0.851 
2 months after 12.6 17.8 to 2.7 0.341 15.3 115.1 to 4.6 0.298 
3 months after 
& 
%;6
# M$$$ 14.4 112.7 to 4.0 0.306 
6 months after 
%  
 ;6
$ $$$ 15.2 111.7 to 1.3 0.115 
9 months after 
#  
%;6
& M$$$ 13.0 18.4 to 2.5 0.286 
Permanent change 11.8 14.3 to 0.7 0.151 2.1 11.2 to 5.4 0.217 
 
34/8 6.;0/.(./43(<
 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 13.5 115.2 to 8.1 0.550 6.8 113.7 to 27.2 0.516 
1 month before 6.4 116.1 to 29.0 0.576 17.6 123.6 to 58.8 0.403 
2 months before 3.8 112.7 to 20.2 0.654 7.5 18.5 to 23.4 0.358 
3 months before 13.5 115.2 to 8.1 0.550 10.5 112.2 to 11.2 0.930 
6 months before 2.4 17.2 to 12.0 0.625 12.9 110.5 to 4.7 0.458 
9 months before 13.5 110.3 to 3.4 0.319 10.5 112.2 to 11.2 0.930 
1 month after   $ ;6& $$   18.8 13.7 to 41.3 0.101 
2 months after  #;6%$ $$$    ;6$ $$$
3 months after 5.6 10.7 to 11.9 0.082    ;6  $$#
6 months after 13.6 18.9 to 1.6 0.177 13.9 19.2 to 1.3 0.141 
9 months after 13.2 18.0 to 1.7 0.206 13.5 18.1 to 1.1 0.140 
Permanent change 11.4 14.1 to 1.3 0.308 10.5 13.2 to 2.3 0.740 
 
 
 
./85.+A+(,67A-1.61+6(
 
	(,43(< 56;43(<
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 0.6 116.9 to 18.2 0.943 11.9 119.2 to 43.0 0.454 
1 month before   $;6%# M$$$ 10.6 171.3 to 70.1 0.987 
2 months before &  ;6% M$$$ 6.9 139.8 to 53.5 0.773 
3 months before & #;6 $$$ 11.9 119.2 to 43.0 0.454 
6 months before $ ;6 $$& 5.9 17.5 to 19.4 0.386 
9 months before 4.8 11.6 to 11.3 0.141 4.7 17.4 to 16.7 0.449 
1 month after 2.5 127.4 to 32.3 0.872 126.3 1170.6 to 118.0 0.721 
2 months after 
  
##;6
 $$$% 117.4 1112.7 to 78.0 0.721 
3 months after 
$ 
# ;6
% $$$% 113.8 181.0 to 53.3 0.686 
6 months after 
% 
 ;6
 $$$% 16.9 131.5 to 17.7 0.582 
9 months after 
 
# ;6
$ $$$ 14.3 117.1 to 8.4 0.505 
Permanent change 13.3 17.9 to 1.2 0.154 13.5 17.2 to 0.3 0.070 
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34/8 6.;0/.(./43(<
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 13.3 14.5 to 31.1 0.142 27.4 1.7 to 53.2 0.037 
1 month before 7.8 148.7 to 64.4 0.786 124.5 1142.1 to 93.1 0.683 
2 months before 11.3 117.1 to 39.7 0.435 112.5 1102.3 to 77.4 0.785 
3 months before 13.3 14.5 to 31.1 0.142 11.5 152.1 to 49.1 0.953 
6 months before   ;6%# $$ $% &;6 $$$
9 months before &  ;6  $$$  # #;6 $$$
1 month after 118.7 177.8 to 40.4 0.535 139.1 1120.4 to 42.1 0.345 
2 months after 117.6 161.6 to 26.5 0.434 
# 
;6
 & $$
3 months after 112.8 141.5 to 15.9 0.381 
$ 
;6
  M$$$
6 months after 18.5 117.4 to 0.3 0.059 113.5 127.5 to 0.5 0.059 
9 months after 
&  
;6
$ M$$$ 110.7 123.2 to 1.8 0.093 
Permanent change 
  
;6
## M$$$ 15.4 112.2 to 1.4 0.120 
 
 
./85.+A+(,67344896:+(,5/883;+6(9/<+53;+6(8
 
	(,43(< 56;43(<
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 2.3 118.4 to 23.1 0.827 4.6 17.2 to 16.4 0.444 
1 month before # &;6$ M$$$ 12.4 16.7 to 31.6 0.203 
2 months before %& ;6& M$$$ 6.3 16.3 to 18.9 0.325 
3 months before  %&;6# M$$$ 4.6 17.2 to 16.4 0.444 
6 months before $ #$;6#% M$$$ 4.1 13.6 to 11.8 0.300 
9 months before %  $;6& $$ 1.1 15.4 to 7.6 0.734 
1 month after 15.3 13.7 to 34.3 0.114 0.4 146.1 to 47.0 0.985 
2 months after 10.1 18.9 to 8.7 0.988 17.9 117.8 to 2.0 0.117 
3 months after 16.1 113.3 to 1.1 0.096 13.9 111.7 to 3.8 0.321 
6 months after 15.6 112.3 to 1.2 0.106 13.4 19.8 to 3.0 0.299 
9 months after 
## 
$;6
$$ $$% 12 18.0 to 4.0 0.514 
Permanent change 11.9 14.9 to 1.1 0.218 10.5 12.9 to 1.9 0.688 
 
34/8 6.;0/.(./43(<
 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 12.9 19.1 to 3.2 0.349 9.7 1161.0 to 180.3 0.912 
1 month before 5.9 18.9 to 20.7 0.436 22.3 122.3 to 66.8 0.327 
2 months before 1.8 18.5 to 12.2 0.729 15.1 116.0 to 46.2 0.340 
3 months before 12.9 19.1 to 3.2 0.349 10.8 117.6 to 39.2 0.454 
6 months before 1.8 110.6 to 14.3 0.772 6.4 13.3 to 16.1 0.197 
9 months before 3.3 15.6 to 12.1 0.468 5.1 11.9 to 12.2 0.151 
1 month after 14.4 112.1 to 40.9 0.288 14.7 15.2 to 34.7 0.148 
2 months after 0.6 16.6 to 7.8 0.871  $;6  $$ 
3 months after 4.2 13.3 to 11.8 0.273 6.6 11.0 to 14.2 0.087 
6 months after 0.5 15.6 to 6.5 0.880 0.1 15.8 to 6.0 0.967 
9 months after 11.8 17.1 to 3.6 0.519 11.5 15.9 to 2.8 0.487 
Permanent change 11.5 14.6 to 1.6 0.340 10.6 13.2 to 2.0 0.674 
 
The estimates of changes in NRT, bupropion and all prescribing in all patients are 
very similar in magnitude, direction and significance to the changes in prescribing 
seen in current smokers only.  
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/56.<+(,67896:+(,8;3;-8
 
	(,43(< 56;43(<
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 5.9 113.3 to 25.0 0.549 12.1 118.8 to 14.6 0.807 
1 month before 11.6 121.7 to 18.7 0.883 #  $;6%# M$$$
2 months before 3.8 122.8 to 30.3 0.780 # $#;6&# M$$$
3 months before 
# 
;6
  $$$ 12.1 118.8 to 14.6 0.807 
6 months before 10.9 16.8 to 5.1 0.774 4.4 118.8 to 27.6 0.710 
9 months before 1.3 15.1 to 7.7 0.691 10.8 118.8 to 17.2 0.933 
1 month after 2.5 117.6 to 22.7 0.807 6.4 110.1 to 22.9 0.446 
2 months after 11.6 138.1 to 34.9 0.932 1.9 179.7 to 83.5 0.964 
3 months after 12.7 135.5 to 30.1 0.872 7.6 16.1 to 21.2 0.277 
6 months after 15.9 113.7 to 1.9 0.138 12.8 128.8 to 23.2 0.831 
9 months after 13.8 110.9 to 3.3 0.294 8.6 11.4 to 18.6 0.093 
Step change 10.9 14.9 to 3.1 0.648 5.9 10.4 to 12.2 0.065 
 
34/8 6.;0/.(./43(<
 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 1.4 17.2 to 10.0 0.750 &# ;6%$ $$ 
1 month before 12.8 10.7 to 26.3 0.063 
 %# 
&;6
  $$$
2 months before 5.4 14.7 to 15.5 0.295 12.1 116.9 to 12.6 0.777 
3 months before 1.4 17.2 to 10.0 0.750 0.9 19.7 to 11.6 0.861 
6 months before & $$;6## $$#$ 7.0 10.1 to 14.0 0.054 
9 months before &% ;6#$ $$$& 3.3 11.3 to 7.8 0.160 
1 month after 
$% 
#;6
% $$ 10.7 180.6 to 79.2 0.986 
2 months after 
 
$%;6
  $$# 12.5 139.1 to 34.1 0.892 
3 months after 14.9 111.3 to 1.5 0.136 12.7 122.5 to 17.2 0.792 
6 months after 14.4 19.8 to 1.0 0.112 12.3 113.2 to 8.7 0.683 
9 months after 12.3 16.8 to 2.2 0.313 11.8 19.8 to 6.1 0.654 
Step change 11.0 13.1 to 1.1 0.350 11.3 14.8 to 2.2 0.466 


When data from January 2000 onwards was analysed, significant short1lived 
reductions in the rate of recording either before or after the introduction of 
smokefree legislation were seen in all four parts of the UK. When analysis is 
restricted to data from April 2004 onwards, a similar magnitude of decline in 
recording is seen in England in the three months before the smoking ban was 
introduced. However, some differences in the estimated effects of smokefree 
legislation in the other countries are apparent. For example, in Scotland a 25.2% 
increase in the rate of recording in the month before legislation was introduced is 
estimated from the shorter time series, though no significant effect is seen when 
all data are modelled. Similarly, significant increases in the rate of recording are 
seen six and nine months before the Welsh smoking ban when data from April 
2004 onwards is modelled, though no significant effect is seen from analysis of 
data from the whole study period.  
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/56.<+(,675/883;+6(3<2+5/
 
	(,43(< 56;43(<
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 1.9 112.2 to 16.0 0.788 12.3 1343.9 to 339.3 0.990 
1 month before 9.0 193.6 to 111.5 0.864 1.3 141.5 to 44.1 0.953 
2 months before 3.1 131.0 to 37.3 0.857 10.4 142.2 to 41.4 0.986 
3 months before 13.4 116.3 to 9.6 0.610 12.3 1343.9 to 339.3 0.990 
6 months before 10.6 19.0 to 7.9 0.894 17.3 17.0 to 41.6 0.163 
9 months before 3.1 17.8 to 13.9 0.581 
% 
$&;6
 # $$
1 month after 17.1 177.9 to 63.7 0.844 15.6 1498.4 to 487.1 0.982 
2 months after 18.3 152.6 to 36.0 0.715 18.4 1190.4 to 173.7 0.928 
3 months after 18.9 142.3 to 24.5 0.600 111.8 175.6 to 52.1 0.718 
6 months after 
& 
$ ;6
# $$ $ 116.4 133.8 to 1.0 0.065 
9 months after 14.8 111.0 to 1.5 0.135 
 
#&;6
 $$$
Step change 11.3 14.9 to 2.3 0.479 11.8 16.7 to 3.1 0.465 
 
34/8 6.;0/.(./43(<
 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 10.3 110.5 to 9.9 0.951 4.0 17.6 to 15.6 0.500 
1 month before 22.5 1187.6 to 232.6 0.834 
% 
#;6
&$ $$$
2 months before 5.1 19.6 to 19.7 0.496 0.1 18.1 to 8.4 0.979 
3 months before 10.3 110.5 to 9.9 0.951 12.3 110.3 to 5.6 0.567 
6 months before 16.8 12.1 to 35.7 0.082 6.5 0.3 to 12.6 0.038 
9 months before 2.9 16.1 to 11.9 0.528 2.4 11.2 to 6.0 0.192 
1 month after 114.6 182.8 to 53.5 0.674 8.1 1237.9 to 254.2 0.948 
2 months after 0.3 137.1 to 37.6 0.989 1.8 130.6 to 34.3 0.913 
3 months after 117.5 141.8 to 6.8 0.158 1.2 130.1 to 32.5 0.939 
6 months after 1.2 116.5 to 18.8 0.897 11.2 122.3 to 19.9 0.910 
9 months after 1.3 114.4 to 17.0 0.870 12.8 118.6 to 13.1 0.734 
Step change 13.4 113.9 to 7.1 0.527 11.3 15.7 to 3.1 0.568 
 
No significant changes in the rate of recording of cessation advice in current 
smokers were seen in any intervention period in any jurisdiction of the UK based 
on analysis of data from January 2000 onwards. However, some significant 
declines in the recording of advice are estimated using the shorter time series. 
 
 
 
/56.<+(,67./7/..34;68;61896:+(,8/.2+5/8
 
	(,43(< 56;43(<
Estimate 
(%) 
95% CI  
(%) 
P1value 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 35.9 156.8 to 128.7 0.447 25.6 129.8 to 81.0 0.366 
1 month before 23.2 188.9 to 135.3 0.685 21.2 131.2 to 73.5 0.428 
2 months before 6.7 145.1 to 58.6 0.799 36.8 129.8 to 103.4 0.278 
3 months before 16.8 180.5 to 66.8 0.856 25.6 129.8 to 81.0 0.366 
6 months before 26.6 115.3 to 68.5 0.214 119.1 151.1 to 12.9 0.241 
9 months before   %;6# M$$$ 9.3 128.4 to 47.1 0.628 
1 month after 28.5 141.2 to 98.1 0.423 120.9 170.0 to 28.3 0.406 
2 months after 16 185.4 to 73.5 0.883 114.8 162.1 to 32.5 0.540 
3 months after 112 191.3 to 67.3 0.767 136.6 1104.4 to 31.2 0.290 
6 months after 130.1 178.9 to 18.8 0.228 
  
%;6
 $$$
9 months after 16.1 192.3 to 80.0 0.889 130.4 185.0 to 24.2 0.275 
Step change 114.3 190.8 to 62.2 0.714 146.7 1134.3 to 40.9 0.296 
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34/8
 
Estimate 
(%) 
95% CI  
(%) 
P1value 
Q1 of SFL year 11.0 116.3 to 38.2 0.430 
1 month before 117.1 153.9 to 19.6 0.361 
2 months before 17.5 128.7 to 13.6 0.485 
3 months before 11.0 116.3 to 38.2 0.430 
6 months before 111.1 136.0 to 13.9 0.385 
9 months before 14.9 127.9 to 18.1 0.677 
1 month after 23.1 122.5 to 68.8 0.320 
2 months after 11.0 126.9 to 24.9 0.939 
3 months after 12.2 121.5 to 17.1 0.825 
6 months after 14.3 113.7 to 5.2 0.375 
9 months after 11.1 18.8 to 6.7 0.785 
Step change 0.7 14.3 to 5.7 0.792 
 
No significant changes in the rate of recording of referrals to smoking cessation 
services were seen in any intervention period in any jurisdiction of the UK based 
on analysis of the whole time series. However, when data from April 2004 
onwards is analysed, an increase in referral in England is estimated to have 
occurred in the nine month period before the introduction of the smoking ban, and 
a decrease in Scotland in the six month period after legislation was enacted. 
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